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.1 Mines  H e w  i i iMin ITiD T I icms
Abstract
Many vascular processes, including the control of vascular tone, coagulation, and 
inflammation are regulated by reactive oxygen and nitrogen species (RONS). Although 
RONS play key roles in vascular physiology they also function in vascular-associated 
pathological processes. The enzyme xanthine oxidoreductase (XOR) generates RONS, 
and its circulatory form has been linked to several pathologies. However, the source and 
mechanism of release of circulating XOR is not known. The vascular endothelium was 
hypothesized to be a source of circulating XOR and using human umbilical vein 
endothelial cells (HUVECs) the release of XOR was studied.
Initial experiments demonstrated that the cell type being isolated was of endothelial 
origin. The expression of active XOR in HUVECs was demonstrated. XOR protein was 
found diffusely in the cytoplasm and also in punctate structures. To measure XOR 
release from HUVECs a sensitive fluorescence-based assay was chosen and modified. 
Endothelial cell activation was verified by von Willebrand factor secretion, and release of 
XOR could be stimulated using known endothelial cell protein secretagogues. XOR 
release was independent of vWf secretion and cell death, could be stimulated by an 
increase in intracellular calcium, and required microtubule function.
The activity of xanthine oxidase (XO) from several sources was shown to increase in the 
presence of thrombin. In the presence of thrombin the protective antibacterial functions 
of XO were significantly enhanced. The mechanism of thrombin-enhanced XO activity is 
unknown. In support of proteolytic “activation” of XO, thrombin recognition and 
cleavage sites were discovered in the XO amino-acid sequence. However, inhibition of 
thrombin did not convincingly inhibit the enhancement of XO activity. Thrombin does 
not increase XO activity through an antioxidant mechanism.
A model was proposed suggesting a protective function for circulating XO, incorporating 
its release and antibacterial function that may be relevant in a wound environment. 
However, as with many inflammatory mediators, XOR has a role in pathology, therefore 
the release mechanism described may function in XOR-related disease states.
-H I-
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1 Introduction: Vascular Biology
1.1 The Circulatory System
In unicellular and simple organisms expulsion of waste products and the acquisition 
o f nutrients to or from the external environment can occur by simple diffusion across 
cell membranes. Exchange time, to or from the external environment, is proportional 
to diffusion distance. Consequendy cells in complex multicellular organisms, located 
at a distance from the external environment, can not rely on diffusion alone to 
support their life. Therefore complex organisms have evolved a circulatory system 
that delivers and removes products from cells not able to rely on diffusion-exchange 
from the external environment direcdy.
The circulatory system not only plays a role in nutrient and waste distribution but also 
has a key role in many processes including: i) Cellular communication, for example, 
the distribution of hormones and cytokines to target cells, tissues, or organs, ii) the 
distribution o f body-defence agents, such as, leukocytes, immunoglobulins, and 
complement components, and iii) the regulation of body temperature.
1.2 Vascular Structure
The circulatory system is composed o f the heart, a series of distributing and collecting 
vessels, and an extensive system o f thin-walled vessels. The general structure of a 
blood vessel, shown in Figure 1, consists o f  three layers: i) the tunica adventitia, a layer 
o f connective tissue that anchors the vessel in place, ii) the tunica media, which is 
composed o f a circular layer of smooth muscle, elastin, and collagen sandwiched 
between two layers o f elastic tissue, and iii) the tunica intima, which consists of a thin 
layer o f connective tissue and a layer o f endothelial cells that make direct contact with 
the blood. However, this describes general vessel structure and is applicable to 
arteries for example, but differences are seen in vessels such as capillaries which are 
composed solely of a simple layer o f endothelial cells and are the principal diffusion- 
exchange vessels.
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Figure 1. The Generalised Structure of a Blood Vessel.
See text for description (adapted from Pocock and Richards, 1999).
The inner most layer of the blood vessel, the vascular endothelium, was once thought 
to play only a simple role in the blood vessel as a semi-selective barrier to the 
diffusion of macromolecules. However, the endothelium is now known to participate 
in many important physiological and pathological processes, for example the 
modulation of inflammation and coagulation, and regulation of vascular tone, 
processes which will be reviewed subsequently.
1.3 Vascular Tone
Vascular tone refers to the degree of constriction experienced by a blood vessel 
relative to its maximal dilation. The tone of a blood vessel is important in the 
regulation of blood pressure and blood flow within an organ, and is determined by 
the balance of vasoconstrictor and vasodilator substances acting ultimately on 
vascular smooth muscle. Loss of control over vascular tone is associated with several 
disease states including hypertension, atherosclerosis, and chronic heart failure. 
Previously it was believed that the control over blood vessel constriction and dilation 
was via the action of neurochemical substances on the vascular smooth muscle.
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However, the importance of the vascular endothelium in the control over vascular 
tone was discovered (Furchgott and Zawadzki, 1980) and it is now known that the 
majority of vasoactive substances act via the vascular endothelium, which in turn 
releases vasoactive factors that dictate vascular tone (Rang et al., 2003) (reviewed in 
Figure 2). Many vasodilatory substances stimulate the production of nitric oxide 
(NO ) by the vascular endothelium which in turn acts on the smooth muscle causing 
relaxation, the action o f NO is given in more detail in section 2.1.2.
Shear
stress

















examples of vasoactive agonists that act via the endothelium.
Figure 2. Vasoactive Substances in Control of Vascular Tone.
Many vasoactive substances control vascular tone via the stimulation o f endothelial cells, and the 
subsequent generation o f  mediators dictate the degree o f  smooth mucle contraction v ’s dilation.
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Abbreviations: A, Angiotensin; ACE, Angiotensin-converting enzyme; CNP, C-natriuretic peptide; 
E D H F, Endothelium-derived hyperpolarising factor; ET-1, Endothelin-1; PG, Prostagalndin 
(adapted from Rang et al., 2003).
1.4 Haemostatsis
Haemostasis, the arrest of bleeding from a site o f vascular damage, is a major host 
defence mechanism that occurs in two stages known as primary and secondary 
haemostasis. In primary haemostasis, vasoconstriction reduces blood flow from the 
damaged vessel, and damage to the endothelial cell layer exposes subendothelial 
tissues which results in platelet adhesion, accumulation, activation, and aggregation, 
forming a structure termed the primary haemostatic plug. The primary haemostatic 
plug is fragile and the consolidation o f the platelet aggregate is essential or bleeding 
will recommence. In secondary haemostasis consolidation of the primary haemostatic 
plug is brought about by the enzymic conversion o f fibrinogen to fibrin, the result of 
the blood coagulation cascade, which forms a tough mesh around the initial plug 
(Pallister, 1994).
1.4.1 Primary Haemostasis -  Haemostatic Plug Formation
Platelets, the smallest blood cells in the body, are anucleated cells formed in the 
cytoplasm o f megakaryocytes. Platelets contain two major types of intracellular 
granule, termed dense- and a-granules. Dense-granules contain ADP, ATP, and 
serotonin, whereas the a-granules contain a variety of substances involved in primary 
and secondary haemostasis, including platelet factor 4, thrombospondin, fibrinogen, 
von Willebrand Factor (vWf), P-selectin, and coagulation factors V and VIII 
(Pallister, 1994).
Platelets display four distinct properties during the formation of the haemostatic plug, 
i) surface adhesion, ii) shape change, iii) granule release, and iv) aggregation. Platelets 
may be activated by a variety of physiological and non-physiological substances. In vivo 
damage to the vessel wall exposes sub-endothelial fibers, for example collagen, which 
promotes platelet adherence. The protein vW f is particularly important for strong
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platelet adhesion to the blood vessel. Platelets contain two vW F receptors, 
glycoprotein lb (GPIb) and glycoprotein Ilb /IIIa  (GPIIb/IIIa), occupation of GPIb 
induces a conformational change and therefore activation o f G P IIb /IIIa  which forms 
the second vW f binding site. Platelet adhesion is usually accompanied by a 
transformation in platelet structure which is associated with the centralization of 
cytoplasmic granules and their subsequent release. The contents o f platelet granules 
promote further platelet adhesion and aggregation. Initial platelet aggregation is 
mediated via fibrinogen, a molecule that contains two domains that binds G PIIb/IIIa 
receptors therefore forming a platelet-platelet bridge. Further aggregation is promoted 
by release o f ADP and the metabolism of arachidonic acid in activated platelets which 
results in the synthesis o f thromboxane A2 (TXA2), a powerful inducer of platelet 
aggregation (Pallister, 1994).
1.4.2 Secondary Haemostasis -  The Coagulation Cascade
The blood coagulation cascade is composed of a series o f protein coagulation factors 
that exist, under normal physiological conditions, in an inactive form. Upon 
stimulation the coagulation factors interact in an ordered sequence that culminates in 
the production of fibrin. The cascade model was originally conceived from in vitro 
data (Davie and Ratnoff, 1964; MacFarlane, 1964) and in vivo data have subsequendy 
been reviewed (Furie and Furie, 1992) (see Figure 3).
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Figure 3. The Coagulation Cascade.
The blood coagulation cascade can be divided into two pathways, the intrinsic and extrinsic pathways, 
which both share a common end-phase that results in the formation o f  a stable fibrin network. The 
intrinsic pathway can be initiated by contact o f  blood with a “foreign” surface, for example collagen, 
basement membrane, lipopolysaccharide, or non-physiological surfaces such as glass. The extrinsic 
pathway, on the other hand, is initiated by the exposure o f  tissue factor (TFac) to blood following 
tissue damage. The coagulation factors, that are referred to by Roman numerals, occur as two main 
types: i) Zymogens, which exist has inactive plasma proenzymes but are activated by enzymatic 
cleavage (the active state is denoted by the suffix “a”), are a group that include factors II 
(prothrombin), X, XI, XII, and XIII, and ii) Accelerators, which act as catalysts for other enzymatic 
reactions are a group that include fators V and VIII. It must be noted that the two pathways are not 
exclusive, this is a simplified diagram and some crossovers do exist other than the common end- 
phase. Abbreviations: Ca2+ : Calcium, PL : Phospholipid. (Adapted from Pallister, 1994).
1.4.3 The Role of von Willebrand Factor in Haemostasis
Many of the factors required for the coagulation cascade are synthesised by the liver 
and platelets. However, the vascular endothelium contributes to the regulation of the 
coagulation cascade through the synthesis and release of thrombomodulin, tissue 
factor pathway inhibitor, and tissue plasminogen activator (tPA) (inhibitors of
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coagulation), and von Willebrand factor (vWf), a promoter of coagulation. 
Endothelial and platelet vWf is an extensively glycosylated 250kDa protein that can 
form disulphide-linked multimers that maybe >20,000kDa. vWf is constitutively 
secreted by endothelial cells from unique cytoplasmic storage granules called Weibel- 
Palade Bodies (WPBs), the formation of which appears to require synthesis o f vW f 
(reviewed in Michaux and Cutler, 2004). Vascular endothelial cells secrete vW f from 
WPBs in response to a variety of agents which can be classified on the intracellular- 
signalling mechanism induced prior to release. Secretagogues such as histamine and 
thrombin induce release by a mechanism dependent on a rise in intracellular free- 
calcium ([Ca2+]i) (Birch et al.y 1994), whereas epinephrine, forskolin, and vasopressin 
stimulate release by a cyclic adenosine monophosphate (cAMP)-dependent 
mechanism (Visher and Wollheim, 1997).
vW f regulates haemostasis in two ways: i) vW f contributes to primary haemostasis via 
the binding to the sub-endothelium of damaged vascular tissue and to platelet 
receptors GPIb and G PIIb/IIIa (reviewed in Sadler, 1998). Thus vWf forms a bridge 
between platelets and subendothelial connective tissue that contributes to platelet 
aggregation, ii) vW f contributes to secondary haemostasis as it binds to and acts as a 
carrier protein for factor VIII, thus protecting the factor from enzymatic degradation 
(reviewed in Sadler, 1998). In the absence of vWf, factor VIII is rapidly removed 
from the circulation significantly reducing blood coagulation. The role o f vW f in 
coagulation is highlighted in patients with von Willebrand’s disease, caused by a 
defect in vWf. von Willebrand’s disease is likely to be the most common inherited 
haemorrhagic disorder (Pallister, 1994).
1.4.4 The Roles of Histamine and Thrombin in Haemostasis
The [Ca2+]i raising agents thrombin and histamine are used in experimental chapters 
of the thesis, therefore it is important to highlight their roles in vascular processes. 
Thrombin has a major role in the coagulation cascade (see Figure 3) in the enzymatic- 
cleavage o f fibrinogen to form fibrin, the component responsible for the
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consolidation of the haemostatic plug. However, thrombin also plays other significant 
roles in haemostasis, which are reviewed in the next section.
1.4.4.1 Thrombin Effects on the Endothelium and Platelets
As mentioned previously, both thrombin and histamine stimulate the release of vWf
from the endothelium. Thrombin is formed in the coagulation cascade by the 
cleavage of prothrombin, whereas the major source of histamine is the mast cell 
which secretes factors during inflammatory stimulus (see later section), thus providing 
a cross over between coagulation and inflammation. The intracellular signalling 
cascade for histamine and thrombin-induced vWf release is shown in Figure 4. 
Additionally, thrombin has a multi-functional role in the regulation o f platelets, it 
triggers shape change and the release of contents from dense- and a-granules 
(Pallister, 1994).
THROM BIN
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Figure 4. Signal Cascades in histamine and Thrombin-Stimulated vWf Release.
The activation o f endothelial G-protein-linked protease-activated receptors (PARS) by thrombin 
stimulates the activity o f the enzyme phospholipase C (PLC). PLC-catalysed generation o f  inositol 1,
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4, 5-lriphospahte (IP3) signals the release o f  calcium (Ca2+) from intracellular stores. The resulting 
increase in [Ca2+]i leads to calcium-calmodulin association (Ca2+/CaM) which activates Ral guanine 
nucleotide exchange factor (GEF). G EF activity switches Ral to its active form, via a conformational 
change induced by guanosine triphospahte-guanosine diphosphate (GTP-GDP) exchange. Activation 
o f  Ral promotes the binding o f  other proteins that are responsible for cytoskeletal rearrangement, 
and ultimately the exocytosis o f  WPBs (adapted from van Mourik and Voorberg, 2002). Histamine 
stimulates a similar signalling cascade resulting in an increase in [Ca2+], but acts via the G-protein 
linked histamine receptor (Lo et al., 1987; Tilly et al., 1990; Hough, 2001).
Thrombin’s stimulatory action on endothelial cells and platelets occurs via protease- 
activated receptors (PARs). There are four members to the PAR family, PAR1-4, but 
thrombin only cleaves PARi,3,4. All PARs belong to a family of seven-transmembrane 
spanning G-protein-linked receptors, which are activated by a novel mechanism, as 
shown in Figure 5. FFuman platelets are regulated by PARi and PAR4 (Kahn et al., 
1998), whereas only PARi and PAR2 play a functional role in the vascular 













Figure 5. Thrombin Activation of Protease-Activated Receptors.
In inactive PARs the extracellular tethered ligand is masked by an amino-acid sequence. Thrombin 
activation o f  PARt and PAR} occurs in a two step process. Firstly, thrombin binds to a hirudin-like 
domain, and secondly, thrombin cleaves to expose the PAR-tethered ligand which subsequendy 
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1.5 Inflammation
Inflammation is an important physiological response to a variety of stimuli including 
bacterial infection, tissue injury, and chemical exposure. Clinically, the inflammatory 
response may be characterized by the following symptoms:
• oedema (swelling) caused by the accumulation o f inflammatory exudate (a fluid that 
contains proteins and cells from local blood vessels and affected tissue).
• rubor (redness) due to dilation of local blood vessels and a consequential increase in 
blood flow.
• calor (heat) caused by increased blood flow and/or systemic fever.
• dalor (pain) as a result o f pressure build up at site o f oedema and release o f certain 
inflammatory mediators.
• loss of function due to pain and swelling o f affected area.
Although the clinical appearance of inflammation may seem deleterious, the increase 
in blood flow and accumulation of fluid at affected tissues has beneficial effects 
including, delivery o f immune cells and proteins, nutrients and oxygen, and the 
dilution o f toxins.
1.5.1 Mediators of Inflammation
During the inflammatory response a variety o f mediators are either released from cells 
or activated in response to certain stimuli and serve to enhance specific aspects o f the 
inflammation.
1.5.1.1 Cytokines
Cytokines form a large group of secreted-proteins that regulate the intensity and 
duration o f an immune response by mediating the actions o f leukoctyes and other 
inflammatory cells. Cytokines important to the inflammatory process include 
interleukin-1, and -6 (IL-1 and IL-6), tumor necrosis factor alpha (TNF-oe), interferon 
gamma (IFN-y), and chemokines (see below). Collectively cytokines influence the 
inflammatory process in many ways, for example, inducing fever and the synthesis o f 
acute-phase response proteins, increase adhesion molecule expression on the 
endothelium, and activate immune cells (Kuby, 1997).
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1.5.1.2 Chemokines
Chemokines are a group o f small polypeptides that are responsible for the 
chemotactic attraction of leukocytes and the regulation o f integrin expression on the 
surface o f leukocytes. Chemokines act by inducing the adherence of leukocytes to the 
vascular endothelium (an essential step for the migration of inflammatory cells into an 
affected area) and attract leukocytes to affected areas following migration from the 
circulation. The chemokine family includes macrophage chemotactic and activating 
factor, macrophage inflammatory protein-1 a and b, RANTES, platelet factor 4, and 
interleukin 8 (IL-8). Probably the best characterized chemokine is IL-8, which is 
generated by a variety of cells including monocytes/macrophages, neutrophils, and 
endothelial cells. IL-8 is retained on the inflamed endothelium where it acts to 
activate integrin expression in neutrophils, allowing firm adhesion (see section 1.5.2) 
(Kuby, 1997).
1.5.1.3 Plasma Enzyme Mediators
The plasma contains four enzyme-mediated systems that are involved in the 
inflammatory response (Kuby, 1997). i) The kinin system is activated following tissue 
damage and results in the formation o f bradykinin. Brady kinin is a vasoactive protein 
that induces vasodilation, increases vascular permeability, induces pain, and activates 
the complement system, ii) The complement system may be activated by several 
pathways but results in a common end point, the formation of the membrane attack 
complex that serves to punch holes in invading pathogens. During the complement 
cascade, enzymatic cleavage of complement components generates both opsonins and 
anaphylatoxins. Anaphylatoxins bind to receptors on tissue mast cells inducing 
degranulation, which results in the release o f histamine and other mediators, iii) The 
coagulation system, which may be activated by damage to blood vessel walls, has an 
important role in inflammation. The generation of the fibrin clot at sites o f vessel 
damage serves as a barrier to stop the spread o f invading pathogens and 
fibrinopeptides formed during thrombin cleavage of fibrinogen to fibrin act by 
increasing vascular permeability and as neutrophil chemotactants. iv) The fibrinolytic
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system opposes the coagulation system by the break down o f the fibrin clot. The end 
product o f the fibrinolytic system is the enzyme plasmin, which activates the 
complement pathway and is responsible for fibrin destruction, which forms 
chemotactic peptides for neutrophils, as mentioned above.
1.5.2 Molecular Biology of Transendothelial Migration
An important step in the inflammatory process is the migration o f inflammatory cells 
from the circulation into the affected tissue. However this is not a simple process as 
the leukocyte must first bind to, remain bound and then traverse the endothelium 
against the shear-forces o f the circulating blood. To achieve this feat the endothelium 
and leukocyte co-ordinate a sophisticated interplay o f signalling and adhesion 
molecules, as reviewed in Figure 6. The principal signalling and adhesion molecules 
will now be discussed in more detail.
1.5.2.1 Selectins and Ligands
Three selectins have been identified and are classified by their site of expression, i.e. 
platelets, endothelium, and leukocytes and are consequently named P-, E- and L- 
selectin, respectively. Selectins have similar structures, each have a lectin-like domain 
(the principal region for ligand binding), an endothelial growth factor motif, a number 
o f consensus repeats (nine, six, and two in P-, E-, and L-selectin respectively), and an 
anchoring transmembrane domain with cytoplasmic tail. Selectins appear to have a 
role in the initial binding and rolling of leukocytes on the vascular endothelium 
(Kuby, 1997).
P-selectin, also called GMP-140, is expressed in preformed secretory granules; a- 
granules in platelets and WPBs in endothelial cells (Hsu-Lin et al., 1984; McEver et al.,
1989). In endothelial cells, surface-expression o f P-selectin occurs when WPBs fuse 
with the plasma membrane on stimulation by histamine or thrombin for example 
(Hattori et al., 1989). Human P-selectin may also be transcriptionally regulated; the 
synthesis of P-selectin mRNA in endothelial cells is upregulated in response to IL-4
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and IL-13 stimulation (Yao et al, 1996; Woltmann et al., 2000). Stimulation of 
transcriptional activity accounts for the bimodal distribution of P-selectin expression, 
an early peak appears within minutes, i.e. release from preformed granules, and later a 
peak after approximately four hours i.e. expression of newly synthesised P-selectin. P- 
selectin is a receptor for neutrophils and monocytes, and therefore regulates binding 
of these cell types to the endothelium and platelets (Larsen et al, 1989; Geng et al.,
1990). The P-selectin glycoprotein ligand (PSGL-1) is expressed on leukocytes and 
platelets, and is responsible for interactions between these two cell types and the 
endothelium (Frenette et al., 2000).
Similar to P-selectin, E-selectin is expressed in vascular endothelial cells, however 
unlike P-selectin its expression is not constitutive. E-selectin synthesis and cell-surface 
upregulation requires stimulation of endothelial cells by inflammatory agonists such as 
TNF-a and IL-1, and maximal expression occurs approximately four hours after 
stimuli and declines after approximately 24 hours (Belvilacqua et al., 1987). Two 
glycoprotein ligands have been identified for E-selectin, the leukocyte-expressed E- 
selectin Ligand (ESL-1) which binds only to E- and not P-selectin (Ehrhardt et al., 
2004), and the above mentioned PSGL-1.
The leukocyte-expressed receptor L-selectin is required for the binding o f leukocytes 
to the endothelium (von Andrian et al, 1992). Four L-selectin ligands have been 
identified in high endothelial venules (HEV), Sgp50 (glycosylation-dependent cell 
adhesion molecule-1, GlyCAM-1), Spg90 (CD34), Spg200, and mucosal vascular 
addressin cell adhesion molecule-1 (MAdCAM-1). Spg90 is identical to CD34 and is 
expressed on endothelial cells.
1.5.2.2 Immunoglobulin Superfamily Receptors and Integrins
Initial tethering o f leukocytes to the endothelium via selectins and their ligands is a
comparatively weak and reversible process. For leukocytes to migrate through the 
endothelium they must arrest on the vessel wall, a process that is exclusively mediated
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by integrin-receptors on leukocytes and immunoglobulin superfamily members 
expressed on the endothelium (see Figure 6).
Similarly to E-selectin, the expression o f intracellular adhesion molecule-1 (ICAM-1) 
and vascular cell adhesion molecule-1 (VCAM-1) occurs after stimulation of the 
endothelium. The platelet endothelial cell adhesion molecule-1 (PECAM-1) on the 
other hand is constitutively expressed. VCAM-1 is an important ligand for the 
integrin VLA-4, whereas ICAM-1 binds to LFA-1 and Mac-1 on the leukocyte (Hou 
and Ley, 2001).
Through their interaction with the above mentioned receptors, leukocyte arrest is 
mediated primarily by the VLA-4 (a4|31), LAF-1 (aL(32) and Mac-1 (aM|32) integrins 
(Springer, 1994). A unique feature o f the integrin family is that their activity is 
regulated independently o f their surface expression, i.e. circulating leukocytes express 
integrins but in non-adhesive states (Hynes, 1992). Conformational changes within 
the integrin are required for adhesion, and stimuli for this change are thought to come 
from chemokines and occurs in a matter of seconds (Grabovsky et a l 2000). 
Chemokines, such as IL-8, are displayed on the endothelial surface at sites of 
inflammation (Weber et al., 1999), therefore it has been proposed that initial tethering 
and rolling events increase the chances of chemokine-stimulation o f leukocytes that 
leads to integrin-conformational change, firm adhesion, and migration.
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Figure 6. Leukocyte-Endothelial Cell Interactions in Inflammation.
The processes involved in leukocyte-transendothelial migration can be split into three stages: i) initial 
binding and rolling, ii) tight adhesion, and iii) trans-endothelial migration. Initial binding of circulating 
leukocytes is established by interactions between endothelial-expressed P- and E-selectin, leukocyte 
L-selectin, and their cognate mucin-ligands. Tight adhesion occurs between activated endothelial cells 
expressing CAM’s and activated leukocytes expressing functional integrin. Leukocytes may then 
migrate across the endothelium (adapted from Ehrhardt et al., 2004).
1.5.3 The Roles of Thrombin and Histamine in Inflammation
As previously stated, the formation of a fibrin-clot following the disruption of the 
endothelium is an important measure to stop the spread of invading microorganisms. 
The processes by which thrombin and histamine modulate haemostasis are reviewed 
in the coagulation section. As thrombin and histamine function to induce the release 
of vWf from endothelial cells, they also stimulate the concomitant release of pre­
synthesised P-selectin, therefore thrombin and histamine contribute to leukocyte 
adhesion events in inflammation. Indeed, the induction of leukocyte adhesion and 
rolling can be mediated by histamine stimulation of the endothelium (Jones et al, 
1993) or by thrombin-activation of endothelial cells mediated via PAR4 (Vergnolle et 
a l, 2002). Also, thrombin and histamine function as mediators of another important 
step in inflammation, the increase in vascular permeability. Thrombin and histamine 
induce shape-change in the endothelial resulting in gap formation that accounts for
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increased permeability. Thrombin and histamine mediate this effect via the PARi and 
H I receptors, respectively (Laposata et al., 1983; Vergnolle et al, 1999; Rotrosen and 
Gallin, 1986).
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Chapter 2. Introduction: 
Reactive Oxygen and Nitrogen 
Species in the Vasculature
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2 Introduction: Reactive Oxygen and Nitrogen 
Species in the Vasculature
Reactive oxygen and nitrogen species (RONS) are a class o f highly reactive molecules 
that have a broad function ranging from host defence to the maintenance of vascular 
processes. Although RONS play important physiological roles their excessive 
generation, with respect to endogenous defence molecules against these highly active 
molecules, can lead to pathological conditions (as discussed in a later section).
Superoxide (02 ~)> hydrogen peroxide (H2O 2), and the hydroxyl radical ( OH), form a 
group of molecules known as reactive oxygen species (ROS). The superoxide anion is 
formed by the single electron reduction of molecular oxygen (O2) by enzymic 
processes or non-enzymic redox-reactive compounds. O 2 ~ is poorly membrane- 
permeable due to its charge and therefore usually remains in the cell compartment 
where it is produced. O 2 ~ has a short half-life and is rapidly converted to the more 
membrane-permeable ROS H 2O 2, which is commonly generated by the dismutation 
of two O 2 ” molecules by a process catalysed by superoxide dismutase (SOD) 
(McCord and Fridovich, 1968; Fridovich, 1978). In the presence of transition metal 
ions, such as iron and copper, O 2 ~ and H 2O2 maybe converted to the damaging 
radical species,'OH, by the Fenton or by the Haber-Weiss reaction (Hancock, 1999).
The reactive nitrogen species (RNS) nitric oxide (NO ) is generated by enzymatic 
processes and depending on the microenvironment N O ' can be converted to other 
RNS including nitrosonium cation, nitroxyl anion, and peroxynitrite (ONOO") 
(Stamler et al.^  1992). N O ' has a half-life of about 5-10 seconds, is lipid soluble, and 
readily diffuses across cell membranes. Although N O ' has a short half-life, studies 
have suggested that other RNS, especially peroxynitrite, can react with thiols to form - 
i ’-nitrosothiols that serve as stable reservoirs of N O ' (Reviewed in Kelm, 1999).
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2.1 Reactive Oxygen and Nitrogen Species in Vascular 
Function
2.1.1 Antioxidant Systems
The effect o f RONS generated within the vascular system are not only dependent on 
the site and quantities generated but also on the processes that scavenge or degrade 
RONS, processes also termed the antioxidant systems. Antioxidant systems comprise 
a group o f enzymatic and non-enzymatic molecules. Enzymatic antioxidants include 
superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH peroxidase), 
however other systems exist including thioredoxin reductase and heme oxygenase 
(Yamawaki et a l, 2003; Parrella and Yet, 2003). If  the generation of RONS is far in 
excess o f the antioxidant systems then a state of oxidative stress arises which can be 
responsible for many pathological conditions in the vasculature (see Xanthine 
Oxidase and Vascular Pathology section for examples).
2.1.1.1 Superoxide Dismutase
SOD was first discovered in 1969 (McCord and Fridovich, 1969) and catalyses the 
following antioxidant reaction:
2 O 2 + 2H H 2O 2 + O 2
Three isoforms o f SOD exist in humans, the mitochondrial manganese-containing 
SOD and two copper/zinc-containing isoforms that exist either in the cytoplasmic 
(CuZnSOD) or extracellular compartment (ecSOD). The secreted SOD, ecSOD, is 
the most abundant in the endothelium and is primarily associated with the vascular 
endothelial surface (Stralin et a l, 1995), where it binds to sulphated polysaccharides, 
such as heparin and heparin sulphate (Fridovich, 1997). ecSOD may function as an 
interceptor o f ROS released from activated phagocytes and/or regulate extracellular 
N O  availability (Oury et al, 1996), whereas the CuZnSOD will predominantly control 
intracellular ROS availability.
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2.1.1.2 Catalase
Superoxide dismutase functions to remove the potentially damaging O 2 ~ radical, 
however in that process the ROS H 2O 2 is generated, a more stable and more 
membrane soluble compared to O 2 "• The enzyme catalase hfunctions in the disposal 
o f  H 2O 2 by the following process (Hancock, 1999):
2 H 2O 2 2H20  + O 2
2.1.1.3 Glutathione
Another mechanism for the breakdown of H 2O 2 into harmless by-products involves 
glutathione (GSH). GSH serves as a substrate for the selenium-containing enzyme 
glutathione peroxidase in the elimination of lipid peroxides and H 2O 2 (Dickinson and 
Forman, 2002). In this reaction GSH becomes converted to oxidised GSH (GSSG), 
however the enzyme glutathione reductase rapidly converts GSSG back to GSH. The 
GSH/GSSG ratio is usually kept at a high level to maintain this antioxidant buffering 
system.
2.1.1.4 Non-Enzymatic Antioxidants
A number of non-enzymatic antioxidants exist within the vasculature including 
ascorbic acid (vitamin C), a-tocopherol (vitamin E), (3-carotene, and uric acid, which 
act as radical scavengers (i.e. they donate an electron to free-radicals which leads to 
the inactivation of the initial radical species) (reviewed in Schultz et al., 2004). Also 
metal chelators, for example transferrin and ferritin, reduce the formation of 
antioxidants by reducing the availability of transition metals. This process limits the 
production of OH by the reaction of O 2 ~ or H 2O 2 with free iron.
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2.1.2 Reactive Oxygen and Nitrogen Species in Vascular Tone
As mentioned in Chapter 1 the control of vascular tone is important in the regulation 
of blood pressure. The loss of control over vascular tone has implications in several 
vascular diseases including hypertension, atherosclerosis, and chronic heart failure 
(CHF) (see Xanthine Oxidase and Vascular Pathology section). The discovery that an 
endothelium-derived relaxation factor (EDRF) was responsible for relaxation of 
smooth muscle in the blood vessel (Furchgott and Zawadzki, 1980) led many 
researchers to attempt to characterise the substance. In 1987 two research groups 
discovered that EDRF is in fact N O ' (Palmer et al'., 1987; Ignarro et al., 1987), one of 
the most influential RONS in the control o f vascular tone. Many of the biological 
effects of N O ' are mediated through the regulation of guanylate cyclase and the 
subsequent generation of cyclic guanosine monophosphate (cGMP), which is 
involved in a broad range of physiological responses (Miinzel et al, 2003). In the 
control of vascular tone, N O ' is synthesised and released by the vascular endothelium 
in response to shear stress or chemical stimulation (e.g. acetylcholine), but acts on 
smooth muscle cells to cause dilation (see Figure 7). However, the presence of 
superoxide may attenuate this signal (Gryglewski et al., 1986) through the diffusion 
limited reaction between O 2 ~ and N O ' forming ONOO* (Huie and Padmaja, 1993), 
which occurs approximately three times faster than the reaction of O 2 ~ with SOD.
Although the role o f N O ' in vasodilation has been well characterised, it appears that 
other RONS may function to induce smooth muscle relaxation. A recent paper has 
suggested that H 2O 2 is responsible for shear stress-induced dilation in human blood 
vessels, probably acting as an endothelium-derived hyperpolarising factor (Miura et al., 
2003).
2-22
James I feu inson I ' M ) T h e s i s












Figure 7. Maintenance of Vascular Tone -  Vasodilation.
In response to an appropriate chemical stimulus or shear stress NO generation by nitric oxide 
synthase (NOS) in endothelial cells is triggered. N O  diffuses into nearby smooth muscle cells where 
it is responsible for the activation o f  soluble guanylate cyclase (cGC). Subsequent generation of 
cGMP activates cGMP-dependent protein kinase I (cGKI). cGKI is responsible for decreasing 
intracellular Ca2+ concentration [C a2+]i, which in turn decreases the activation o f  calcium-calmodulin 
myosin light chain kinase. Decreased phosphorylation of myosin light chains induces smooth muscle 
relaxation and therefore vasodilation (adapted from Ignarro and Kadowitz, 1985; Archer et al., 1994; 
Miinzel et al., 2003).
2.1.3 Reactive Oxygen and Nitrogen Species in Coagulation
With respect to the coagulation cascade (as discussed in chapter 1) very little 
information regarding the effects of RONS is known. In Bayele et al 2002, it was 
suggested that the extrinsic and intrinsic coagulation cascades are modulated by shifts 
in redox balance, but their work was based on in vitro experiments that may not apply 
in vivo. Conversely, the influence of RONS on platelet aggregation has been well 
studied.
In haemostasis, platelets function to form the primary haemostatic plug that is 
consolidated by fibrin. It is essential that under physiological conditions circulating 
platelets do not aggregate as this leads to thrombosis. N O ' is an important molecule
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in the inhibition of platelet aggregation, and akin to its vasodilatory actions it can 
signal via guanylate cyclase activation, as reviewed in Figure 8. An important source of 
NO in the inhibition of platelet aggregation is the vascular endothelium (Azuma et 
ai, 1986; Radomski et al., 1987), and is likely to be generated by endothelial nitric 
oxide synthase. However, xanthine oxidoreductase (found in the vascular 
endothelium) also generates NO ' in the presence of glyceryl trinitrite, which inhibits 
platelet aggregation (O’Byrne et al., 2000). Also, a constitutive N O ' synthase has been 
found in human platelets (Sase and Michel, 1995; Zhou et al., 1995) which modestly 
modulates platelet function (Freedman et al., 1997).
Platelet
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Figure 8. The Effects of Nitric Oxide on Platelet Function.
N O ' from endothelial cells or platelets inhibits aggregation via several signalling pathways. NO' is 
responsible for the generation o f  cGMP by activating soluble guanylate cyclase and reduces 
cytoplasmic [Ca2+] by activation o f  calcium-ATPases. As a result o f  these mechanisms cytoplasmic 
[Ca2+] is reduced which suppresses the expression o f  P-selectin and the active conformation o f  
glycoprotein Ilb/IIIa (GPIIb/IIIa). N O  inhibition o f  phosphoinositide 3-kinase (PI3K) inhibits the 
activation o f platelet N A D PH  oxidase and therefore significant generation o f  O 2 NO ' may react 
with O 2 " forming O N O O  which inhibits the enzyme cyclooxygenase (COX-1) and the generation 
o f  prostaglandin G 2 and H 2 (PG G 2/H 2) from arachidonic acid (AA). PG G 2 and PGPhare precursors 
o f thromboxane A 2 synthesis, a potent inducer o f platelet aggregation and vasoconstriction, (adapted 
from Loscalzo, 2001).
In vitro experiments have shown that thrombin activated platelets exposed to O 2 ” 
present increased aggregation and adhesion properties compared to controls 
(Salvemini et al., 1989). Enhanced aggregation and adhesion occurred with O 2 "  but
2-24
Jam es [ k  u m v .m l 5h l ) T h e s is
not H 2O 2. Stimulated platelets are a rich source of O 2 ” themselves, and exhibit the 
above mentioned characteristics (Jahn and Hansch, 1990). The role O 2 ~ has over the 
regulation of platelet function is probably conducted through its reaction with N O ’ 
and the subsequent reduction in N O -inhibition of aggregation (Clutton et a l, 2004).
2.1.4 Reactive Oxygen and Nitrogen Species in Inflammation
Controlled changes in cell adhesive properties play a key role in the early stages o f an 
inflammatory response. As mentioned in Chapter 1, the adhesion of leukocytes to 
endothelial cells in post-capillary venules prior to transendothelial migration is an 
early and critical step in inflammation. The expression of a range o f  cell-surface 
adhesion molecules is required for firm adhesion between leukocytes and endothelial 
cells and RONS are important regulators o f adhesion molecule expression.
One o f the first cell-surface molecules to be expressed in response to an 
inflammatory signal is the Weibel-Palade body-associated protein P-selectin, an 
endothelial cell protein that binds to counter receptors on circulating leukocytes. It 
has been know for several years that the cell-surface expression of P-selectin can be 
induced by ROS (Patel et a l, 1991). Further studies have confirmed this finding and 
have attempted to decipher the ROS signalling mechanism. In Terada et a l, 1997 and 
Folch et a l, 2000 the role o f H 2O 2 in P-selectin up-regulation was demonstrated. In 
the latter publication it was discovered that H 2O 2 activation of the enzyme Poly 
(ADP-ribose) synthatase (PARS) mediates the expression of P-selectin in pulmonary 
endothelial cells (Folch et al., 2000). To contradict these findings other publications 
have suggested a role for O 2 ~ in the upregulation of P-selectin expression (Suzuki et 
al., 1989; Gaboury et al., 1994). Also, studies have revealed that O 2 ” upregulates the 
expression o f endothelial platelet activating factor (PAF) (Gaboury et al, 1994; Folch 
et al, 2000), a protein that acts cooperatively with P-selectin in the binding of 
leukocytes, for example neutrophils (Zimmerman et al, 1990) (see Figure 18).
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Further analysis into ROS control over P-selectin expression has shown that 
thrombin-induced P-selectin expression is ROS-dependent. Takano et al., 2002 have 
demonstrated that thrombin-induced early expression o f P-selectin was reduced when 
inhibiting endogenous cellular ROS generators, thus suggesting that ROS may serve 
as signalling intermediates in this process.
Although the expression o f the adhesion molecule P-selectin may be rapidly 
upregulated by release from preformed stores, other adhesion molecules such as 
ICAM-1, VCAM-1, and E-selectin require synthesis before being expressed 
significantly. The role o f ROS in the regulation of ICAM-1 expression has been 
investigated, and the treatment of endothelial cells with ROS upregulates ICAM-1 
expression (Bradley et al., 1993; Lo et al., 1993). Similar to the thrombin-induced P- 
selectin release, TNF-a-stimulated endothelial cells regulate ICAM-1, VCAM-1, and 
E-selectin expression via ROS signalling intermediates, a process that may be 
inhibited by antioxidants (Chen et al., 2003). In this process ROS are believed to 
increase adhesion protein expression through the regulation o f the redox sensitive 
transcription factor NF-xB. A summary of ROS induced transcription is shown in 
Figure 9.
Nitric oxide appears to have an opposing role in the regulation of inflammation 
compared to ROS. Two lines o f evidence have suggested that N O  has a role in 
modulating leukocyte-endothelial cell interactions: 1) the inhibition of N O ’ 
generation by endothelial cells elicits the recruitment and adhesion o f leukocytes to 
endothelial cells (Kubes et al., 1991) and 2) the exposure o f NO-generating 
substances attenuates adhesion (Gaboury et al., 1993). The mechanism by which N O ’ 
modulates these processes is thought to be through its reaction with O2 ” (thus 
forming O N O O  ), leading to a reduction in the bioavailability o f ROS and therefore 
down-regulation of the ROS-mediated processes mentioned above. However, to 
complicate this theory the formation of O N O O - elicits leukocyte adhesion molecule
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expression via the Raf/M EK /Erk pathways (see Figure 9) which leads to leukocyte- 
endothelial association (Zouki et al., 2000), and has been shown to cause inflammation 
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Figure 9. Reactive Oxygen Species Control over Gene Expression.
Intracellular ROS signal changes in gene expression via redox-sensitive signal transducers, a group made up o f  
monomeric G-proteins (Ras and Rac), protein kinase C (PKC), the ratio o f  GSH and GSSG, and thioredoxin. 
ROS species promote nuclear translocation and binding o f  STAT (Signal Transducers and Activators o f  
Transcription) to promoter elements. NF-xB is usually maintained in the cytoplasm in an inactive form by the
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association o f the inhibitory factor I-xB. Upon stimulation I-xB dissociates and active NF-xB translocates to 
the nucleus. NF-xB activation is modulated by glutathione, thiredoxin and PKC. The AP-1 transcription factor 
is composed of a Jun and Fos heterodomer. AP-1 is activated by three MAP Kinase pathways that regulate the 
transcription of jun  and fos, and phosphorylate these proteins. The three transcription factors STAT, NF-xB, 
and AP-1 may act independendy or cooperatively to activation transcription of genes such as ICAM-1. 
(Adapted from Lum and Roebuck, 2001)
2.2 Endothelial Reactive Oxygen and Nitrogen Species 
Generators
Potential sources of RONS within the vascular endothelium include nitric oxide 
synthase, NAPDH oxidase, the mitochondrial electron transport chain, and xanthine 
oxidoreductase. Each generator has implications in pathological processes and 
therefore it is important to highlight the function of each generator in turn. Other 
endothelial sources o f RONS include cytochrome P-450 (Fleming, 2001).
2.2.1 Nitric Oxide Synthase
The Nitric Oxide Synthase (NOS) family o f enzymes, consisting o f neuronal NOS 
(nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS), (reviewed in 
Porasuphatana et al., 2003), are well documented for the generation o f N O ' from the 
oxidation o f L-arginine to L-citruline in an oxygen dependent process. However it has 
been demonstrated that each isoform is also capable o f generating O 2 ~ (reviewed in 
Porasuphatana et al., 2003). The constitutively expressed isoform eNOS is a 
functionally active as a homodimer. Each monomer is composed of a flavin- 
containing C-terminal domain with binding sites for flavin adenine dinucleotide, 
flavin mononucleatide, and NADPH, and a catalytic N-terminal oxygenase domain 
with binding sites for L-arginine and tetrahydrobiopterin (BH4). 
Calcium/calmodulin-activated eNOS generates N O ’ in the presence of the 
ubiquitous pterin cofactor BH4. However the absence of functional BH4 switches 
activated eNOS to generate O 2 ~ (Vasquez-Vivar et al., 1998; Vasquez-Vivar et al, 
2003), which is often referred to as “uncoupling”. Interestingly BH4 is susceptible to 
oxidative degradation. It has been shown that the oxidative loss o f functional BH4 by 
increased ROS generation, by NADPH oxidase for example (Landmesser et al., 2003),
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amplifies oxidative stress through the resultant loss in N O  generation and increased 
NOS-dependent O 2 ~ production.
2,2.2 NADPH Oxidase
The O 2 "-generating enzyme NADPH oxidase has been well characterised in the 
phagocyte (Hancock, 1999). NADPH oxidase is located in the plasma membrane and 
within the membrane of specific granules of neutrophils. The enzyme consists of four 
components required for activity: a heterodimeric membrane-associated
flavocytochrome bsss, composed of gp91 -phox and p22-phox, and cytoplasmic 
components pM-phox, pGl-phox, and GTPase Racl or Rac2. Upon neutrophil 
stimulation the cytoplasmic components associate with the membrane-bound 
cytochrome to form an active enzyme complex that catalyses the production of O 2 ~ 
essential for host defence (see
Figure 10). In recent years it has become clear that endothelial cells express an O 2 ”- 
generating enzyme analogous to phagocyte NADPH oxidase (Bayraktutan et al., 2000; 
Gorlach et al., 2000; Li and Shah, 2002). The endothelial-NADPH oxidase differs 
from that of the neutrophil as it continuously generates a low level of O2 ~ in 
unstimulated cells and O 2 ~ generation occurs mainly intracellularly (Li and Shah, 
2002).






p h o x
N A D P H
Figure 10. Superoxide Generation by NADPH Oxidase.
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The membrane-bound, functional, N A D P H  complex o f  the neutrophil catalyses the production o f  
O 2 from the substrates O 2 and N A D P H , note O 2 ” generation occurs mainly in the extracellular 
compartment.
2.2.3 Mitochondrial Electron Transport Chain
The electron transport chain (ETC) o f mitochondria has been recognised as one of 
the major cellular generators of ROS, known to generate O 2 and H 2O 2, (Loschen et 
a l, 1971; Loschen et al, 1974). Electrons donated to the chain by N A D H  or succinate 
are passed along a series o f electron carrier molecules (complexes I-IV, ubiquinone 
[Q], and cytochrome c [C]) embedded in the inner mitochondrial membrane. At each 
transfer electrons fall to a lower energy state and released energy is used to maintain 
an electrochemical proton gradient across the inner mitochondrial membrane. The 
gradient drives a flux of electrons through an enzyme, ATP synthase, thus generating 
ATP, “cellular energy”. Electrons are believed to leak from the ETC, from complexes 
I and III (Turrens and Boveris, 1980; Turrens et al, 1985; St-Pierre et a l, 2002), and 
reduce O 2 forming O 2 ~ (see Figure 11) that can be dismutated by mitochondrial 
SOD thus forming H 2O 2 (Loschen et al., 1974). It has been stated that 2% of electron 
flow during mitochondrial respiration gives rise to H 2O 2 (Chance et a l, 1979), which 
would indicate significant ROS species generation. However, experimental evidence 
which proves that mitochondria are a source of ROS under physiological conditions 
is lacking (Forman and Azzi, 1997; Staniek and Nohl, 2000; St-Pierre et a l, 2002) as 
procedures used to demonstrate O 2 ~ and H 2O 2 generation by the ETC disrupt 
normal antioxidant function and/or the ETC. In Staniek and Nohl, 2000, it was 
discovered that intact mitochondria could not be made to release H 2O 2. However it 
has been concluded that mitochondria could be a significant source o f  ROS under 
certain conditions, for example insufficient ROS scavenging by SOD or catalase or 
the presence o f free transition metals that could initiate Habor-Weiss or Fenton 
chemistry.
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Figure 11. Superoxide Formation by the Mitochondrial Electron Transport Chain.
Leakage o f  electrons (e ) from the mitochondrial ETC complexes I and III are believed to be 
responsible for the reduction o f  O 2 thus forming O 2' (arrows indicate electron movement through 
the electron carrier molecules o f  the ETC)
2.2.4 Xanthine Oxidoreductase
The enzyme Xanthine Oxidoreductase (XOR), first identified over 100 years ago 
(Schardinger, 1902), belongs to a family of molybdenum cofactor-containing enzymes 
which also includes Sulphite oxidase, Aldehyde oxidase, and DMSO reductase (Kisker 
et al., 1997; Garattini et al., 2003). XOR exists as one of two interconvertible forms, 
xanthine oxidase (XO) and xanthine dehydrogenase (XDH), which historically have 
been differentiated by their oxidizing substrate, i.e. XO reduces oxygen, whereas 
XDH preferentially reduces nicotinamide adenine dinucleaotide (oxidized) (NAD+) 
(Waud and Rajagopalan, 1976). XOR may oxidise a variety of compounds including 
purines, pteridines, and aldehydes. However hypoxanthine and xanthine appear to be 
physiological substrates for XOR, and therefore XOR has been assigned the 
physiological role of catalysing the terminal two steps in purine degradation; the 
conversion of hypoxanthine to xanthine to uric acid (Berg et al., 2001). All mammalian 
XOR’s are inhibited by allopurinol, one of the oldest and most selective inhibitors of 
XOR (Massey et al., 1970).
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As XOR is the principal enzyme reported on in this thesis, the enzyme will be 
reviewed in sufficient detail for understanding o f experimental chapters.
2.2.4.1 Gene and Protein
2.2.4.1.1 The gene
The evolutionary conserved gene xanthine oxidoreductase (xor) has been sequenced in 
many organisms from bacteria to man (Ichida et al., 1993; Xu et al., 1994; Cazzaniga et 
al., 1994; Kunst et al., 1997; Schultz et al., 2001). Human xor has been mapped to a 
single locus on the p22 band o f chromosome two (Xu et al., 1994) and is composed of 
36 exons and 35 introns that span at least 60 000 nucleotide bases (Xu et al., 1996). 
The mouse xor ge.ne, for example, has a similar composition but is about lOkb longer 
(Cazzaniga et al., 1994), however the organisation of the xor gene in insects is 
significandy different. The Drosphila melangaster xor gene is composed o f just four 
exons (Keith et al., 1987). Interestingly, the four exon/intron junctions o f the D. 
melangaster xor gene are retained at exactly the same positions of corresponding 
junctions in the human gene, thus suggesting that the division of the xor gene into 
more exons has occurred during evolution (Xu et al., 1996).
2.2.4.1.2 Transcriptional Control
In general, XOR activity in humans is low compared to other mammalian species (see 
XOR tissue distribution section), thus indicating a potential difference in control over 
human XOR expression and/or posttranslational activity. Investigations by Xu et al., 
2000 have produced a model whereby the human xor gene is repressed. They 
discovered that the human xor gene is suppressed by factors bound to upstream E- 
box and TATA-like elements. The TATA-like element is not found in other 
mammalian species such as the mouse (Cazzaniga et al., 1994) and may account for 
differences in XOR activity between species. However human XOR gene expression, 
as in other mammals, is know to be activated in response to various stimuli.
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In 1996 the 5 '-flanking region o f the human xor gene consisting of approximately 
2000 nucleaotide base pairs was analysed for consensus sequences of potential 
promoter elements (Xu et al., 1996). Potential binding sites for factors involved in 
inflammation and the acute phase response (a response characterised by a 
coordinated change in the production of plasma proteins acting to protect the host) 
were discovered. These sites included, four CCAAT/enhancer binding protein 
binding sites, three IL-6 responsive elements, a NF-xB site and potential tumour 
necrosis factor-, interferon-y-, and interleukin-1-responsive elements. Indeed, the 
treatment of cell cultures with tumour necrosis factor-a (TNF-a), interleukin-1 (3 (IL- 
1 p), interleukin-6 (IL-6), and interferon-y (INF- y) have lead to the increase in xdh 
gene expression (Pfeffer et al., 1994; Page et al., 1998). Therefore suggesting 
expression of xdh during an inflammatory episode and potentially a role for XOR in 
inflammation.
Further regulatory factors include the ubiquitous transcription factor, Nuclear Factor- 
Y (NF-Y), its binding to the human xor gene promoter sequence, CCAAT motif 
(Mantovani, 1998), has been demonstrated to enhance promoter activity (Martelin et 
al., 2000). NF-Y functions through the interaction with TATA-binding proteins 
(Bellorini et al., 1997), and promotes the binding of other TFs to nearby sequences 
(Mantovani, 1999). Also xor expression is under hormonal control. Treatment of 
cultured mouse mammary epithelial cells with prolactin and cortisol led to elevated 
levels o f XOR mRNA (McManaman et al., 2000).
2.2.4.1.3 Amino-Acid sequence
The amino acid sequence o f human XOR protein contains 1333 residues that have 
been calculated to form a protein with a molecular weight o f 146.6 kilodaltons (kDa) 
(Ichida et al., 1993). The sequence length in other species is homologous, for example 
compared to the cow, mouse, rat, and insect, residue number only differs + /-  two 
amino acids (Keith et al., 1987; Amaya et al, 1990; Terao et al., 1992; Berglund et al.,
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1996). Avian X DH on the other hand contains 1358 residues due to additional amino 
acids at the N H 2-terminal portion (Sato et al., 1995).
Human XOR protein expression is highest in the liver, small intestine, and the 
lactating mammary gland (Linder et al., 1999; Harrison, 2002). The presence of XOR 
in other tissues has been investigated, but results from separate studies are 
contradictory. However, using sensitive detection methods XOR has been found in 
other tissues including the heart, lung, kidney Qarasch et al., 1986). Significantly, XOR 
protein has been located in the human vascular endothelium Qarasch et al., 1981) and 
in the serum (Battelli et al., 1999), therefore XOR is distributed throughout the body.
In the past the subcellular localisation of XOR was thought to be solely cytoplasmic 
(Ichikawa et al., 1992). However, more recent studies have shown that intracellular 
XOR has a punctuate stain, suggesting vasicularisation, and may also have a 
perinuclear location (Rouquette et al., 1998). Also, XOR is found in peroxisomes of 
rat heptaocytes (Frederiks and Vreeling-Sindelarova, 2002) and on the endothelial and 
epithelial cell surface of human cells (Rouquette et al., 1998), probably by association 
with cell surface glycosaminoglycans (GAGs) (Adachi et al., 1993).
The XOR enzyme, a non-glycosylated protein, exists as a homodimer forming a 
290kDa protein (Enroth et al., 2000). The two subunits are traditionally thought to be 
catalytically independent, however a recent study has shown that catalysis is 
“cooperative” in the homodimer subunits (Tai and Hwang, 2004). That is, in the 
presence of substrate at one active site affects the affinity of substrate binding at the 
other, and if both active sites where filled, conversion rate is increased by 2.95 fold 
compared to only one being filled.
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2.2.4.2 Cofactor Synthesis and insertion
A substantial part of all biological reactions rely on the action o f cofactor-dependent 
enzymes. The final two steps o f purine metabolism are no exception, as they require 
the catalytic activity o f the cofactor-dependent enzyme XOR. For a full spectrum of 
catalytic activity, the XOR apoenzyme monomer requires the posttranslational 
insertion of four cofactors into four distinct redox centres; one molybdenum cofactor 
(MoCo), two non-identical iron-sulphur clusters (of the 2Fe-2S type) and one flavin 
adenine dinucleotide (FAD) moiety, forming the MoCo-, two Fe-S- and FAD- 
containing redox centres respectively (Massey et al, 1969). In addition to cofactor 
insertion, the XOR enzyme can undergo another important posttranslational 
modification, the conversion o f X DH to XO which can have significant bearing on 
catalytic activity. These processes are discussed below.
2.2.4.2.1 Molybdenum Cofactor Synthesis and Insertion
Molybdenum cofactor biosynthesis is an evolutionary conserved pathway essential for 
cofactor production for a diverse group o f redox enzymes including, XOR, aldehyde 
oxidase, and sulphite oxidase (Kisker et al., 1997). In humans, mutations in MoCo 
biosynthetic genes leads to MoCo deficiency (Reiss and Johnson, 2003), a disease that 
is manifested as severe neurological abnormalities, including seizures and attenuated 
brain growth that are mainly associated with lack of sulphite oxidase activity. Many of 
the details regarding the MoCo biosynthetic pathway have arisen from mutation 
studies in Escherichia Coli (Rajagopalan, 1997), however the enzymes involved in the 
human pathway have recently been described (Reiss and Johnson, 2003) and are 
summarised in Figure 12.
The amino acid sequences o f the MoCo contact and insertion in human XOR have 
been indicated in Ichida et al., 1993 but are described in more detail for Cape buffalo 
and cattle XOR (Wang et al., 2002). The sequences given in Wang et al., 2002 are 
highly conserved in human XOR (Ichida et al, 1993) and it is likely that they 
correspond.
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Human Molybdenum Cofactor Sulphurase
Molybdenum Cofactor 
(Active, sulpho)
Figure 12. The Human Molybdenum Cofactor Biosynthesis Pathway.
The steps involved in M oCo biosynthesis can be split into three stages: i) Conversion o f  guanosine 
derivative into Precursor Z, ii) Transformation o f Precursor Z into molybdopterin (MPT), and iii) 
Metal incorporation. The mechanism o f Precursor Z formation (i) has not yet been determined, 
however it is known to be formed from a guanosine derivative and requires the MOCS1A and 
MOCS1B proteins for conversion. The transformation o f  Precursor Z into molybdopterin (MPT) (ii) 
is catalysed by MPT synthase (MOCS2A and MOCS2B), requires MPT synthase sulphurylase 
(MOCS3) for activity, and is responsible for the generation o f  a dithiolene group that is required for 
Molybdenum (Mo) insertion. The final step in MoCo biosynthesis is the incorporation o f  Mo into 
MPT (iii) and is catalysed by Gephyrin. In XOR the inactive “desulpho” MoCo is converted to its 
active “sulpho” form by human molybdenum cofactor sulphurase (Ichida et al., 2001). This final 
conversion step is also required for active aldehyde oxidase, however active sulphite oxidase utilizes 
the desulpho MoCo form.
2.2A.2.2 Iron-Sulphur Cluster Synthesis and Insertion
The formation of the Fe-S cluster is not spontaneous but requires a consortium of 
highly conserved proteins for their synthesis (Frazzon et al., 2002). The proteins
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required for the synthesis o f Fe-S clusters for the metallocentres o f the nitrogenase 
enzyme in A^otobacter vinelandii have been characterised and will be described here, as 
the process is applicable to Fe-S cluster synthesis in humans. Three key proteins are 
required for the synthesis process, NifS, NifU, and CysEl, but others form a greater 
repertoire (Frazzon et al., 2002). The NifS protein uses L-cysteine as a substrate to 
form a NifS-cysteine persulphide complex that is thought to contain the source of 
sulphur for the Fe-S cluster. NifU, which is believed to provide a molecular scaffold 
for Fe-S synthesis may complex with NifS-cysteine persulphide which donates 
sulphur, thus forming the NifS-NifU-sulphur complex and following the acquisition 
o f iron, Fe-S cluster synthesis occurs on the NifU scaffold. Finally, the CysEl 
protein, a homologue of serine acetyltransferase (a rate limiting enzyme in cysteine 
biosynthesis), probably serves to boost the generation o f L-cysteine (the substrate of 
NifS).
The insertion o f the Fe-S cluster occurs by a mechanism that is currently not 
understood (Frazzon et al\, 2002). However, the amino acid sequence for the insertion 
o f the two 2Fe-2S clusters has been described for XOR (Ichida et al., 1993; Nishino 
and Okamoto., 2000).
Interestingly, cellular iron levels have been shown to be critical for XO activity. In cell 
culture and animal studies it has been demonstrated that iron depletion results in 
markedly reduced XO activity, which may be associated with an increase in the 
proportion o f iron-lacking apoenzyme, and an increase in XO activity is measured 
when intracellular iron concentration is increased (Martelin et al., 2002; Ghio et al., 
2002). These findings are of clinical importance as the release o f cellular-stored iron 
following ischaemia (Huang et al., 2001) could contribute to increased XO activity as 
part o f XO mediated ischemia-reperfusion injury (McCord , 1985).
2.2.4.2.3 Flavin Adenine Dinucleotide Synthesis and Insertion
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Flavin adenine dinucleotide is synthesised from riboflavin (Vitamine B2) and two 
molecules of adenosine triphosphate (ATP) by a series of reactions catalysed by 
riboflavin kinase (EC 2.7.1.26) and FAD synthase (EC 2.1.1.2) (Berg et al., 2001), see 
Figure 13. The Synthesis of Flavin Adenine Dinucleotide.
Details of the flavinylation process (FAD-cofactor insertion) of the XDH apoenzyme 
have not been published. However flavinylation o f other enzymes, for example 
monoamine oxidase and vanillyl-alcohol oxidase, have been investigated and is 
believed to occur by an autocatalytic process (Edmondson and Newton-Vinson, 
2001; Fraaije et al., 2000). Although there is evidence for autocatalytic flavinylation o f 
several enzymes, flavinylation of the mitochondrial matrix enzyme dimethylglycine 
dehydrogenase (Me2GlyDH) precursor is strictly dependent on the presence o f 
mitochondrial proteins. It is believed that a mitochondrial flavinylation stimulating 
factor is required to promote holo-Me2GlyDH formation (Brizio et al., 2002). As the 
XDH apoenzyme is expressed in the cytoplasm it is unlikely that a mitochondrial 
flavinylation stimulating factor is responsible for the flavinylation process. Therefore 
flavinylation o f X DH apoenzyme is more likely to be via an autocatalytic process, 
although further more specific work is required in this area.
The amino acid residues that are believed to be.required for FAD cofactor binding 
into the XDH apoenzyme have been predicted and are conserved between many 
species (Wang et al., 2002). In comparison to the MoCo and Fe-S redox centres, 
naturally occuring FAD-lacking XOR (deflavo) has not so far been described.
EC 2.7.1.26
Riboflavin + ATP _ Riboflavin 5 '-Phosphate + ADP
EC 2 7 7 2
Riboflavin 5 "-Phosphate + ATP ^  FAD + PPi
Figure 13. The S yn thesis  of Flavin Adenine Dinucleotide.
The synthesis o f  FA D  from riboflavin is catalysed by riboflavin kinase and FAD synthase, 
respectively, and requires two molecules o f  ATP per FAD molecule formed.
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2.2.4.3 Xanthine Dehydrogenase -  Oxidase Conversion
Historically the XOR enzyme form, either XDH or XO, has been differentiated by
the preference of oxidising substrate, either NAD+ or O 2, respectively. As will be 
discussed in a later section (see Xanthine Oxidase and Vascular Pathology), the form 
of the XOR enzyme has a bearing on catalytic activity, physiological processes and 
the aetiology of several pathological conditions. The XOR protein is apparently 
expressed as XDH in tissues but can be converted, either reversibly or irreversibly, to 
XO by posttranslational modification (Stirpe and Della Corte, 1969; Della Corte & 
Stirpe, 1972).
XDH can be reversibly converted to XO via heating or oxidation o f cysteine thiols of 
XDH to form intra-subunit disulphide bonds (Stripe and Corte, 1969; Corte and 
Stirpe, 1972), a process that is reversible by treatment with agents such as 
dithiothreitol (Corte and Stirpe, 1972). Structural and conformational analyses of the 
reversible conversion process have been investigated (McManaman and Bain, 2002). 
These studies have shown that significant disulphide bonding occurs in the N- 
terminal region, but not between the N- and C-terminal regions and it seems likely 
that the conversion process requires a structural change within the Phe 560- 
containing region. Residues Cys 535 and Cys 992 have been shown to be critical in 
the disulphide bond formation process but probably form bonds with so far 
unidentified cysteine residues.
XDH may also be irreversibly converted to XO via limited proteolytic cleavage 
(Stirpe and Della Corte, 1969) that can occur in the presence o f proteases, low oxygen 
tension, and in response to inflammatory cytokines (Friedl, et a l, 1989; Meneshian 
and Bulkley, 2002). The determination o f the crystal structure o f both XDH and XO 
has allowed detailed studies into a structural-based mechanism of the irreversible 
conversion process (Enroth et al., 2000). It was discovered that in X D H , two closely 
associated side chains, one around Phe 549 and the other from Arg 427, may be cut 
causing a structural rearrangement in another highly charged loop, Gin 423-Lys 433,
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close to the FAD cofactor. The rearrangement of loop Gin 423-Lys 433 is thought to 
block the access o f the N A D + acceptor substrate and alter the local electrostatic 
environment of the FAD cofactor, therefore reflecting the shift in preferred oxidising 
substrate from N AD+ in X DH to O 2 in XO.
A study published in 2003 (Kuwabara et al., 2003) confirmed that both reversible and 
irreversible XDH-XO conversion processes result in a conformational change in the 
active loop (Gin 423-Lys 433). It was also noted that the conformational change in 
the active loop opens a solvent channel leading to the FAD-moiety, allowing easier 
access for molecular oxygen.
2.2.4.4 Reactive Oxygen and Nitrogen Species Generation
The ability o f XOR to generate a diverse range of RONS has been the driving force
for the intense study o f the XOR enzyme. The XOR-generation of the reactive 
oxygen species O 2 H 2O 2 (see Figure 14), and ’OH, and the reactive nitrogen 
species N O ’ and O N O O " have been demonstrated (Kuppusamy and Zweier, 1989; 
Millar et al., 1998; Godber et al., 2000) and are dependent on substrate availability in 
the microenvironment in which XOR is situated.. The hypothesised scheme for O 2 ~ 
and H 2O 2 generation during the re-oxidation of reduced XO with O 2 was confirmed 
in 1981 (Porras et al., 1981) and is summarised in Figure 15. It was concluded that a 
fully reduced (six electron reduced) XO monomer could generate two H 2O 2 and two 
O 2 ~ molecules.
2-40








Figure 14. Generation of Reactive Oxygen Species by Xanthine Oxidase.
Highlighted are the redox centres (Mo =  Molybdenum Cofactor; Fe-S = Iron-Sulphur Clusters; FAD  
= Flavin Adenine Dinucleotide Moiety) and substrates required for O 2 ~ and H 2O2 generation by 
XOR (Electron movements between the centres are represented by dashed-line arrows). Electrons 
involved in the reduction o f XO are derived from the oxidation o f hypoxanthine or xanthine, for 
example, and O 2 ~ and H 2O 2 are generated via the oxidation o f  reduced XO by O 2. However, XOR  
also possesses N A D H  oxidase activity. Electrons donated to XOR during N A D H  oxidation may be
used in the reduction o f  O 2 thus forming O 2 " and H 2O 2 (Sanders et al., 1997). Catalysis o f  this
process is much quicker by dehydrogenase than the oxidase enzyme form. Also, X D H  has been 
shown to generate O 2 ” and H 2O 2 in the presence o f  xanthine as a reducing substrate (Harris and 
Massey, 1997), although the generation o f  ROS occurs at about 16 % o f  the rate o f XO catalysis.
h 2o 2 h 2o 2 o 2 o 2
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Fast-Phase Slow-Phase
Figure 15. The Proposed Scheme of XO Oxidisation with Oxygen.
In each o f the oxidation steps with O 2 (except the last), O 2 can bind to the fully reduced FAD-moiety  
and an electron is transferred, thus forming the flavin semiquinone-superoxide complex. When the 
enzyme contains more than two electrons, fully reduced FAD is regenerated so rapidly that a second 
electron can be passed to flavin semiquinone-superoxide complex, and form H 2O2 before O 2 can 
diffuse out o f  the FAD-active site. The two electron oxidation process, forming H 2O 2, continues 
until XO(2) is formed. Following the subsequent binding o f  O 2 to XCK2) one electron is transferred to
2-41
Jill  l i e s  I l e w  i list in Pi l l )  T h e s i s
form O 2 , however fully reduced FAD cannot be regenerated, therefore O 2' is released. The XQW 
enzyme only has the potential to form the flavin semiquinone-active site that may generate O2 but at 
a much slower rate than the previous oxidations. The release o f  H 2O 2 is confined to the fast-phase of 
enzyme-oxidation and the release o f  O 2" occurs at the close o f the fast-phase and in the slow phase of 
oxidation (adapted from Porras et al, 1981). The generation o f  ROS by NADH-reduced XOR 
follows the same scheme, but only from XOW, as N A D H  will not reduce XOR beyond this point 
(Hunt and Massey, 1994). (n) represents the electron number contained within the enzyme.
The discovery of XOR-nitric oxide synthase and -peroxynitrite synthase activity has 
added further interest to the XOR enzyme. The initial discovery that XOR is capable 
of reducing organic and inorganic nitrate to nitrite, and nitrite to N O ', under hypoxic 
conditions, was made in 1998 (Millar et a l, 1998) (see Figure 16A). XOR as a 
peroxynitrite synthase has been the subject of a recent review (Millar et al., 2002) and 














Figure 16. Reactive Nitrogen Species Generation by Xanthine Oxidoreductase.
A) T he generation o f  N O '. Under hypoxic conditions, electrons required for the reduction of 
nitrate to nitrite and nitrite to N O ' are derived from either hypoxanthine, xanthine, or NADH  
oxidation. The reduction o f inorganic nitrates and nitrites is thought to occur at the MoCo whereas 
organic nitrates and nitrites are likely to be reduced at the FAD cofactor (Millar et al., 1998; Doel et 
al., 2001). B) T he generation o f  O N O O '. Under hypoxic conditions XOR can generate N O ', 
however if  O 2 concentrations rise to around 70 pM (Millar, 2004), pairs o f  electrons derived from 
either hypoxanthine, xanthine, or N A D H , can be used to reduce nitrite or O 2 (the preferred 
substrate), therefore generating N O ’ and O 2 ", respectively. N O ’ and O 2 ” can react together forming 
ONOO" (Huie and Padmaja, 1993).
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2.2.4.5 X anthine O x idase  and  V ascu la r-A ssoc ia ted  Pathology
Chronic endothelial dysfunction is associated with several cardiovascular disorders 
including atherosclerosis, heart failure, and hypertension (reviewed in Li and Shah, 
2004). The term vascular dysfunction covers a range o f abnormalities but the most 
widely studied is the loss of N O ’ bioavailability which can promote pro-inflammatory 
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Figure 17. The Regulation of Vascular Tone, Inflammatory, and Thrombotic Environments 
by Reactive Oxygen and Nitrogen Species.
Under physiological conditions (left hand side o f diagram) levels o f  N O  - gready exceed those o f  O 2 ” 
and antioxidant systems are sufficiendy expressed to detoxify comparatively low levels o f ROS. 
Under these conditions the action o f NO ' gives good control over vascular tone, and an anti-
2-43
Jiiines I lew i iis tu i P h D  T h e s is
inflammatory and anti-thrombotic environment. However, under periods o f  oxidative stress, i.e. 
when antioxidant systems are overrun by levels o f  ROS, the bioavailability o f  N O ' is reduced and 
results in loss o f  control over vascular tone and a pro-inflammatory and pro-thrombotic environment 
arises. N O ' bioavailability may be reduced by several ways: reduced expression o f  N O S, deficiency o f  
N O S substrate or cofactors (especially B H 4), and by the fundamentally important mechanism, 
increased inactivation o f  N O ' by O 2 ~ (adapted from Cooper et al., 2002).
Although this section focuses on the role of XOR-generated ROS in vascular 
pathology, other ROS generators, for example NADPH oxidase and un-coupled 
NOS, are likely to contribute to the aetiology of the disease states mentioned.
2.2.4.5.1 Xanthine Oxidase and Heart Failure
Chronic Heart Failure (CHF) is a complex clinical syndrome characterised by reduced 
cardiac contractile function, increased vasoconstriction, decreased vasodilator 
response during exercise, and reduced peripheral perfusion (Linke et al., 2003). These 
symptoms have previously been attributed to reduced cardiac myocyte function. 
However it is now believed that a vascular component contributes to heart failure, 
and the endothelium forms a potential therapeutic target for the condition (Linke et 
al., 2003). The contributing vascular component is likely to be N O ’, or lack of, as a 
reduction in the production o f N O ’ by eNOS (Smith et a l, 1996) or the depletion 
N O ' bioavailability by increased O 2 ~ (Miinzel and Harrison, 1999) are know to be 
involved in heart failure.
As the generation of O 2 ” has a significant function in the aetiology of CHF 
researchers have investigated the role o f ROS-generating enzymes in this disease. The 
contribution o f XO to CHF in human subjects has been investigated. In studies by 
Landmesser et al., 2002 endothelial-bound XO and ecSOD levels were measured (via 
a bolus dose o f heparin and subsequent release o f the two enzymes into the plasma) 
in patients with CHF and controls. Compared to controls it was discovered that 
ecSOD activity was reduced in CHF patients and correlated with flow-dependent, 
endothelium-mediated vasodilation (FDD) (i.e. with reduced ecSOD a reduced 
vasodilatory response was observed), whereas XO activity was significantly increased
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and was inversely related to FDD. Also, in CHF patients FD D  response was 
improved by vitamin C administration, whereas no such improvement was seen in 
controls. These results suggest that increased XO-ROS generation and reduced 
ecSOD activity are responsible for increased oxidative stress and therefore endothelial 
dysfunction in CHF.
The beneficial effect o f vitamin C in improving endothelial function in CHF patients 
has also been shown in Hornig et al., 1998. However, evidence for a role of XO- 
generated ROS in CHF is better provided in experiments where the XOR-inhibitor 
allopurinol is given to patients (reviewed in Landmesser and Drexler, 2002). In 
Farquharson et al., 2002, CHF patients were administered allopurinol or placebo and 
endothelial function was measured by a change in forearm blood flow (FBF) in 
response to acetylcholine stimulation (which should stimulate vasodilation and 
therefore increased blood flow). Allopurinol treatment significantly improved FBF 
and reduced oxidative stress in the vasculature, and therefore improves endothelial 
dysfunction in CHF patients. These findings are supported by other studies 
suggesting improved peripheral vasodilator capacity with allopurinol treatment 
(Doehner et al., 2002).
2.2A5.2 Xanthine Oxidase and Coronary Heart Disease
Coronary heart disease (CHD) is a condition where the vascular supply to the heart is 
impeded. This may impair the supply of oxygenated blood to cardiac tissue 
sufficiently to cause myocardial ischemia, which if prolonged may present with death 
o f cardiac tissue or with pain (angina) if reversible. A reduction in blood supply may 
be caused by thrombosis, spasm o f coronary arteries, or widespread atherosclerosis. 
O f these causes, the vast majority o f CHD occurs in patients with atherosclerosis of 
the coronary arteries.
The formation of an atherosclerotic plaque is responsible for the narrowing of the 
blood vessel and reduction in blood flow that can be responsible for myocardial
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ischemia. Plaque formation is initiated by the transendothelial migration of monocytes 
and the accumulation o f “fatty streaks” which contain lipid rich macrophages and T  
lymphocytes. Following the formation of “fatty streaks” smooth muscle cells may 
migrate into the tunica intimae and proliferate. The smooth muscle cells together with 
fibroblasts can secrete collagen, proteoglycans, elastin, and glycoproteins that form a 
fibrous cap termed a plaque (Walker and Edwards, 2003).
Traditional causes of atherosclerosis include hypercholesterolemia and heavy smoking 
that both affect the endothelium by increasing the generation o f ROS. Increased ROS 
production decreases NO ' bioavailability, which leads to vascular dysfunction and to a 
proinflammatory state, as summarised in Figure 17. The contribution of NADPH 
oxidase to the formation o f the atherosclerotic plaque is reviewed in Li and Shah, 
2004, however XO has also been implicated in this pathology. Spiekermann et al., 
2002 compared XO activities in CHD patients v’s controls. Subcellular fractionation 
of vessel homogenates, and heparin injection into subjects, revealed that endothelial- 
bound XO activity was significantly increased in CHD patients compared to controls, 
(a study comparable to that performed by Landmesser et al., 2002 in the above 
section). Also, treatment o f patients with vitamin C significantly improved FDD 
whereas as no change was seen in controls, which was also discovered in Landmesser 
et al., 2002. Therefore, these findings underline the suggestion that endothelial 
dysfunction due to reduced N O  bioavailability is common in the aetiology of various 
vascular pathologies.
In support of a role for XO in CHD, other publications suggest XO provides a link 
between the traditional causes of atherosclerosis (i.e. heavy smoking and 
hypercholesterolemia) and endothelial dysfunction that can lead to the disease itself. 
In heavy smokers, inhibition of XO by the administration o f allopurinol improved 
endothelial dysfunction, whereas no such effect was seen in controls (Guthikonda et 
al., 2002). Also, the level o f circulating XO in hypercholesterolemic rabbits is
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increased two-fold and is associated with reduced endothelial-dependent 
vasorelaxation. Due to improved vasorelaxation in the isolated aorta following 
heparin, allopurinol, or SOD treatment, it was suggested that increased circulating 
XO results in an increase in endothelial-bound enzyme that interferes with N O  - 
dependent relaxation via O 2 ~ generation (White et al.9 1996).
2.2.4.5.3 Xanthine Oxidase and Acute Respiratory Distress Syndrome
Inflammation o f the pancreas, pancreatitis, can be classified as acute or chronic.
Acute pancreatitis is usually caused by excess alcohol consumption or by gallstones 
and is sudden, lasts for a short period of time, and resolves itself. Whereas chronic 
pancreatitis does not resolve itself and results in the slow destruction of the pancreas. 
Acute pancreatitis is often associated with systemic complications including 
pulmonary dysfunction, observed in about 50% o f human patients (Folch et a l 2000). 
Respiratory dysfunction is often mild and reversible but in one third of cases can lead 
to Acute Respiratory Distress Syndrome (ARDS), the most important factor 
contributing to death in these patients (Willemer et al.y 1991).
The development o f the inflammatory response in the lung is reliant on interactions 
of circulating leukocytes with the pulmonary vascular endothelium, and the 
subsequent activation and migration o f leukocytes into the lung parenchyma. As 
mentioned in section 1.5.2., this process is controlled by interactions between 
leukocyte and endothelial cell receptors and ligands. P-selectin, found integrated into 
the surface o f WPBs, is one of the first cell surface receptors to be expressed on the 
endothelial cell surface in response to inflammatory stimuli, and is responsible for the 
initial leukocytes binding events.
Until recently the mechanism by which inflammation in the pancreas leads to 
secondary inflammation in the lung was unknown, however it was thought to be a 
neutrophil and O 2 ' "-mediated event (Guice et al., 1989; Inoue et al.y 1995). Studies 
have suggested that XO-generated ROS can induce lung damage in vivo and
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neutrophil adhesion to cultured endothelial cells (Johnson et al, 1981; Ichikawa et a l,
1997), and a potential mechanism that describes circulating XO as a link between the 
two pathologies has been suggested in a series of papers (Folch et al., 1998; 1999; 
2000). In the Folch et al investigations, pancreatitis was induced in rats by an injection 
o f sodium taurocholate into the biliopancreatic duct. Following pancreatitis induction, 
P-selectin expression on the endothelium o f various organs was measured and was 
shown to be significantly upregulated in the lung and pancreas only, whereas ICAM-1 
expression was unaffected (Folch et a l, 1999). As predicted, the upregulation of P- 
selectin appears to be responsible for neutrophil accumulation seen at the lung, as this 
was attenuated by the administration o f anti-P-selectin during pancreatitis induction 
(Folch et al, 1999). The upregulation o f P-selectin expression was shown to be by an 
oxidant-mediated process in experiments where the administration o f antioxidants 
(SOD and catalase) reduced P-selectin expression to control levels (Folch et a ly 2000). 
Results indicate that three hours after pancreatitis induction (the time it takes for 
inflammation to be seen at the lung) there is a significant rise in circulating XO 
activity (Folch et a l, 1998). The induction of P-selectin expression and neutrophil 
infiltration in the lung was attributed to the rise in circulating XO as this process was 
inhibited with the administration o f the specific XO-inhibitor oxypurinol (Folch et a l, 
1998; Folch et a l, 1999). Further analysis into the mechanism of XO-upregulated P- 
selectin expression and neutrophil binding was carried out in Folch et a l, 2000 and is 
reviewed in Figure 18.
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Figure 18. Xanthine Oxidase Regulated Expression of Endothelial Adhesion Molecules.
The suggested mechanism whereby XO-generated ROS upregulate the expression o f  endothelial- 
leukocyte receptors. XO  catalysed ROS induce the cell-surface expression o f  platelet activating factor 
(PAF) and P-selectin, which subsequently bind circulating leukocytes. PAF expression is likely to be 
regulated by O2 ”, whereas H2O 2 can upregulate P-selectin expression via a mechanism involving poly 
(ADP-ribose) synthetase. Extracellular expression o f ROS species, especially the membrane- 
permeable ROS H 2O 2, could also contribute to this process. (Adapted from Folch et al., 2000)
But why is the lung affected by the rise in circulating XO more so than other organs 
of the body? It has been hypothesised that as XO requires molecular oxygen to 
generate ROS, the concentration o f free oxygen in the lung capillaries is sufficient for 
XO-ROS-mediated P-selectin expression. In the blood and in other organs the 
concentration of free oxygen is less and is not sufficient for such a response. In a 
recent paper with Folch, E. (Granell et al., 2004) this hypothesis was investigated. 
Pancreatits was induced as in previous experiments, however rat lungs were 
cannulated and one was ventilated with air and the other with nitrogen. P-selectin 
expression and inflammation were compared between the lungs. Results 
demonstrated that in the absence of oxygen, XO-mediated P-selectin expression did 
not occur and inflammation was significantly reduced, indicating that only free- 
oxygen concentrations in the lung are sufficient to cause this response.
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Acute pancreatitis is not the only pathological example where an increase in 
circulating XO-activity occurs, circulating levels o f  XO  also increase in liver disease 
(Battelli et al., 2001), thermal injury (Friedl et al., 1989), hemorrhagic shock (Tan et al., 
1993), and ischemia-reperfusion injury (Terada et al., 1992; Koike et al., 1993) which 
can lead to secondary pathologies, especially in the lung.
2.3 Hypothesis
As mentioned in the introductory chapters XO exists in a circulatory form. The 
quantity of circulating XO in a healthy human has been measured in several 
publications but results vary substantially (reviewed in Harrison et al., 2002). However 
there is agreement that levels of circulating XO increase in several disease states (as 
mentioned in section 2.2.4.5), for example, in liver disease such as chronic hepatitis, 
levels rise to an average o f 7.6pg/ml compared to a normal of <1 fig/ml, as assessed 
by enzyme-linked immunosorbent assay (ELISA) (Battelli et al., 2001). But the 
question that has not been answered in studies that provide evidence for increased 
circulating XO is: how does XO enter the circulation? Researchers have speculated 
that XO maybe released from ailing cells rich in cytosolic enzyme (Meneshian and 
Bulkley, 2002; Wang et al., 2002), similar to enzymes such as alkaline phosphatase 
(AP) (Kristensen, 1994). However levels of AP, transaminases, or necrosis in 
histological sections do not correlate with circulating XO in the liver diseases cirrhosis 
and chronic hepatitis for example (Battelli et al., 2001). But, another hypothesis for the 
source of circulating XO  exists.
The endothelium is a rich source of XO (Jarasch et al., 1981; Jarasch et al., 1986), and 
studies by Partridge et al., 1992 have demonstrated the release of XO from 
microvascular endothelial cells (MVEC). This paper shows the constitutive release of 
XO from MVEC independent of cell death, which is reduced under hypoxic 
conditions, therefore they suggest that XO is released by an active process. However
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comparisons between controls and test sample in this paper should be taken with 
caution as the data presented only show standard error from the mean values, and do 
not show n numbers or statistics. This was a limited study where no attempt was 
made to look further at the release mechanism, but nonetheless it serves as a good 
indication o f a constitutive XOR-release process. Other proteins in the endothelium 
are released by constitutive processes, for example vW f (see section 1.4.3) but release 
may also be stimulated, could this be the same for XO? Inflammatory agents can 
induce XOR expression (see section 2.2.4.1.2) and elevation in circulating XO occurs 
in several disease states, particularly in inflammatory pathology. Can inflammatory 
agents induce the release of XO from the endothelium?
Hypothesis: The vascular endothelium can release xanthine oxidoreductase by 
constitutive and controlled mechanisms.
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Chapter 3. Results: Characterisation 
of Xanthine Oxi do reductase 
Expression in a Vascular Model
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3 Results: Characterisation of Xanthine 
Oxidoreductase Expression in a Vascular Model
3.1 Introduction
Once thought to be an inert lining of the blood vessel, the vascular endothelium is 
now know to contribute a vast number of vascular processes, a selection of which are 
reviewed in the introductory chapters. The emergence o f the human umbilical vein 
endothelial cell (HUVEC) as an endothelial model has allowed scientists to rapidly 
study endothelial processes and has certainly contributed to the vast number of 
publications with reference to the endothelium (Nachman and Jaffe, 2004). The 
isolation and culture of endothelial cells was probably achieved in 1958 (Ingenito, 
1958), however at that time there was no way of verifying an endothelial cell culture, 
except by morphological assessment. Five years later the culture of HUVECs may 
have been accomplished (Maruyama, 1963), but the means to positively identify cells 
from endothelial origin were still not available. However this would soon change, an 
antihaemophilic factor (now know as von Willebrand factor) was discovered in 
endothelial cells that was not expressed in smooth muscle cells or fibroblasts (Hoyer 
et al., 1973). This discovery quickly led to the verified isolation o f endothelial cells 
from the human umbilical vein (Jaffe et al., 1973; Jaffe et al., 1973a), the HUVEC.
As mentioned in the hypothesis section microvascular endothelial cells express active 
XOR. However, the HUVEC (a macrovascular cell) was chosen as a vascular model 
for the analysis o f XOR release, and this choice was selective. Firstly, cells are isolated 
from human tissue, therefore results using this model would be more applicable to 
human physiology/pathology compared to the bovine cells used in previous studies 
(Partridge et al., 1992). Secondly, the source of cells is easily accessible (once Ethical 
Approval is aquired) as the umbilical cord is essentially a waste product. Finally, the 
HUVEC model maintains many important properties o f the microvascular 
endothelium and therefore should behave in a similar fashion compared to previous 
investigations (Partridge et al., 1992). For example, with respect to inflammation,
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HUVECs contain WPBs and P-selectin and their expression, along with other 
adhesion molecules, can be upregulated by inflammatory stimuli (Kagawa and 
Fujimoto, 1987; Sugama et al., 1992; Jones et al., 1993).
3.2 Chapter Aim
To investigate the hypothesis set, the use of a vascular endothelial model was 
essential. The aim o f this chapter is to characterise the vascular endothelial model 
chosen for investigations, the HUVEC, with emphasis on xanthine oxidoreductase 
expression. As in Jaffe et al., 1973, isolation of cells from endothelial origin will be 
confirmed using vW f as a positive marker. Expression o f the XOR gene and protein 
will be assessed by the polymerase chain reaction and antibody-based techniques, 
respectively.
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3.3 Principles, Materials, and Methods
Frequently used protocol are described below, however less frequently used methods, 
as indicated below, can be found in the appendix.
3.3.1 Tissue Preparation and Haematoxylin and Eosin Stain
3.3.1.1 Materials
DePeX Mounting Medium, Iso-pentane; Superfrost Plus Microscope Slides (VWR 
International Ltd, Dorset, UK); Tissue-Tek (Sakura. Berkshire, UK); Harris 
Haematoxlin, Eosin (Sigma Aldrich Company Ltd. Dorest, UK).
3.3.1.2 Protocol
A beaker o f iso-pentane was chilled in liquid nitrogen. Tissue-Tek was spotted onto a 
cork disk and was submerged in the iso-pentane for approximately 5 minutes after 
which time the Tissue Tek was sufficiently hardened. The cork disk was removed and 
a tissue sample, approximately 0.5cm2, was pressed into the set Tissue-Tek. The 
sample was then covered in Tissue-Tek and was incubated in the chilled iso-pentane 
for about 5mins, or until all Tissue-Tek was solidified. Following this preparation, the 
sample mounted onto the cork-disk was stored at -70°C for several hours to ensure 
the sample was completely frozen.
Using a Cryostat (Bright Instruments Company Ltd, Huntingdon, UK) the frozen 
sample was sectioned into 5pm slices which were immediately placed onto 
microscope slides. Sections were then stained with Haematoxylin and Eosin using the 
protocol given in Appendix I Section 8.1. Samples were viewed under a Zeiss 
Axioscope microscope and images were captured using the Zeiss KS300 program 
(Carl Zeiss Ltd. Hertfordshire, UK). Following the above mentioned staining protocol 
cell nuclei appear blue and cytoplasmic structures pink-red.
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3.3.2 Cell Isolation and Culture
The human umbilical cord contains two arteries and one vein, the vein being the 
largest o f the three blood vessels. Isolated HUVECs were used as a model for the 
vascular endothelium.
3.3.2.1 HUVEC Isolation and Culture Materials List
Cell Disociation Solution, Collagenase (Type II from Clostridium histolyticum) (Sigma 
Aldrich Company Ltd. Dorest, UK). 95% CO 2 in air (BOC Gases. Guildford, UK). 
Endothalial Cell Growth Medium, Proliferating HUVECs (PromoCell. Heidelberg, 
Geramny). Glass cover slips (VWR International Ltd. Dorset, UK). HANKS 
balanced salt solution (HBSS; Invitrogen. Paisley, UK). Syringe filters (0.22pm) 
(Fisher Scientific UK Ltd. Leicestershire, UK). Tissue culture plastics: T25 filter-cap 
flasks, 12-well plates, 15 and 50ml centrifuge tubes (Triple Red Ltd. Oxfordshire, 
UK).
3.3.2.2 HUVEC Isolation Protocol -  Collagenase Digestion
The isolation of HUVECs by collagenase digestion is a commonly used technique
(Jaffe et al., 1973; Visher et al., 2000; Kuhlmann et al., 2005). Umbilical cords were 
kindly donated by mothers attending the local maternity ward (with full ethical and 
R&D approval; Bath Local Research Ethics Committee reference number BA635). 
Cords were stored at 4°C for no longer than three days before HUVEC isolation 
under sterile conditions. Before the introduction of cannula into one end of the 
umbilical vein, any punctured or clamped regions of the cord were removed. 
Cannulated umbilical veins were washed using HBSS until the expelled medium ran 
true to its starting colour (i.e. the majority of cord blood was removed). HUVECs 
were dissociated from the vessel wall by collagenase digestion. The cord was blocked 
at the non-cannula-inserted end and 37°C filter-sterilised lm g/m l collagenase in 
HBSS was used to fill the umbilical vein (as shown in Figure 19). The collagenase 
filled cord was incubated at room temperature for 30-45mins. Following this 
incubation the collagenase solution was collected, and the vein was washed once with 
HBSS to ensure a full harvest of endothelial cells. HUVECs were brought out of
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suspension by centrifugation at 1600rpm for 5mins at room temperature. Following 
centrifugation the supernatant was removed and the cell pellet was resuspended in 
Endothelial Cell Growth Medium (ECGM).
Figure 19. The Cannulated Human Umbilical Cord.
Cannulae were inserted into the human umbilical cord vein. Following initial washing steps the non­
cannula end was blocked o ff and the human umbilical cord vein was filled with a collagenase 
solution.
3.3.2.3 HUVEC Culture  Protocol
Following isolation the HUVEC culture was routinely grown in T25-flasks (one flask 
per cord) with 5mls ECGM , incubated at 37°C and 5%C02 in air, in a Jencons 
Millenium CO 2 incubator (Jencons Ltd. Bedfordshire, UK). The initial culture was 
termed the primary culture. Alternatively HUVECs were aquired from PromoCell, 
but were incubated and treated under the same conditions as isolated HUVECs 
(Note: HUVECs purchased from Promocell were passage 1, not primary cultures). 
W hen the HUVECs reached confluence (100% monolayer covering o f the flask base) 
they were split l-to-5 into T25-flasks by the following process. Confluent HUVECs 
were dissociated from each T25-flask using 3mls non-enzymic Cell Dissociation 
Solution (CDS), incubated at 37°C for about 20mins (tapping the flask occasionally 
helped the dissociation process), and cells were pelleted by centrifugation as 
previously decribed. This culture, Passage One (PI), was grown under the same 
conditions as the primary isolation. Upon reaching confluence, PI cells were split, as 
above, into 12-well plates (with, flame-sterilised 13mm diameter glass coverslips 
number 1 thickness for cell staining experiments, or without coverslips, for HUVEC 
protein secretion experiments), one flask per plate, and were incubated with 1ml
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ECGM per well in the same conditions as above. These cells, Passage Two (P2), were 
used in all HUVEC experiments. At all stages, medium was changed three times a 
week.
3.3.2.4 Mean Generation Time
In HUVEC experiments (and bacterial experiments in a later results chapter), the 
mean generation time for the cell population was calculated. The mean generation 
time may be calculated from the following equation (Equation 1) using data from the 
exponential growth phase o f cell division.
k  — n /t 
= (log N t— log No) /  0.301/
If  the population doubles t  — g, therefore N / = 2No, which can be substituted into the 
above equation:
k  — (log(2No) -  log No) /  0.301g 
= (log2 + logNo — log No) /  0.301g 
k  = i  ig
Therefore the mean generation time is the reciprocal of the mean growth rate 
constant (k):
g = \ i k
Equation 1. Calulation of th e  Mean Generation Time of a Cell Culture.
Where g — mean generation time; k — mean growth rate constant; n — number o f 
generations in time % No = the initial population number; N t = the population at time 
t; /  — time (Prescott et a l.1996).
3.3.3 MDA-MB-231 Culture
The immortalised human mammary epithelial cell line MDA-MB-231 served as a 
positive control for the expression of XOR.
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3.3.3.1 Materials List
Cryo 1°C Freezing Container and 1ml NUNC Cryo-tubes (Fisher Scientific UK Ltd. 
Leicestershire, UK), Dimethyl Sulphoxide (DMSO; Sigma Aldrich Company Ltd. 
Dorest, UK), Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen. Paisley, 
UK), Foetal calf serum (FCS) (GlobePharm Ltd. UK), MDA-MB-231 (LGC 
Promochem. Middlesex, UK), Pencillin/Streptomycin (Invitrogen. Paisley, UK), 
Normal human dermal neonatal fibroblasts (American Type Culture Collection, UA, 
USA).
3.3.3.2 Culture Protocol
MDA-MB-231 and fibroblasts were routinely grown in T25 flasks in 5mls DM EM  + 
10% FCS + Penicillin and Streptomycin 20U /m l and 20[ig/ml, respectively, and were 
incubated at 37°C and 5%CC>2. Medium was changed two times a week until cells 
reached desired confluence and as the MDA-MB-231 cell line is immortalised passage 
number was not recorded. For cell staining, cells were passaged onto 13mm diameter 
cover slips in 12-well plates, as previously described, and were incubated in 1ml o f  the 
DMEM-based medium.
3.3.3.3 MDA-MB-231 Cell Storage
MDA-MB-231 cell stocks were routinely stored in liquid nitrogen. Confluent T25- 
flasks were harvested by non enzymatic cell dissociation solution treatment. The cell 
pellet was then resuspended in a freeze-down medium, consisting of 50% FCS, 40% 
growth medium and 10% DMSO. 1ml volumes o f freeze-down medium were used to 
resuspend the pellet from each T25 flask o f cells. Cell suspensions were stored in 
NUNC Cryo-tubes and were frozen to -70°C, -1°C per min, in the Cryo 1°C Freezing 
Container, and were then placed in liquid nitrogen storage. Cells were resurrected 
rapidly by placing NUNC Cryo-tubes under warm running water. Cells were washed 
once by centrifugation of the cell suspension at 1600rpm for 5mins and the 
subsequent pellet resuspended in normal DMEM-based medium.
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3.3.4 Trypan Blue-Exclusion Cell Viability Counts
Trypan blue does not permeate viable cells which appear clear under the light 
microscope, whereas dead/com prom ised cells allow entry o f trypan blue and appear 
blue in colour.
3.3.4.1 Materials List
Accutase (TCS Cellworks LTD. Buckinghamshire, UK), Trypan Blue (Sigma Aldrich 
Company Ltd. Dorest, UK).
3.3.4.2 T rypan Blue E xclusion Cell C ount Protocol
HUVECs grown in 12-well plates or T25-flasks were dissociated by incubation with 
500pl or 2000pl Accutase, respectively, per well/flask at 37°C, 5% C02 for about 
5mins. The resulting cell suspension was mixed 1:1 with trypan blue and cells were 
counted using a Neubauer double rhodium coated counting chamber (Fisher 
Scientific U K  Ltd. Leicestershire, UK). Approximately 15pl of the cell/trypan blue 
mixture was applied to fill the counting chamber and, blue (dead) and clear (viable) 
cells were counted from five of the nine 1mm2 squares on the counting chamber (as 
indicated in Figure 20). The average number o f cells per square was used in the 
calculation o f  the number o f cells per ml o f the starting cell suspension, as shown in 
Equation 2.
Figure 20. Cell Counts Using the Haemacytometer.
The typical grid layout o f  the haemocytometer, divided into nine 1mm squares. Cell counts were 
taken from the five highlighted squares (as indicated by a red stars in A). Only cells in contact with
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two o f  the four boundaries o f  each square were counted (as indicated in B, crossed cells were not 
counted)
Viable cells/ml = Mean cells per square x 2 x 10 000 
Equation 2. Cell Viability Count.
Following trypan blue-exclusion protocol cells viable cell counts could be calculated using this 
equation The percentage o f  viable cells could be calculated after repeating the above calculation for 
trypan blue stained cells only. (x2: dilution factor, trypan blue dilution, xlO 000: volume correction 
from volume o f 1mm square under cover slip, KMml, to 1ml).
3.3.5 SDS-PAGE, Western and Dot Blot
The immunodetection of proteins were assessed using the sensitive Western Blot and 
D ot Blot techniques.
3.3.5.1 Materials List
ECL™ Western Blot Detection Reagents, Hybond™-C extra nitrocellulose 
(Amersham Biosciences U K  Ltd. Buckinghamshire, UK). Kodak BioMax XAR Film 
(VWR International Ltd. Dorset, UK). Polyoxyethylene sorbitan monolaurate (Tween 
20) (Sigma Aldrich Company Ltd. Dorest, UK). Xanthine Oxidase (Biozyme, UK).
3.3.5.2 Western Blot Protocol
All materials and recipes for sample buffer, running buffer, blotting buffer, washing 
buffer, blocking buffer, the stacking gel, and the resolving gel are shown in Appendix 
I 8.2. All antibodies are shown in Appendix I 8.3.
Protein samples and the molecular weight marker were mixed one-to-one with 
reducing sample buffer and were heated to 100°C for 5mins. Sample proteins were 
separated by sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS- 
PAGE) at 100V for about 2hrs or until the gel-front neared the end o f the resolving 
gel. Following SDS-PAGE, proteins were transferred onto nitrocellulose under 
reducing conditions at 150mA for 2hrs.
The nitrocellulose-bound proteins were prepared for immunodetection by a lh r 
incubation in blocking buffer at room temperature with continuous agitation (this
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step could also be performed overnight at 4°C; all further steps were performed at 
room temperature with continuous agitation). Blocking buffer was discarded and 
replaced with the 1° antibody o f choice, diluted in fresh blocking buffer (for vWF and 
XOR analysis a 1 in 5000 and a 1 in 1000 dilution o f the 1° antibody was used, 
respectively). The nitrocellulose was incubated with the 1° antibody for l-1.5hrs (in 
some control experiments partially saturated 1° antibody was used, this was achieved 
by incubating the antibody with an equal amount o f antigen (w/w) for 5min at room  
temperature before applying to nitrocellulose). Unbound 1° antibody was removed by 
6 x 5mins wash steps in excess washing buffer. To enable visualisation of the antigen- 
bound 1° antibody, the nitrocellulose was incubated with a 1 in 200 dilution 2°-horse 
radish peroxidase (HRP)-conjugated antibody, prepared in blocking buffer, for lhr. 
Excess 2° antibody was removed by 6 x 5mins wash steps in excess washing buffer. 
Following the wash steps, the nitrocellulose membrane was bathed in ECL detection 
reagents (prepared using manufacturers instructions) and luminescence was detected 
on Kodak film (the principle behind the use o f the ECL reagents in visualising 
antigen is shown in Section 3.3.5.4)
3.3.5.3 Dot Blot Protocol
The main difference between the Dot and Western Blot protocols is the method o f 
protein transfer onto the nitrocellulose. In the Dot Blot, SDS-PAGE is not necessary, 
instead proteins are transferred onto nitrocellulose by applying samples to a Dot Blot 
apparatus (Jencons Ltd. Bedfordshire, UK) attached to a vacuum. The D ot Blot has 
advantages compared to the Western blot as it takes a shorter time to run, and 
proteins can be concentrated to one small space, but has the disadvantage that the 
molecular weight o f the protein detected cannot be calculated.
Blotting paper and nitrocellulose where soaked in transfer buffer before assembling 
the Dot Blotter (see Figure 21). See Western Blot protocol for the visualisation o f 
bound protein.
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Figure 21. The Assembled Dot-Blotter.
Blotting paper and nitrocellulose were soaked in transfer buffer before assembly as shown in this 
figure. The screws were tightened and the vacuum was applied for approximately one minute before 
sample application. The top part o f  the dot-blotter is arranged in a 96-well format, samples were 
applied to wells with the vacuum running.
3.3.5.4 The E C L -R eagent Principle
In combination with a relevant HRP-conjugated antibody, the ECL reagent detection 
system provides a non-radioactive detection method for immobilised antigen. The 
ECL system is based on luminol-chemiluminescence for antigen detection, the 
process is summarised in Figure 22.







1 ° Antibody 




r~~i r n n Nitrocellulose
Membrane
Figure 22. The ECL Reagent System in the Detection of Immobilised Antigen.
3-63
Ja i iK s I l e u  i i i s o n P h D  T h e s i s
Following the incubation o f  nitrocellulose-immobilise antigen with the relevant 1° and 2° HRP- 
conjugated antibody the ECL reagents are employed. In the presence o f  the peracid substrate luminol 
is oxidised by HRP. Oxidised luminol is in an “excited-state” which decays to “ground-state” via a 
light emitting/luminescent pathway, which may be detected using light-sensitive film. In the presence 
o f  chemical enhancers such as phenols, the intensity and duration o f luminescence is increased 
greatly. The generation o f luminescence in the ECL system peaks at around 5-20mins and the half life 
o f  decay is about 60mins (Adapted from manufacturers information).
3.3.6 Immunofluorescent and Fluorescent Labelling of Cells
3.3.6.1 F lu o re sc en c e  -  T he P rin c ip les
Fluorescent molecules or fluorophores are widely used in research, especially in 
imaging and quantification studies. When sufficiently excited by a certain wavelength 
of light, fluorophores emit fluorescent light at an intensity proportional to the amount 
of fluorophore present, a property that is exploited for research applications. As 
fluorescence-based techniques are widely used in this thesis, some background 
information on this subject will be mentioned here.
3.3.6.1.1 Atomic Structure - Orbitals
A volume of space around an atom’s nucleus where an electron is likely to be found is 
termed an orbital. Several different types of orbitals exist including s, p, and d (see 
Figure Figure 23). Orbitals are organized into different layers, or shells, that increase 
successively in both size and energy. Shells contain different numbers and types of 
orbital, as summarised in Figure 24.
t -
p Y Orbital
Figure 23. The Orbitals of an Atom.
The s orbitals are spherical with the nucleus at the centre;p orbitals are dumbbell-shaped, whereas the 
d orbitals (not shown) are usually cloverleaf in shape.
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Figure 24. The Electron Energy Levels within an Atom.
Each consecutive shell increases in both energy and electron capacity. N o t shown in this diagram is 
the 4s energy level that lies between 3p  and 3d
3.3.6.1.2 Fluorescence - Excitation
During excitation a fluorophore absorbs a photon of light. If the energy from the 
absorbed photon is sufficient an electron will “jump” from a lower energy orbital to a 
higher one, the fluorophore is said to have been excited from ground-state energy 
level (So) to an excited-state energy level (Sn) (see Figure 25). The probability that a 
fluorophore will be excited is dependent on the wavelength of light that is absorbed, 
i.e. certain wavelengths will more efficiently excite certain fluorophores. This 
information may be presented on an Excitation and Emission Spectra, an example is 
shown in Figure 26.
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Figure 25. Electron Energy Levels.
The energy levels within a fluorescent molecule, including vibrational and rotational energy 
levels.
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3.3.6.1.3 Fluorescence Emission
Following excitation, fluorescence emission begins instantaneously, the half-life of the 
emission stage for many fluorophores is usually a few nanoseconds. During emission 
the electron initially decays towards the lowest vibrational energy level within the 
electronic excited state, during this decay energy is lost in the form of heat, this 
process is termed internal conversion. However during the decay from the excited 
electronic level to ground state, energy is dissipated as a photon of light — 
fluorescence. The energy of an emitted photon equals the energy from the excited 
level minus the energy of the ground state to which it falls, this energy difference 
determines the wavelength of emitted light and consequently the colour of the 
admission (Figure 27 illustrates the colour associated with different wavelengths o f 
light). Due to the loss of energy as heat during internal conversion, the emission 
spectrum is always shifted toward a longer wavelength of light (lower energy) relative 
to the excitation spectrum (see Figure 26), this phenomenon is referred to as the 
Stokes Shift. From a practical point of view the Stokes Shift is very important as it 











Figure 26. Excitation and Emission Spectra for Fluorescein Isothiocyanate (FITC).
The green-fluorescent fluorophore FITC is typically analysed using the maximal excitation and 
emission wavelength o f  approximately 495nm and 525nm, respectively (Homer and Beighton, 1990).
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Figure 27. The Wavelength of Light and its Associated Colour.
From an emission wavelength o f  a fluorophore it is possible to predict its fluorescent colour.
3.3.6.1.4 The Photobleaching Effect
The photodestruction or photobleaching of a fluorophore usually occurs when a 
fluorophore is in its excited state. The excited state of a fluorophore is generally more 
chemically reactive compared to its ground state and may undergo chemical reactions 
that alter the fluorophore’s structure generating a molecule with reduced fluorescence.
There are many applications of fluorescence for research purposes. O f particular 
interest to my research are the applications for studying enzyme activity, for example 
in the detection of xanthine oxidase activity in the isoxanthopterin assay, and also for 
immunofluorescent detection of cellular antigens. A list o f commonly used 
fluorophores and their spectral characteristics is given in Table 1.






4',6-Diamidino-2-Phenylindole (DAPI)* 358 461
Fluorescein-5-isothiocyanate (FITC) 494 518
Propidium Iodide (P.I)* 536 617




Isoxanthopterin (IXP)** 345 390
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Maximum excitation and emission wavelengths for popular fluorophores. (Haugland 2002a; Beckman 
et a l , 1989). *Excitation and Emission peaks for the fluorophore-DNA complex. **Values are not 
maximum wavelengths but the wavelengths used in IXP analysis.
3.3.6.2 Fluorescent Staining of Cultured Cells
3.3.6.2.1 Materials
4'-6-diamidino-2-phenylindole, dilactate (DAPI), Prolong Anti-Fade, Propidium 
Iodide (PI) (Molecular Probes Europe BV. Leiden, Netherlands). Nuclear Yellow, 
Paraformaldehyde, RNase, Saponin, Triton X-100 (Sigma Aldrich Company Ltd. 
Dorest, UK). Phosphate Buffered Saline (PBS) Tablets (Oxoid Ltd. Hampshire, UK). 
A list o f antibodies used in staining procedures is given in Appendix I 8.3.
3.3.6.2.2 Fixation of Cells
Adherent cells were grown on 13mm diameter coverslips in 12-well plates. 
Conditioned medium was aspirated and cells were washed with 1ml 37°C HBSS 
which was subsequently removed. Cells were fixed using either 1ml 4% 
Paraformaldehyde at 37°C or Ice-cold acetone/methanol (50:50) at 4°C, and were 
permeabilised with 0.2% Triton X-100 in PBS at 37°C, 0.08% Saponin in PBS at 
37°C, where appropriate. At the required incubation time point the fixative was 
aspirated and cells were kept in 1ml PBS per well before staining.
3.3.6.2.3 Fluorescent Staining,
PBS was aspirated and cells were blocked in 500|d blocking buffer/well (5% Marvel 
in PBS) for 20mins at room temperature. The blocking buffer was removed and cells 
were incubated with the primary (1°) antibody (optimal concentrations are determined 
in results section) in 500pl blocking buffer/well for lh r  at room temperature. Excess 
1° Antibody was removed by washing cells in 1ml PBS/well with continuous 
agitation, three times for 5mins. If  required, 500pil o f 2° antibody in blocking buffer 
was added to the cells for 30mins at room temperature. Excess 2° antibody was 
removed by a repeat o f the wash steps used for the 1° antibody. Cellular DNA was 
stained using DAPI, PI, or Nuclear Yellow (optimal concentrations were determined 
in results section) in distilled water (dH20) per well, incubated for 5mins at room
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temperature. When using PI, cells were treated with 500(jl1 100pg/ml RNase per well 
before the application o f the nuclear stain. Excess stain was removed by three 5min 
wash steps using dPhO (PBS was not used as crystals on drying that interfere with 
visualisation). Note: All staining with fluorophores was performed in limited light 
conditions to reduce photobleaching.
Coverslips holding the fluorescendy stained cells were turned out of the 12-well plate 
and mounted cell-side-down onto microscope slides using a couple of drops of 
ProLong Antifade (Antifade reduces the photobleaching process of certain 
fluorophores), and were viewed under a Zeiss Axioskop 2 microscope (Carl Zeiss 
Ltd. Hertfordshire, UK) equipped with a mercury arc lamp and Zeiss filter sets 01 
(for DAPI), 10 (FITC), and 15 (for Cy3). Separate fluorescent images were captured 
using a Nikon Coolpix digital camera and were overlaid using Adobe Photoshop 5.0 
LE (Adobe Systems Inc).
3.3.7 Preparation of HUVECs for Electron Microscopy
HUVECs were prepared for electron microscopy using a new procedure developed 
by QuantomiX™ (Nes-Ziona, Israel). In this protocol, sample preparation is 
comparable to that used for light microscopy however the visualisation of samples is 
achieved using a scanning electron microscope, therefore resulting in far better 
magnification and resolution compared to light microscopy techniques. The 
technology is based on a capsule that contains a thin, electron-transparent membrane 
on which samples can be attached or grown. The capsule seals the sample from the 
vacuum generated within the electron microscope sample-chamber, and thus enables 
imaging o f fully hydrated samples.
3.3.7.1 Materials
Antibodies: See Appendix I 8.3. Glycine, Saponin, Triton X-100, Uranyl Acetate 
(Sigma Aldrich Company Ltd. Dorest, UK). Goat Serum (DAKO. Chambridgeshire, 
UK). LI silver enhancement kit (Nanoprobes. NY, USA). Calibration capsule, MA-4
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Multi-well aspirator, MP-10 Multi-well plates, QX-102 Imaging buffer, QX-102 
Capsules (QuantomiX™. Nes-Ziona, Israel).
3.3.7.2 Protocol
This protocol can be found in Appendix I 8.4.
3.3.8 Reverse Transcriptase-Polymerase Chain Reaction (RT- 
PCR)
3.3.8.1 Materials
Agarose, blue/orange loading dye 6x, boric acid, EDTA (Promega. WI, USA). 
Ethidium bromide, Mineral oil, Tris-Base (Sigma Aldrich Company Ltd. Dorest, UK). 
Molecular Weigh Marker (MWM XIV) (Roche Diagnostics GmbH. Mannheim, 
Germany). ReddyMix 2x, Reverse-iT™ 1st Strand Synthesis Kit, Total RNA Isolation 
Reagent (TRIR) (Abgene. Surry, UK). Mouse Liver RNA (Chemicon, UK). RNA-Stat 
60 (AMS Biotechnology Ltd. Oxford, UK). UltraPure water, DNAse and RNase-free 
(Invitrogen. Paisley, UK). Sequences o f designed primers are shown in Appendix I 
8.5.
3.3.8.2 RNA Isolation
Following manufacturer’s protocol, RNA was isolated from cultured cells using either 
RNA-Stat 60 or TRIR, however the method will be briefly described here. Cells were 
lysed by the addition o f 1ml RNA isolation solution per confluent T25 flask o f 
cultured cells, the lysate was passed through a pipette several times. Following lysis 
the homogenate was transferred to a 1.5ml centrifuge tube and incubated at room  
temperature for 5mins to allow dissociation o f nucleo-protein complexes. After this 
time 0.2mls chloroform was added to the lysate, was mixed vigorously for 15secs, and 
allowed to stand at room  temperature for 2-3mins. The lysate was then centrifuged at 
12 OOOg for 15min at 4°C. During this step the lysate well form two phases, the lower 
organic phase and interface containing DNA and protein, and an upper aqueous 
phase containing RNA. The aqueous phase was carefully transferred to a fresh 1.5ml 
centrifuge tube and 0.5mls isopropanol. After incubation at room temperature for 5-
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lOmins the RNA was centrifuged at 12 OOOg for lOmin at 4°C, forming a RNA pellet 
in the bottom  o f the tube. Supernatant was removed and the pellet was washed in 1ml 
75% ethanol (diluted in UltraPure water) and centrifuged at 7 500g for 5min at 4°C. 
Supernatant was removed and the pellet was air-dried, then resuspended in 
approximately 30pl UltraPure water. An aliqote of RNA solution was diluted and 
absorbaces at 260 and 280nm were recorded. The RNA concentration was calculated 
using the equation below (Equation 3) and purity was calculated using the 
A260/A280 ration. A ratio >1.8 signifies a clean preparation free o f significant 
protein contamination.
[RNA] ((jig/ pi) = (A26O * 40 * dilution factor) /  1000 
Equation 3. RNA Concentration.
3.3.8.3 Reverse Transcriptase Reaction
The reverse transcriptase reaction was carried out using the Reverse-iT™ 1st strand 
synthesis kit, following manufacturer’s instructions. Briefly, 1 pi anchored oligos were 
added to 2fig RNA solution in 12pi UltraPure water and was heated to 70°C for 
5mins using Touchgene Gradient Thermocycler (Techne, Cambrigde, UK). Then 4pl 
1st strand synthesis buffer, 2pl dNTP mix, and lp l reverse transcriptase blend were 
added to the tube. The contents were vortexed and briefly centrifuged to ensure 
mixing, then heated to 42°C for lhour then 75°C for lOmin. Following this 
procedure cDNA concentration was determined by measuring A260 as previously 
described.
3.3.8.4 PCR
Specific gene products were amplified by the PCR. lp l of forward and reverse 
primers (see Appendix I 8.5) were added to lpg  cDNA and 15pl ReddyMix. 
Following vortex and brief centrifugation, samples were overlaid with 30 pi mineral 
oil, and a specific PCR program was run depending on primer set used (see Appendix 
I 8.5). PCR products were analysed using agarose gel electrophoresis. PCR reaction
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products were applied directiy to a 1.2% agarose gel (see Appendix I 8.5) (lOpl per 
well), which was run at 50V until gel front ran approximately % o f the gel length. To 
calculate PCR product size a standard was also applied, prepared as follows: 4pl 
MWM, 2pl loading dye, 6pi UltraPure water. PCR products were visualised under UV 
light.
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3.4 Results
3.4.1 The HUVEC: Morphological Analysis
The aim of this section is to assess the predominant cell type isolated from the human 
umbilical cord vein by appearance, i.e. to show that the cell type isolated is the 
HUVEC as expected.
The human umbilical cord contains three large blood vessels, two arteries and one 
vein. The vein is easily distinguished due to its larger diameter compared to the 
arteries (see Figure 28). HUVECs were isolated using the collagenase digestion 
method, a method that gently removes cells lining the human umbilical cord vein (see 
Figure 29), without significant removal of other cell types.
Figure 28. The Human Umbilical Cord Cross Section.
A specimen o f  human umbilical cord was fixed using the Tissue-Tek/liquid nitrogen method as 
described in section 3.3.1. 5pm sections o f  umbilical cord were stained using haematoxylin and eosin- 
stain protocol. The morphological differences between the umbilical cord vein and arteries are clear, 
especially vessel diameter, and are important to note when selecting a vessel for endothelial cell 
isolation protocol. Bar =  1mm.
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Figure 29. The Human Umbilical Vein and Artery.
The umbilical cord was prepared as described in Figure 28. The umbilical vein and artery are shown 
in A, and C, and B, and D , respectively. With the haematoxylin-eosin stain cell nuclei appear 
blue/purple, whereas cytoplasmic structures are pink/red. Higher magnification clearly demonstrates 
the differences between the vein and artery, considerably more smooth muscle is present in the artery 
wall. In C, the HUVEC layer is clearly visible. Bar =  500pm in A and B, and 100pm in C and D.
For investigations into the hypothesis, HUVECs were used at passage two (P2). 
Living, cultured HUVECs at this stage are shown Figure 30. Confluent HUVECs 
form sheet-like, polygonal monolayers, and have morphology distinct from that of 
smooth muscle and fibroblasts which confirms early investigations (Jaffe et al., 1973).
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Figure 30. Living HUVECs in Cell Culture.
Living P2 HUVECs were viewed under phase contrast microscopy and images were captured using a 
Nikon Coolpix digital camera (Nikon UK  Ltd. Surrey, UK). A and B show sub-confluent and 
confluent human umbilical vein isolations, respectively (Bar = 50pm).
To further characterise the morphology of isolated cells and to help confirm the cells 
were from endothelial origin, cultures were initially compared to purchased HUVECs 
(see Figure 31). HUVECs purchased from PromoCell undergo several tests to ensure 
the population is from endothelial origin. The morphology of isolated cells was 
identical to the cells purchased from PromoCell.
.  - V ,  g
Figure 31. PromoCell HUVECs in Cell Culture.
Living P2 HUVECs purchased from PromoCell were viewed under phase contrast microscopy. (Bar 
= 100pm).
The formation of tubular structures by cultured HUVECs has been described (Maciag 
et al., 1982). To further characterise the isolated cells as HUVECs cultures were 
assessed for tube formation. In these experiments PI cell-isolates were cultured to
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confluence, however instead of passage the isolated cells were incubated and fed as 
normal. After a period of approximately 7-14days it was apparent that in some areas 
groups of cells changed to a more elongated morphology, and ran parallel with one 
another. Within a week of this time tube-like structures were observed. With 
continued culture, cells growing close to the tube became more sparse leaving a free­
standing tubular structure (see Figure 32).
To assess the isolated cell type further, the generation time of the cultures was 
measured. To achieve this 20 000 PI cells/well were seeded into 12-well plates 
(therefore P2 cells) and were cultured under normal conditions. At selected time 
points viable cell counts were taken using the trypan blue-exclusion protocol, two 
wells of cells were counted for each time point. A growth curve was plotted (see 
Figure 33) and generation time was calculated using Equation 1. The generation time 
of this culture was 32hr, compared to a 49hr generation time calculated by PromoCell 
for their HUVECs (PromoCell GmbH. Heidelberg, Germany).
Figure 32. HUVEC Tube Structure Formation.
Cell isolates (PI) were cultured in T25 flasks for approximately 21 days beyond confluence under 
normal culture conditions. During this time tube-like structures were observed as shown under phase
3-76
J itiucs I l e w i i i s o n F i l l » 'I h e - i
contrast microscopy. N ote that although cells are confluent near the ends o f tubes areas running 
alongside tubes have lost confluence (Bar =  lOOpm).










Figure 33. HUVEC Growth Curve.
Over selected time points the cell number o f cultured umbilical vein-cell isolates was calculated. Time 
zero was the first cell count (the morning after the cells were seeded). Generation time was calculated 
from the linear portion o f the growth curve (Error bar = SD).
3.4.2 The HUVEC: Protein Expression Analysis
The aim of this section is to assess the predominant cell type isolated from the human 
umbilical cord vein by protein expression, i.e. to show that the cell type isolated is the 
HUVEC as expected. A technique frequendy employed for this purpose is the 
staining of isolated cells for the endothelial cell marker von Willebrand factor. This 
technique was used in the first confirmed isolation of HUVECs (Jaffe et ai, 1973) and 
has been widely used ever since.
3.4.2.1 O ptim isation  of F luo rescen t S tain ing
To visualise protein expression in HUVECs it is important to label cells for DNA to 
confirm cellular location. Several DNA-binding fluorophores can be employed for 
this purpose, and fluorophore selection was based on the fluorescent emission 
wavelength of the immuno-labelled protein of interest, i.e. nuclear and protein 
fluorophores of different colours were used. DNA staining with three chemical
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nuclear-labels, DAPI, PI, and Nuclear Yellow, was optimised. The optimal 
concentrations for the protocol were found to be lOnM DAPI, O.lpg/ml PI, and 
50|jiM  Nuclear Yellow. DAPI and Nuclear Yellow stains were specific to DNA, 
however PI stained the cell nucleus and cytoplasm, i.e. DNA and RNA were both 
detected (see
Figure 34). Therefore an additional step was added to the PI stain protocol, the 
incubation of fixed cells with 100pg/ml RNase for 0.5hours prior to PI staining (see
Figure 34).
Figure 34. Optimisation of Fluorescent Nuclear Stains.
Different nuclear labels were assessed in HUVECs. The concentrations o f  the A) DAPI, B) Nuclear 
Yellow, and PI were optimised. The cellular stain with PI with and without RNase treatment is 
shown in D  and C, respectively. Optimum concentrations o f stain are described in text. (Bar =  
50[im).
The nuclear stain aids in locating cells during the staining procedure, however to see 
cellular boundaries staining of cytoskeletal elements can be used. Microtubules are a 
major cytoskeletal component and are predominantly composed of molecules of a-
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and (3-tubulin (Alberts et al., 1994). Optimal staining of microtubules was achieved 
using a 250x dilution of a (3-tubulin antibody (see Figure 35). Using the microtubule 
staining protocol the different fixation methods were assessed. A more intense 
microtubule stain was seen in permeabilised cells, especially those fixed with 
acetone/methanol combinations (see Figure 36).
Figure 35. Microtubule Stain in HUVECs.
P2 HUVECs grown on coverslips were fixed with acetone/methanol for 5mins and were stained for 
(3-tubulin (red) and DAPI (blue) using optimal conditions (see text) (Bar =  50pm).
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Figure 36. The Effect of Fixation Techniques on Membrane Permeability.
HUVECs were fixed with: A) Paraformaldehyde for lOmins, B) Paraformaldehyde for lOmins 
followed by Saponin for lm in, C) Paraformaldehyde for lOmins followed by Triton X-100 for lmin, 
D) Paraformaldehyde for lOmins followed by Acetone/M ethanol for lmin, or E) Acetone/M ethanol 
for 5mins or F) lOmins, and stained for [3-tubulin with a Cy3-conjugated antibody (red fluorescence). 
Mercury arc lamp intensity and camera exposure times were constant for all images Bar = 50pm).
3.4.2.2 von W illebrand E x p ress io n  in HUVECs
Staining for the endothelial cell marker, vWf, was optimised. A 150x dilution of the 
polyclonal and 300x dilution of the monoclonal anti-human vWf antibodies was 
optimal. vWf staining of human umbilical vein cell isolates (see Figure 37) revealed
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staining of compartmentalised, punctate, or “rod”-shaped structures, and a more 
diffuse stain around the nucleus (probably staining the endoplasmic reticulum).
Figure 37. von Willebrand Factor Immunofluorescent Stain in HUVECs.
P2 umbilical cord vein cell isolates were grown on coverslips were fixed with acetone/methanol for 
5mins. Immunofluorescent stains for vW f (green) and (3-tubulin (red) were carried out. vW f was 
stained using a polyclonal antibody and FITC-conjugated secondary. Cellular nuclei were stained with 
DAPI (Blue) (Bar = 50pm).
To assess the number of endothelial cells in a typical umbilical cord vein isolation, the 
percentage of vWf positive cells was measured by fluorescent staining. Fields of view 
were chosen randomly by observing the nuclear stain under the fluorescence 
microscope. An image was captured and filters were changed to view the vWf stain, 
and a second image was captured. Images of the same field of view were overlaid and 
the number of vWf positive cells was counted and total number of cells was 
calculated by nuclear stain (see Table 2).
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Total cells Percentage 
vWf positive
274 6 279 98.2%
P2 cell isolates were fixed with paraformaldehyde and permeabilised with triton X-100. Cells were 
stained for vW f using DAK O  polyclonal and nuclei were stained with DAPI. Pictures were taken 
randomly and vWf-positive and total cells were counted.
3.4.3 Xanthine Oxidoreductase Expression in HUVECs
The aim of this section is to assess the expression of XOR within the chosen vascular 
endothelial model, the HUVEC. Microvascular endothelial cells have been shown to 
express and release XOR (Jarasch et at., 1981; Jarasch et at., 1986; Partridge et at’, 
1992). However, for HUVECs to be used in investigations into the hypothesised 
endothelial release of XOR, it is essential to demonstrate XOR expression within this 
cell type.
3.4.3.1 XOR Protein  E x p ress io n
A range of XO antibodies were commonly used within the laboratory. The 
effectiveness of the antibodies was compared on Western Blots of purified XO and 
milk samples which contain XO (see Figure 38). No staining was observed using the 
monoclonal antibody and the most intense staining was seen using the polyclonal 
Polysciences antibody with a specific secondary antibody.
A B C D
7
Figure 38. Comparison of Xanthine Oxidase Antibodies in Western Blot.
Pure XO (25ng; Lane 1) and milk (10[jLg protein; Lane 2) were run on SDS-PAGE and following 
Western Transfer nitrocellulose membranes were probed with four commercially available XO- 
andbodies: A: Chemicon 5000x dilution; B: BioDesign lOOOx dilution; c: NeoMarkers lOOOx dilution;
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D: Polysciences 5000x dilution. The secondary antibody was used as appropriate: 200x dilution o f  
swine anti-rabbit IgG or lOOOx dilution o f rabbit anti-mouse IgG.
To demonstrate the presence or absence of XOR in the HUVEC vascular endothelial 
model, a T25 flask o f confluent P2 HUVEC was lysed direcdy in 150pl sample buffer. 
20[il of the lysate was loaded direcdy onto SDS-PAGE, and following Western- 
transfer XOR was probed using the optimal antibody conditions (i.e. using the 
Polysciences XO antibody; see Figure 39). XOR is detected in HUVECs, strong 







Figure 39. The Detection of Xanthine Oxidoreductase in the HUVEC -  Western Blot.
Two T25 flasks o f  HUVECs (Lanes 1 and 2) were lysed in sample buffer and lysates were loaded 
directly onto SDS-PAGE. Following Western-transfer nitrocellulose membranes were probed with 
Polysciences Anti-XO.
With Western-Blot confirmation that HUVECs contain XOR, the cellular expression 
of the enzyme was investigated using fluorescence microscopy. P2 HUVECs were 
grown on glass coverslips and using two fixation methods staining for XOR was 
compared (see Figure 40). Irrespective of fixation method, XOR expression in 
HUVECs has a granular, cytoplasmic appearance in all cells, however in some cells a 
more punctuate stain is seen. As a control, XOR staining in the mammary epithelial 
cell line MDA-MB-231 was performed using two XOR antibodies (see Figure 41). 
Compared to the HUVEC a similar staining profile was seen, i.e. all cells express a 
granular cytoplasmic stain but some cells exhibit a more punctate appearance (see 
Figure 42). As in the Western blot (Figure 38) the Polysciences antibody stain was 
more intense compared to the Chemicon equivalent. Saturatation of the 1° antibodies
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before application reduced staining and no detection of XOR was seen using the 1° 
or 2° antibodies alone.
F
20pm 10pm
Figure 40. HUVEC XOR Expression -  Immunofluorescence Study.
P2 HUVECs were grown on coverslips and were fixed with acetone/methanol for 5mins at 4°C (A- 
C, E, F) or 4%Paraformaldehyde for lOmins at 37°C and with 0.2% Triton X-100 for lm in at 37°C 
(D). Cells were stained using the Polyscience XO-antibody and either a FITC (green) or Rhodamine
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(red)-conjugated 2°antibody. Cell nuclei were stained using DAPI. Results are from two experiments. 
A-D bar = 50pm).
Figure 41. MDA-MB-231 XOR Expression -  Immunofluorescent Control.
Subconfluent MDA-MB-231 cells grown on coverslips were fixed with acetone/methanol for 5mins 
at 4°C. Fixed cells were stained with: A) Chemicon XO antibody, B) Saturated Chemicon XO  
antibody C) Chemicon X O  antibody only, D) Polysciences XO  antibody, E) Saturated Polysciences 
XO antibody, F) Polysciences XO  antibody only, G) 2° antibody only, H) N o  antibody stain, I) N o  
staining. All cells, apart from condition I, were DNA-stained with DAPI (blue). A FITC conjugated 
2°antibody was applied to A-G (Bar = 50pm).
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Figure 42. MDA-MB-231 XOR Expression Profile -  Immunofluorescence.
Subconfluent MDA-MB-231 cells grown on coverslips were fixed with acetone/methanol for 5mins 
at 4°C. Fixed cells were stained with the Polysciences X O  antibody and a FITC-conjugated 
2°antibody (green) and nuclei were stained with DAPI (blue) (Bar =  50[i.m).
To confirm the staining profiles seen with the immunofluorescent technique, 
HUVECs were prepared and labelled for electron microscopy using the Quantomix 
kit (as described in section 3.3.7). The resultant labelling of vWf and XOR was 
consistent with findings using immunofluorescent techniques (see Figure 43).
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Figure 43. HUVEC Expression of vWf and Xanthine Oxidoreductase -  Electron Microscopy 
Study.
P2 HUVECs were grown on Quantomix capsules and were fixed with 4% Paraformaldehyde and 
permeabilised with 0.2% Triton X-100. vW f (B and C) and XO R  (D) were labelled with D A K O  and 
Polysciences l°-antibodies, respectively. A gold-conjugated 2°-andbody was applied and labelling was 
silver-enhanced. Uranyl acetate was used to faindy stain general cell structure. Incubation with the 2°- 
antibody alone (E) and HUVECs growing on the capsule membrane (A) are shown. N =  Nucleus, 
WPBs = Weibel-Palade Bodies. Unless indicated arrows show punctate XOR staining.
Xanthine oxidoreductase appears to be expressed in a cytoplasmic form but also in a 
packaged form in HUVECs. To attempt to characterise the storage granule of XOR, 
co-localisation studies with the WPB-protein vWf were performed, a positive co­
localisation would suggest WPB storage of XOR. In this study HUVECs were stained 
using a dual immunofluorescent technique, whereby XOR and vWf were labelled with 
1° antibodies (raised in different species) and cognate 2° antibodies. XOR and vW f 
were probed with rhodamine-, and FITC-conjugated 2° antibodies, respectively. 
Images were taken and overlaid as previously described. In overlaid pictures, any co­
localisation is indicated by a yellow colour (see Figure 44). The majority of XOR 
staining was independent of vWf staining.
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Figure 44. Co-localisation of Xanthine Oxidoreductase Storage with vWf?
P2 HUVECs were grown on glass coverslips and were fixed with acetone/m ethanol for 5mins at 
4°C. XOR (A, red) and vW f (B, green) were detected using l°antibodies raised in different species in 
combination with relevant 2° antibodies. Nuclei were stained the DAPI (C, blue). Yellow areas 
indicate co-localisation o f  vW f and XOR (D) (Bar =  20pm).
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3.4.3.2 XOk G ene  E x p ress io n
Vascular-associated XOR could originate from two sources: i) endogenous 
expression, or ii) by endocydc retrieval of the protein from the circulation following 
its release from XOR-rich organs (a process that has not yet been verified). Therefore 
RT-PCR for the detection of HUVEC mRNA expression was performed to help 
answer this question. In this experiment conditioned ECGM from confluent T25 
flasks of P2 HUVECs was replaced with fresh ECGM, and at relevant time points 
medium was removed and cells were lysed in RNA STAT-60. RNA was isolated and 
integrity was checked by agarose gel electrophoresis (see Figure 45). It is expected 
that intact RNA separated by agarose gel electrophoresis should from two bands, the 
18S and 28S rRNA (Skrypina et al., 2003), therefore the RNA in the sample shown is 
intact.
Figure 45. HUVEC RNA Integrity Checks.
lpg  HUVEC RNA was separated by agarose gel electrophoresis: Lane 1) Base pair (bp) ladder, which 
runs in lOObp increments except where indicated, Lane 2) lp g  HUVEC RNA.
cDNA was prepared using the l st-Strand Synthesis Kit as described in the 
methodology section and lpg cDNA was used in PCR reactions with Rat XOR and 
human GAPDH primers. The XOR primers were originally designed to anneal to the 
rat XO sequence, however these primers are complementary to the human XO 
sequence (see Figure 46). PCR results are shown in Figure 47. XOR was constitutively 
expressed in HUVECs and no change in expression occurs following the medium 
change. 1 pg Mouse liver cDNA was used as a positive control for the PCR reaction 
and a lane with no cDNA served as a negative control. Using the same samples PCR 
for the constitutively expressed gene glyceraldehyde-3-phosphate dehydrogenase
2642bps —  
1000bps —
 28S rRNA
—  18S rRNA
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(GAPDH) was used as a loading control. Therefore demonstrating that equal 
quantities of cDNA from each HUVEC sample were used in the PCR reactions and 
therefore no change in XOR expression occurred. GAPDH expression is commonly 
used as a constitutive control for PCR in HUVECs (Tabengwa et al., 2000; Sasaki et 
al., 2004) (as well as other cell types).
R a t  P r i m e r  
H u m a n  X O
R a t  P r i m e r  
H u m a n  X O
S e n s e  ( f o r w a r d )  5 ' - 3 '
----------------------------------------------------------------------------------------------------------C T G T C C A T C G A G A T C C C C T A --------------------------2 0
A G A A A G A C C C T G C T G A G C C C G G A G G A G A T A C T G C T C T C C A T A G A G A T C C C C T A C A G C A G G  1 3 2 0★* ★★★★★ *★★★★*★★★★*
N o n - s e n s e  ( r e v e r s e )  3 ' - 5 '
--------------------------------------------------------------------------------------------------- T C T C A G C C C T C A A G A C C A C T ........................................... 2 0
C T T T G C T A T G G T G G A A T G G C C A A C A G A A C C A T C T C A G C C C T C A A G A C C A C T C A G A G G C A G  1 5 0 0
* * * * * * * ★ * * ★ * * ★ ★ * * * * *
Figure 46. Binding of the Rat XO Primer Pair to the Human XO Sequence
The annealing positions o f  the rat X O  primer set to the human nucleotide sequence are given. The 
non-coding human XO sequence is shown, numbers at the right hand side o f the sequence indicate 
the position o f the last nucleotide.
500 base pairs
Figure 47. HUVEC xor Gene Expression.
Fresh ECGM was added to HUVECs and cells were lysed in RNA STAT-60 at 0, 1, 2, and 4 hours 
following medium change. RNA was isolated and cDNA was prepared. PCR reactions were 
performed using rat XOR and human G A PD H  primer sets, expected product sizes are 288 and 576 
base pairs, respectively. A) XOR PCR, lane 1: base pair ladder, lane 2: mouse liver cD N A , lane 3: no 
cD N A , lane 4: HUVEC cD N A  Ohr, lane 5: HUVEC cDNA lhr, lane 6, HUVEC cD N A  2hr, and 
lane 7: HUVEC cDNA 4hr. B) G APDH  PCR, lane 1: base pair ladder, lane 2: HUVEC cDNA Ohr, 
lane 3: HUVEC cDNA lhr, lane 4, HUVEC cD N A  2hr, and lane 5: HUVEC cD N A  4hr.
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3.5 Discussion
3.5.1 Umbilical Cord Cell Isolates -  Morphological and 
Behavioral Analyses
Cells that form the endothelial cell model, the HUVEC were isolated from umbilical 
cords kindly donated by mothers attending the maternity ward at Bath Royal United 
Hospital (with Bath Local Research Ethics Committee approval: Ref: BA635). As 
indicated in stained transverse sections o f the human umbilical cord (Figure 28 and 
Figure 29) there are three blood vessels; two arteries and one vein. These vessels are 
easily distinguished from one another by eye, by differences in vessel diameter, and by 
microscopy, by differences in vessel morphology. The arteries and vein have 
morphologies that match text-book descriptions o f these vessels, i.e. the arteries 
contain significantly more smooth muscle compared to the vein (Figure 29; Pocock 
and Richards, 1999).
For planned endothelial XOR-release experiments, it was important to demonstrate 
that the cells being isolated from the umbilical cord are in fact from endothelial 
origin. Therefore following collagenase digestion, a range of morphological and 
protein expression analyses were performed to assess the cell type being isolated. 
Initial studies observing isolated cells under phase contrast microscopy showed a 
culture with uniform structure (Figure 30).'Cultures grown to confluence formed a 
monolayer of polygonal cells, and look identical to cultures of cells confirmed to be 
HUVECs (Jaffe et al., 1973; Nachman and Jaffe, 2004). Components of the human 
umbilical vein that could potentially contaminate HUVEC cultures include fibroblasts 
and smooth muscle cells. However, the morphology of the isolated cells is distinct 
from that of smooth muscle and fibroblasts which grow as overlapping layers o f 
parallel arrays o f spindle-shaped cells (Jaffe et al., 1973). The morphology o f the 
cultured umbilical cord vein cell-isolate was compared to that of commercially 
available HUVECs (Figure 31). Cultures appeared identical, therefore suggesting that, 
by appearance, the isolated cells were indeed HUVECs.
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An interesting feature o f HUVECs is their ability to form tube-structures. In 
conditions that do not favour proliferation, the HUVEC may non-terminally 
differentiate, as seen by an organisational change in their structure that ultimately 
leads to tube-structure formation (Maciag et al., 1982). Endothelial cell growth can be 
regulated by contact inhibition (Buonassisi and Venter, 1976), therefore when 
confluent, HUVECs would be growing under conditions that do not favour 
proliferation. Cultures that were grown to confluence and were incubated without 
passage formed tube-like structures within 21 days (Figure 32), therefore 
demonstrating that the cells isolated from the umbilical cord vein have endothelial cell 
properties.
3.5.2 Umbilical Cord Cell Isolates -  Protein Expression Analyses
3.5.2.1 Protein Staining in Cultured Cells - Fixation
For the protocols used within this thesis, a fixative step is required for the detection 
of cellular proteins in cultured cells. Several fixation techniques available were 
compared for their effect on plasma membrane integrity by the subsequent staining of 
the intracellular antigen (3-tubulin (Alberts et al., 1994) (Figure 36). The action of the 
fixation agents used has been described (Bacallao et al., 1995). Paraformaldehyde, a 
protein-cross^ linking fixative, fixes cells by forming covalent crosslinks between 
proteins, whereas acetone/methanol, a protein-coagulation fixative, fixes cells by 
rapidly changing the hydration state o f  the cell and proteins are either extracted or 
coagulate during this process. Triton X-100 and Saponin, at the concentrations used, 
are mild detergents that gently permeabilise the fixed cells by removing some lipid 
from membranes. In Figure 36, significant (3-tubulin staining was only seen in 
acetone/methanol fixed cells, which would suggest that much o f the plasma 
membrane is removed during the fixation process, thus allowing excellent cellular- 
entry of the |3-tubulin antibody. Whereas paraformaldehyde-fixed cells showed 
little/no (3-tubulin staining, suggesting that the plasma membrane remains intact, 
therefore not allowing the antibody to enter. The detection of (3-tubulin increases in
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paraformaldehyde-fixed cells following the addition o f the permeabilising detergents 
Triton X-100 or saponin, therefore reinforcing the view that paraformaldehyde 
fixation leaves the plasma membrane intact. The opposing effects of the different 
fixation techniques on plasma membrane structure can be exploited. Using either 
paraformaldehyde or acetone/methanol fixation the location of an antigen could be 
discovered. For example, an intracellular antigen will only be significantly stained if 
the cell was fixed with acetone/methanol or permeabilised with a mild detergent 
following paraformaldehyde fixation. Whereas a cell surface-located antigen, which is 
likely to be removed using acetone/methanol fixation, is more likely to be detected if 
paraformaldehyde fixation was used. Using these fixation techniques would be 
particularly useful when investigating the secretion o f a protein, for example, using 
different fixation techniques at different time periods one could track the release o f a 
protein from an intracellular store to the plasma membrane (i.e. its cell-surface 
expression or disappearance). This reasoning has been exploited in experiments by 
Takano et al., 2002, whereby the cell surface expression of P-selecdn was measured by 
a cell-based ELISA on paraformaldehyde fixed HUVECs, thus avoiding the detection 
of intracellular stores o f this protein.
3.5.2.2 Protein Staining in Cultured Cells -  von Willebrand Factor
To discover the localisation of individual cells and cellular boundary definition in 
immunofluorescence, nuclear stains and cytoskeletal stains were optimised (Figure 34 
and Figure 35). Depending on the fluorophore being used to probe cellular proteins, 
different nuclear stains could be used to enable a contrast in fluorescence between 
stained structures. For the analysis of vWf protein expression in HUVECs, nuclei 
were stained with DAPI as FITC and rhodamine were used in immunofluorescent 
detection of vW f and (3-tubulin, respectively (Figure 37). Within the HUVEC, vW f 
was seen in classic punctate, often rod-shaped storage granules and more diffusely 
near to the cell nucleus (Figure 37 and Figure 43). The punctate staining described is 
vWf packaged into WPBs (Kagawa and Fujimoto, 1987), whereas the more diffuse 
staining is likely to be newly formed vWf found in the rough endoplasmic reticulum
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and Golgi apparatus where the protein is synthesised and modified (reviewed in van 
Mourik et al., 2002). The vWf staining profile seen in HUVECs in this study is 
identical to other studies where vW f protein has been labelled in endothelial cells 
(Jaffe et al., 1973; Knop et al., 2002).
Weibel Palade Bodies are only found in endothelial cells (Weibel and Palade, 1964). 
Therefore, the WPB acts as a unique marker for endothelial cells, and was used to 
determine the cell type being isolated during collagenase treatment o f the umbilical 
cord vein. Together with morphological and behavioural characteristics of the isolated 
cell type, one could be confident that the cell type isolated is predominantly 
endothelial in origin and is therefore the HUVEC.
3.5.2.3 Xanthine Oxidoreductase Expression in HUVECs
3.5.2.3.1 Protein Expression Profile
To detect XOR protein expression in cultures of HUVECs an immunofluorescent 
technique, similar to that used for vW f detection, was planned. However, before 
HUVEC expression could be assessed, certain control experiments were required to 
ensure the XOR antibodies available bind to XOR protein. Several XOR antibodies 
are available and therefore their binding to purified and milk-XOR was compared by 
western blot (Figure 38). No detection was seen using the NeoMarkers antibody, 
possibly because the stock was old and the antibody may have come out of solution. 
Comparing the other three antibodies, the Polysciences antibody appears to bind 
better to XOR, as indicated by a stronger signal-to-noise ratio. The HRP-conjugated 
BioDesign XOR-antibody predictably resulted in less exposure as no 2° antibody is 
used to amplify the HRP-signal, however equal quantities o f Chemicon and 
Polysciences antibody were used, therefore the Polysciences antibody was chosen to 
be used in subsequent XOR protein-detection experiments. Prior to cellular staining 
with the XOR antibody, a HUVEC lysate was probed for XOR content using the 
western blot technique (Figure 39). The lysates tested showed the XOR protein is 
found in HUVECs and the banding pattern seen was very similar to that seen with
3-94
J a n i e ' .  I L ‘\'. nis i i i i I Mi l ) l l i c s i
liver XOR (Waud and Rajagopalan, 1976). These results suggest HUVECs contain 
the XOR enzyme, which confirms results with other vascular endothelial cell types 
(Jarasch et al., 1981; Jarasch et al, 1986; Partridge et al., 1992).
3.5.2.3.2 The Endothelial XOR Storage Granule?
The HUVEC endothelial cell model was probed for XOR using an 
immunofluorescent technique, the results from two separate experiments are shown 
in Figure 40. The results from these experiments were interesting, XOR appeared as a 
diffuse cytoplasmic stain in all cells, however in some cells, a punctate stain could be 
seen, which would suggest packaging of this protein. The appearance of this punctate 
stain is unlikely to be an artefact from the fixation process for two reasons: i) the 
punctate stain is not seen in all cells but a diffuse stain is always present. Therefore if 
fixation caused the coagulation of XOR resulting in a punctate stain, then it should 
appear in all cells, however it does not, and ii) Acetone/methanol fixation does result 
in punctate staining (Figure 40 A-B, E and F), however this staining is not an artefact 
o f this technique because it is also seen with paraformaldehyde fixation plus triton X- 
100 permeabilisation (Figure 40 D). To confirm the staining seen using 
immunofluorescence a different technique was used, scanning electron microscopy 
with gold-conjugated 2° antibodies (Figure 43). Again, cytoplasmic and punctate 
staining of XOR could be seen.
The appearance o f XOR-“packages” was not expected, because the XOR protein 
does not contain any known signal sequences for cellular compartmentalisation 
(Ichida et al., 1993). Despite this fact, several research groups believe they discovered 
XOR in peroxisomes o f rat hepatocytes (Angermuller et a l, 1987; Dikov et al., 1988; 
Frederiks and Vreeling-Sindelarova, 2002). This finding would suggest that XOR 
must contain a sequence for direction to the peroxisome. However a separate study 
has questioned these findings (Ichikawa et al., 1992), in their experience XOR was 
present in the cytosol of these cells only.
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Interestingly, the mammary epithelial cell line, MDA-MB-231, also contained 
punctate staining of XOR (Figure 42). A control for the XOR-stain was performed 
with the 1° or 2° antibody alone, or with a saturated 1° in combination with the 2° 
antibody, which resulted in fluorescent staining being absent or greatly reduced 
(Figure 41), suggesting that the antibody binding is specific. In the mammary 
epithelial cell, however, the punctate appearance can be explained. Milk lipid occurs in 
two forms, as membrane fragments in the skim phase and as milk lipid droplets 
(MLDs) that provide essential nutrition to the suckling neonate. MLDs are released 
from mammary epithelial cells by a novel mechanism. Lipid droplets form at the 
endoplasmic reticulum (Deeney et al.^  1985) and are transported to the apical plasma 
membrane before being secreted. The process of secretion involves the enveloping of 
the MLD in plasma membrane, which pinches-off to release the MLD into the 
mammary alveolar lumen. The mechanism of MLD release from mammary epithelial 
cells has been proposed by Mather and Keenan, 1998 (see Figure 48).
A
Figure 48. The Proposed Protein Interactions Involved in MLD Secretion from Mammary 
Epithelial Cells.
A) The enveloping o f the MLD, which occurs prior to its release, is thought to be driven by the 
interactions between the apical plasma membrane (APM)-protein butyrophilin, the cytoplasmic 
protein XO , and the MLD-associated protein adipocyte differentiation-related protein (ADRP). 
These inactions are summarised in B). X O  is thought to be responsible for the dimerisation of 
butyrophilin, therefore increasing the affinity o f  butyrophilin for ADRP. These interactions maybe 





.Ij i i k ''. I lew iiiMtn
Considering the proposed process, the concentrated areas o f XOR seen in MDA- 
MB-231 cells could be regions where milk lipid droplet-release is in process. However 
the process of lipid-droplet secretion does not occur in the vascular endothelium, and 
previous studies have demonstrated that butyrophilin is only present in mammary 
epithelial cells (Jack and Mather, 1990). Therefore the endothelial XOR-“package” 
must have a different function.
In an attempt to characterise the endothelial XOR-“package”, colocalisation studies 
with vWf and therefore WPBs was performed (Figure 44). However co-localisation 
was not significandy observed and therefore XOR is “packaging” independently of 
the WPB (the few areas o f co-localisation seen are only by virtue of the microscopy 
technique being used, i.e. visualising the entire depth o f the cell. Images taken using 
confocal microscopy on the other hand, looking at a single plain through the cell, are 
likely to show no colocalisation). To discover whether the punctate XOR stain is in 
fact an XOR-storage granule, then co-localisation with other endothelial-packaged 
proteins should be performed, for example with tissue-type plasminogen activator 
(tPA) (an anti-coagulant, fibrolytic protein), which is stored in small punctate 
structures independent o f WPBs (Emeis et al., 1997; Knop et al., 2002; Zupanic et al., 
2002) [However it must be noted that other research groups have found tPA to 
colocalise with vW f (Rosnoblet et al., 1999)]. If the XOR-package does not colocalise 
with another endothelial-stored protein, either a new storage granule has been 
discovered or packaged XOR is formed by another process, e.g. by endocytosis. As 
mentioned in the introductory chapters, XOR is known to bind to the surface of the 
vascular endothelium by association with GAGs (Adachi et al., 1993). Endothelial- 
bound XOR may be internalised by endocytic events (Houston et al., 1999) that would 
result in compartmentalisation of XOR protein. These events could explain the 
structures seen in HUVECs, however the process is reliant on an extracellular source 
of the enzyme. To assess whether the punctate staining o f XOR observed is derived 
from endocytic processes, colocalisation with endocytic markers should be attempted,
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for example with EEA-1 for early endosomes or Lamp-1 for late endosomes and 
lysosomes (reviewed in Watson et al., 2005).
3.5.2.3.3 HUVEC XOR-Gene Expression?
To detect whether HUVECs express the XOR gene an RT-PCR technique was used. 
RNA was purified from HUVEC lysates and was shown to be intact (Figure 45). The 
Rat XOR primers used in the PCR protocol were shown to be complimentary to the 
human XO sequence (Figure 46), and therefore were used in these studies. PCR 
applification o f cDNA preparations showed that XOR mRNA was present in 
HUVEC lysates. Furthermore, the expression o f XOR appears to be constitutive and, 
as indicated by the expression of GAPDH, does not vary over the time course tested 
(i.e. 4 hours; Figure 47). Therefore the XOR enzyme within HUVECs is likely to be 
of endogenous origin.
As a note o f caution. GAPDH is a catalytic enzyme involved in glycolysis. The 
enzyme is constitutively expressed and therefore is often used as a positive control for 
PCR and/or as an indication of equal loading o f RNA or cDNA in the PCR process 
(Tabengwa et al., 2000; Sasaki et al., 2004). However, care should be taken when using 
the expression o f GAPDH as a control, as under certain conditions the expression o f 
GAPDH can be effected, for example under hypoxia or in diabetes (Graven et al., 
1994; Wentzel et al., 2003).
3.6 Summary
Through morphological, behavioural, and protein marker analysis, cells isolated from 
the human umbilical vein have been shown to be predominantly of endothelial origin 
and are therefore the HUVEC. Using immunofluorescent and immuno-gold labelling, 
XOR protein expression in the HUVEC has been demonstrated. In the HUVEC, 
XOR is distributed diffusely throughout the cytoplasm but may also be found in 
possible storage granules. As XOR is not believed to contain any signal sequences for 
compartmentalisation the mechanism of granule formation, is unknown. However
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XOR has been localised to peroxisomes in other studies, therefore a mechanism for 
XOR compartmentalisation must exist. The expression o f the XOR gene was shown 
in HUVECs by RT-PCR.
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Chapter 4. Assessment of Methods 
for the Measurement of Xanthine 
Oxidoreductase
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4 Results: Assessment of Methods for the 
Measurement of Xanthine Oxidoreductase
4.1 Introduction
As demonstrated in Chapter 3 the chosen vascular model (the HUVEC) has XOR 
distributed throughout the cytoplasm and is also found packaged into granules. If the 
hypothesised release o f XOR by the endothelium is to have any impact on human 
physiology or pathology, then enzyme released would have to be active. In this 
chapter, various XOR activity assays will be assessed and in some cases optimised, 
ultimately for the purpose o f measuring XOR activity in HUVEC vascular endothelial 
model.
Many XOR activity assays have been produced and measure XOR activity through 
the formation of reaction products, either by analysing oxidised electron-donating 
substrates or the generation o f reduced electron-acceptors, typically ROS. Techniques 
available for the measurement o f reduced electron-acceptors include the ROS- 
detecting methods: lucigenin-based chemiluminescent assays (Storch and Ferber,
1988), the cytochrome C assay (Murrell et al., 1990), nitroblue tetrozolium 
precipitation assays (Ozer et al., 1998), and electron spin resonance spectroscopy 
(Speikermann et al., 2003). Techniques that measure oxidised electron-donating 
substrates include: the uric acid assay (as used in Saunders et al., 1997) and the 
fluorescence-based isoxanthopterin assay (Beckman et al., 1989).
4.2 Chapter Aim
The aim of this chapter is to compare the XOR-activity assays available to the lab for 
specificity, sensitivity, and through-put. The XOR assays to be compared include, 
ROS-detecting assays based on lucigenin and nitroblue tetrazolium reduction, the 
assay of uric acid generation in the presence of the xanthine substrate, and the 
fluorescence based assay based on XOR-catalysed generation o f isoxanthopterin from 
the xanthine analogue pterin. The effectiveness of each assay will be discussed and
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the most specific and sensitive assay will be used in later results chapters for analysis 
endothelial derived XOR activity.
4.3 Principals, Materials, and Methods
4.3.1 Bio-Rad Protein Assay
The Bio-Rad assay was used to determine unknown solubilised protein 
concentrations in samples. The assay is based on the method of Bradford (Bradford, 
1976), which analyses a dye-colour change, and therefore absorbance change in the 
presence of protein. The reagent used in this procedure is an acid solution of 
Coomassie® Brilliant Blue G-250 dye. Free o f protein the reagent’s maximal 
absorbance is 465nm, however in the presence of soluble protein the dye binds and 
absorbance shifts to 595nm. Absorbance at 595nm is proportional to soluble protein.
4.3.1.1 Materials
Bovine serum albumin (BSA) standard (1.35mg/ml), Protein assay dye reagent 
concentrate (Bio-Rad Laboratories Ltd. Hertfordshire, UK). 20ml syringe without 
needle, 0.22pm syringe filter (Fisher Scientific UK Ltd. Leicestershire, UK).
4.3.1.2 Method
The method used is based on manufacturer’s instructions, which will briefly be 
described here. Depending on the expected protein concentration in a sample, two 
methods for detection are available, the Standard and Microassay procedures, each 
run in the 96-well plate format. In the standard procedure the dye reagent concentrate 
was diluted one part to four parts Milli-Q water, and was filtered to remove 
particulate matter. The BSA standard was serial diluted in Milli-Q water, and in a 96- 
well plate, lOpl diluted standard and of unknown-protein sample were applied in 
triplicate. 200pi o f the diluted dye reagent was added to each well and samples were 
mixed by gende pipeting ensuring no bubbles were formed. Following a five minute 
incubation at room  temperature the absorbance at 595nm was measured using a plate 
reader (Dynex Technologies Ltd. West Sussex, UK). Using the absorbance values 
from the BSA standard, a standard curve was created enabling the calculation of
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unknown protein concentrations in samples. The Microassay procedure followed the 
same protocol as above, however, 160(il serial-diluted sample and unknown-protein 
samples were mixed with 40|il dye reagent concentrate.
4.3.2 Lucigenin-Enhanced Chemiluminescence
Lucigenin-enhanced chemiluminescence has been widely used as a method for 
detecting O 2 ~ generation by O 2 ’ "-generating systems (Corbisier et al., 1987; Storch 
and Ferber, 1988) and been used to determine O 2 ~ generation by cultured cells, tissue 
homogenates, and even whole vascular tissue (Gyllenhammer, 1987; Pagano et al., 
1993). The mechanism of O 2 -induced luminescence is believed to require the 
univalent reduction of lucigenin (Luc++), forming Luc+‘, followed by a secondary 
reaction with O 2 "  that results in the formation of light (Faulkner and Fridovich, 
1993).
4.3.2.1 Materials
Lucigenin, N AD H  (Sigma Aldrich Company Ltd. Dorest, UK).
4.3.2.2 Luminescence Measurement Protocol
2mM solutions of lucigenin and NADH were prepared in PBS. Using a 96-well plate, 
wells were filled with lOOpl sample diluted in PBS. The plate was placed into the 
luminescence-reader (Anthos Lucy 1.0 Microplate Luminometer. Anthos. Wals, 
Austria). Following the programmed injection of 5 0 jjl1 2mM solutions o f  lucigenin 
and NADH, luminesecence readings were recorded at set time intervals, and 
luminescence generation over time was calculated.
4.3.3 In-Gel Xanthine Oxidase Assay
Like lucigenin, the compound nitroblue tetrazolium (NBT) may also be used to detect 
O 2 ' "-generation. When in solution, NBT can react with O 2 ~ and forms a blue/purple 
formazan precipitate. NBT has frequently been used to detect O 2 ~ generation in 
cultured cells (Czerniecki, et al., 1986; DiGregorio et al., 1987; Joneson and Bar-Sagi, 
1998). However, taking advantage o f precipitate formation, Ozer et al., 1998
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developed an in-gel assay that enables the detection of O 2 " -generating systems and 
was used for the detection o f XO activity.
4.3.3.1 Materials
For polyacrylamide gel see Section 3.3.5. Nitroblue tetrazolium, Tris-HCl, 
Hypoxanthine (Sigma Aldrich Company Ltd. Dorest, UK).
4.3.3.2 Protocol
Adapted from Ozer */al., 1998. Samples were run on polyacryamide gels as described 
in Section 3.3.5, however in the in-gel assay procedure non-denaturing and non­
reducing conditioned were used, i.e. SDS and (3-mercaptoethanol were omitted from 
all buffers and the gel. Following electrophoresis, the gel was bathed in a solution that 
enabled the detection o f XOR activity (see Appendix I 8.6). Gels were incubated at 
room temperature for sufficient time for blue/purple formazan-precipitate bands to 
develop (see individual results). Following this period gels were rinsed several times in 
distilled water to remove non-reduced NBT, and could be stored in water at 4°C in 
the dark before analysis.
4.3.4 Uric Acid Assay
As described in the introductory Chapter 2 Section 2.2.4.4, XOR generates uric acid 
during the oxidation of xanthine. This fact forms the basis o f a simple assay 
measuring XOR activity through the formation of uric acid, as used in Sanders et al.t 
1997.
4.3.4.1 Materials
Xanthine (Sigma Aldrich Company Ltd. Dorest, UK). Xanthine Oxidase (10.61U/ml; 
10.5mg/ml) (Biozyme Laboratories. Gwent, UK).
4.3.4.2 Protocol
Xanthine oxidoreductase activity in selected samples was measured 
spectrophotometrically (Hitachi U-2010 spectrophotometer. Hitachi. Berkshire, UK). 
In the presence of lOOpM xanthine at 25°C, the formation o f uric acid at absorbance 
295nm ( A 2 9 5 )  was recorded. Using an extinction coefficient of 9.6m M 1 cm 1 (Avis et
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al., 1956), data were anaylsed to calculate XOR activity as a function of uric acid 
generation per unit time.
4.3.5 Isoxanthopterin Assay
A sensitive, fluorometric assay for XO and XDH has been developed over several 
decades (Lowry et al., 1949; Haining and Legan, 1967; Markley et al, 1973; Beckman et 
al., 1989.). The fluorometric assay is based on the use of pterin (2-amino-4- 
hydroxypteridine) as a substrate for XOR, which is oxidised to the fluorescent 
compound isoxanthopterin (2-amino-4,7-dihydroxypteridine, IXP). The protocol 
from the Beckman et al., 1989 assay will now be described and, where indicated, is 
used as the XOR assay in the results chapters. XO activity is assayed in the presence 
of the pterin substrate alone, using oxygen as an electron acceptor for the reduced 
enzyme. With the addition o f methylene blue, an electron acceptor from the Fe-S 
clusters of XO and XDH, the combined activity o f XO and XDH are assayed 
(methylene blue is used instead of NAD+ as an XDH electron acceptor, as NADH 
fluorescence overlaps with that of IXP). Allopurinol is added to the sample to inhibit 
XOR activity, thus allowing the calculation of XO- and XDH-specific generation o f 
IXP [both lactoperoxidase in the presence o f H 2O 2 and aldehyde oxidase were shown 
to catalyse pterin-IXP conversion but were not allopurinol inhibitable (Beckman et al., 
1989)]. Finally the addition o f an IXP internal standard, o f a known concentration, 
allows for the correction o f any fluorescence quenching and the quantification of IXP 
production. The XOR catalysed conversion of Pterin to IXP and the role o f 
methylene blue and allopurinol are shown in Figure 49.
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Figure 49. XOR Catalysed Generation of IXP from the Pterin Substrate.
Electrons donated to XO R  during the oxidation o f  pterin to IXP (leading to increased fluorescence) 
are accepted by O 2 at the FAD-containing moiety in XO, however in the presence o f methylene blue 
electrons are accepted at the Fe-S cluster-containing moiety o f  XO and XDH. Allopurinol inhibits 
the oxidation o f  pterin at the Mo-containing moiety.
4.3.5.1 M aterials
Allopurinol, Isoxanthopterin (IXP), Methylene Blue (MB), and Pterin (Pt) (Sigma 
Aldrich Company Ltd. Dorest, UK). Quartz crystal cuvettes (Fisher Scientific UK 
Ltd. Leicestershire, UK). Xanthine Oxidase (Biozyme Laboratories. Gwent, UK).
4.3.5.2 P ro toco l
To analyse XOR-acdvity the protocol described in Beckman et al., 1989 was followed, 
except for minor adjustments. Briefly, samples to be assayed were made up to 960pl 
in PBS in quartz-crystal cuvettes with magnetic stirrers. As a control lOOng/ml XO 
(final concentration) was typically used. Using a Hitachi F-4500 Fluorescence 
Spectrophotometer (set at: excitation wavelength (Ex) 345nm, emission wavelength 
(Em) 390nm, m onochrom ator Ex slit width 5nm, Em slit width 5nm, and the 
photomultiplier voltage set at 700V) fluorescence measurements were initiated. After 
a baseline reading o f about 30secs 10pM pterin was added and measurements 
continued for sufficient time to enable rate calculations, following this period 10pM 
methylene blue was added. Again after sufficient time, lOpM allopurinol was applied 
to inhibit the reaction and after fluorescence measurements had stabilised a solution
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of approximately lOOnm isoxanthopterin was added (the exact concentration of IXP 
added was calculated from the IXP stock absorbance at 336nm using £ 3 3 6  = 13mM- 
1cm_1 and Beer’s Law). All incubations were at room temperature. A typical plot for 
the measurement of XOR activity is shown diagrammatically in Figure 50.
i k
Fluorescence




A = Sample Alone.
B = Pterin.
C = Methylene Blue. 
D = Allopurinol.
E = IXP Standard.
Figure 50. A Typical Spectum  from the Time-Scan XOR Assay.
X O  is assayed in the presence o f  pterin alone (with oxygen as the acceptor substrate), whereas the 
combined activities o f  XO and X D H  are measured in the presence o f  methylene blue, which replaces 
the need o f  N A D + as an electron acceptor for X D H . Following the inhibition o f  X O R  activity using 
allopurinol, the measurement o f  the fluorescence change following the addition o f  a known 
concentration o f  IXP (which acts as an internal standard) allows the quantification o f  IXP generation 
by XO  and X D H .
From the data recorded the change in fluorescence per unit time was calculated, and 
using the change in fluorescence readings following the addition of the IXP standard 
it was possible to calculate [IXP] generated, as shown in Equation 4.
[IXP] = A F * (.IXPc / F ixp)
Equation 4. Calculation of Isoxanthopterin G eneration in XOR Activity Tim e-Course Assay.
Where A F  =  Change in fluorescence units per unit time, IXPc =  concentration o f  IXP standard 
added, and Frxp =  the change in fluorescence units immediately following the addition o f  the EXP 
standard.
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4.4 Results
4.4.1 Lucigenin-Based Chemiluminescence Xanthine Oxidase- 
Assay
The lucigenin-based chemiluminescence XOR assay was routinely performed in the 
laboratory. To assess this assay, XOR activity in human milk samples was measured. 
Milk samples were kindly donated by lacating mothers post partum, and were stored 
at -20°C before the XOR-assay was performed. An example o f a raw data read-out is 
given in Figure 51A which includes a negative control o f PBS without milk. XOR 
activity in a series o f milk samples was compared over a period o f 18 days post­
partum (see Figure 5IB). During the first week post-partum XOR activity is 
comparatively high, however after this time milk-XOR activity decreases and remains 
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Figure 51. Lucigenin-Based Chemiluminescence XOR-Assay on Human Milk Samples.
Human milk samples were assayed in triplicate for XOR-activity by recording luminescence generated 
as a result o f  XOR-O2 ~ generation (B). An example o f a raw data progress curve with a PBS negative 
control is shown (A).XOR activity was recorded in arbitrary luminescence units (A.L.U.). Error Bars 
=  SD.
4.4.2 In-Gel Xanthine Oxidase Assay.
The in-gel XO-assay was developed in Ozer et al., 1998 and is based on the reduction 
o f a yellow nitroblue tetrazolium solution by superoxide forming a dark blue 
precipitate. The assay was developed using partially-purified XO from bovine milk
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(Ozer et al., 1998), a sample with high activity compared to other XO-containing 
substances or tissues. Therefore before this assay could potentially be applied to 
detect XO release from HUVECs, its sensitivity was tested on various XO-containing 
samples.
Using XO purified from bovine milk as a positive control, an initial study compared 
the activity o f different plasma, liver, and milk samples. Rat liver and plasma, and 
human plasma samples were kindly donated by Dr D. Speden and D r T. M. Millar, 
respectively. In plasma and liver preparations from tungsten or allopurinol-fed rats, 
XOR activity was shown to be effectively inhibited (Speden, 2003), therefore these 
preparations were used as negative controls for XOR activity. The preparation of 
these samples is described in Appendix I 8.7. Total protein in each sample 
preparation was measured using the Bio-Rad protein assay. The linear region o f a 
bovine serum albumin (BSA) standard curve was used to calculate unknown sample- 
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Figure 52. An Example of the  Bio-Rad Protein Assay S tandard  Curve.
The Bio-Rad protein assay standard curve was generated using a doubling-dilution o f a BSA stock o f  
known concentration. A t higher protein-standard concentrations absorbance readings are no longer 
linear (A). Therefore, for the generation o f  the standard curve, linear regression was only performed 
using the absorbance values o f  the lower concentrations o f  BSA (B). Unknown protein 
concentrations could be calculated from the curve following linear regression.
In all in-gel assays, except where indicated, 30pg of each sample was run on a non­
reducing and non-denaturing gel. In this initial study, XO activity was assessed using
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concentrations of hypoxanthine and NBT as described in Ozer et al., 1998. For 
activity analysis, gels were incubated at 37°C and following 30mins incubation a 
strong band could be seen in the lane containing the purified XO sample. After 2hrs 
incubation additional bands could be seen in the lanes containing rat plasma, rat liver, 
and human milk. However, with an overnight incubation no additional bands formed 
(see Figure 53), therefore activity in human plasma and in tungsten-fed rat liver could 
not be detected by this assay.
HP RP RL TRL HM 


















Figure 53. Initial Test of In-Gel Assay Sensitivity.
A) XO-activity in 2pg purified XO  (XO), and 30jig protein from human plasma, rat plasma, rat liver, 
tungsten-fed rat liver, and human milk (HP, RP, RL, TRL, and HM, respectively) was assessed using 
the in-gel assay method as described in Ozer et al., 1998. The activity gel shown results from an 
overnight incubation at 37°C. Arrows indicate bands o f  XO-activity. B) The gel was replicated and 
stained with coomassie blue. C) Activity gels were scanned and density analysis was performed 
(Arbitrary Density Units, A.D.U).
With a view to improve the sensitivity of the in-gel assay described by Ozer et al., 
1998, reaction conditions, i.e. concentrations o f assay substrates and incubation
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temperature, were optimised. Firstiy, concentrations of hypoxanthine equal to and 
greater than those used in Ozer et al.y 1998 were tested in the analysis of XO-activity 
in purified XO and rat plasma (see Figure 54A). Increasing concentrations of 
hypoxanthine were not proportional to an increase in the detection of XO-activity in 
rat plasma samples. However, it was found that by increasing the concentration of 
NBT stronger activity-bands were detected in purified XO and rat plasma (see Figure 
54B).
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Figure 54. In-gel Assay Optimisation of Hypoxanthine and NBT Concentrations.
A) XO  activity in lp g  purified X O  (XO) and 30pg protein from rat plasma (RP) was assessed using 
the in-gel assay solution containing 0.5mM N BT and 0.5, 1.0, 1.5, or 2.0mM hypoxanthine, see gels 1, 
2, 3, and 4, respectively. B) For the same samples, in-gel assays solutions containing 0.5mM 
hypoxanthine 0.25, 0.5, l.OmM NBT were assessed, see gels 1, 2, and 3, respectively. C) The gel was 
replicated and stained for protein using coomassie blue. D  and E) Density analysis was performed on 
the resulting gels (Arbitrary Density Units, A.D.U).
From other experiments performed in the laboratory it was discovered that the 
activity of purified XO was stable when incubated at temperatures up to ~60°C (Dr 
Millar, unpublished results). Therefore a range of incubation temperatures, up to
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50°C, were compared in the in-gel assay. After approximately 30mins incubation 
strong activity-bands were observed in both XO and rat plasma lanes in the 50°C 
incubation, activity-bands were present in the 25 and 37°C incubations but appeared 
much fainter in comparison. Following lh r of incubation strong activity-bands were 
seen in gels incubated at all temperatures, however intensity increased as incubation 
temperature increased (see Figure 55), i.e. temperature was proportional to activity- 
band intensity in purified XO and rat plasma preparations. Therefore, the optimal 
conditions for the in-gel assay were found to be incubation at 50°C in an activity- 
assay solution containing 0.5mM hypoxanthine and ImM NBT.
25°C 37°C 50°C
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Figure 55. In-gel Assay Optimisation of Incubation Temperature.
A) X O  activity in lp g  purified X O  (XO) and 30(jig protein from rat plasma (RP) was assessed using 
the in-gel assay solution containing l.OmM hypoxanthine and ImM NBT, incubated at 25, 37, and 
50°C for equal periods o f time. B) The gel was replicated and stained for protein using coomassie 
blue. C) Density analysis was performed on the resulting gels (Arbitrary Density Units, A.D.U).
As a control for the optimal conditions, purified XO and rat plasma samples were 
incubated in a XO-activity assay solution without hypoxanthine (therefore just NBT)
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or with the XO-inhibitor allopurinol (see Figure 56). Compared to the positive 
control, the presence o f allopurinol greatly reduced XO activity and therefore the 
formation of the formazan precipitate, and in the absence of the XO-substrate 
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Figure 56. Control for Optimal In-gel Assay Conditions.
A) XO-activity in 2pg purified X O  (XO), and 30[j.g protein from rat plasma, was assessed using the 
optimal in-gel assay method (+ve control), in the presence o f  0.5mM allopurinol (allopurinol), or in 
the absence o f hypoxanthine (N BT only). B) The gel was replicated and stained with coomassie blue. 
C) Activity gels were scanned and density analysis was performed (Arbitrary Density Units, A.D.U).
The optimal in-gel assay conditions were used to assess XO-activity in the original 
samples tested (see Figure 57, compare with Figure 53), therefore allowing a 
comparison of the published assay conditions against the new protocol. Using 
optimal conditions, activity-bands developed in purified XO, rat plasma, and rat liver 
after just 30mins incubation. After 1.5hrs incubation faint bands could also be seen in 
human milk and tungsten-fed rat liver samples. However no change was observed 
following an overnight incubation (as shown in Figure 57).
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Figure 57. Assessment of In-Gel Assay Sensitivity Using Optimal Conditions.
A) XO-activity in 2pg purified XO (XO), and 30pg protein from human plasma, rat plasma, rat liver, 
tungsten-fed rat liver, and human milk (HP, RP, RL, TRL, and HM, respectively) was assessed using 
the optimised in-gel assay method. Arrow indicates bands o f  XO-activity B) Activity gels were 
scanned and density analysis was performed (Arbitrary Density Units, A.D.U).
4.4.3 Isoxanthopterin-Based Xanthine Oxidase Assay
To assess the sensitivity of the fluorescence-based isoxanthopterin (IXP) assay, the 
assay was compared to the in-gel assay with optimal incubation conditions. For the 
in-gel assay lpg  purified XO and 30pg plasma, liver, and milk samples were loaded. 
For the IXP-assay comparison, the same quantities were assessed using the method 
described by Beckman et al., 1989, except for purified-XO where only 0.1 pg was used 
(see Figure 58). An example of the raw data output in the IXP-assay is shown in 
section 4.4.4. The results from the in-gel assay presented are following 2hrs 
incubation, whereas in the IXP-assay an activity rate for each sample was calculated 
from just lm in assays at 37°C. Comparing the samples used, a similar XO-activity 
profile was seen from both XO-assays (Figure 58B and C). Interestingly, in a protein-
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to-protein comparison more activity is seen in cow milk compared to human, and the 
XO-inhibitory effects are greater using tungsten feeding compared to allopurinol in 
rats.
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Figure 58. Isoxanthopterin Sensitivity Test -  Comparison with In-gel Assay.
A) XO-activity in 2pg purified XO  (XO), and 30pg protein from human plasma, rat plasma, 
allopurinol-fed-rat plasma, tungsten-fed-rat plasma, rat liver, tungsten-fed-rat liver, human milk, and 
cow milk (HP, RP, ARP, TRP, RL, TRL, HM and CM, respectively) was assessed using the optimised 
in-gel assay method. Arrow indicates bands o f  XO-activity, loading order is described in table. B) 
Activity gels were scanned and density analysis was performed (Arbitrary Density Units, A.D.U). C) 
The samples, as described in A, were assayed using the Beckman et al., 1989 method, however only 
0.1 pg purified X O  was used. Assays were duplicated and error bars represent SD.
Equal quantities of total protein were analysed in the in-gel and IXP-based assays. 
However, to assess the quantity of XOR-protein in each sample in comparison with 
enzyme activity, Western-blot analysis was performed (see Figure 59). 50ng purified 
XO and 10pg of each sample were loaded onto a SDS-PAGE gel. Transferred 
proteins were probed for XO using the Polysciences 1° XO-antibody with relevant
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2°. It is interesting to note that even though similar quantities of XO-protein are 
present in both human and cow’s milk (see Figure 59 lanes 10 and 11, respectively), 
the enzyme activity in these samples is quite different (Figure 58), i.e. far greater 
activity is present in cow’s milk. Also, a band approximately 20kDa is present in 
plasma samples that is weakly visible or absent from liver and milk samples.
Figure 59. XOR-Protein Content in In-gel Assay Samples.
The XOR-protein content in the samples used in the in-gel and IXP-based XO-assays was assessed 
using the Westem-Blot technique. Proteins in lOpg o f each sample were separated by SDS-PAGE 
under reducing conditions. Transferred proteins were probed using a 1 in 5000x dilution of 
Polysciences anti-XO and a 1 in 200x dilution o f  the relevant secondary antibody. The gel-loading 
order is given in the table above.
To improve detection of XO-activity in the IXP-based assay, an assay time greater 
than lmin maybe required. To assess the generation of IXP over time, the activity of 
purified XO was measured in the presence of lOpM pterin and lOpM methylene blue, 
with and without 10pM allopurinol at intervals up to 24hrs at 37°C. In this 
experiment the allopurinol-inhibitable activity of 5ng XO was measured, essentially 
using the Beckman et al., 1989 assay, however an end-point concentration of IXP 
generated was calculated for each time point (see Figure 60). The generation of IXP, 
and therefore XO activity, appears to be linear over a 24hr time period (linear 
regression analysis of data resulted in r2 = 0.95).
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Figure 60. Isoxanthopterin-B ased Assay of XO Activity in Long-Term Incubation.
The activity o f  5ng purified X O  was assayed using IXP-generation method. At desired time points 
the allopurinol-inhibitable portion o f  EXP generation was assessed. Each time point was in triplicate 
and error bars represent SD. lin ear  regression was performed and 95% confidence intervals are 
shown.
4.4.4 Uric Acid-Based Xanthine Oxidase Assay
The uric acid generation-based XO-activity assay was also assessed. Using a change in 
absorbance (at 295nm) over time, this assay detects the generation o f uric acid from 
the substrate xanthine, a reaction catalysed by XOR. The generation o f uric acid over 
lmin was assessed and compared to IXP-generation over the same time period (see 
Figure 61), examples o f raw data collected from both assays is shown in Figure 61A 
and C and the calculated activity rates in Figure 61B and D. Compared to the IXP- 
based XO-assay, a greater quantity of purified XO was required in the uric acid-based 
XO assay to produce a readout where XO activity could easily be calculated.
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Figure 61. Comparison of the Uric Acid and IXP-Based XO-Assays.
The activity o f  lp g  purified XO was assessed using the uric-acid assay. The raw data output is shown 
in A, and activity was calculated from the linear regions o f  absorbance change (B). As a control the 
assay was also run in the absence o f  XO, i.e. with phosphate buffered saline (PBS) and xanthine, see 
bar labelled PBS (B). For the IXP-assay, only lOOng X O  was required to produce easily-measurable 
activity. The raw data output is shown in C, and activity was calculated from the linear regions o f  
fluorescence generation (arbitrary fluorescence units, A.F.U.) (D). The addition o f pterine (Pt), 
allopurinol (Alio), and isoxanthopterin standard (IXP) are indicated. As a control the assay was also 
run in the absence o f  X O , i.e. with phosphate buffered saline (PBS) and pterin, see bar labelled PBS 
(D). Each assay was repeated in triplicate and error bars represent SD.
4.5 Discussion
4.5.1 The Lucigenin-Based Chemiluminescent XO-Assay
The chemiluminescent XO-assay was sufficiently sensitive to detect XO activity in 
human milk (Figure 51) and in this respect this assay is comparable to the IXP-assay. 
It is interesting to note the activity in the series o f milk samples tested. Early post-
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partum samples contain higher levels of XO activity compared to later samples, this 
result coincides with findings in other publications where XOR-NO' generation was 
measured (Stevens et al., 2000).
Although the lucigenin-based chemiluminescent assay is sensitive, the use of this 
assay for future experiments measuring XO-release from the endothelium was quickly 
disregarded because the assay is flawed in two ways. Firstly, the assay is no t specific to 
XOR, the activity of any O 2 ~ generator will be detected. However, a certain amount 
of specificity can be generated by using XOR-specific substrates. Calculation of 
XOR-inhibitable portions o f activity is not feasible, as no specific inhibitor exists for 
XOR-NADH oxidase activity. XOR-NADH oxidase activity can be inhibited using 
diphenyleneiodonium (DPI) (Sanders et al., 1997), however DPI also inhibits other 
ROS-generating enzymes such as NADPH oxidase and NOS. Secondly, and most 
importandy, lucigenin can generate O 2 ~! (Liochev and Fridovich, 1998). As described 
in section 4.3.2, the mechanism o f O 2 ’"-induced luminescence requires the univalent 
reduction o f lucigenin (Luc++), forming Luc+ ‘, followed by a secondary reaction with 
O 2 that results in the formation o f light. However Luc+' has been shown to 
autoxidise and thus generate O 2 ”  (Liochev and Fridovich, 1997; Vasquez-Vivar et al., 
1997). Furthermore, evidence suggests that O 2 ” can not reduce Luc++, and therefore 
will not induce chemiluminescence alone (Faulkner and Fridovich, 1993), it is 
believed that some enzymes catalyse the reduction of Luc++ to Luc+‘, however the 
exact mechanism is not known. Therefore, in the presence of O 2, any system that 
results in the univalent reduction o f Luc++ will result in the generation o f O 2 ~ and 
therefore chemiluminescence, which will result in the false detection o f  superoxide 
generation. This process has been shown in systems where O 2 ~ is not ordinarily 
produced, as demonstrated using glucose + glucose oxidase in Liochev and Fridovich, 
1997. As Luc++ may accelerate the formation o f O 2 "  in O 2 ’ “-generating systems and 
produce false positives for O 2 ~ generation, this assay should not be used for the 
detection or quantification of O 2 ~.
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4.5.2 The In-Gel, IXP, and Uric Acid-Based XO Assays
An initial test o f the in-gel assay proved that XO activity could be detected in the 
purified XO control, in rat plasma, rat liver, and in human milk (Figure 53). In this 
first test the incubation conditions stated in Ozer et al.^  1998 were followed. One 
would assume these conditions to be optimal, however further experiments were 
carried out and it was discovered that by increasing both the NBT concentration and 
incubation temperature the assay could be improved (Figure 54; Figure 55), i.e. by 
increasing the intensity and decreasing the formation time o f activity-bands. The 
optimal conditions discovered in this thesis were: incubation at 50°C in an activity- 
assay solution containing 0.5mM hypoxanthine and ImM  NBT. As a control, both 
purified XO and rat plasma samples were incubated in an assay medium without 
hypoxanthine or with allopurinol (Figure 56). Activity was greatly reduced in the 
presence of allopurinol and absent without hypoxanthine, which suggests that only 
XO-activity is being measured in this assay. The optimal assay conditions were 
applied to the original samples tested (Figure 57) and an improvement was seen over 
the Ozer et al., 1998 conditions, i.e. activity-band formation was quicker and XO- 
activity was detected in all samples tested.
XO-activity measurements from the in-gel assay were compared with another XO- 
activity assay, the IXP-based assay (Figure 58). The activity measured in each sample 
was very similar in each assay, suggesting that both assays are measuring XO-activity 
accurately. However, this experiment highlighted a major flaw in the in-gel assay. 
Activity readings in the IXP-based assay were easily duplicated as each assay took 
approximately one minute to perform, whereas the in-gel assay requires several hours 
preparation before activity can be measured. Also, due to the addition of an IXP 
standard, XO-activity in the IXP-based assay can be quantified. To quantify the in-gel 
assay a dilution o f purified-XO, of known concentration, would have to be loaded 
onto each gel, therefore constituting a standard curve from which unknown sample- 
XO quantities could be calculated. However, this would reduce the number of lanes 
unknown samples could be loaded onto and make this process more laborious than it
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already is. As with the lucigenin-based assay, the problem of specificity also arises in 
the in-gel assay. NBT will be reduced by any radical-generating system, however using 
pterin and the addition of allopurinol, the IXP-assay is XO-specific (Beckman et al’,
1989). In addition, the IXP-based assay linearly accumulates the IXP reaction product 
(Figure 60) whereas product formation the in-gel assay appeared to plateau after a few 
hours incubation. Therefore the IXP-based assay can be used as an end-point reaction 
where even very low levels of XO-activity could be recorded.
Compared to the IXP-based XO-assay, similar enzyme-specificity should apply to the 
uric acid assay and theoretically the accumulation o f reaction product could be used in 
the uric acid-based XO-assay. However, this assay was not as sensitive as the IXP- 
based assay (Figure 61), generation rates o f hundreds of nM min4 uric acid were 
required for detection of activity, whereas tens o f nM min4 IXP-generation were 
easily detected in the IXP-based assay. Therefore the IXP-assay appears to be the 
most specific, sensitive, and rapid assay tested and will be used to assess the 
hypothesised secretion o f XOR from the vascular endothelium.
4.5.3 Differences in Activity between Samples Assayed
Some interesting results have been generated assaying samples for XO activity with 
the in-gel and IXP-based protocols. Firstly, comparing the human and cow’s milk 
samples. From the Western blot (Figure 59) it is evident that similar quantities of XO- 
protein are present in each milk sample and therefore similar quantities o f XO- 
protein will have been measured for activity. However, activity in the cow’s milk 
sample was far greater (Figure 58). Both the IXP-based and in-gel assay require 
functional MoCo insertion to catalyse the reaction being measured in each assay (see 
Figure 62) and the reason for discrepancy in activities may lie in the putative 
differences in the MoCo between the two species, i.e. there maybe a greater 
proportion o f functional MoCo in bovine compared to human milk enzyme (Godber 
et al.t 1997). However, in the experiments in this thesis only one human milk sample
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was analysed to form this comparison, and therefore conclusions should not be 









Figure 62. Cofactors Involved in the Xanthine Oxidase Assays.
The in-gel and IXP-based assays require binding o f  electron-donating substrates (xanthine and pterin, 
respectively) to the functional MoCo. Pterin is converted to the fluorescent compound IXP, whereas 
O 2 generation is required for the formation o f  the formazan precipitate in the in-gel assay. In 
comparison the lucigenin-based assay does not require the MoCo, N A D H  acts an electron donating 
substrate and binds to the FAD-moiety.
Also of interest was the appearance of a ~20kDa XOR-fragment in plasma which was 
more pronounced compared to liver and milk samples (in some samples this fragment 
was absent; Figure 59). A fragment of this size is formed during the irreversible 
conversion of XDH to XO by proteolytic cleavage (Della-Corte and Sdrpe, 1968; 
Waud and Rajagopalan, 1976; Saksela et al., 1999). It has also been shown that XDH 
in plasma is rapidly converted to XO (Kooij et al., 1994), and in fact the majority of 
circulating XOR is in the XO form (see results chapter 6). Taken together with the 
appearance of a ~20kDa XOR-fragment in plasma, these results suggest the existence 
of a possible plasma protease responsible for XDH-XO conversion.
4.5.4 Summary
Although the lucigenin-based XO-assay appeared to be sensitive, serious flaws exist 
with this assay, i.e. Luc+ can create O 2 the XO-generated product the assay should 
be measuring. Therefore the use of the lucigenin-based assay was disregarded. The in­
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gel XO-assay was tested, and although reaction conditions have been optimised 
beyond those published (Ozer et al., 1998), due to its laborious nature the in-gel assay 
would be inefficient to assay many samples simultaneously, especially as replicates of 
each sample are required. Therefore a more high-through-put technique was sort 
after, and based on sensitivity, specificity, and processing speed the IXP-based XO- 
assay will be used for the assessment of XOR-release from the endothelium.
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Chapter 5. The Release of Xanthine 
Oxidoreductase from the Vascular
Endothelium
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5 The Release of Xanthine Oxidoreductase from 
the Vascular Endothelium
5.1 Chapter Aims
The reasons for targeting the vascular endothelium as a potential source o f circulating 
XOR are discussed in the Introductory chapters (especially in the Hypothesis section). 
The aim o f this chapter is to investigate whether the endothelium can release XOR, 
and experiments will be performed using known endothelial cell protein secretion 
agonists. The release of vW f will be used as a positive control, and using the sensitive 
IXP-based XOR assay developed in Chapter 4, the release of XOR from HUVECs 
will be measured. An initial aim o f this Chapter is to develop a lactate dehydrogenase 
assay to detect whether the concentrations o f agonist applied to the HUVECs are 
cytotoxic.
5.2 Principals, Materials, and Methods
5.2.1 Stimulation of Protein Secretion from HUVECs
5.2.1.1 Materials List
A23187, Colchicine, Histamine, Thrombin (Sigma Aldrich Company Ltd. Dorest, 
UK).
5.2.1.2 Stimulation Protocol
Note: Cell culture procedures are described in Chapter 3. Confluent P2 HUVECs 
grown in 12-well plates were used in all HUVEC stimulation studies. Conditioned 
medium was aspirated from wells and cells were gently washed with 1ml 37°C HBSS 
to remove any loose extracellular antigen. Cells were exposed to stimulant prepared in 
37°C HBSS (always 1ml per well) and were incubated for the desired time at 37°C, 5% 
CO2 in air (standard culture conditions). After the desired incubation, medium above 
the cells was removed and stored on ice before further analysis. 100% secretion of the
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protein of interest was achieved by lysing cells with 1ml Triton X-100-based lysis 
buffer (Park et a l, 2001; Anrather et a l, 1999; for lysis buffer recipe see Appendix I 
8.8) per well, at 4°C for about 5mins or until all cells appeared lysed under the 
microscope.
5.2.2 XOR Activity Measurements
All measurements of XOR release from HUVEC were performed using the over­
night IXP-based XOR assay developed in Chapter 4, the most sensitive assay of those 
compared. Data generated from this experiment were used to calculate XOR activity 
expressed as Units XOR, where one XO R Unit is defined as the quantity of XO R required to 
cause a reaction to process one micromole of IX P  per minute at 37 °C. An example of the 
calculation, starting from the activity data in the form “IXP generation (nM ml'1 106 
cells'1)”, is given below (Figure 63):
XOR-Generated IXP (nMolar) ml conditioned media*1106 viable cells*1
Divide by 1000 *
XOR Generated IXP (nmoles) 106 viable cells*1
Divide by 1260 **
XOR Generated IXP (nmoles) min*1106 viable cells*1
Divide by 1000 ***
XOR Units 106 viable cells*1
(XOR Units may be converted to mUnits or to [lUnits by subsequent 
mulitplications of 1000)
* nMolar = nmoles per litre. As 1ml conditioned media was used in the XOR assay 
dividing by 1000 gives nmole ml'1.
** The generation of IXP was measured at 37 C for 21hrs (usually), therefore 
dividing by 1260 converts IXP-generation per minute.
*** Converts the number of nmoles into pmoles and therefore the XOR Enzyme 
Unit definition.
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Figure 63. The Calculation of XOR Units from IXP-based XOR Assay Data
5.2.3 Molybdenum Supplementation of ECGM
5.2.3.1 Materials List
0.22pm syringe filter, Ammonium Molybdate (Fisher Scientific UK Ltd. 
Leicestershire, UK)
5.2.3.2 Supplementation Protocol
A 50mM ammonium molybdate stock was prepared in PromoCell ECGM and the 
pH adjusted back to that of fresh ECGM. The stock was filter sterilised using a 
0.22pM filter and was diluted to 10, 1, 0.1, O.OlmM working concentrations in 
ECGM. Confluent HUVECs in 12-well plates were fed 1ml ECGM with and without 
Mo-supplement per well, for 24hours at 37 °C, 5% CO 2 in a humidified incubator. 
Following the 24hour incubation period HUVECs were washed once in HBSS and 
lysed in lysis buffer, cell debris was removed by centrifugation at 1600rpm for 5mins. 
The lysate was analysed for XOR activity using the modified IXP-based XOR assay 
developed in Chapter 4. Trypan blue-exclusion cell counts were performed to assess 
whether Mo-supplementation affected viable cell number.
5.2.4 Lactate Dehydrogenase Assay
The cytoplasmic enzyme lactate dehydrogenase (LDH) is released from compromised 
cells due to a cytotoxic environment. An assay for LD H is commonly used to assess 
whether treatment o f cultured cells has been cytotoxic (Gruenhagen and Yeung, 2004; 
Kikkawa et al., 2005). In experiments in this thesis, the LDH assay will serve as a 
control indicating whether proteins (especially vW f and XOR) have been secreted 
from HUVECs by a controlled mechanism or have been released by compromised 
cells as the stimulant was cytotoxic.
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5.2.4.1 Materials List
Allopurinol, Lactate Dehydrogenase, N AD+, Sodium Lactate (Sigma Aldrich 
Company Ltd. Dorest, UK). Diphenyliodonium Chloride (DPI) (ICN Biochemical 
Inc. OH, USA).
5.2.4.2 Protocol
An established LDH assay protocol (www.worhtington-biochem.com), described 
below, was optimised for use in experiments in this thesis (see Results section). 2.8ml 
0.2M Tris-HCl (pH 7.3), 0.1ml 6.6mM NADH, and 0.1ml 30mM sodium pyruvate 
were added to a cuvette and incubated in a spectrophotometer at 25°C for 4-5mins to 
achieve temperature equilibration. Following the addition of 0.1ml en2 yme/sample 
the absorbance at 340nm was recorded over time. The change in NADH 
concentration was calculated using the extinction coefficient 6.22mM_1 c m 1.
5.2.5 Statistical Analysis
Statistical analysis of data collected was performed using GraphPad Prism Version 
4.00 (GraphPad Software Inc.). Presented below are the background details to the 
tests used in the analysis o f sample data.
5.2.5.1 The Gaussian (or Normal) Distribution and Normality Testing
Many statistical tests, including ANOVA and t-tests, assume that the population from
which you are sampling follows a Gaussian “bell-shaped” distribution. Biological data 
do not follow the Gaussian distribution, as the Gaussian distribution extends 
infinitely in both positive and negative directions. However statistical tests, such as 
the ones mentioned above, work well even if the distribution is only approximately 
Gaussian. Using a normality test it is possible to determine whether sample data 
collected are likely to have been selected from a population that follows a Gaussian or 
normal distribution, an important factor when selecting further statistical analysis. 
The Prism program uses the Kolmogorov-Smirnov test for deviations from a 
Gaussian distribution and answers the following question: If you randomly sample
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from a Gaussian population, what is the probability o f obtaining a sample that 
deviates from a Gaussian distribution as much (or more so) as this sample does? A 
high probability would indicate that your sample is likely to be derived from a 
population with a Gaussian distribution.
5.2.5.2 Standard Deviation
The standard deviation (SD) o f a data set quantifies data variability/scatter. Assuming 
the sample data follow a Gaussian or Normal distribution, then 68% of the values lie 
within one SD of the mean and 95% of values lie within two SD of the mean. The 
sample SD is calculated in all instances in this document (rather than the population 
SD), as data collected are only a sample of the population (i.e. in HUVEC stimulation 
studies, only a portion o f the total HUVEC population is tested, the population SD 
would only be calculated if all the HUVECs in the world were tested!).
5.2.5.3 Standard Error of the Mean
The standard error o f the mean (SEM) is a measure o f how far the calculated sample 
mean is from the true population mean and is derived from the following formula:
SEM = SD /
The SEM will decrease as the sample number increases, as the larger your sample, the 
closer the sample mean will be to the true population mean. The true population 
mean does not necessarily lie within the SEM limits. In fact, assuming the sample data 
follow a Gaussian distribution, there is only a 68% chance that the population mean 
will fall within this error.
5.2.5.4 Analysis of Variance (ANOVA)
The ANOVA statistical test is commonly used in a laboratory setting for the 
comparison of a number o f different treatments (3 or more unmatched groups) and 
assumes that sample data are derived from populations with a Gaussian distribution 
and equal variances (Prism tests variances with Bartlett’s test for equal variances). The
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ANOVA test partitions variability between treatment means and variability between 
values within a treatment group (residual or error variation). Residual variability is 
quantified as the sum o f squares (SS) of the differences between each value within a 
treatment and its treatment mean, whereas variation between groups is quantified as 
the SS of the differences between treatment means and the grand mean (the mean of 
all values in all groups). The treatment and residual SS values are used to calculate 
Mean Square (MS) values (SS divided by degrees o f freedom), which are used to 
calculate the F-ratio (the ratio of Treatment MS /  Residual MS). The F-ratio is used to 
confirm or reject the null hypothesis that the resulting treatment means are equal, i.e. 
the test will indicate whether different treatments have made any difference to the 
system being tested.
T-tests should not be used to test between multiple groups (3 or more) of data. Each 
time a hypothesis test is carried out at the 5% significance level for example, there is a 
5% risk of claiming that the means of two treatments differ when they do not. 
Therefore if multiple tests are performed on the subsets of the same data, the risks of 
claiming that means differ when they do not, increase.
5.2.5.5 Dunnett’s and Bonferroni’s Post-Test
The ANOVA test will indicate whether there is a statistical difference between 
treatment means, but does not indicate where differences may lie. Therefore it is 
necessary to perform a post test. The D unnett’s and Bonferroni’s post-tests are 
modifications o f the t-test which take into account the above mentioned problem of 
multiple comparisons. The Dunnett’s test allows the comparison o f one set o f data 
(e.g. a control set) with all other data sets (e.g. treatment groups) and will indicate the 
level of statistical difference. The Bonferroni’s test allows comparisons between 
selected pairs o f data, and will indicate the level o f statistical difference between data 
sets of each pair. Using the Dunnett’s and Bonferroni’s post-test the following system 
was used to describe statistical significance: not significant (ns) = p>0.05, * = p<0.05, 
** = P<0.01, and *** = p<0.001.
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5.3 Results
5.3.1 LDH Assay Development
The LDH assay described in the methodology section uses the conversion of NADH 
to NAD+ to detect activity. However, in the Introductory chapters, the enzymatic 
conversion o f NADH to NAD+ was described for XO (i.e. XO NADH-oxidase 
activity). As the release of XO from HUVECs will be followed (in the same samples 
where LDH activity will be assayed) it is important to consider this activity and the 
potential affects on the apparent LDH activity. Therefore it was decided to assay 
LDH activity measuring the conversion of NAD+ to NADH, as shown in Figure 64. 
As XO could potentially utilise any NADH formed, and therefore affect the LDH 
assay, initial experiments were designed to show the inhibition of XO-NADH oxidase 









Figure 64. Generation of NADH by LDH and Potential Interference of XO
In the presence o f  lactate and N A D +, LDH  will generate NADH. The generation o f  N A D H  will be 
followed in the LDH assay by an increase o f  absorbance at wavelength 340nm. Potentially, XO  
present in the sample could utilise N A D H  forming N A D +, thus interfering with the LDH assay. 
However, X O  NADH-oxidase activity can be inhibited using DPI.
5.3.1.1 DPI inhibits XO NADH O x idase  activity
An initial experiment was designed to show that XO NADH-oxidase activity could be 
inhibited, and therefore eliminate this activity from interfering with the LDH assay. 
The inhibitory activity of DPI has been shown in the XO NADH-oxidation process
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(Sanders el al.> 1997; Zhang et al^ 1998), therefore this experiment aimed to show that 
inhibition occurs in the system used in this thesis. The NADH-oxidase activity of 
50pg/ml Biozyme XO was measured using lOOpM NAD H  with or without lpM 
DPI. The depletion o f N A D H  was followed at A 3 4 0  for approximately 15mins at 
37°C, and NAD+ generation was calculated from the linear portion o f the progress 
curve using the extinction coefficient of 6.22mM-1 cm-1 (Figure 65). In the absence of 
XO, NADH concentrations do not change, however with XO present NADH is 
oxidised to NA D + and this process is inhibited by DPI. DPI inhibits activity by 
91.4%, a similar value as previously described (90.2% inhibition was achieved using 
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Figure 65. Inhibition of XO NADH-Oxidase Activity using DPI
X O  was incubated with N A D H  with and without D PI and N A D H -oxidase activity was measured at 
wavelength 340nm. In the absence o f  X O  no N A D H  oxidation occurs, however in the presence o f  
X O  N A D H  is oxidised by a process that is inhibited by DPI. Results are from a single experiment 
with no replicates.
5.3.1.2 Does DPI Inhibit LDH Activity?
As DPI will be used in the LDH assay to inhibit any XO present in test samples, it 
was important to control for the effects of DPI on LDH activity. Therefore the 
activity of 0.05U LDH with 330pM NAD+ and 1.5mM sodium lactate was measured 
in the presence of various D PI concentrations. Activity was measured at 37°C at A 3 4 0  
and NADH generation was calculated as previously described (Figure 66). The 
concentrations of DPI tested do not inhibit LDH activity, therefore 1 pM DPI may be 
used in the LDH assay to inhibit XO NADH-oxidase activity without affecting LDH.
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Figure 66. The Affect of DPI on LDH Activity
The activity o f  0.05U L D H  was measured in the presence o f  various D PI concentrations. Results are 
from one experiment performed in triplicate, therefore n=3. Error bar =  SD.
5.3.1.3 Optimisation of NAD* Concentration in the LDH Assay
The substrate concentration given in the original assay (www.worhtington- 
biochem.com) referred to NADH. As the LDH assay used in this thesis was run in 
reverse compared to the original assay, optimisation of the NAD+ substrate 
concentration was performed. Here the activity o f 0.05U LDH was measured with 
1.5mM sodium lactate and a range of NAD+ concentrations at 37°C at A340. LD H  
activity was calculated, and maximal activity occured in the presence of ImM N A D + 
(Figure 67).
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Figure 67. Optim isation of NAD* Concentration in the  LDH A ssay
The activity o f  0.05U L D H  was measured in the presence o f  various N A D + concentrations. Activity 
data was fitted with Michaelis-Menton Kinetics. Results are from one experiment performed in 
triplicate, therefore n=3. Error bar =  SD.
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5.3.1.4 Optimised LDH Assay Test
The optimised LDH assay (using ImM  N A D +, 1.5mM sodium lactate, lpM  DPI, and 
10pM allopurinor at 37°C; *allopurinol was added to inhibit XDH that in the 
presence o f substrates hypoxanthine or xanthine could utilise NAD+ as an electron 
accepting substrate) was tested on medium samples from compromised cells. MDA- 
MB-231 cells were grown to confluence (as described in Chapter 3) in T25 flasks, 
medium was removed and cells were incubated with a range o f concentrations of the 
ROS, H 2O 2 in PBS, for 1.5hours under standard culturing conditions. Under the 
microscope, compared to the OmM H 2O 2 treated sample, all cells looked normal 
except for the lOmM H 2O 2 treated flasks where cells appears stringy and fragmented. 
Medium above cells was removed for analysis using the LDH assay (Figure 68). A 
baseline level of LDH activity was measured in cells treated with <0.1 mM H 2O 2. 
However in the sample where cells appeared compromised under the microscope 
(lOmM H 2O 2 treated) a greater level o f LD H activity was recorded.
0 0.00001  0.001 0.1 10
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Figure 68. The Optimised LDH A ssay Test
MDA-MB-231 cells were exposed to various H 2O 2 concentrations for 1.5hours. The medium above 
cells was assayed for LDH using the optimised m ethod with XO inhibition. Activity was highest in 
the sample where cells appeared compromised (lOmM H 2O 2). Results are from one experiment 
performed in triplicate, therefore n=3. Error bar =  SD.
5.3.2 Lysate Distribution of HUVEC XOR
As a control to show the IXP-based XOR assay could detect XOR in HUVEC 
lysates, and to determine whether XO is found in the soluble or insoluble lysate 
fraction, confluent P2 HUVECs grown in 12-well plates were lysed using 1ml lysis
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buffer per well. Following the incubation of cells in lysis buffer for approximately 
5mins at 4°C, adherent cell debris was suspended using a cell scraper. The total lysate 
was removed from each well and cell debris was broken-up by repeated pipetting, 
lysates were stored on ice until needed. Soluble lysate was prepared by centrifugation 
of total lysate at 13 OOOrpm for 5mins, the resulting supernatant constitutes the 
soluble lysate fraction. XOR activity in both soluble and total lysates was determined 
using the developed overnight IXP-based XOR assay. XOR activity can be detected 
in HUVEC lysates, and the majority, if not all activity, is found in the soluble lysate 
fraction (Figure 69).
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Figure 69. Can XOR Activity be  D etected in HUVEC Lysates?
Confluent P2 HUVECs grown in 12-well plates were lysed and soluble and total cell lysate fractions 
were prepared. X O R  activity was determined in each fraction using the IXP-based XOR assay. 
Results are from one experiment in triplicate, therefore n=3. Error bar =SD .
5.3.3 Supplementation of Endothelial Cell Growth Medium
The aim of the medium supplementation section was to determine whether XOR 
activity within HUVECs could be increased. From a practical point of view, an 
increase in HUVEC XOR activity maybe required if the IXP-based assay was not 
sufficiently sensitive under normal culture conditions, especially in XOR-release 
studies later in this chapter.
Both molybdenum and FCS supplementation were tested. Firstly, supplementation of 
cell lines with molybdenum (Mo) has been shown to increase XO activity. For 
example, L929 fibroblast cell line normally expresses XOR mRNA however does not
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contain active XOR, however with Mo supplementation in the millimolar range active 
XOR was expressed (Falcinani et al., 1994). Mo is an important constituent o f  the 
MoCo and supplementation is thought to convert a pool of XOR apoenzyne into its 
active, holoenzyme, form (Falcinani et al., 1994). Therefore I hypothesis that Mo- 
supplementation o f PromoCell ECGM (which only contains 3nM ammonium 
molybdate) may assist in the conversion o f inactive enzyme to holoenzyme in 
HUVECs. Secondly, supplementation with FCS will be tested. The PromoCell 
ECGM contains just 2% FCS, other media routinely contain 10 or 20% FCS (Jaffe et 
al., 1973a; Emeis et al., 1997; Rosnoblet et al., 1999). Therefore a comparison of 
different FCS concentrations was investigated and the affect on active XOR was 
measured.
5.3.3.1 Molybdenum Supplementation
HUVECs (P2) grown in 12-well plates were incubated in Mo-supplemented ECGM  
for 24hrs under normal culture conditions. Following incubation cells were washed in 
HBSS, lysed using 1ml lysis buffer per well or were dissociated using Accutase for cell 
viability counts. XOR activity in cell lysates was measured as described in the 
methodology section to this chapter. Supplementation with 0.01 and O.lmM 
ammonium molybdate did not alter cells appearance under the microscope compared 
to the control (Figure 70B, C). However, with the addition of ImM ammonium 
molybdate cells were altered in structure and seemed to contain large vacuoles 
(Figure70D), and lOmM appeared to be fatal to the HUVECs (Figure 70E). The 
ammonium molybdate came out of solution at the 50mM concentration (Figure 70F). 
Cell lysate XOR activity was measured using the IXP-based XOR assay (Figure 71). 
Data was analysed using one-way ANOVA with Dunnett’s post test. Supplementation 
with O.lmM ammonium molybdate significantly increases cellular XOR activity 
compared to the OmM control. XOR activity in cells grown in medium supplemented 
with >0.1mM ammonium molybdate should not be compared as cellular appearance 
was altered in these samples.
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Figure 70. The Effect of Ammonium Molybdate Supplementation of ECGM on HUVEC 
Appearance
P2 HUVECs were incubated with ECGM supplemented with various concentrations o f  ammonium 
molybdate OmM (A), O.OlmM (B), O.lmM (C), ImM (D), lOmM (E), and 50mM (F). Cells were 
viewed under phase contrast microscopy.
*★*
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Figure 71. The Effect of Ammonium Molybdate Supplem entation of ECGM on HUVEC XOR 
Activity.
P2 HUVECs were incubated with ECGM supplemented with various concentrations o f  ammonium 
molybdate. Cells were lysed and X O R  activity was measured using the IXP-based assay. Data was 
analysed using one-way A N O V A  with Dunnett’s post test (where ns =  not significant (p>0.05); * =  
p<0.05, *** =  p<0.001). Results are from one experiment with five replicates, therefore n=5. Error 
bar =  SD. $ A N O V A  analysis requires that all samples have equal variances. The variance o f the 
50mM sample data was not the same as the other samples (data did not pass Bardett's test for equal 
variances with the 50mM data points included) and was therefore not included in statistical analysis.
5.3.3.2 FCS supplementation
HUVECs (P2) grown in 12-well plates were incubated in FCS (GlobePharm. Esher, 
UK)-supplemented ECGM  for 72hrs under normal culture conditions. Cells were 
washed in HBSS, lysed using 1ml lysis buffer per well or were dissociated using 
Accutase for cell viability counts. XOR activity was measured as described in the 
molybdenum-supplementation section. The addition o f FCS to ECGM increases cell 
number in a dose-dependent manner (Figure 72A), however no increase in cellular 
XOR activity was observed (Figure 72B).
A B
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Figure 72. The Effect of FCS-Supplem entation of ECGM on HUVEC XOR Activity
P2 HUVECs were incubated with ECGM  supplemented with various concentrations o f  FCS. Cells 
were lysed and X O R  activity was measured using the IXP-based assay. Results are from one 
experiment with four replicates, therefore n=4. Error bar =  SD.
5.3.4 Thrombin Dose-Response
As mentioned in the Introductory chapters to this thesis, thrombin is known to 
stimulate the release o f protein from the vascular endothelium. In particular the
5-138
.1 ill I k ‘s I L'W i 11 st. i il I ' h i )  r i i c s i s
release of vW f has been well characterised and therefore vWf release was used as a 
positive control for endothelial cell protein release. To begin to investigate whether 
the vascular endothelium can release XOR, the HUVEC endothelial model was 
stimulated with known endothelial-protein secretagogues, in this section the effect of 
thrombin was investigated. Initial experiments measured the effects of various 
thrombin concentrations on HUVECs. As a guideline, previously published protocols 
(Hattori et al., 1988; Vischer et al., 1998) were used to judge thrombin concentrations 
and incubation times that should be used.
5.3.4.1 Thrombin Stimulated vWf Release from HUVECs
Confluent P2 HUVECs, grown in 12-well plates were stimulated with a log dilution
of thrombin (1ml total volume per well) for lOmins under normal culture conditions. 
Following this time, medium above cells was collected for analysis. Also, in each 
repeat of the thrombin dose-response protocol three wells of HUVECs were lysed in 
lm l lysis buffer and the soluble lysate fraction was prepared (as previously described). 
vWf release into the medium above cells was analysed using the dot-blot technique 
(as described in Chapter 3). A volume of lOpl o f each sample was loaded, and using 
density analysis the percentage total-cellular release of vWf was calculated from a 
standard curve generated from a dilution o f the HUVEC lysate. An example o f a vW f 
dot-blot is shown in Figure 73A and thrombin stimulated vWf release is shown in 
Figure 73B. Thrombin stimulates a dose-dependent release of vWf from HUVECs 
(an exception is seen using lOU/ml where release is not greater than stimulation with 
lU /m l thrombin, where the sensitivity o f the assay may have reached its upper 
limits).
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Figure 73. Thrombin Stimulated vWf Release from HUVECs
Confluent P2 HUVECs were stimulated with various concentrations o f thrombin. Medium above 
cells was collected and vW f content was assessed using the dot-blot technique. A) An example o f a 
vW f dot-blot is shown, control samples are 1. HBSS, 2. lOU/ml thrombin in HBSS (unconditioned), 
3. lOng X O  in PBS, and 4, lysis buffer. B) vW f release into medium above cells was calculated from a 
standard curve generated from a dilution o f  HUVEC lysates. Data were analysed using one-way 
ANO VA with Dunnett’s post test comparing thrombin-stimulated vW f release against the OU/ml 
control (ns = not significant (p>0.05), * =  P<0.05, *** = p<0.001). Results are from three 
experiments in triplicate, therefore n=9. Error bar = SEM.
5.3.4.2 Thrombin Stimulated XOR Release from HUVECs
Using the same protocol as described for vWf release, HUVECs were treated with
various concentrations of thrombin and medium above cells was collected for 
analysis. XOR activity in medium above cells was analysed using the over-night IXP- 
based XOR assay and data collected were converted in Units XOR released using the 
equation given in the methodology section of this chapter. Controls for the XOR
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assay are given in Figure 74. Various negative controls [HBSS, lOOOpM histamine in 
HBSS (unconditioned), lOU/m l thrombin in HBSS (unconditioned) and lysis buffer], 
and positive controls (5ng XO and cell lysate) were tested. Significant activity was 
only seen in the positive control samples. These controls also serve the histamine 
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Figure 74. Controls for Throm bin and Histamine Stim ulated XOR Release Experiments
Positive and negative controls were run parallel to test samples in the overnight IXP-based XO R  
assay and the number o f  X O R  units was calculated. Results are from experiments performed in 
triplicate: HBSS n=24, Hist. n= 12, Thr. n=15, Lys. B. n=21, X O  n= 27, Cell Lys. n=21. Where Hist. 
= 1000pM histamine (unconditioned), Thr. =  lO U /m l thrombin (unconditioned), Lys. B. = Lysis 
Buffer, XO =  5ng Biozyme X O , and Cell Lys. =  Cell Lysate. Error bar =  SEM.
XOR activity in medium above thrombin-stimulated HUVECs is shown in Figure 7 5 
XOR activity follows a “bell-shaped” curve, with higher concentrations of agonist 
reducing the activity measured in the medium above cells after an initial dose- 
response-like increase in activity. Peak XOR activity is measured in medium above 
cells that are stimulated with 0.01-lU/m l thrombin. The increase in XOR activity 
indicates that XOR enzyme has been released from HUVECs in response to 
thrombin stimulus. The activity curve makes an interesting comparison to the dose- 












Figure 75. XOR R elease from Thrombin Stim ulated HUVECs
Confluent P2 H U V EC s were stimulated with various concentrations o f  thrombin. Medium above 
cells was collected and X O R  content was assessed using the overnight IXP-based XO R assay, and 
XO R activity Units were calculated. Data were analysed using one-way A N O V A  with D unnett’s post 
test comparing thrombin-stimulated XOR release against the OU/ml control (ns = not significant 
(p>0.05), *** =  p<0.001). Results are from three experiments in triplicate, therefore n=9. Error bar 
=  SEM.
In an attempt to detect XOR protein released into the medium above cells following 
thrombin stimulation, the samples used in the XOR activity assay were analysed by 
dot-blot analysis. 20pi o f each sample were loaded onto the dot-blot which was 
subsequently probed for XOR using the Chemicon Polyclonal XO l°-antibody. The 
1 OU/ml thrombin negative control is strongly detected in dot-blot process (Figure 76 
indicated by an arrow), therefore it is not possible to use this technique to assess 
XOR protein release with thrombin-stimulation. The apparent release of XO in the 
conditioned medium samples is likely to be the detection of thrombin only. The 
experiment was repeated using the Polysciences Polyclonal anti-XO, however this 
made no difference to the outcome (data not shown).
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Figure 76. Dot-blot Analysis of XOR Released from Thrombin-Stimulated HUVECs
The medium above thrombin-stimulated HUVECs was analysed for XOR protein using the Dot-blot 
technique. The dot-blot is shown in A and the loading order in B. Where, Thr. =  lO U /m l thrombin 
in HBSS; Lys.B.: Lysis Buffer; XO: lOng Biozyme XO. Conditioned medium refers to medium above 
cells stimulated with thrombin, concentrations as indicated.
Two further controls were run to show, i) whether the thrombin concentrations used 
in the stimulation o f HUVECs are toxic and ii), whether thrombin direcdy effects the 
activity o f XO. To assess whether throm bin treatments were cytotoxic, the medium 
above cells taken from thrombin dose-response experiments and was analysed for 
LDH activity using the assay developed at the start o f this chapter. In the dose- 
response experiments described the exposure of HUVECs to throm bin does not 
cause the release of LDH (Figure 77). Positive (HUVEC lysate) and negative (HBSS) 
controls for the assay worked as predicated.
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Figure 77. Are the  Thrombin Concentrations used  in D ose-R esponse Experiments 
Cytotoxic?
Confluent P2 HUVECs were stimulated with various concentrations o f  thrombin. Medium above 
cells was collected and LD H  content was assessed using L D H  assay. Results are from one experiment 
in triplicate, therefore n=3. Error bar =  SD.
A further control was run to demonstrate whether XO activity could be directly 
influenced by thrombin. In these experiments lOOng/ml Biozyme XO was incubated 
with thrombin (the same concentrations used in the dose-response experiments) for 
approximately 3mins at room temperature. XO activity was then analysed using the 
IXP-based assay as described by Beckman et al., 1989. Results show that the presence 
o f thrombin increases XO activity in a dose-dependent manner (Figure 78) that is 
cell-independent.
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Figure 78. The Effect of Thrombin on XO Activity
Purified X O  was incubated at room  temperature with thrombin (various concentrations) for ~3mins 
and X O  activity was assessed using the IXP-based XO R assay as described in Beckman et al., 1989. 
Results are from one experiment perform in triplicate, therefore n=3. Error bar =  SD.
5.3.5 Histamine Stimulated XOR Release from HUVECs
5.3.5.1 Histamine Dose-Response Experiments on Isolated HUVECs
The thrombin dose-response experiments were repeated using histamine as an
endothelial cell protein secretagogue. As a guideline, previously published protocols 
(Hattori et al., 1988; Vischer et al., 2000) were used to judge histamine concentrations 
and incubation times that should be used. Firstly, as a control, the release of vWf 
from HUVECs stimulated with a log dilution of histamine was investigated. vWf
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content in medium above cells was analysed using the protocol described for 
thrombin-stimulated cells. Similar to thrombin, histamine generated a dose-dependent 
release of vWf from HUVECs (Figure 79).
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Figure 79. Histamine Stim ulated vWf Release from HUVECs
Confluent P2 HUVECs were stimulated with various concentrations o f  histamine. Medium above 
cells was collected and vW f content was assessed using the dot-blot technique. The percentage total 
cellular vW f released into medium above cells was calculated from a standard curve generated from a 
dilution o f  HUVEC lysates. Data was analysed using one-way A N O V A  with Dunnett’s post test 
comparing histamine-stimulated vW f release against the O U/m l control (ns =  not significant 
(p>0.05), * =  P<0.05, *** =  p<0.001). Results are from three experiments in triplicate, therefore 
n=9. Error bar =  SEM.
The medium above histamine stimulated cells was analysed for XOR-activity using 
the overnight IXP-based XOR assay. Like experiments with thrombin a “bell-shaped” 
release curve is generated (Figure 80A) in comparison to the dose-dependent release 
of vWf. Unlike experiments using thrombin however, dot-blot analysis of medium 
above histamine stimulated HUVECs was possible (i.e. the polyclonal XO antibodies 
did not bind to the lOOOpM histamine unconditioned sample), 20pl of each sample 
were used in analysis. The release of XOR protein appears to follow the “bell­
shaped” curve generated analysing XOR activity (Figure 80B).
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Figure 80. Histam ine-Stim ulated XOR Release form HUVECs
Confluent P2 H U V EC s were stimulated with various concentrations o f  histamine. Medium above 
cells was collected and X O R  content was assessed using the overnight IXP-based X O R  assay, and 
XO R  activity Units were calculated (A). Data were analysed using one-way A N O V A  with D unnett’s 
post test comparing thrombin-stimulated XOR release against the OU/ml control (ns =  not 
significant (p>0.05), *** =  p<0.001). Results are from three experiments in triplicate, therefore n=9. 
Error bar =  SEM. Medium samples were probed for XOR-protein content using the dot-blot 
technique (B). Results are from one experiment in triplicate, therefore n=3. Error bar =  SD.
The control experiments described in the thrombin dose-response section 
demonstrating; i) whether the stimulant concentrations used in the stimulation of 
HUVECs are toxic and ii), whether the stimulant directly affects the activity o f XO, 
were repeated using histamine. Histamine cytotoxicity to HUVECs was assessed 
using the LDH assay as described in the thrombin dose-response section o f this 
chapter. In the dose-response experiments described, the exposure of HUVECs to 
histamine does not cause the release of LD H (Figure 81). Positive (HUVEC lysate) 
and negative (HBSS) controls for the assay worked as predicated.
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Figure 81. Are the Histamine C oncentrations used in D ose-R esponse Experim ents 
Cytotoixic?
Confluent P2 HUVECs were stimulated with various concentrations o f histamine. Medium above 
cells was collected and LD H  content was assessed using LDH  assay. Results are from one experiment 
in triplicate, therefore n=3. Error bar =  SD.
A further control was run to demonstrate whether XO activity could be directly 
influenced by histamine. In these experiments lOOng/ml Biozyme XO was incubated 
with histamine (the same concentrations used in the dose-response experiments) for 
approximately 3mins at room temperature. XO activity was then analysed using the 
IXP-based assay as described by Beckman et al, 1989. In contrast to thrombin, the 
presence o f histamine does not increase the activity of XO (Figure 82).
Figure 82. The Effect of Histamine on XO Activity
Purified X O  was incubated at room  temperature with histamine (various concentrations) for ~3mins 
and X O  activity was assessed using the IXP-based XO R assay as described in Beckman et al., 1989. 
Results are from one experiment performed in triplicate, therefore n =3. Error bar =  SD.
5.3.5.2 Histamine Time Course Experiment on Isolated HUVECs
In dose-response experiments the release of protein from HUVECs was measured
following a lOmin incubation period with histamine or thrombin. To further 
characterise the release o f XOR from HUVECs stimulated with histamine, a time 
course experiment was performed. Here, confluent P2 HUVECs grown in 12-well 
plates were stimulated with lOpM histamine. Cells were incubated under standard 
culture conditions and at relevant time points medium the above cells was removed 
and stored on ice before analysis (for each time point three wells o f HUVECs were
m i l l
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used). For the time zero sample, 10pM histamine was added to each of three wells 
and removed instandy. vW f release was analysed using the dot-blot technique and 
XOR activity was measured using the overnight IXP-based XOR assay as previously 
described. Release of XOR was rapid with maximal release occurring by the second 
time point (2.5mins incubation), whereas the release o f vW f was a slower process 
requiring approximately 12.5mins for maximal release to occur (Figure 83).
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Figure 83. Histamine Stim ulation of HUVECs -  A Time C ourse S tudy
Confluent P2 HUVECs were stimulated with lOpM histamine. A t desired time points medium above 
cells was collected. X O R  content was assessed using the overnight IXP-based X O R  assay and vWf 
release was determined using the dot-blot technique. Results are from one experiment in triplicate, 
therefore n=3. Error bar =  SD.
5.3.5.3 Histamine Dose-Response Experiments on Purchased 
HUVECs
To confirm the results observed using HUVECs isolated in the laboratory, HUVECs 
were purchased (PromoCell. Heidelberg, Germany) and histamine dose-response 
experiments were repeated. However, as PromoCell HUVECs arrived as PI cells, 
experiments using these HUVECs were performed at P3. The histamine dose- 
response protocol, medium collection, and analysis for vW f and XOR were 
performed as described previously. vWf (Figure 84) and XOR (Figure 85B) release
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was comparable to that seen with HUVECs isolated within the laboratory. Control 
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Figure 84. Histamine Stim ulated vWf Release from P urchased  HUVECs
Confluent P3 HUVECs (PromoCell) were stimulated with various concentrations o f  histamine, 
medium above cells was collected, and vW f content was assessed using the dot-blot technique. The 
percentage total cellular vW f released into medium above cells was calculated from a standard curve 
generated from a dilution o f  HUVEC lysates. Results are from one experiments in triplicate, 
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Figure 85. Histam ine-Stim ulated XOR Release form P urchased  HUVECs
Confluent P3 HUVECs (PromoCell) were stimulated with various concentrations o f  histamine. 
Medium above cells was collected and XO R content was assessed using the overnight IXP-based 
XOR assay, and XO R activity Units were calculated (B). Positive and negative controls were run 
parallel to test samples in the overnight IXP-based XO R assay (A). Results are from one experiment 
in triplicate, therefore n=3. Error bar =  SD.
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5.3.6 The Mechanism of XOR Release from Isolated HUVECs
5.3.6.1 A23187 Dose-Response
In the preceding experiments the stimulated release o f XOR from HUVECs has been 
demonstrated. To analyse the mechanism of XOR release in more detail HUVECs 
were firstly stimulated with the ionophore A23187. The ionophore works by inserting 
itself into the plasma membrane of a cell forming a pore allowing entry of 
extracellular cations, such as Ca2+, into the cytoplasm (Alberts et al., 1994). Therefore, 
by applying the ionophore to HUVECs, the effects o f a rise in intracellular calcium 
can be observed, and may indicate a role o f calcium in the signalling processes 
involved in protein release from HUVECs. The ionophore, A23187, has been shown 
to stimulate the release of vWf from HUVECs (Hattori et aL> 1988). Therefore the 
release of vW f was used as a positive control to show that stimulation o f endothelial 
cell protein secretion has occurred.
In A23187 dose-response experiments, HUVECs isolated in the laboratory were used. 
P2 HUVECs were grown in 12-well plates and were stimulated using the same 
protocol as described for thrombin and histamine dose-response experiments (except 
A23187 was used in place of the afore-mentioned agonists). Analysis of vW f protein 
and XOR activity in medium above cells was performed using the previously 
described protocol. The release of vW f from HUVECs exposed to A23187 was dose- 
dependent (Figure 86A) and XOR release tended to follow a “bell-shaped” curve 
(Figure 86B), however the increase in XOR activity was not statistically significant for 
any A23187 concentration tested. The results described using A23187 are comparable 
to those seen using thrombin and histamine stimulation.
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Figure 86. A23187 Stim ulated Protein R elease from HUVECs
Confluent P2 HUVECs were stimulated with various concentrations o f  A23187 and medium above 
cells was collected. vW f content was assessed using the dot-blot technique (A) and X O R  content was 
assessed using the overnight EXP-based X O R  assay (B). Data were analysed using one-way A N O V A  
with Dunnett’s post test comparing A23187-stdmulated vW f release or XO R activity against the OpM 
control (ns =  not significant (p>0.05), * =  P<0.05, ** =  p<0.01). Results are from two experiments 
in triplicate, therefore n=6. Error bar =  SEM.
5.3.6.2 The Effect of Colchicine on Histamine-Stimulated XOR Release 
from Isolated HUVECs
The observation that HUVEC XOR is found in a “packaged” form was made in
Chapter 3. The aim of this section was to discover whether this packaged form could 
be released, and therefore constitute the source of XOR released into the medium 
above HUVECs. To achieve this aim, experiments by Vischer et al., 2000 were 
repeated, however XOR release was assessed. In the experiments by Vischer et al 
(Vischer et a l, 2000) the role of microtubules in the release of packaged vWf from 
HUVECs stimulated by intracellular Ca2+ increasing agents (including histamine and 
thrombin) was established. This was achieved using colchicine-induced microtubule 
disruption, which inhibited the stimulated release of vWf stores. Similar results were 
achieved in earlier studies on HUVECs (Sinha and Wagner, 1987).
In experiments in this thesis, P2 HUVECs were grown in 12-well plates using 
standard culture conditions. Conditioned medium was removed and HUVECs were 
incubated in fresh ECGM with or without 1 pM colchicine for 30mins under standard
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culture conditions. The effects of colchicine treatment on microtubule structure are 
shown in Figure 87. Here HUVECs were fixed using acetone/methanol and stained 
for [3-tubulin and nuclei using the protocol described in Chapter 3. It is apparent that 
incubation with colchicine breaks down microtubule structure, results are comparable 
to those seen in other publications (Vischer et al., 2000).
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Figure 87. The Effect of Colchicine on HUVEC Microtubule Structure
Laboratory isolated P2 HUVECs were grown on glass cover slips in 12-well plates. HUVECs were 
incubated with or without colchicine for 30mins and fixed using ice cold acetone/methanol for 5mins 
at 4°C. Fixed cells were stained for (3-tubulin and nuclei as previously described. Bar =  50pm.
Confluent P2 HUVECs grown in 12-well plates treated with or without colchicine, 
were immediately stimulated with or without lpM  histamine in HBSS for lOmins 
under standard culture conditions. Following this time period, medium above cells 
was removed and vWf and XOR content were analysed as previously described. In 
the absence of colchicine and histamine stimulation vWf is constitutively released, 
and with histamine stimulation vWf release is increased as expected. The constitutive 
and histamine-stimulated release of vWf in HUVECs incubated with colchicine is 
reduced compared to HUVECs without colchicine treatment (Figure 88A). The 
release of XOR into medium above cells follows the same pattern as described for 
vWf release (Figure 88B).
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Figure 88. The Effect of M icrotubule Disruption on vWf and  XOR Release from HUVECs
Confluent P2 HUVECs grown in 12-well plates were incubated with or without colchicine, +C and — 
C, respectively. Following colchicine treatment HUVECs were immediately stimulated with or 
without histamine, + H  and —H , respectively. The release o f  vW f and XO R was assayed as previously 
described. Results are from one experiment with five replicates. Error Bar =  SD.
5.4 Discussion
5.4.1 Medium Supplementation
In Chapter 3 it was demonstrated that HUVECs express XOR mRNA and protein. 
In this chapter, using the overnight IXP-based XOR assay developed in Chapter 4, an 
initial study proved that HUVEC-expressed XOR was active (Figure 69). Activity was 
found in the soluble cell-lysate fraction, which was expected as the enzyme was 
shown to have a diffuse, cytoplasmic, expression (see Chapter 3).
The aim of the medium supplementation experiments were to determine whether the 
activity of HUVEC X O R could be increased. Potentially, a method to increase 
HUVEC XOR activity could have been advantageous, especially if XOR activity 
could not be detected in HUVEC XOR-secretion studies. ECGM contains a level of 
molybdenum that is sufficient to allow the expression o f active XOR in HUVECs. 
However it appears that the addition of a molybdenum supplement increases the 
cellular content o f active XOR (Figure 71), an effect that was not observed with FCS 
supplementation (Figure 72). O f the concentrations tested, lOOpM ammonium 
molybdate was optimal for increasing cellular XOR activity. Concentrations greater 
then this, i.e. >lm M , appear, to have cytotoxic effects on HUVECs (Figure 70). In
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previous studies using fibroblast cell lines, supplementation of medium with up to 
50mM ammonium molybdate could be administered before causing cytotoxic effects 
(Falciani et al., 1994), suggesting that fibroblasts are more resistant to molybdenum or 
ammonium toxicity compared to HUVECs. If  supplementation of ECGM was 
required or is required in future experiments, it would be interesting to study the 
effect of riboflavin (Vitamin B2) and iron-sulphur supplementation on activity, 
therefore providing substrate for all of the XOR redox centres. Also, as a negative 
control, supplementation with tungsten could be used.
It is interesting to note that in Falciani et al., 1994 they suggest that under basal 
conditions or with molybdenum supplementation, HUVECs do not contain active 
XOR. The data presented in this thesis contradict these findings. The XOR-assay 
used in Falciana et al., 1994, with a detection limit of 5pmol of hypoxanthine 
transformed into xanthine or uric acid, should be senstitive enough. Therefore, to 
explain this discrepancy, in Falciani et al., 1994 there is no indication of the HUVEC 
passage number or length of culture prior to experimentation. As a general 
observation HUVECs tend to lose XOR activity over time, therefore the HUVECs 
used in Falciani et al, 1994 may have lost XOR activity due to a prolonged culture 
time.
5.4.2 Thrombin and Histamine Dose-Responses
5.4.2.1 LDH Assays
The LDH assay developed at the start o f this chapter proved sensitive enough to 
detect LDH release from cell cultures that showed morphological signs of 
cytotoxicity (Figure 68). The respective LDH assay results of medium above 
HUVECs from the histamine and thrombin dose-response experiments were negative 
(Figure Wand Figure 81). These results suggest that the concentrations o f thrombin 
and histamine used in each dose-response were not cytotoxic. Therefore the release 
of vWf and XOR from HUVECs were stimulated by controlled mechanisms and not 
by compromised cells with fragmented plasma membranes.
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5.4.2.2 von Willebrand Factor Release
Synthesised vWf is released by two different secretion pathways, the constitutive or 
regulated pathways (reviewed in van Mourik et al, 2002). In the dose-response 
experiments, during the lOmin incubation of HUVECs with just HBSS (i.e. OpM 
histamine and OU/ml thrombin) vW f is released into the medium above cells (Figure 
73 and Figure 79). This release is probably accounted for by the constitutive release 
pathway. Using the known vascular endothelial cell protein secretagogues, histamine 
and thrombin, it was demonstrated that vW f is released in a dose-dependent manner 
(Figure 73 and Figure 79). vWf release data was analysed using one-way AN OVA 
with Dunnett’s post-test comparing protein release in the presence o f an agonist with 
a control (i.e. no agonist). Statistically significant release o f vWf occured at >10pM 
histamine and >0.1U/ml thrombin in the dose-response. These results are 
comparable to previously published data (Hattori et al., 1988; Vischer et al, 1998) and 
therefore the release of vW f acts as a positive control for stimulation o f HUVEC- 
protein secretion.
5.4.2.3 Xanthine Oxidoreductase Release -  Dose-Response
Using the sensitive overnight IXP-based XOR assay and dot-blot techniques the
release of XOR from HUVECs into medium above cells was measured (Figure^ 75, 
and Figure 80). Although it was possible to measure XOR protein released from 
histamine stimulated HUVECs this was not possible when using thrombin. It is 
apparent from dot-blot experiments that the Polysciences and Chemicon polyclonal 
XO-antibodies were detecting thrombin (Figure 76). This positive detection would 
suggest that thrombin and XOR share epitope(s), i.e. regions of structural similarity. It 
is known that both thrombin and XOR can bind to heparin (Adachi et a l, 1993; 
Sheehan et al., 1994), therefore this region could be conserved in both enzymes, and 
thus be detected by the XOR polyclonal antibodies. A monoclonal XOR-antibody 
should be assessed for the detection o f XOR in the dot-blot technique.
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XOR is observed in medium above HUVECs with no agonist simulation, i.e. 
incubation in just HBSS (Figure 75 and Figure 80), therefore suggesting the 
constitutive release o f XOR from HUVECs. This release mechanism is supported by 
published work using microvascular endothelial cells (Partridge et al., 1992) and is 
comparable with the release of vWf as previously described. In addition to a 
constitutive release pathway, the results in this thesis demonstrate a regulated 
secretion pathway that is stimulated by histamine or thrombin treatment (Figure 75 
and Figure 80). To my knowledge, these experiments are the first demonstration o f 
controlled XOR release by vascular endothelial cells, in fact by any cell type except 
mammary epithelial cells (Mather and Keenan, 1998). Although XOR may be released 
by two separate secretion pathways (as with vWf), the dose-response results differ. 
vWf release is dose-dependent (Figure 73 and Figure 79), whereas XOR release into 
the medium above cells does not follow the same trend (Figure 75 and Figure 80). 
Instead a “bell-shaped” release curve is seen for XOR, with lower concentrations o f 
agonist stimulating a significantly higher release o f X O R compared to controls, and 
with higher concentrations of agonist (>10pM histamine or >1 U /m l thrombin) 
XOR release is either reduced or non statistically significant release is seen. As 
previously described, these results can not be explained by the suggestion that the 
higher concentrations o f agonist are cytotoxic to HUVECs, because, i) vWf release 
follows a dose-dependent release curve at these higher concentrations, and ii) LD H 
activity could not be detected in medium above cells following their incubation with 
histamine or thrombin.
A possible explanation for the apparent reduction in XOR release, when stimulating 
HUVECs with higher concentrations of agonist, is that XOR is being released but is 
binding back to the cell surface, to an XOR receptor. To fit this scenario the agonist 
would have to upregulate the cell-surface expression o f an XOR receptor, in a dose- 
dependent manner, to produce the “bell-shaped” curves seen in (Figure 75 and Figure 
80). An XOR receptor has been defined and is believed to be a glycosaminoglycan 
(GAG) structure (Adachi et al., 1994; Houston et al., 1999), however, there is nothing
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in the literature to suggest increased cell-surface expression o f GAGs in response to 
histamine or thrombin stimulation. An obvious group o f receptors that are 
ugregulated in response to histamine and thrombin treatment belong to a group of 
proteins found integral to the Weibel-Palade body membrane. The Weibel-Palade 
body is an intracellular storage granule that contains luminal proteins including vWf, 
and integral proteins including P-selectin, CD63, and fiicosyl transferase VI. 
Following stimulation, these proteins are released when Weibel-Palade bodies fuse 
with the plasma membrane (reviewed in Michaux and Cutler, 2004). The release of 
vW f is dose-dependent, therefore the cell-surface expression o f Weibel-Palade body 
membrane integral proteins would follow suit, making them a potential target for an 
XOR receptor.
To assess whether the cell-surface expression of GAGs is upregulated in response to 
histamine or thrombin treatment, a cell-based ELISA could be performed. Following 
stimulation, cells could be fixed with paraformaldehyde, therefore avoiding disruption 
of the plasma membrane, and be probed for cell-surface expression o f  GAGs using 
immunodetection. A similar protocol has been used to assess the cell surface 
expression o f P-selectin in cultured cells (Takano et a l, 2002). To demonstrate 
whether GAGs or any o f the Weibel-Palade body-membrane proteins are binding 
XOR in the dose-response experiments, competitive molecules could be added to see 
if more XOR remains in the medium above cells. For example, the addition of 
heparin or a P-selectin antibody to HUVECs with the agonist would compete with 
XOR for binding to GAGs (Adachi et al1, 1993) or P-selectin, respectively. If  the 
concentration of XOR in the medium above cells increases with the addition of a 
competitive molecule compared to without, it is likely that this receptor is binding 
XOR following its release from HUVECs. Alternatively, experiments could be run 
under flow conditions, therefore any XOR released from HUVECs will be given less 
time to bind to any cell-surface receptors that may be upregulated in response to 
agonist stimulation.
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5.4.2.4 The Influence of Histamine and Thrombin on XO Activity
As a control, the effect o f the agonists tested (either histamine or thrombin) on
purified XO activity was analysed (Figure 78 and Figure 82). In theory, if the agonist 
did not alter XO then any changes in XOR activity in medium above cells could be 
attributed to release of enzyme. Histamine has no effect on XO activity (Figure 78) 
but thrombin seems to increase XO activity in a dose-dependent manner (Figure 82). 
Therefore it is not possible to conclude, outright, that thrombin stimulates the release 
o f XOR from HUVECs. It is possible that XOR is constitutively released but the 
presence of thrombin increases XOR activity. However, in support o f thrombin 
stimulating the release o f X O R from HUVECs it must be noted that the “bell­
shaped” dose-response curve seen stimulating HUVECs with histamine and A23187 
(Figure 86) is also observed with thrombin. Suggesting that release, or lack of, is not 
an artefact if increased activity from thrombin treatment.The effect of thrombin on 
XO activity is investigated further (see Chapter 6).
5.4.3 Xanthine Oxidoreductase Release -  Time Course
In co-localisation studies o f X O R and vWf in Chapter 3 it was demonstrated that 
vWf and XOR are stored independently o f one another. In this chapter an 
experiment was performed observing the release times o f both XOR and vWf (Figure 
83). It was shown that XOR release was very rapid compared to vWf. As the release 
o f the two proteins occurred at different rates, this provides more evidence to suggest 
that XOR and vW f are not associated with one another in the HUVEC.
5.4.4 The Mechanism of XOR Release
Results from this chapter have shown that signalling via thrombin and histamine can 
stimulate XOR release from HUVECs. However experiments were performed to 
investigate the release process in more detail. Stimulation o f HUVECs with the 
calcium ionophore A23187 resulted in the dose-dependent release of vWf (Figure 
86A). Interestingly,, the maximal release of vWf with A23187 treatment was higher.
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than that seen with thrombin and histamine. This is in agreement with previous 
findings (Hattori et al., 1988), where release o f vW f from HUVECs treated with 
A23187 is much higher than that from cells exposed to histamine, thrombin, or 
phorbol 12-myristate 13-acetate. The release o f XOR from A23187-stimulated cells 
(Figure 86B) follows a similar “bell-shaped” curve seen with both thrombin and 
histamine treatment. Therefore these results suggest that the signalling mechanism for 
the release o f XOR from HUVECs involves a rise in intracellular calcium. This could 
be confirmed by chelating intracellular calcium stimulated by histamine or thrombin.
To further investigate the mechanism of XOR release, the effect of microtubule 
disruption was investigated (Figure 88). Incubating HUVECs with colchicine before 
stimulation with histamine reduced the release o f both vWf and XOR. In a similar 
study observing vW f release it was concluded that intracellular calcium-rising agents 
(such as histamine, thrombin, and A23187) recruit Weibel-Palade bodies to the 
plasma membrane for secretion, an effect that is dependent on intact microtubules 
for granule migration (Sinha and Wagner, 1987; Vischer et al., 2000). Therefore, as 
XOR release is affected by colchicine in the manner as described for vWf, then 
similar conclusions can be drawn. That is, XOR release may be dependent on the 
migration o f granules within the cell, which would suggest that the XOR “packages” 
observed by immunofluorescent and SEM techniques could in fact be storage 
granules that are the source of secreted XOR.
5.4.5 Other Potential Release Mechanisms
Although the release of XOR by a “traditional” secretion pathway is possible, other 
mechanisms exist that could potentially suit the release of XOR from the vascular 
endothelium. As the first alternative release mechanism it is worth discussing the only 
reported XOR secretion mechanism, the secretion o f XOR during the release o f milk 
lipid globules (MLG).
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Milk lipid occurs in two forms, as membrane fragments in the skim phase (Kitchen, 
1974) and as milk lipid globules (MLGs) that provide essential nutrition to the 
suckling neonate. MLG precursors are believed to originate from the endoplasmic 
reticulum o f mammary epithelial cells (Deeney et al., 1985) and may fuse with one 
another during their transit to the apical plasma membrane (APM) to form larger 
structures (1 -5 |jiM  in diameter). The release o f MLGs from mammary epithelial cells 
into the mammary alveolar lumen can occur by one o f two mechanisms, reviewed in 
Mather and Keenan, 1998. The m ost frequently occurring mechanism involves the 
enveloping o f the MLG by the APM which pinches-off, therefore expelling the 
globule from the cell. The molecular process of globule enveloping, that is the 
formation o f the Milk Lipid Globule Membrane (MLGM), and globule release has 
been hypothesised by Mather and Keenan, 1998, as a process in which XO is 







Figure 89. The Release of XO during MLG Secretion from Mammary Epithelial Cells
The release o f  MLGs from mammary epithelial cells occurs via a mechanism in which the MLG is 
enveloped in apical plasma membrane (A). The hypothesised protein interactions that are involved in 
this process are shown (B). The apical transmembrane glycoprotein, butyrophilin, contains a region 
o f  about 166 amino acids known as the B30.2 domain (Vernet et al., 1993). Xanthine oxidase has 
been shown to bind to the cytoplasmic domain o f  butyrophilin via the B30.2 domain (Ishii et al., 
1995), forming the membrane XO-butyrophilin complex which is believed to interact with ADRP on 
the surface o f  the MLG (Heid et al., 1996). The formation o f the XO-butyrophilin-ADRP has been
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proposed to function in the enveloping and eventual “pinching-off” and release o f  the MLG, 
therefore resulting in X O  secretion from the mammary epithelium.
A limited immunofluorescence microscopic survey o f the bovine tissues suggested 
that butyrophilin was only expressed in mammary epithelial cells during lactation 
(Franke et al, 1981). Also, the expression of the butyrophilin gene has been examined 
in many bovine organs including the liver, intestine, and kidney (Jack and Mather, 
1990) but yielded negative results. As tissue samples were homogenised for RNA 
analysis in these experiments, RNA from tissues other than the parenchymal tissue 
would have been examined, for example the microvascular endothelium. The negative 
butyrophilin mRNA results would therefore suggest the absence of butyrophilin gene 
expression in the microvascular endothelium as well. The results from these two 
experiments would suggest that butyrophilin is only expressed in lactating mammary 
epithelial tissue and therefore an identical XOR-secretion mechanism in the vascular 
endothelium is unlikely.
Another potential route for XOR secretion is through the release of membrane 
microparticles (MPs). MPs are membrane vesicles that are shed from the plasma 
membrane and contain cytoplasmic components. MPs can be formed by several cells 
types including platelets, macrophages, and vascular endothelial cells. The release of 
the cytokine IL-1J3, a protein that like XOR does not contain a signal sequence for 
secretion and is found in the cytoplasm (Wingren et al., 1996), has been shown to 
occur by MP release in macrophages (MacKenzie et al., 2001). Therefore this process 
could apply to the release o f XOR. However, the stimuli for MP formation in 
HUVECs only include bacterial lipopolysacchaides, TN Fa, IL-1, complement, and 
A23187, but thrombin did not stimulate MP formation above basal levels (Simak et 
al, 2002; reviewed in VanWijk et al., 2003). As thrombin (lU /m l) did not cause an 
increase in MP release from HUVECs (Simak et al, 2002) but does stimulate XOR 
release (results from this thesis), it is unlikely that this mechanism is responsible for 
XOR release. However, repeating the experiments of Simak et al, 2002, including a 
histamine stimulus, would be required to confirm this.
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5.4.6 Summary
The release o f XOR can be stimulated from HUVECs using known endothelial 
protein secretagogues. XOR release is independent o f cell death, and therefore occurs 
by a controlled process that is independent o f vWf. The mechanism of release may 
require a rise in intracellular calcium and a functioning microtubule network. 
Packaged XOR is a likely source of the secreted enzyme, however the release of 
cytoplasmic XOR by microparticle formation remains a possibility.
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Chapter 6. The Effect of Thrombin on 
Xanthine Oxidoreductase Activity
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6 The Effect of Thrombin on Xanthine 
Oxidoreductase Activity
6.1 Introduction: Thrombin in detail
After its formation from prothrombin (reviewed in Mann et a l , 2003), thrombin plays 
paradoxically opposing roles in the blood (Griffin, 1995). As a procoagulant thrombin 
cleaves the terminal step of the coagulation cascade, the conversion o f fibrinogen into 
insoluble fibrin (as described in Introductory Chapters). In addition, thrombin can 
proteolytically activate coagulation factor XIII (which is responsible for stabilising the 
fibrin clot), and factors V, VIII, and XI (Griffin, 1995). However, opposing this role 
is the function of thrombin as an anticoagulant (reviewed in Esmon, 2000). Thrombin 
can activate protein C, which in the presence of its cofactor protein S, cleaves and 
inactivates factors Va and V illa  (Esmon, 1989), two essential cofactors in the 
formation of Xa and IXa that are required for thrombin generation. Therefore 
protein C down-regulates the amplification and progression o f the coagulation 
cascade. Effective thrombin activation of protein C requires thrombin-binding to the 
endothelial cell-surface receptor, thrombomodulin (Esmon et al., 1982; Esmon, 1989). 
Binding to thrombomododulin is a key event in the switch from thrombin’s 
procoagulant activity to anticoagulant activity. The interaction with thrombomodulin 
suppresses the ability o f thrombin to cleave fibrinogen and factor V (Esmon et a l, 
1982) and enhances the specificity (>1000 fold) toward the zymogen protein C 
(Esmon and Owen, 1981; Owen and Esmon, 1981), the latter reaction being assisted 
by an endothelial cell receptor for protein C (Taylor et al, 2001).
Additional to the substrates described above thrombin may also cleave other proteins 
including PARs 1, 3, and 4 (as described in Introductory Chapters), thrombin- 
activatable fibrinolysis inhibitor (TAFI) (Bajzar et al, 1995), troponin C (Leavis et al, 
1978), and growth hormones (Graf et al, 1976). Recognition o f substrates is achieved 
by specific sequences in thrombin’s structure. The crystal structure o f thrombin has
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been investigated in detail (Bode et a l 1992). Thrombin is composed of two 
polypeptide chains, A and B, which are covalently linked by disulphide bonds. In 
humans, the A and B-chains consist of 36, and 259 amino-acid residues, respectively 
(Butkowski et al., 1977). The B-chain has been shown to be homologous to the 
catalytic domains of other pancreatatic and coagulation trypsin-like proteases, whereas 
the A-chain, previously thought to have no function (Di Cera, 2003), may have an 
important role in dictating the conformation and subsequently the activity of the 
catalytic B-chain (De Cristofaro et al, 2004). The B-chain is shaped like a sponge with 
deep crevices and protuberances on its water accessible side and contains the active 
site responsible for cleavage of substrates (Bode et al., 1992). Although thrombin has 
trypsin-like activity, unlike trypsin thrombin contains regions distant from the active 
site that are responsible for substrate recognition. The crystal structure of thrombin 
has revealed two cationic patches on the enzymes surface that are denoted anion 
binding Exosites I and II (Bode et al, 1992). Through various mutagenesis studies 
Exosite I has been shown to play an important role in the recognition of the 
substrates fibrinogen, fibrin, PAR 1, protein C, and thrombomodulin, whereas 
Exosite II is the locale for interaction with heparin and glycosaminoglycans (reviewed 
in Leung and Hall, 2000).
Consensus sequences for thrombin recognition and cleavage have been proposed 
(Rose and Di Cera, 2002). Exosite I-binding sequences have the consensus of OPO 
and for active site-binding sequences the L ins PRGO consensus has been proposed, 
where substrate cleavage occurs preferentially between the R and G residues (G = 
glycine , L = Leucine P = proline, R = arginine, and O  = either phenylalanine, 
tyrosine, histidine, or proline).
6.2 Chapter Aim
Results in chapter 5 demonstrate that the presence of thrombin increases XO-activity, 
independent o f cell culture, in a dose-dependent manner (Figure 78). Using XOR 
enzyme from various sources and by inhibiting thrombin’s proteolytic activity, the
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aim of this chapter is to further characterise the effects of thrombin on XOR activity 
and attempt to decipher the mechanism by which XOR activity is altered.
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6.3 Prinicples, Materials, and Methods
6.3.1 XOR Actvity Measurement
6.3.1.1 Materials
Ascorbic acid, Catalase from bovine liver, Hirudin recombinant from yeast, NADH, 
SOD from bovine erythrocytes, Thrombin from bovine plasma, Xanthine (Sigma 
Aldrich Company Ltd. Dorest, UK). Semi-skimmed milk (shop bought)
6.3.1.2 Methods
XOR activity was measured using the IXP- and uric acid-based assays (as described in 
Chapter 5), and also using the NADH oxidase assay. In the IXP-based assay 
lOOng/ml Biozyme XO, 73pg/ml rat liver protein, 39pg/ml rat serum protein, and 
68jjig/ml milk protein were routinely assayed (preparation of rat liver and serum 
samples are described in Appendix I 8.7). Where appropriate, thrombin, heat- 
inactivated thrombin (heated to 99°C for 5mins), hirudin, SOD, catalase, or ascorbic 
acid were added to the assay (as described in results). In the uric acid-based assay 
lpg /m l Biozyme XO was used, and thrombin and ascorbic acid were added where 
indicated in results.
^.3.1.3 XOR-NADH Oxidase Activity Assay
The NADH Oxidase-based XO assay was adapted from Sanders et al, 1997. In this 
assay, XO was incubated with lOOpM N A D H  at 25°C and the change in absorbance 
at 340nm (A340) was recorded using a spectrophotometer (Hitachi U-2010 
spectrophotometer. Hitachi. Berkshire, UK). The reaction is shown schematically in 
Figure 90. The change in A340 was measured over a period of approximately 5mins 
and the rate o f NADH oxidation was calculated using the extinction coefficient for 
NADH, e = 6.22mM 1 cm4. Following an initial experiment it was discovered that 
40pg/ml Biozyme XO was required to generate measurable XO-NADH oxidase 






Figure 90. Measurement of XO-NADH Oxidase Activity
N A D H  oxidation by X O  occurs at the FAD-containing moiety. The oxidation o f  N A D H  forming 
N A D + can be followed as a decrease in A 3 4 0 .  Electrons donated to XO during the oxidation step may 
be used to reduce molecular oxygen forming O 2 or H2O 2.
6.3.2 Escherichia coli Growth and XO Treatment
6.3.2.1 M aterials
Agar No. 1 (Oxoid Limited. Hampshire, UK); Allopurinol, Hypoxanthine, Luria 
Broth, Thrombin, Xanthine (Sigma Aldrich Company Ltd. Dorest, UK). Petri dishes 
(Fisher Scientific UK Ltd. Leicestershire, UK).
6.3.2.2 M ethod
6.3.2.2.1 Bacterial Culture
Agar plates were produced by adding 12.5g Luria Broth (LB) and 6g Agar to 500mls 
distilled water. The LB/Agar mix was sterilised by autoclaving. Sterile, set agar was 
heated in a microwave until fully dissolved and was poured into Petri dishes to a 
depth of about 5mm. The Petri dish was covered and the agar was allowed to set at 
room temperature. The resulting agar plates were stored at 4°C until required. Luria 
Broth was used for liquid culture of Escherichia coli. LB was produced by dissolving 
25g LB powder in 1000ml distilled water and was sterilised by autoclaving.
The Long term storage of Escherichia coli strain MC4100 (E. coli) was achieved by 
freezing at -70°C. Using a flamed loop, E. coli from the long-term storage stock were 
streaked-out onto an agar plate and incubated at 37°C until colonies formed. Once
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colonies had formed plates were stored at 4°C. When required single colonies were 
used to inoculate baffled flasks containing 20mls LB and cultures were incubated 
overnight at 37°C with continuous agitation.
6.3.2.2.2 Treatment of E. coli with XO
To determine the effect XO activity has on cultures o f E. coli (in the presence and 
absence of thrombin) a 96-well plate method was used (Millar, 1999). In these 
experiments a 200fil well volume was used and overnight E. coli cultures were diluted 
in LB to a final optical density 600nm (OD 600) o f approximately 0.02. E. coli were 
treated with relevant combinations of lOOpM Allopurinol, lOOfxM hypoxanthine, 
lOU/ml thrombin, and 50mU/ml Biozyme XO made up in a LB (all values stated are 
final concentrations). Cultures were incubated at 37°C and O D 600 was measured every 
30mins. An optical reading following the addition o f the E. coli culture to the plate 
constituted time zero. Log optical density values were plotted against time, and 
generation time was calculated from the linear growth stage o f each data set using the 
equation given in Equation 1.
6.3.3 Amino-acid Sequence Alignments and 3D-Structure 
Analysis
Relevant amino-acid sequences were retrieved from the National Center for 
Biotechnology Information Protein database (http://www.ncbi.nlm.nih.gov/entrez/). 
The following sequences were used in analysis (sequence accession numbers are 
shown in brackets following the sequence name): Human Coagulation factor II 
(P00734), V (P12259), VII (P08709), VIII (P00451), XI (P03951), and XIII 
(CAB99356), Human Fibrinogen Aa (P02671), Human Fibrinogen Bp (P02675), 
Human Thrombin Actdvatable Fibrinolysis Inhibitor (TAFI; g4503005), Human 
PARI (P25116), PAR3 (000254), and PAR4 (AAC28860), Human Protein C 
(P04070), Bovine XOR (P80457), Chicken XOR (P47990), Human XOR (P47989), 
Mouse XOR (Q00519), and Rat XOR (NP 058850). Sequences were aligned using the 
Clustal W program (Chenna et al., 2003) with default settings. The following symbols
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were used to indicate the degree o f conservation between the aligned sequences: 
means amino-acids in that column are identical, means in that column conserved 
substitutions have occurred according to the table below (Table 3), and means in 
that column semi-conserved substitutions have occurred. 3D protein structures were 
viewed using the National Center for Biotechnology Information 3D-Structure 
Database (http://www.ncbi.nlm .nih.gov/entrez/) and Cn3D program version 4.1 
(Chen et al., 2003a). Images are displayed using the following settings: rendering 
setting = tubes, and colouring setting = secondary structure (which distinguishes 
helix, strand, and coils with different colours). The 3D structure of Bovine XO was 
deposited by Enroth et al., 2000.
Table 3. Amino-acid Grouping
Amino-Acid Description
AVFPMILW Small (small + hydrophobic (including aromatic -Y))
D E Acidic
RHK Basic
STYHCNGQ Hydroxyl + Amine + Basic - Q
The Clustal W program (Chenna et al., 2003) uses the groups o f  amino-acids described to judge 
whether conserved substitutions have occurred between amino-acids in aligned sequences.
6.3.4 Fibrin turbidity assay
6.3.4.1 Materials
Fibrinogen Type I-S from bovine plasma; Hirudin recombinant from yeast, 
Thrombin from bovine plasma (Sigma Aldrich Company Ltd. Dorest, UK).
6.3.4.2 Method
The thrombin-catalysed polymerisation o f fibrin was measured using a turbidity-based 
assay. A previously published procedure (Choi et al., 1998; Chu et al., 2003) was 
followed, whereby the turbidity of a fibrinogen solution was recorded at absorbance 
450nm ( A 4 5 0 )  on a spectrophotometer (Hitachi U-2010 spectrophotometer. Hitachi. 
Berkshire, UK). The catalytic activity of thrombin causes the polymerisation of fibrin 
which increases the turbidity of the assay solution. Briefly, a final concentration o f
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0.5% (w/v) fibrinogen with hirudin (various concentrations) were made up to 1990[xl 
with buffer (containing 50mM Tris-HCl pH7.4, 5mM CaCh, and lOOmM NaCl) and 
were allowed to warm to 37°C in the spectrophotometer. With continuous stirring a 
time course assay at A 4 5 0  was started and a final concentration of 0.5U /m l thrombin 
was added, constituting time point zero. The assay was run for approximately 3mins 
and A 4 5 0  was recorded at lOsec intervals.
6.3.5 Cytochrome c -  based Superoxide Assay
6.3.5.1 Materials
Cytochrome c from equine heart, Hypoxanthine, SOD from bovine erythrocytes 
(Sigma Aldrich Company Ltd. Dorest, UK).
6.3.5.2 Method
The cytochrome c — based method o f measuring O 2 " was adapted from the method 
o f McCord and Fridovich (McCord and Fridovich, 1968; McCord and Fridovich, 
1969). The generation of O 2 ~ was calculated as the SOD-inhibitable portion of 
cytochrome c reduction, therefore each assay was repeated in the presence or absence 
of SOD. In each assay a final concentration o f 50pM cytochrome c + /-  50U /m l SOD 
was incubated with Im U /m l Biozyme XO and 500pM hypoxanthine. Reactions were 
incubated at 25°C and an absorbance change at 550nm was measured. Linear portions 
of absorbance change and the extinction coefficient for reduced cytochrome c (e = 
21.1mM-1 cm-1) were used to calculate the rate of SOD-inhibitable O 2”  generation, as 
cytochrome c is reduced by O 2 ” in a molar-to-molar manner then the rate of 
cytochrome c reduction equals the amount o f O 2 "  generation.
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6.4 Results
6.4.1 The Effect of On-lce-lncubation on XO Activity
For many of the experiments in this chapter a ln g / pi purified XO stock was prepared 
and was incubated on ice until required. Potentially the stock could be incubated on 
ice for several hours before being used in assays. Therefore as a control, the effect of 
storing the XO stock on ice, over time, was assessed by determining XO-activity at 
different incubation time points. At selected time points lOOpl aliquots of XO stock 
were measured for activity using the IXP-based XO assay as described in Beckman et 
al, 1989. Activity was recorded over Imin time periods and was calculated by linear 
regression from recordings at 20sec intervals (see Figure 91). Over the time period 
assessed (up to 6hrs) XO  activity remained unchanged.
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Figure 91. The Effect of Time-on-lce Incubation on XO-Activity
A ln g /p i  stock solution o f  pure-XO was incubated on ice. At selected time points enzyme activity 
was measured. Data was analysed using one-way A N O V A  with the Dunnett’s post test [results are 
from two experiments in triplicate, therefore n=6; error bar =  SD; ns =  not significant (p>0.05)].
6.4.2 Thrombin’s Effect on Purified (Biozyme)-XO Activity
6.4.2.1 Dose Response
An initial study was used to confirm the effect of thrombin on XO activity seen in the 
previous results chapter (Figure 78). Here lOOng/ml pure XO was incubated with 
various concentrations of thrombin for approximately three minutes at room 
temperature. The X O /throm bin mixture was assayed for XO activity using the IXP-
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based XO assay as described in Beckman et al., 1989 (see Chapter 5), however 
methylene blue was not used in the reaction process. Using the pterin substrate only, 
IXP accumulation was measured at 20sec intervals over a one minute period at room 
temperature, and enzyme-activity was calculated using linear regression of the 
progress curves (see Figure 92A). As controls, IXP-generation from the pterin 
substrate was assessed with XO, PBS without XO, and thrombin without XO (see 
Figure 92B). In accordance with the original study performed in Chapter 5, the 
presence of thrombin increases XO activity in a dose-dependent manner. Controls 
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Figure 92. The Effect of Throm bin on the Activity of Pure XO -  IXP-Based A ssay
A) lOOng/ml Biozyme XO  was incubated with various concentrations o f  thrombin for approximately 
3mins at room temperature. Following the incubation step, X O  activity was measured using the EXP- 
based XO assay and XO-activity was calculated. Data was analysed using one-way A N O V A  with the 
Dunnett’s post test (results are from three experiments in triplicate, therefore n=9; error bar =  SEM; 
ns = not significant (p>0.05), * =  p<0.05, ** = p<0.01). B) Control experiments were performed 
analysing IXP-generation from the pterin substrate in the presence o f  lOOng/ml pure XO, without 
X O  with substrate (PBS), and lO U /m l thrombin without X O  with substrate (results are from one 
experiment in triplicate, therefore n=3; error bar =  SD)
6.4.2.2 Michaelis-Menton Kinetics
Using the methodology described above, the influence of thrombin on XO activity 
was compared using different concentrations of ptrein substrate. Enzyme activity was
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calculated as previously described and data was fitted to the Michaelis-Menton 
equation (see Figure 93). In the presence o f lU /m l thrombin XO-Vmax increases to 
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Figure 93. XO-Activity in th e  P resence and A bsence of Thrombin
The effect o f  thrombin on X O  (100ng/m l Biozyme) activity was compared in the presence o f  various 
pterin-substrate (S) concentrations. Enzyme activity/velocity (V) was calculated and Michaelis- 
Menton kinetics were applied (results are from three experiments in triplicate, therefore n=9; error 
bar =  SEM).
6.4.2.3 Is Thrombin’s Effect Assay-Dependent?
In chapter 5 it was demonstrated that the pH o f the thrombin solutions tested did not 
deviate from the OU/ml sample and as the IXP-based assay is pH dependent, this can 
be ruled out as a possible cause of the change in enzyme activity. However, to 
support the data derived from the IXP-based assay, the thrombin-dose response assay 
was repeated, using the uric-acid assay. As with the IXP-based assay, XO and 
thrombin were incubated together at room temperature for approximately 3mins 
before XO activity was measured. However, in the uric-acid based assay lpg /m l X O  
with thrombin (various concentrations) was assayed using lOOpM xanthine, and uric 
acid generation was measured following an increase in A 2 9 5 ,  at 25°C, over time. From  
the linear portion o f enzyme activity uric acid generation was calculated using the 
extinction coefficient e = 9.6mM4cnr1 (see Figure 94). The influence of thrombin on
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XO-activity measured using the uric acid-based assay is comparable to that using the 
IXP-based assay (see Figure 92).
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Figure 94. The Effect of Thrombin on th e  Activity of Pure XO -  Uric Acid B ased  Assay
ljjig/m l Biozyme X O  was incubated with various concentrations o f  thrombin for approximately 
3mins at room  temperature. Following the incubation step, X O  activity was measured using the uric 
acid-based X O  assay and XO-activity was calculated (results are from one experiment in triplicate, 
therefore n=3; error bar =  SD).
6.4.2.4 Time Course
In the dose-response experiments described above, XO and thrombin were incubated 
for approximately 3mins at room temperature prior to enzyme assay. To investigate 
the effect o f incubation time on XO activity, lU /m l thrombin and lOOng/ml purified 
XO were incubated for various times before XO activity was assessed using the IXP- 
based assay (Figure 95). A significant change in XO-activity occurs after 30secs 
incubation with thrombin with a maximal increase occurring between 60-120secs 
incubation.
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Figure 95. The Effect of Thrombin-XO Incubation Time on XO Activity
lU /m l thrombin was incubated with lOOng/ml Biozyme X O  for various time periods at room  
temperature. After the desired time XO  activity was measured and data was analysed using one-way 
A N O V A  with the D unnett’s post test (N.T. =  no thrombin; results are from three experiments in 
triplicate, therefore n=9; error bar =  SEM; ns =  not significant (p>0.05), * = p<0.05, ** =  p<0.01).
6.4.2.5 Superoxide Generation
Thrombin has been shown to increase XO-activity as measured by the formation o f 
uric acid and IXP. As electron donating substrates are being catalysed at a more rapid 
rate in the presence o f thrombin, it would be expected that ROS-products would also 
be generated at a quicker rate compared to controls. To assess whether the presence 
of thrombin increases the generation of 02*" by XO compared to controls, the 
cytochrome c assay was used. In each o f the five repeats of the experiment O 2 
generation was greater in the presence o f thrombin compared to the no thrombin 
control. However following data analysis, the increase in O 2 "-generation was found 
not to be statistically significant (Figure 96).
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Figure 96. The Effect of Thrombin on XO-02'~ generation
A) Im U /m l Biozym e X O  was incubated with various concentrations o f  thrombin for approximately 
3mins at room  temperature. Following the incubation step, X O -O 2 ' generation in the presence o f  
500pM hypoxanthine was measured using the cytochrome c assay. The rate o f  O 2 ' generation was 
calculated and data was analysed using one-way A N O V A  with the Dunnett’s post test (results are 
from five experiments in triplicate, therefore n=15; error bar =  SEM; ns =  not significant P>0.05).
B) Controls showing O 2 ” generation with just X O  [no hypoxanthine (hypo.), no thrombin (thr.)] and 
with X O  and thrombin without hypoxanthine substrate.
6.4.2.6 XO-NADH Oxidase Activity
In experiments investigating the effect o f thrombin on XO activity, the substrates 
tested (i.e. pterin and xanthine) act at the M0 C0  redox centre of the enzyme. To gain 
further insight into how and where thrombin maybe affecting XO, the influence of 
thrombin on XO-NADH oxidase activity was determined. As mentioned in the 
Introduction to Chapter 2, the NADH substrate is oxidised at the FAD-containing 
active site o f XO, a reaction that does not require MoCo-binding for catalysis. The 
influence o f thrombin on XO-NADH oxidase activity was assessed using the 
protocol described in the Methodology section. As a control thrombin was shown to 
increase XO activity, as measured using the uric acid-based activity assay (Figure 
97B), however the presence of thrombin did not alter XO-NADH oxidase activity 
(Figure 97A).
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Figure 97. The Effect of Thrombin on XO-NADH Oxidase Activity
A) The influence o f  thrombin on X O -N A D H  oxidase activity was assessed following N A D H -N A D + 
conversion at A 340. The rate o f  N A D H -N A D + conversion was calculated and data was analysed using 
one-way A N O V A  with the Dunnett’s post test (results are from three experiments in triplicate, 
therefore n=9; error bar =  SEM; ns =  not significant P>0.05). B) As a control, i.e. to show that the 
thrombin stock functions to increase XO-activity as shown in previous experiments, XO-activity was 
measured using the uric acid-based assay in the presence or absence o f  thrombin (results are from 
one experiment in triplicate; error bar =  SD).
6.4.3 Thrombin’s Effect on Non-Purified-XO Activity
As demonstrated in the experiments described above, thrombin has an effect on 
purified-XO activity. In this section the influence of thrombin on X O R contained 
within complex samples was investigated.
6.4.3.1 The Effect of Thrombin on Milk-XO Activity
XO from Biozyme (Biozyme. Blaenavon, UK) is prepared from bovine buttermilk, 
therefore to determine whether thrombin alters XO from complex samples, bovine 
milk was initially tested. Dose-response and time course experiments were carried out 
using the same protocol as described for purified-XO, however, each assay contained 
68pg/ml milk protein and in time-course experiments lOU/ml thrombin was 
incubated with milk for the selected time points. XO-activity was assayed using the 
IXP-based protocol. In dose-response experiments (Figure 98A), similar to Biozyme- 
XO, a statistically significant change in XO-activity occurs in the presence of >0.1 
U /m l thrombin. However in comparison with Biozyme XO a significant change in
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activity only occurs after 120secs incubation with thrombin (Figure 98B), even though 
lOx more thrombin was used in milk-XO studies.
B
0 0.001 0.01 0.1 1 10 
[Thrombin](Units/ml)
o 35
N.T. 0 30 60 120 180 240
Incubation Time (secs)
Figure 98. The Effect of Throm bin on XO-Activity in Milk
A) 68fig/m l semi-skimmed milk was incubated with various concentrations o f  thrombin for 
approximately 3mins at room  temperature. Following the incubation step, X O  activity was measured 
using the IXP-based X O  assay and XO-activity was calculated. Data was analysed using one-way 
A N O V A  with the Dunnett’s post test (results are from three experiments in triplicate, therefore n=9; 
error bar =  SEM; ns =  not significant (p>0.05), ** =  p<0.01). B) lO U /m l thrombin was incubated 
with 68pg/m l semi-skimmed milk for various time periods at room  temperature. After the desired 
time X O  activity was measured and data was analysed using one-way A N O V A  with the Dunnett’s 
post test (N.T. =  no thrombin; results are from three experiments in triplicate, therefore n=9; error 
bar =  SEM; ns =  not significant (p>0.05), * =  p<0.05, ** =  p<0.01).
6.4.3.2 The Effect of Thrombin on Rat Liver and Serum-XOR Activity
As a continuation into the study into the effect of thrombin on complex XOR-
containing samples both rat liver and serum were tested. Previous studies have shown 
rat liver and serum contains both XDH and XO and activity (Al-Khalidi and 
Chaglassian, 1965; Stirpe and Della-Corte, 1969; Kooij et al’, 1994). Therefore the 
effect of thrombin on XDH activity could also be determined using these samples. 
Dose-response and time course experiments were carried out using the same protocol 
as described for purified-XO, however, each assay contained 73fjig/ml and 39pg/ml 
rat liver supernatant and serum protein, respectively. In time-course experiments 
lOU/ml thrombin was incubated with rat liver and serum protein for the selected 
time points. Total XOR and XO-activities were assayed using the IXP-based protocol
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in the presence and absence of methylene blue, respectively. In dose-response 
experiments (Figure 99A), unlike Biozyme-XO and XO contained in milk, a 
statistically significant change in XO-activity occurs only in the presence of lOU/m l 
thrombin, and thrombin has no effect on total (X D H /X O ) enzyme activity (Figure 
99B). However, similar to Biozyme-XO a significant change in XO-activity occurs 
after just 30secs incubation with thrombin (Figure 99C), but no significant change in 
total enzyme activity was seen over the incubation time points assessed (Figure 99D).
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Figure 99. The Effect of Thrombin on XOR-Activity in Rat Liver
73|ig/m l rat liver-supernatant was incubated with various concentrations o f  thrombin for 
approximately 3mins at room  temperature. Following the incubation step, X O  (A) and total enzyme 
activity (B) were measured using the IXP-based XOR assay. Data was analysed using one-way 
A N O VA with the D unnett’s post test (results are from three experiments in triplicate, therefore n=9; 
error bar =  SEM; ns =  not significant (p>0.05), ** =  p<0.01). In incubation time course experiments 
lO U /m l thrombin was incubated with 73pg/m l rat liver-supernatant for various time periods at room
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temperature. After the desired time X O  (C) and total enzyme activity (D) activity were measured and 
data was analysed using one-way A N O V A  with the D unnett’s post test (N.T. =  no thrombin; results 
are from three experiments in triplicate, therefore n=9; error bar =  SEM; ns =  not significant 
(p>0.05), ** =  p<0.01).
Dose-response experiments were also performed on rat serum samples. Both XO, 
and XO/XDH-com bined activities were measured as described for rat liver- 
supernatant analysis. However a final concentration of 39pg/ml rat serum protein 
was assayed (Figure 100A, B). In accordance with dose-response experiments with 
other XO-containing samples, the XO-activity in rat serum increases in the presence 
of thrombin. There is no increase in enzyme activity in the presence o f methylene 
blue compared to pterin alone, which suggests that rat serum does not contain 
measurable XDH activity. This is an interesting comparison with rat liver which 
contains a greater amount of XDH than XO. Statistical analysis was not performed 
on this data set due to insufficient replicates.
B
xo
a >  0 1
XDH/XO
c  ‘a> 70 ■A +*
5  2 60 ■
a >  o i
§  £  40
2  10
0.001 0.01 0.1 1 
Thrombin (U/ml)
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Figure 100. The Effect of Thrombin on XOR-Activity in Rat Serum
39(j.g/ml rat serum protein was incubated with various concentrations o f  thrombin for approximately 
3mins at room  temperature. Following the incubation step, X O  (A) and total enzyme activity (B) 
were measured using the EXP-based X O R  assay (results are from one experiment in triplicate, 
therefore n=3; error bar =  SD).
6.4.4 Thrombin and the Antibacterial Properties of XO
ROS generated by XO have been shown to have antibacterial properties, in particular 
it was shown that H 2O 2 has an antibacterial function (Stevens et a l, 2000). The 
function o f XO as an antibacterial agent is discussed in greater detail in Chapter 7
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(Main Discussion). In the following set of experiments the effect o f  thrombin on 
XO-antibacterial activity was assessed. As thrombin increases XO-activity it is likely 
that the antibacterial properties o f XO will be enhanced in the presence of thrombin. 
In these experiments overnight cultures of E. coli were diluted and exposed to 
combinations of hypoxanthine, XO, thrombin, and allopurinol. Bacterial cultures 
were incubated at 37°C and growth was analysed by measuring a change in 
absorbance at 600nm (A600). The population generation time was calculated from the 
exponential growth phase for each condition, an increase in generation time is 
indicative o f an antibacterial or bacteriostatic environment. An example o f resulting 
bacterial growth curves is given in Figure 101 A. As a control, each o f the substances 
(hypoxanthine, XO, thrombin, and allopurinol) used in these experiments were added 
singularly to E. coli cultures, none o f the substances had a significant effect on 
generation time (Figure 101B). Compared to the generation time o f control E. coli 
cultures, the presence o f XO and hypoxanthine increase generation time, but this 
effect is not statistically significant (Figure 101C), more repeats maybe needed to 
reach statistical significance. However, with the addition of throm bin to XO, the 
generation time of E. coli cultures is significantly increased (p<0.01). The effect of 
XO and hypoxanthine + / -  thrombin on generation time was inhibited back to a level 
seen in control cultures by allopurinol.
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Figure 101. The Effect of Throm bin on XO-Antibacterial P roperties
Cultures o f  E. coli were incubated with combinations o f  hypoxanthine, X O , thrombin, and 
allopurinol. Growth curve examples are shown in A, and the effect o f  substances added on 
generation time are shown in B and C. Population generation time was calculated from Af,cx) readings 
over time and data was analysed using One-Way A N O V A  with Dunnett’s post test. Results are from 
two experiments performed in triplicate, therefore n=6, error bar =  SEM (where A  =  Allopurinol, E 
=  E. coli, H  = Hypoxanthine, T  =  Thrombin, and X  = XO).
6.4.5 How Does Thrombin Effect XO Activity?
To begin to decipher the mechanism by which thrombin alters XO activity, this 
section investigates the possible ways that thrombin effects XO.
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6.4.5.1 An Alteration by Enzymatic Cleavage of XO?
As described in the introduction section to this results chapter, thrombin is a protease
that cleaves a variety o f substrates. It has long been known that proteases affect the 
activity o f the X OR enzyme, particularly in the irreversible conversion of XD H  to 
XO (see Introduction: Chapter 2). In this process, limited proteolytic cleavage o f 
XDH results in structural alteration allowing more efficient oxygen entry to the FAD- 
containing moiety, and therefore a switch between XDH and XO-activities. The 
following section investigates the possibility that thrombin could cleave XO resulting 
in a structural alteration that ultimately allows more efficient substrate turn-over in 
the enzyme, accounting for the increase in XO-activity seen in the presence of 
thrombin.
6.4.5.1.1 Do Thrombin-Cleavage and Exosite I Sequences Exist in XO?
To determine whether thrombin could cleave XO, the human XO amino-acid
sequence was screened for potential thrombin cleavage and Exosite I recognition 
sites. The sequences o f these sites were derived from Rose and Di Cera, 2002. Using 
the Clustal-W program the amino-acid sequence o f human XO was aligned with the 
consensus sequence for thrombin cleavage and the actual cleavage sequences from 
several thrombin substrates (see Table 4). The consensus sequences for thrombin 
cleavage were not found in the human XO sequence, however the actual sequence for 
cleavage o f human fibrinogen Aa showed good homology to a human XO sequence. 
The position of the positive alignment lies between human XO amino-acid residues 
1222-1225 (see Figure 102). It is interesting to note the leucine residue upstream from 
the potential thrombin cleavage site in human XO (see Figure 102), as leucine 
residues up to seven amino-acids from the Argine-Glycine cleavage site of thrombin 
catalysis forms part o f the consensus sequence for thrombin cleavage, and is import 
for thrombin-substrate contact (Rose and Di Cera, 2002).
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PRGF Consensus N ot Found
PRGY Consensus N ot Found
•PRGH Consensus N ot Found
PRGP Consensus N ot Found
P R S E Coagulation Factor II N ot Found
P R T F Coagulation Factor II N ot Found
I R S F Coagulation Factor V N ot Found
P R T F Coagulation Factor V N ot Found
G R IV Coagulation Factor VII N ot Found
I R S V Coagulation Factor VIII N o t Found
P R S F Coagulation Factor VIII N o t Found
P R I V Coagulation Factor XI N o t Found
PRGV Coagulation Factor XIII N o t Found
VRGP Fibrinogen A a TRGP (see below, Figure 102)
ARGH Fibrinogen B(3 N o t Found
P R S F PARI N o t Found
IK T F PAR3 N o t Found
PRGY PAR4 N o t Found
P R L I Protein C N o t Found
P R A S TAFI N o t Found
To discover potential sites for thrombin cleavage o f  human X O , the thrombin-cleavage sequences 
from known substrates were aligned with the human X O  amino-acid sequence.
HumXO V Q G L G L F T L E E L H Y S P E G L H T R G P S T Y K IP A F G S IP IE F R V S L L R D C P N K K A IY A S K A V  1 2 6 0
F i b A  -------------------------------------------------V R G P ---------------------------------------------------------------------------------------* ★ ★
Figure 102. The Alignment of Known Thrombin Cleavage Sequences with Human XO
The four amino-acid thrombin-cleavage sequence o f  human fibrinogen Aa (FibA) shows good  
homology to the human X O  (HumXO) amino-acid sequence position 1222-1225. N ote  the leucine 
residue upstream from the potential cleavage site (residue 1220). The number following the sequence 
indicates the position o f  the last amino-acid residue shown.
As mentioned in the introduction to this chapter, Exosite I is an important structure 
within the thrombin protein that is involved in substrate recognition. In the thrombin 
substrate sequences analysed in the Table above (Table 4), the Exosite I-binding 
sequence is located not more than 18 amino-acid residues down-stream from the end 
of the thrombin cleavage consensus sequence. Therefore, using the Clustal-W
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program, the region following the potential thrombin-cleavage sequence (1222- 
TRGP-1225) in XO was analysed for the Exosite I-binding consensus (Rose and Di 
Cera, 2002) and actual Exosite I-binding sequences found in known thrombin 
substrates (see Table 5). Exosite I-binding sequences of coagulation factor V and VIII 
showed homology to the human XO  sequence (residues 1240-1242 and 1236-1239, 
respectively) following the potential thrombin-cleavage site, and lie within 18 amino- 
acids from the cleavage site (see Figure 103).




Sequence in XO 
Following TRGP?
3>P<D Consensus N o t Found
VPD Coagulation Factor II N o t Found
RPL Coagulation Factor II N o t Found
FNL Coagulation Factor V FRV (see below, Figure 103)
H SL Coagulation Factor V N o t Found
CPW Coagulation Factor VII N o t Found
WDY Coagulation Factor VIII N o t Found
IP E Coagulation Factor VIII IP-E (see below, Figure 103)
WPW Coagulation Factor XI N o t Found
HLF Coagulation Factor XIII N o t Found
WPF Fibrinogen Aa N o t Found
P P P Fibrinogen B(3 N o t Found
E PF PARI N o t Found
F P F PAR3 N o t Found
LDP PAR4 N o t Found
SPW Protein C N o t Found
YSW TAFI N o t Found
Using known Exosite I-binding sequences, potential Exosite I-binding sites in the human XO  
sequence, downstream o f  the putative thrombin-cleavage site (1222-TRGP-1225), were analysed. 
Where <X> =  amino-acid residues F, H, P, or Y.
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Figure 103. The Alignment of Known Exosite I Sequences with Human XO
The Exosite I-binding sites o f  known thrombin substrates were aligned with the human XO amino- 
acid sequence. The Exosite I-binding sequence o f coagulation factor V  (FacV) and VIII (FacVIII) 
show homology to human XO. The number following the sequence indicates the position o f the last 
residue shown.
If the proposed Exosite I and thrombin cleavage sequences in the XO amino-acid 
sequence are important for enzyme function, i.e. in its interaction with thrombin, then 
the sequences should be conserved between different species. To investigate this 
possibility amino-acid sequences (local to the potential thrombin cleavage site), from 
different species were aligned (see Figure 104). It is interesting to note that the 
potential thrombin-cleavage sequence (L-TRGP) and the Exosite I sequences (IP-E
and FRY) show good homology between species.
Rat XOR LHYSPEGSLHTRGPSTYKIPAFGSIPIEFRV 1241
Mouse XOR LHYSPEGSLHTRGPSTYKIPAFGSIPIEFRV 1244
Human XOR LHYSPEGSLHTRGPSTYKIPAFGSIPIEFRV 1242
Bovine XOR LHYSPEGSLHTRGPSTYKIPAFGSIPTEFRV 1241
Chicken XOR LRYSPEGNLYTRGPGMYKIPAFGDIPTEFYV 
*.****★_*.****_ * * * * * * * * *  * *  *
1270
Figure 104. Alignment of Potential Thrombin Cleavage Sequences in XOR from Different 
Species
Using the Clustal-W program the region o f  human XOR containing potential thrombin cleavage and 
Exosite I-binding sites were aligned with XOR from different species. Highlighted (in bold) are the 
possible thrombin cleavage and Exosite I sites. The number following the sequence indicates the 
position o f the last residue shown.
6.4.5.1.2 Where do the Potential Thrombin-Cleavage and Exosite I Sites Lie 
in XO?
Using the Clustal-W program, regions homologous to known thrombin Exosite I- 
binding and cleavage sequences have been discovered in human XO. However, for 
these sequences to have any functional significance they should be exposed on or 
near to the surface of the XO-enzyme, where thrombin could interact and cleave. The
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crystal structure of monomeric bovine milk XO has been given at 2.5-A resolution 
(Enroth et al., 2000) and is deposited on the National Center for Biotechnology 
Information 3D-Structure Database. Using this sequence viewed with the Cn3D 
program version 4.1 (Chen et al.^  2003) the location of the potential Exosite I-binding 
and thrombin-cleavage sites were visualised. In Figure 105 the region containing the 
proposed thrombin cleavage and Exosite I-binding domains (1219- 
LHTRGPSTYKIPAFGSIPIEFRV-1241) are highlighted in the bovine XO 
molecule. This 23 amino-acid sequence (see yellow strand) runs through the centre of 
the XO monomer. The potential thrombin cleavage site (1219-LHTRGP-1224) and 
Exosite I-binding sites (1235-IPIE-1238; 1239-FRV-1241) regions are shown in 
Figure 106 (see yellow strands). For clarity the putative thrombin-interacting 
sequences only, are shown in Figure 106B, demonstrating that potential thrombin- 
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Figure 106. Potential Thrombin-Cleavage and Exosite l-Binding Sequences in the XO 
Monomer
A) Potential thrombin-interaction sequences in XO  are highlighted in yellow and B) for clarity the 
highlighted sequences are shown alone.
Figure 105. The Region Containing Potential Thrombin-Cleavage and Exosite l-Binding 
Sequences in the XO Monomer.
The region containing potential thrombin-interaction sequences in XO  are highlighted in yellow. The 
sequence is shown in two XO-orientations (A and B) and for clarity the highlighted region alone is 
shown in C.
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6.4.5.2 Inhibition of Thrombin Activity and the Effect on XO-Activity
Natural inhibitors o f thrombin include antithrombin III and heparin, and hirudin (Di
Cera, 2003). The inhibitor hirudin is naturally found in leeches, particularly in the 
salivary secretion o f the medicinal leech, Hirudo medicinalis. The secretion of hirudin 
has a distinct advantage to the leech, inhibiting blood coagulation and therefore 
maintaining blood flow from the site of attachment. Results from crystal structure 
analysis (Rydel et a l 1990) show that hirudin binds to Exosite I, blocking thrombin- 
substrate interactions and therefore the coagulation cascade. The genes encoding 
natural hirudin have been cloned and recombinant variants have been assessed for 
thrombin inhibition (Lyer and Fareed, 1995). Recombinant hirudins have been 
developed as anticoagulation drugs, for example Lepirudin (British National 
Formulary 47, March 2004).
6.4.5.2.1 Hirudin Inhibition and Heat-lnactivation of Thrombin - Controls
To discover whether thrombin-proteolytic activity is required to alter XO activity, in
this section the effect o f inhibited thrombin (in the presence o f hirudin or heat 
inhibition) will be investigated. Firstly as a control to demonstrate that the addition of 
hirudin inhibits thrombin activity, and to calculate the quantity o f hirudin required to 
inhibit thrombin, the fibrinogen-turbidity assay was used. The assay described in the 
Methodology section (Section 6.3.4) was used and the following concentrations of 
hirudin were tested: 0.05, 0.25, 0.5,'and 5U/ml. As a negative control 0.5% fibrinogen 
was incubated in the absence o f thrombin and as a positive control in the presence of
0.5U/ml thrombin with no hirudin (see Figure 107A). The effect of hirudin on 
thrombin’s activity is shown in Figure 107B, in the presence o f an equal number of 
units o f thrombin and hirudin, turbidity does not alter and therefore thrombin activity 
is inhibited.
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Figure 107. Hirudin inhibition of Thrombin Activity - Control
The thrombin catalysed formation o f  fibrin was followed using the turbidity assay. A) Positive and 
negative controls for the assay were performed in the presence and absence o f  thrombin. B) A range 
o f  hirudin concentrations were analysed for their inhibitory effect on thrombin catalysed fibrin 
formation. Each condition was repeated in triplicate and error bars represent the SD.
In addition to the thrombin-inhibition method using hirudin, the catalytic activity of 
thrombin was also inhibited by heat-inactivatibn. As a control to show heat- 
inactivation is effective the turbidity assay was used. Unlike the hirudin inhibition 
experiment, 1 OU/ml thrombin was used in the incubation. Heat-inactivation was 
performed on the lU /p l  stock by heating to 99°C for lOmins. As can be seen in 
Figure 108, the heat-inactivation of thrombin inhibits the increase in A 4 5 0  to a level 
that was seen in the negative control (in the absence o f thrombin).
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Figure 108. Heat-inactivation of Thrombin Activity - Control
The thrombin catalysed formation o f  fibrin was followed using the turbidity assay. As positive and 
negative controls fibrinogen was incubated with and without thrombin, respectively, and heat- 
inactivated thrombin was also tested. Each condition was repeated in triplicate and error bars 
represent the SD.
6.4.5.2.2 The Effect of Inhibited Thrombin on Biozyme XO Activity
To discover whether the catalytic activity o f thrombin was required to alter XO
activity, thrombin was treated with one o f the two established methods o f inhibition 
and was added to XO-containing samples, and compared to controls. Preliminary 
experiments were carried out on purified XO (Biozyme) using a range o f thrombin 
concentrations in the presence or absence o f 5U/m l hirudin. In these experiments 
thrombin and hirudin were incubated at room temperature for approximately 30secs 
before being added to lOOng/ml Biozyme XO about 3mins before XO activity was 
assessed using the method of Beckman et al., 1989. At the higher concentrations of 
thrombin tested (>0.1U/ml) the addition o f 5U /m l hirudin seems to reduce XO 
activity compared to thrombin alone (see Figure 109).
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Figure 109. Hirudin-lnhibition of Throm bin and its Effect on XO Activity -  A Preliminary 
S tudy
A range o f  concentrations o f  thrombin with or without 5U /m l hirudin were incubated with 
lOOng/ml Biozyme XO , and X O  activity was measured. Results are from one experiment in triplicate 
and error bar =  SD.
To assess the effect o f  heat-inactivated thrombin on pure XO compared to native 
thrombin, a range of thrombin concentrations with or without heat-inactivation were 
incubated with lOOng/ml Biozyme XO for approximately 3mins at room  temperature 
before XO activity was measured. From these preliminary results (Figure 110) it 
appears that heat-inactivation o f thrombin reduces the change in XO-activity seen 
with native thrombin concentrations >0.01U/ml.
Thrombin
Heat-Inactivated Thrombin
0 0.001 0.01 0.1 1 10 
[Thrombin](U/ml)
Figure 110. Heat-inactivation of Thrombin and its Effect on XO Activity -  A Preliminary 
Study
A range o f  concentrations o f  thrombin with or without heat-inactivation were incubated with 
lOOng/ml Biozyme XO, and X O  activity was measured. Results are from one experiment in triplicate 
and error bar =  SD.
6-193
. h u l k '  •> I k ‘ \*. i i ) M ) n
To farther investigate the effect of inhibited-thrombin on XO activity, and in 
particular compare the XO-activity in the presence of inhibited-thrombin with a non­
thrombin treated sample (which was not compared in the preliminary studies), the 
experiment was repeated using thrombin concentrations where the greatest difference 
in activities were demonstrated in the preliminary study. Here lOOng/ml XO was 
incubated with 1 OU/ml thrombin (native, heat-inactivated at 99°C for lOmins, or 
incubated at room temperature with 1 OU/ml hirudin for 30secs) for about 3mins 
before XO-activity was measured. Data was analysed using one-way ANOVA with 
Bonferroni’s post test (Figure 111). Compared to XO alone, the presence of 
thrombin increased XO-activity (p<0.001) as expected. The presence of inhibited 
thrombin does not significantly reduce XO activity when compared to the XO + 
thrombin sample. However, compared to the XO alone control, the increase in XO 
activity seen in samples with thrombin is statistically less significant when hirudin is 
included (i.e. XO v ’s XO + Thrombin: p<0.001; XO v’s XO + Thrombin + Hirudin: 
p<0.01), which may suggest some inhibition, but this was not apparent when 
compared to the heat-inactivated thrombin sample (i.e. XO v’s XO + Thrombin: 
p<0.001; XO v’s XO + Heat-inactivated Thrombin: p<0.001).
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XO XO xo xo xo




1 P-Value 1 Star Rating 1
X O  v's X O  + Hir. P>0.05 1 ns 1
X O  v's X O  +  Thr. P<0.001 I *** I
X O  v's X O  + Thr. +  Hir. P<0.01 1 ** 1
X O  v’s XO  +  H-I Thr. PC0.001 I *** I
X O  +  Thr. v's X O  + Thr. +  Hir. P>0.05 1 ns 1
X O  +  Thr. v's XO +  H-I Thr. 1 P>0.05 1 ns |
Figure 111. Inhibition of Thrombin and its Effect on XO-Activity
The effect o f  inhibited thrombin on X O  activity was compared to that o f native thrombin (A). In all 
cases thrombin final concentration was 1 OU/ml. Statistical results o f  various activity comparisons are 
shown in B. Results are from three experiments repeated in triplicate, therefore n=9. Error Bar =  
SEM. Where H-I Thr. =  Heat-Inactivated Thrombin, Hir. =  Hirudin, Thr. =  Thrombin, and ns =  
not significant.
As results from the latter experiment were not conclusive the procedure was repeated, 
however a final concentration of lU /m l thrombin was used in the relevant samples. 
The concentration o f hirudin remained at 1 OU/ml. Data was analysed using one-way 
ANOVA with Bonferroni’s post test (see Figure 112). Compared to XO alone, the 
presence of thrombin increased XO-activity (p<0.001) as expected. But again, the 
presence of inhibited thrombin does not significantly reduce XO activity when 
compared to the XO + thrombin sample. However as before, compared to the XO 
alone control, the increase in XO activity seen in samples with thrombin is statistically 
less significant when hirudin is included (i.e. XO v’s XO + Thrombin: p<0.001; XO 
v’s XO + Thrombin + Hirudin: p<0.05), which may suggest some inhibition, and this
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was also apparent when compared to the heat-inactivated thrombin sample (i.e. XO 
v’s XO + Thrombin: p<0.001; XO v’s XO + Heat-inactivated Thrombin: p<0.01).
xo xo xo xo xo
+ Hir. + Thr. + Thr. + H-I Thr. 
+ Hir.
1 Bonferroni s  Multiple I Com parison Test P-Value 1 Star Rating 1
I X O  v ’s XO +  Hir. P>0.05 1 ns 11 X O  v's X O  +  Thr. P<0.001 I *** I1 X O  v's X O  +  Thr. +  Hir. P<0.05 * II X O  v's X O  +  H-I Thr. P<0.01 1 ** I1 X O  + Thr. v's X O  +  Thr. +  Hir. P>0.05 1 ns 1I X O  + Thr. v's X O  +  H-I Thr. 1 P>0.05 1 ns |
Figure 112. Inhibition of Thrombin and its Effect on XO-Activity - Repeat
The effect o f  inhibited thrombin on X O  activity was compared to that o f  native thrombin (A). In all 
cases thrombin final concentration was lU /m l. Statistical results o f  various activity comparisons are 
shown in B. Results are from three experiments repeated in triplicate, therefore n=9. Error Bar = 
SEM. Where H -I Thr. =  Heat-Inactivated Thrombin, Hir. =  Hirudin, Thr. =  Thrombin, and ns = 
not significant.
6.4.5.2.3 The Effect of Inhibited Thrombin on XO Activity in Milk
The thrombin-inhibition experiments performed using purified-XO were repeated
investigating the effect on milk-XO activity. Here 68(ig/ml milk protein was 
incubated with 1 OU/ml thrombin (native, heat-inactivated at 99°C for lOmins, or 
incubated at room  temperature with 1 OU/ml hirudin for 30secs) for about 3mins 
before XO-activity was measured. Data was analysed using one-way ANOVA with 
Bonferroni’s post test (see Figure 113). Compared to milk alone, the presence of
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thrombin increased milk-XO activity (p<0.05) as expected. The presence of inhibited 
thrombin does not significandy reduce milk-XO activity when compared to the milk 
+ native thrombin sample. Unlike the results seen using purified XO, the increase in 
milk-XO activity in the presence o f inhibited-thrombin is not statistically less than the 
increase seen with native thrombin. (Milk v’s Milk + Thrombin: p<0.05; Milk v ’s Milk 
+ Thrombin + Hirudin: p<0.05). In fact in the presence o f heat-inactivated 
thrombin, the increase in milk-XO activity compared to that induced by native 
thrombin is greater (Milk v’s Milk + Thrombin: p <0.05; Milk v ’s Milk + Heat- 
Inactivated Thrombin p<0.001).
Milk Milk Milk Milk Milk
+ Hir. + T h r. + T h r . +  H-I Thr. 
+ Hir.
B Bonferroni's Multiple 
Com parison T est
P-Value S tar Rating
Milk v's Milk +  Hir. P>0.05 ns
Milk v's Milk +  Thr. P<0.05 *
Milk v's Milk +  Thr. +  Hir. P<0.05 *
Milk v's Milk +  H -I Thr. P<0.001 ***
Milk +  Thr. v's Milk +  Thr. +  Hir. P>0.05 ns
Milk +  Thr. v's Milk +  H-I Thr. P>0.05 ns
Figure 113. Inhibition of Thrombin and its Effect on Milk XO-Activity
The effect o f  inhibited thrombin on milk-XO activity was compared to that o f  native thrombin (A). 
In all cases thrombin final concentration was lOU/ml. Statistical results o f  various activity 
comparisons are shown in B. Results are from three experiments repeated in triplicate, therefore n=9. 
Error Bar =  SEM. Where H -I Thr. =  Heat-Inactivated Thrombin, Hir. =  Hirudin, ns =  not 
significant, Thr. =  Thrombin.
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6.4.5.3 Does Thrombin have an Antioxidant Effect and Therefore 
Increase XO Activity?
A n  i n t e r e s t i n g  f e a t u r e  o f  t h e  X O  e n z y m e  i s  t h a t  t h e  g e n e r a t i o n  o f  R O N S  m a y
r e g u l a t e  e n z y m e  f u n c t i o n .  A  n e g a t i v e  f e e d b a c k  p r o c e s s ,  k n o w n  a s  s u i c i d e  i n a c t i v a t i o n ,  
w a s  d e s c r i b e d  a f t e r  i t  w a s  d i s c o v e r e d  t h a t  R O N S  d e r i v e d  f r o m  X O  c a n  i n h i b i t  t h e  
e n z y m e .  E a r l y  s t u d i e s  d e s c r i b e  t h a t  X O - g e n e r a t e d  R O S ,  i n  p a r t i c u l a r  O 2 ” o r  H 2 O 2  
r e d u c e  e n z y m e  a c t i v i t y  ( L y n c h  a n d  F r i d o v i c h ,  1979; T e r a d a  et al,  1988) ,  a n d  t h a t  
H 2 O 2  i s  l i k e l y  t o  a f f e c t  t h e  M 0 C 0  i n  t h e  i n h i b i t o r y  p r o c e s s  ( L i n d e r  et a l , 2003) .  A l s o  
t h e  a d d i t i o n  o f  O N O O '  b u t  n o t  N O '  t o  X O  i n h i b i t s  e n z y m e  a c t i v i t y  ( L e e  et al.,2000) ,  
h o w e v e r  d u r i n g  t h e  g e n e r a t i o n  o f  N O '  f r o m  i n o r g a n i c  n i t r i t e  i t  w a s  d e m o n s t r a t e d  t h a t  
X O  i n h i b i t s  i t s e l f  ( G o d b e r  et a l , 2001)  l i k e l y  t h r o u g h  t h e  f o r m a t i o n  o f  a n  e n z y m e -  
s u b s t r a t e / p r o d u c t  c o m p l e x  t h a t  i n h i b i t s  t h e  M 0 C 0  b y  c o n v e r t i n g  i t  t o  i t s  d e s u l p h o  
f o r m .
T h e r e f o r e  I  h y p o t h e s i s e d  t h a t  i f  t h r o m b i n  w e r e  t o  a c t  a s  a n  a n t i o x i d a n t  a n d  “ m o p  
u p ”  t h e  R O S  g e n e r a t e d  b y  X O ,  t h e n  t h e  X O  e n z y m e  c o u l d  b e  s a v e d  f r o m  s u i c i d e  
i n h i b i t i o n .  T h e r e f o r e  a  g r e a t e r  p o r t i o n  o f  t h e  e n z y m e  w o u l d  r e m a i n  a c t i v e ,  w h i c h  
w o u l d  a c c o u n t  f o r  t h e  i n c r e a s e  i n  a c t i v i t y  s e e n  i n  t h e  p r e s e n c e  o f  t h r o m b i n  a n d  
t h e r e f o r e  d e s c r i b e  a  r o l e  f o r  t h r o m b i n  i n  r e g u l a t i n g  X O  a c t i v i t y .  I n  t h e  X O - a c t i v i t y  
a s s a y  s y s t e m  u s e d  i n  t h i s  t h e s i s ,  R O S  b u t  n o t  R N S  a r e  g e n e r a t e d ,  t h e r e f o r e  
a n t i o x i d a n t s  t h a t  a r e  k n o w n  t o  a c t  o n  R O S  ( s e e  I n t r o d u c t o r y  C h a p t e r s )  w e r e  u s e d  i n  
s t u d i e s  t o  a t t e m p t  t o  e m u l a t e  t h r o m b i n ’s  e f f e c t  o n  X O  ( i . e .  a  d o s e - d e p e n d e n t  i n c r e a s e  
i n  X O - a c t i v i t y ) .
6.4.5.3.1 The Influence of Catalase and SOD on XO Activity
F i r s t l y ,  t h e  i n f l u e n c e  o f  c a t a l a s e  o n  X O  a c t i v i t y  w a s  m e a s u r e d .  I n  t h e s e  e x p e r i m e n t s
t h e  p r o t o c o l  u s e d  t o  i n v e s t i g a t e  t h e  e f f e c t  o f  t h r o m b i n  o n  X O  a c t i v i t y  w a s  r e p e a t e d ,
i . e .  t h e  a n t i o x i d a n t ( s )  w e r e  i n c u b a t e d  w i t h  l O O n g / m l  X O  f o r  a p p r o x i m a t e l y  3m i n s  
b e f o r e  a c t i v i t y  w a s  m e a s u r e d .  U s i n g  t h e  B e c k m a n  et a l 1989 a s s a y ,  a c t i v i t y  w a s  
r e c o r d e d  o v e r  a  l m i n  p e r i o d  a n d  r a t e s  o f  I X P  g e n e r a t i o n  w e r e  c a l c u l a t e d  a s  
p r e v i o u s l y  d e s c r i b e d .  A  d o s e - r e s p o n s e  o f  c a t a l a s e  w a s  t e s t e d  i n c o r p o r a t i n g  e f f e c t i v e
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concentrations that have been used by other researchers [e.g. 250U/ml catalase, with 
lOmU/ml XO (~10jjig/ml Biozyme XO) and ImM  hypoxanthine, Murrell et al., 1990; 
and 200U/ml catalase with lOmU/ml XO, Bonini et al., 2004]. The addition of 
catalase has no effect on XO activity (Figure 114C). As the IXP-based assay was used 
for activity measurements the pH o f working concentration catalase stocks was 
measured as a control (Figure 114A), also the activity of samples without XO and 
catalase (PBS) or without XO (Catalase, 500U/ml) were measured as negative 
controls (see Figure 114B).
A B
0 0.05 0.5 5 50 500
[Catalase](U/ml)
c
0 0.05 0.5 5 50 500
[Catalase](U/ml)
Figure 114. The Effect of Catalase on XO-Activity
A log dilution o f  catalase was added to pure X O  and enzyme activity was measured using the pterin- 
based assay (C). Results are from three experiments repeated in triplicate, therefore n=9. Error Bar =  
SEM. Statistical analyses were performed using One-Way A N O V A  with Dunnett’s post test (ns =
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not significant (P>0.05). As controls, the pH  o f  the catalase working concentrations were measured 
(A) and activity was measured in the absence o f  XO and catalase (bar labelled PBS) or XO (bar 
labelled catalase) (B) (in A  and B results are from one experiment in triplicate, therefore n=3, and 
error bar =  SD.
The experiments performed using catalase were repeated but in the presence of SOD. 
Again a log dilution o f antioxidant was tested, and the quantity o f SOD to include 
was calculated from the Cytochrome t-based O 2 ~ assay. Cytochrome c reduction by 
O 2 _ generated from Im U /m l XO is completely inhibited using 50U/ml SOD. 
Im U /m l XO = ~ lp g /m l XO, which is approximately ten times more XO than is 
used in the pterin-based XO assay. Therefore using >50U /m l SOD will easily 
dismutate O 2 ~ generated in this assay. The addition o f SOD has an inhibitory effect 
on XO activity (Figure 115C). Once more, as the IXP-based assay was used for 
activity measurements the pH o f working concentration SOD stocks was measured as 
a control (Figure 115A), also the activity o f samples without XO and SOD (PBS) or 
without XO (SOD, lOOU/ml) were measured as negative controls (see Figure 115B).
A B
C. 10





0 0.01 0.1 1 10 100 
[SOD](U/ml)
6-200
H e u  h i m  m i i ’ l l !  ') 'I  I i h s h ,
^ 2 5 %
0.01 0.1 1 10 
[SOD](U/ml)
Figure 115. The Effect of SOD on XO-Activity
A log dilution o f  SO D  was added to pure X O  and enzyme activity was measured using the DCP- 
based assay (C). Results are from three experiments repeated in triplicate, therefore n=9. Error Bar =  
SEM. Statistical analyses were performed using One-Way A N O V A  with Dunnett’s post test (ns =  
not significant (P>0.05). As controls, the pH o f  the SOD working concentrations were measured (A) 
and activity was measured in the absence o f  X O  and SO D  (bar labelled PBS) or X O  (bar labelled 
SOD) (B) (in A and B results are from one experiment in triplicate, therefore n=3, and error bar =  
SD.
The effect of the combination of catalase and SOD on XO activity was also tested 
using the same protocol as described. Using a ratio o f 5 parts catalase to one part 
SOD (Figure 116A) it is evident that inhibition of XO occurs, however compared to 
SOD alone (Figure 115) the inhibition is less. But if a high level of catalase (200U/ml) 
is present with a range o f SOD concentrations then no inhibition or increase in XO 
activity occurs (Figure 116B).
A B
0/0 0.01/0.05 0.1/0.5 1/5 10/50
[SOD/Catalase](U/ml)
5> 10
0/200 0 .01/200 0.1/200 1/200 10/200 
[SOD/Catalase] (U/ml)
6-201
. h l i n e s  I l e w  iii^t>i I ' l i i ) T I k ' s ^
Figure 116. The Effect of SOD and C atalase on XO Activity
A  log dilution o f  SO D in combination with a five times greater concentration o f  catalase was added 
to pure X O  and enzyme activity was measured using the EXP-based assay (A). This process was 
repeated with an invariable catalase concentration o f  200U /m l (B). Results are from three 
experiments repeated in triplicate, therefore n=9. Error Bar =  SEM. Statistical analyses were 
performed using One-Way A N O V A  with D unnett’s post test (* =  p<0.05, ns =  n o t significant 
(P>0.05).
6.4.5.3.2 The Influence of Ascorbic Acid on XO Activity
Using the antioxidants SOD and catalase it was not possible to emulate the effect 
thrombin has on XO activity, therefore another commonly used antioxidant was 
tested. Using the same protocol described to investigate the effect of thrombin, SOD, 
and catalase on XO, XO activity was measured in the presence o f ascorbic acid. 
Ascorbic acid was prepared in PBS, however it was important to adjust the pH of 
stocks to ~7.3 using 1M NaOH, as the acidic solution would likely effect the IXP- 
based XO assay (Beckman et ai, 1989). A log dilution of ascorbic acid was added to 
XO and activity was calculated over a minute initial reaction period. As a positive 
control for an increase in activity, lOU/m l thrombin was added to XO (Figure 117 
Thr.), and as a negative control activity was measured in the absence o f X O  (Figure 
117 PBS). The addition of ascorbic acid did not increase XO activity as seen with 
thrombin, instead ascorbic acid inhibited XO activity in a dose-dependent manner 
(Figure 117).
PBS Thr. 0 0.1 1 10 100
-5
[Ascorbic Acid] (pM)
Figure 117. The Effect of Ascorbic Acid on XO Activity in the IXP-Based Assay
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A log dilution o f  ascorbic acid was added to XO and activity was measured using the IXP-based XO  
assay. As controls X O  activity was measured after ~3m in incubation with lO U /m l thrombin (Thr.) or 
in the absence o f  X O  (PBS). Results are from one experiment performed in triplicate, therefore n=3, 
and error bar =  SD.
The effect ascorbic acid has on XO activity was confirmed using the uric acid-based 
assay (Figure 118), previously described observing the effect of thrombin earlier in 
this chapter. Comparing the two experiments the inhibitory profile o f ascorbic acid 
was very similar, any differences (especially between the lpM  ascorbic acid samples) 
can be explained because o f differences in XO quantities and substrate concentrations 
in the two assay protocol.
[Ascorbic Acid] (|jM)
Figure 118. The Effect of A scorbic Acid on XO Activity in the  Uric Acid-Based Assay
A log dilution o f  ascorbic add was added to X O  and activity was measured using the uric acid-based 
X O  assay. As a control, activity was measured in the absence o f  X O  (PBS). Results are from one 
experiment performed in triplicate, therefore n=3, and error bar =  SD.
To further characterise the effect o f ascorbic acid, an effective inhibitory dose of 
ascorbic acid (lOfiM) was added during the measurement o f XO activity in the IXP- 
based assay (Figure 119A). It is clear that inhibition occurs following the addition of 
ascorbic acid and that activity rates significantly drop (Figure 119B). It is interesting to 
note that addition o f the known inhibitor allopurinol at the same concentration 
(10(jlM ) has similar effect as shown here with ascorbic acid (see Chapter 4: 
Assessment of Methods for the Measurement of Xanthine Oxidoreductase, Figure 
61). Although a control without the addition of ascorbic acid is not shown in Figure
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119 the initial XO activity rate is maintained for at least 400secs without the addition 
of an inhibitor (as shown in see Chapter 4: Assessment of Methods for the 
Measurement of Xanthine Oxidoreductase, Figure 61).
Figure 119. The Effect of A scorbic Acid on XO Activity During a Time C ourse M easurement
An effective inhibitory dose o f  ascorbic acid (lOpM) was added to X O  during activity measurement 
in the IXP-based assay. Raw data is given in A  and the activities before and after the addition are 
shown in B. Results are from a single experiment, n =  4, and error bar =  SD.
In an attempt to gain an insight into how ascorbic acid may function as an inhibitor 
o f XO the chemical structure of ascorbic acid was compared to that of known 
substrates and inhibitors (Figure 120). Known substrates (xanthine and pterin) and 
inhibitors (allopurinol) share a common structure, a six-membered ring containing 
two nitrogen atoms divided by a single carbon atom, however this structure is not 
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Figure 120. A Com parison of XO S u b stra te  and Inhibitor Chemical S truc tu res with 
Ascorbic Acid
The chemical structures if xanthine, pterin, allopurinol, and ascorbic add are given.
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6.5 Discussion
6.5.1 The Effect of Thrombin Dose-Response and Incubation 
Time
In the previous results chapter, the discovery that thrombin alters XO activity in a 
dose-dependent manner was made. This is a novel finding and warranted further 
investigation into the processes involved. Initial studies in this chapter replicated the 
limited study shown in the last chapter and confirmed the finding that thrombin 
increases purified XO activity in a dose-dependent manner (Figure 92). The presence 
o f thrombin alone does not increase IXP generation (Figure 94B), therefore only 
changes in XO activity are being measured. To verify the thrombin dose-response 
finding and remove the possibility that results were method-dependent, the dose- 
response studies were repeated using the uric acid-based protocol (Figure 94). The 
same dose-dependent increase in activity was observed. It was interesting to discover 
that the increased activity seen in the presence o f thrombin is not instantaneous. 
When incubating XO with a fixed amount of thrombin (lU /m l) for different time 
periods it was discovered that a maximal increase in activity occurs between 60- 
180secs incubation (Figure 95). Therefore suggesting that an “XO-activation process” 
takes place in the presence of thrombin.
6.5.2 ROS Generation by XO in the Presence of Thrombin
In enzyme kinetic studies, compared to XO alone, the presence o f thrombin increases 
both the Vmax and K m of the enzyme (Figure 93), meaning there was a greater turn­
over o f substrate and therefore greater XO activity in the presence o f thrombin. As 
electron-donating substrate (pterin or xanthine in these studies) turn-over is increased 
in the presence of thrombin, one would predict that the generation o f ROS by the 
enzyme would increase equally (i.e. the electrons being donated to the enzyme must 
be passed to an acceptor substrate for donating substrate to continue being 
consumed, and as the electron accepting substrate in the system being used is O 2 then 
ROS generation should increase). However, studies recording the generation of O 2 ~ 
by XO in the presence and absence of thrombin were not conclusive. The presence
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of 0.1 and lOU/ml thrombin consistendy increased the generation of O 2 ~, however 
statistical analysis did not demonstrate this increase to be significant (Figure 96). It 
could be that the assay is not sensitive enough to detect the change in O 2 ”  generation 
between treatments, it is worth pointing out that the cytochrome c assay requires ten 
times more XO compared to the IXP-based assay, and therefore the effect o f 
thrombin may not be so pronounced in the assay for O 2 However, compared to the 
cytochrome c assay a similar concentration o f enzyme is used in the uric acid-based 
assay, where a measurable change in XO activity is seen when thrombin is present 
(Figure 94). Another explanation lies in the ROS-generation profile of XO. As 
described in the introductory chapters, fully reduced XO can generate two H 2O 2 and 
two O 2 ~ molecules (Porras et al., 1981). Therefore the increase in electron donator 
(pterin or xanthine) turn-over in the presence o f thrombin may result in the increased 
generation of H 2O 2 which would not be detected by the cytochrome c assay. To 
confirm whether there is an increase in H 2O2 generation, the experiment would have 
to be repeated measuring H 2O 2 generation using, for example, a commercially 
available colourimetric H202-detection kit.
6.5.3 Antibacterial Properties of XO in the Presence of Thrombin
The antibacterial properties of XO have long been known, and the generation o f 
ROS are known to have this function. Therefore it was interesting to assess whether 
the increase in XO activity in the presence o f thrombin had a functional role, i.e. 
increase the antibacterial properties of XO. As none o f substances added to the E. 
coli culture alone inhibited growth (Figure 101B), then any alterations in the culture 
generation time were due XO activity and the generation of ROS. Further more, as 
thrombin alone did not inhibit the growth o f E. coli then differences between 
samples with and without thrombin were due to altered XO activity. It was 
discovered that active XO had mild antibacterial properties but in the presence o f 
thrombin the generation time increased significantly (Figure 101C), indicating that the 
increased XO-activity thrombin induces elevates the antibacterial properties of XO.
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T h e  e f f e c t s  o f  X O ,  w i t h  a n d  w i t h o u t  t h r o m b i n ,  w e r e  i n h i b i t e d  b y  a l l o p u r i n o l ,  
s u p p o r t i n g  t h e  r o l e  o f  a c t i v e  X O  a s  t h e  a n t i b a c t e r i a l  a g e n t .  T h e  i m p l i c a t i o n s  o f  X O ’s  
a n t i b a c t e r i a l  a c t i v i t y  a r e  d i s c u s s e d  i n  m o r e  d e t a i l  i n  t h e  m a i n  d i s c u s s i o n  c h a p t e r .  I t  
w a s  a l s o  i n t e r e s t i n g  t o  n o t e  t h a t  b y  t h e  e n d  o f  t h e  c u l t u r e  i n c u b a t i o n  t i m e ,  a l l  c u l t u r e s  
r e a c h e d  a p p r o x i m a t e l y  t h e  s a m e  O D 600 v a l u e .  ( F i g u r e  1 0 1  A ) .  T h i s  c o u l d  b e  d u e  t o  t h e  
s e l e c t i o n  o f  a  r e s i s t a n t  b a c t e r i a l  p o p u l a t i o n  o r  m o r e  l i k e l y ,  s u b s t r a t e  r u n s  o u t  a n d  
r e m a i n i n g  v i a b l e  c e l l s  c o n t i n u e  g r o w i n g .
A s  a n  a d d i t i o n a l  e x p e r i m e n t  i t  w o u l d  b e  i n t e r e s t i n g  t o  i n v e s t i g a t e  t h e  e f f e c t  t h r o m b i n  
h a s  o n  X O  R O S - s t i m u l a t e d  e x p r e s s i o n  o f  P - s e l e c t i n  i n  t h e  i n f l a m m a t o r y  p r o c e s s .  A s  
a n  i n i t i a l  s t e p  e x p e r i m e n t s  b y  T a k a n o  et al.t 2 0 0 2 ,  i n v e s t i g a t i n g  P - s e l e c t i n  u p -  
r e g u l a t i o n  b y  X O - R O S  u s i n g  a  c e l l - b a s e d  E L I S A ,  s h o u l d  b e  r e p e a t e d  w i t h  a n d  
w i t h o u t  t h r o m b i n .
6.5.4 The Complex XO-Containing Samples
C o m p a r i s o n s  w e r e  m a d e  b e t w e e n  t h e  e f f e c t  o f  t h r o m b i n  o n  p u r i f i e d - X O  a n d  X O  
c o n t a i n e d  w i t h i n  c o m p l e x  s a m p l e s .  F i r s t l y ,  t h e  a c t i v i t y  o f  X O  i n  s h o p  b o u g h t  b o v i n e  
m i l k  i n  t h r o m b i n  d o s e - r e s p o n s e  t r e a t m e n t  w a s  s i m i l a r  t o  t h a t  s e e n  w i t h  B i o z y m e  X O  
( F i g u r e  9 8 ) .  T h i s  i s  n o t  u n e x p e c t e d  a s  B i o z y m e  X O  i s  i s o l a t e d  f r o m  b o v i n e  m i l k .  
H o w e v e r ,  t h e  i n c u b a t i o n  t i m e  r e q u i r e d  t o  a c h i e v e  m a x i m a l  i n c r e a s e  i n  X O  a c t i v i t y  
w a s  l o n g e r  i n  b o v i n e  m i l k  c o m p a r e d  t o  p u r i f i e d  X O ;  e v e n  t h o u g h  t e n  t i m e s  m o r e  
t h r o m b i n  w a s  u s e d  i n  t h e  m i l k  s t u d i e s .  T h i s  c o u l d  b e  d u e  t o  r e d u c e d  i n t e r a c t i o n s  
b e t w e e n  X O  a n d  t h r o m b i n  i n  t h e  m o r e  c o m p l e x  m i l k  s a m p l e .  C o m p a r e d  t o  b o t h  t h e  
p u r i f i e d  a n d  m i l k  X O  s a m p l e s ,  t h e  r a t  l i v e r  h o m o g e n a t e  s h o w s  l i t t l e  i n c r e a s e  i n  X O  
a c t i v i t y ,  w i t h  a  s i g n i f i c a n t  i n c r e a s e  i n  a c t i v i t y  o c c u r r i n g  o n l y  i n  t h e  p r e s e n c e  o f  
l O U / m l  t h r o m b i n  ( F i g u r e  9 9 ) .  A l t h o u g h ,  a n  i n c u b a t i o n  t i m e  o f  o n l y  3 0 s e c s  w i t h  
l O U / m l  t h r o m b i n  w a s  s u f f i c i e n t  t o  s i g n i f i c a n t l y  i n c r e a s e  a c t i v i t y ,  a  s h o r t e r  p e r i o d  
c o m p a r e d  t o  t h e  o t h e r  X O - c o n t a i n i n g  s a m p l e s .  T h e  r e a s o n  w h y  t h e  d o s e - r e s p o n s e  
w a s  l e s s  e f f e c t i v e  c o u l d  b e  d u e  t o  t h e  c o m p l e x i t y  o f  t h e  l i v e r  h o m o g e n a t e  o r  c a n  b e  
a c c o u n t e d  f o r  b y  t h e  p r e s e n c e  o f  a  t h r o m b i n  i n h i b i t o r .  T h e  t h r o m b i n  i n h i b i t o r
6-208
J;mws I le u  h i m  h i Pil l > Tlie-n-
a n t i t h r o m b i n  I I I  i s  e x p r e s s e d  i n  t h e  l i v e r  ( P a l l i s t e r ,  1 9 9 7 )  a n d  w o u l d  t h e r e f o r e  b e  
p r e s e n t  i n  t h e  h o m o g e n a t e ,  i n t e r a c t i o n  w i t h  t h r o m b i n  c o u l d  d e c r e a s e  a c t i v i t y  t o w a r d s  
X O  a n d  a c c o u n t  f o r  t h e  l a r g e  d o s e  o f  t h r o m b i n  r e q u i r e d  t o  a l t e r  l i v e r  X O  a c t i v i t y .
T h e  r a t  s e r u m  X O R  s a m p l e s  s h o w e d  a  g o o d  r e s p o n s e  t o  t h r o m b i n  ( a n  i n c r e a s e  i n  
a c t i v i t y  i n  a  d o s e - d e p e n d e n t  m a n n e r )  ( F i g u r e  1 0 0 ) ,  w i t h  n o  s i g n  o f  t h e  i n h i b i t i o n  s e e n  
w i t h  t h e  l i v e r  h o m o g e n a t e  ( s t a t i s t i c s  w e r e  n o t  a p p l i e d  t o  t h i s  d a t a  d u e  t o  l o w  n 
n u m b e r s ) .  A n  i n t e r e s t i n g  f i n d i n g  w a s  m a d e  w h e n  c o m p a r i n g  r a t  l i v e r  r e s u l t s  w i t h  
t h o s e  f r o m  r a t  s e r u m .  I n  t h e s e  t w o  s a m p l e s  b o t h  X O  a n d  t o t a l  X O R  ( X D H  a n d  X O  
c o m b i n e d )  a c t i v i t i e s  w e r e  m e a s u r e d .  R a t  s e r u m  X O R  w a s  m a i n l y ,  i f  n o t  e n t i r e l y ,  i n  
t h e  X O  f o r m  w h e r e a s  l i v e r  i s  p r e d o m i n a n t l y  i n  t h e  X D H  f o r m  [ w h i c h  h a s  p r e v i o u s l y  
b e e n  d e s c r i b e d  ( D e l l a  C o r t e  a n d  S t i r p e ,  1 9 6 8 ;  S t i r p e  a n d  D e l l a  C o r t e ,  1 9 6 9 ) ] .  T h i s  
f i n d i n g  r e i n f o r c e s  p r e v i o u s  d a t a  f r o m  s t u d i e s  s u g g e s t i n g  c i r c u l a t i n g  X O R  i s  m a i n l y  i n  
t h e  X O  f o r m  ( K o o i j  et al' ,  1 9 9 4 ) .  I n  K o o i j  et al., 1 9 9 4  r a t  l i v e r  X D H  i n c u b a t e d  w i t h  
r a t  p l a s m a  w a s  r a p i d l y  c o n v e r t e d  t o  X O  b y  a n  u n k n o w n  f a c t o r .  T h e  i m p l i c a t i o n s  o f  a  
p r e d o m i n a n t  X O - c i r c u l a t i n g  f o r m  a r e  d i s c u s s e d  i n  t h e  m a i n  d i s c u s s i o n .  T h e  r e s u l t s  
f r o m  t h e  c o m p l e x  X O - c o n t a i n i n g  s a m p l e s  r e v e a l  t h a t  t h r o m b i n  a l t e r s  t h e  a c t i v i t y  o f  
a l l  X O  s a m p l e s  t e s t e d  a n d  n o t  j u s t  t h e  p u r i f i e d  s a m p l e .
6.5.5 The REDOX Centres Involved in Thrombin Increased XO 
Activity
A s  d e s c r i b e d  i n  t h e  i n t r o d u c t o r y  c h a p t e r s ,  X O  p o s s e s s e s  N A D H  o x i d a s e  a c t i v i t y .  T h e  
p r o c e s s  o f  N A D H  o x i d a t i o n  a n d  s u b s e q u e n t  R O S  g e n e r a t i o n  o c c u r s  a t  t h e  F A D -  
c o n t a i n i n g  m o i e t y ,  i . e .  t h e  o t h e r  r e d o x  c e n t r e s  a r e  n o t  i n v o l v e d  i n  s u b s t r a t e  b i n d i n g  
f o r  N A D H  o x i d a s e  a c t i v i t y  t o  o c c u r .  U s i n g  t h i s  t h e o r y  i t  i s  p o s s i b l e  t o  d i s c o v e r  
w h e t h e r  t h e  F A D - m o i e t y  i s  a f f e c t e d  b y  t r e a t m e n t s  o f  X O .  I n  t h i s  t h e s i s  t h e  e f f e c t  o f  
t h r o m b i n  o n  N A D H - o x i d a s e  a c t i v i t y ,  a n d  t h e r e f o r e  o n  t h e  F A D - m o i e t y ,  w a s  
i n v e s t i g a t e d .  H o w e v e r  t h e  i d e a  h a s  b e e n  e x p l o i t e d  i n  o t h e r  p u b l i s h e d  r e s e a r c h ,  f o r  
e x a m p l e ,  T e r a d a  et a i,  2 0 0 3  w e r e  i n v e s t i g a t i n g  t h e  i n h i b i t o r y  e f f e c t  o f  o x y g e n  a n d  i t s
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m e t a b o l i t e s  o n  X O  a c t i v i t y .  T h e y  d i s c o v e r e d  t h a t  i n c r e a s i n g  o x y g e n  c o n c e n t r a t i o n s  
h a d  n o  e f f e c t  o n  X O  N A D H - o x i d a s e  a c t i v i t y  h o w e v e r  t h e y  a b o l i s h e d  t h e  c o n v e r s i o n  
o f  x a n t h i n e  t o  u r a t e .  T h e r e f o r e  s u g g e s t i n g  t h e  F A D - m o i e t y  i s  u n a f f e c t e d  w h e r e a s  t h e  
M o C o  i s  a  l i k e l y  t o  b e  i n v o l v e d  i n  t h e  m e c h a n i s m  o f  i n h i b i t i o n .  I n  t h i s  t h e s i s  a  s i m i l a r  
s c e n a r i o  h a s  u n f o l d e d ,  t h e  p r e s e n c e  o f  t h r o m b i n  i n c r e a s e s  s u b s t r a t e  ( x a n t h i n e  a n d  
p t e r i n )  t u r n  o v e r  a t  t h e  M o C o ,  h o w e v e r  t h r o m b i n  h a s  n o  e f f e c t  o n  N A D H - o x i d a s e  
a c t i v i t y  ( F i g u r e  9 7 ) .  T h e r e f o r e  t h r o m b i n  i s  l i k e l y  t o  b e  a l t e r i n g  t h e  e n 2 y m e  i n  s u c h  a  
w a y  t h a t  t h e  e n v i r o n m e n t  a t  t h e  M o C o  i s  a l t e r e d  b u t  t h e  F A D - m o i e t y  i s  u n c h a n g e d .
6.5.6 Could Thrombin Theoretically Cleave XO?
T h r o m b i n  i s  a  s e r i n e  p r o  t e a s e  t h a t  i s  k n o w n  t o  c l e a v e  m a n y  p r o t e i n s .  T o  d i s c o v e r  
h o w  t h r o m b i n  i s  a f f e c t i n g  X O  a c t i v i t y  i n i t i a l  s t u d i e s  i n v e s t i g a t e d  t h e  p o s s i b i l i t y  t h a t  
t h r o m b i n  c o u l d  c l e a v e  X O .  A s  d e s c r i b e d  i n  i n t r o d u c t o r y  c h a p t e r s ,  i t  i s  k n o w n  t h a t  
l i m i t e d  p r o t e o l y t i c  c l e a v a g e  o f  X O  c a n  r e s u l t  i n  s t r u c t u r a l  a l t e r a t i o n s  e f f e c t i n g  t h e  
F A D - m o i e t y  a n d  c o n s e q u e n t l y  s u b s t r a t e  b i n d i n g  a t  t h i s  r e d o x  c e n t r e  o f  X O  ( k n o w n  
a s  i r r e v e r s i b l e  X D H - X O  c o n v e r s i o n ) .  P o t e n t i a l l y  a  s i m i l a r  p r o c e s s  c o u l d  o c c u r  w i t h  
t h r o m b i n  w h i c h  e f f e c t s  s u b s t r a t e  b i n d i n g  t o  t h e  M o C o  ( r e s u l t s  a l r e a d y  d i s c u s s e d  
c o n c l u d e d  t h a t  t h e  F A D  c e n t r e  i s  n o t  e f f e c t e d  b y  t h r o m b i n ) .
I n i t i a l  s t u d i e s  a i m e d  t o  f i n d  c o n s e n s u s  s e q u e n c e s  w i t h i n  X O  f o r  t h r o m b i n  r e c o g n i t i o n  
( t h e  E x o s i t e  I  s e q u e n c e )  a n d  f o r  c l e a v a g e  a s  d e s c r i b e d  i n  R o s e  a n d  D i  C e r a . ,  2 0 0 2 .  A  
p o t e n t i a l  t h r o m b i n - c l e a v a g e  s e q u e n c e  w a s  f o u n d  t h a t  s h o w e d  h i g h  h o m o l o g y  t o  t h a t  
o f  f i b r i n o g e n  A a  c h a i n  ( T a b l e  4 ) .  T h i s  s i t e  c o n t a i n s  a  l e u c i n e  r e s i d u e  f o u n d  t w o  
a m i n o - a c i d s  u p s t r e a m  f r o m  t h e  s t a r t  o f  t h e  p o t e n t i a l  c l e a v a g e  s e q u e n c e ,  w h i c h  a l s o  
f o r m s  p a r t  o f  t h e  c o n s e n s u s  s e q u e n c e  a n d  i s  f o u n d  i n  t h i s  p o s i t i o n  i n  t h e  t h r o m b i n  
s u b s t r a t e s  P A R I ,  3 ,  a n d  4 ,  a n d  c o a g u l a t i o n  f a c t o r  V  ( R o s e  a n d  D i  C e r a . ,  2 0 0 2 ) .  
H o m o l o g y  s e a r c h e s  o n  t h e  r e g i o n  i m m e d i a t e l y  d o w n s t r e a m  o f  t h e  p o t e n t i a l  c l e a v a g e  
s i t e  r e v e a l e d  t w o  p o t e n t i a l  E x o s i t e  I  b i n d i n g  s e q u e n c e s ,  h o m o l o g o u s  t o  t h o s e  f o u n d  
i n  c o a g u l a t i o n  f a c t o r  V  a n d  V I I I  ( T a b l e  5 ) .  T h e  h o m o l o g o u s  s e q u e n c e s  w i t h i n  t h e
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h u m a n  X O  a m i n o - a c i d  c h a i n  a r e  h i g h l i g h t e d  i n  t h e  f o l l o w i n g  s e q u e n c e :  1 2 4 2 -  
L H Y S P E G S L H T R G P S T Y K I P A F G S I P I E F R V - 1 2 7 2 .  T h e  r e g i o n s  h i g h h g h t e d  a r e  
l i k e l y  t o  h a v e  a n  i m p o r t a n t  f u n c t i o n  w i t h i n  t h e  X O  e n z y m e  a s  t h e y  a r e  h i g h l y  
c o n s e r v e d  b e t w e e n  X O - s e q u e n c e s  f r o m  s e v e r a l  s p e c i e s  ( F i g u r e  1 0 4 ) .  T h e  l o c a t i o n s  o f  
t h e  p o t e n t i a l  t h r o m b i n - i n t e r a c t i n g  s e q u e n c e s  w e r e  a s s e s s e d  u s i n g  t h e  p u b l i s h e d  3 D  
c r y s t a l  s t r u c t u r e  o f  a n  X O  m o n o m e r  ( F i g u r e  1 0 5  a n d  F i g u r e  1 0 6 ) .  I n t e r e s t i n g l y ,  t h e  
p o t e n t i a l  c l e a v a g e  s e q u e n c e  w i t h i n  X O  i s  f o u n d  o n  a  l o o p  e x p o s e d  o n  t h e  e n z y m e  
s u r f a c e ,  a n d  t h e r e f o r e  c o u l d  t h e o r e t i c a l l y  i n t e r a c t  w i t h  t h r o m b i n .  T h i s  c l e a v a g e  s i t e  
f o r m s  p a r t  o f  a  c h a i n  t h a t  r u n s  t h r o u g h  t h e  c e n t r e  o f  t h e  X O  m o n o m e r  c l o s e  t o  t h e  
r e d o x  c e n t r e s  o f  t h e  e n z y m e .  T h e r e f o r e  c l e a v a g e  a t  t h i s  s i t e  c o u l d  a l t e r  t h e  s t r u c t u r e  
o f  t h e  e n z y m e  e f f e c t i n g  s u b s t r a t e  b i n d i n g  t o  t h e  M o C o .  H o w e v e r ,  t h e  l o c a t i o n  o f  t h e  
E x o s i t e  I - h o m o l o g o u s  s e q u e n c e  d o e s  n o t  s u i t  a  r o l e  o f  t h r o m b i n  r e c o g n i t i o n  a n d  
c l e a v a g e  o f  X O  a s  i t  i s  f o u n d  o n  t h e  o p p o s i t e  f a c e  o f  t h e  X O  m o n o m e r .  B u t  t h i s  d o e s  
n o t  e l i m i n a t e  t h e  p o s s i b i l i t y  o f  a n  E x o s i t e  I - b i n d i n g  s i t e  b e i n g  a v a i l a b l e  t o  t h r o m b i n  
b y  v i r t u e  o f  t h e  t e r t i a r y  s t r u c t u r e  o f  t h e  X O  p r o t e i n .
T o  d i s c o v e r  w h e t h e r  X O  i s  c l e a v e d  b y  t h r o m b i n ,  a n d  i f  s o ,  w h e t h e r  c l e a v a g e  a t  t h e  
p r o p o s e d  s e q u e n c e  a l t e r s  t h e  a m i n o - a c i d  s t r u c t u r e  a r o u n d  t h e  M o C o  l e a d i n g  t o  
i n c r e a s e d  s u b s t r a t e  a f f i n i t y ,  e x p e r i m e n t s  s u c h  a s  t h o s e  u s e d  i n  E n r o t h  et al. , 2 0 0 0  
w o u l d  h a v e  t o  b e  r e p e a t e d .  I n  t h e s e  s t u d i e s  t h e  c r y s t a l  s t r u c t u r e  o f  X D H  a n d  X O  
w e r e  c o m p a r e d ,  w i t h  p a r t i c u l a r  e m p h a s i s  o n  t h e  r e g i o n  s u r r o u n d i n g  t h e  F A D - m o i e t y .  
T o  s h o w  w h e t h e r  t h r o m b i n  i n f l u e n c e s  X O  s t r u c t u r e ,  t h e  c r y s t a l  s t r u c t u r e  o f  X O  
e x p o s e d  t o  t h r o m b i n  w o u l d  h a v e  t o  b e  d e t e r m i n e d  a n d  c o m p a r e d  t o  n o r m a l  X O .
6.5.7 Is Proteolytic Activity of Thrombin Required to Alter XO 
Activity?
S e q u e n c e  a n a l y s i s  a n d  s t r u c t u r a l  d a t a  p r e s e n t e d  s u g g e s t  t h a t  t h r o m b i n  c o u l d  c l e a v e  
X O .  I n  a n  a t t e m p t  t o  s h o w  t h i s  e x p e r i m e n t a l l y ,  t h e  a c t i o n s  o f  i n h i b i t e d  t h r o m b i n  
w e r e  c o m p a r e d  t o  n o r m a l  t h r o m b i n .  A s  c o n t r o l s  t o  s h o w  t h a t  t h e  t h r o m b i n -
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i n h i b i t i o n  p r o c e s s e s  w e r e  s u c c e s s f u l ,  t h e  a s s a y  o f  f i b r i n o g e n - f i b r i n  c o n v e r s i o n  w a s  
e m p l o y e d .  T h e s e  e x p e r i m e n t s  d e m o n s t r a t e d  t h a t  t h r o m b i n  i s  i n h i b i t e d  u s i n g  a n  e q u a l  
c o n c e n t r a t i o n  ( U n i t s )  o f  h i r u d i n  o r  b y  h e a t i n g  t o  9 9 ° C  f o r  5 m i n s  ( F i g u r e  1 0 7  a n d  
F i g u r e  1 0 8 ) .  I n i t i a l  d o s e - r e s p o n s e  e x p e r i m e n t s ,  l o o k i n g  a t  t h e  e f f e c t  o f  n o r m a l  
t h r o m b i n  v ’s  i n h i b i t e d  t h r o m b i n  o n  X O  a c t i v i t y  l o o k e d  p r o m i s i n g .  W i t h  b o t h  
i n h i b i t i o n  p r o c e s s e s ,  a t  t h e  h i g h e r  t h r o m b i n  c o n c e n t r a t i o n s ,  i t  a p p e a r e d  t h a t  X O  
a c t i v i t y  w a s  r e d u c e d  i n  t h e  p r e s e n c e  o f  i n h i b i t e d  t h r o m b i n  c o m p a r e d  t o  n o r m a l  
t h r o m b i n  ( F i g u r e  1 0 9  a n d  F i g u r e  1 1 0 ) .
T h e s e  i n i t i a l  s t u d i e s  w e r e  r e p e a t e d  u s i n g  t h e  h i g h e r  c o n c e n t r a t i o n s  o f  t h r o m b i n  o n l y  
( i . e .  1  a n d  l O U / m l )  w i t h  o r  w i t h o u t  i n h i b i t i o n  ( l O U / m l  h i r u d i n  o r  9 9 ° C  f o r  5 m i n s )  
( F i g u r e  1 1 1  a n d  F i g u r e  1 1 2 ) .  N o r m a l  t h r o m b i n  i n c r e a s e d  t h e  a c t i v i t y  o f  X O  
s i g n i f i c a n t l y  b u t  t h e  p r e s e n c e  o f  i n h i b i t e d  t h r o m b i n  w o u l d  n o t  r e d u c e  a c t i v i t y  l e v e l s  
b a c k  t o  t h a t  o f  X O  a l o n e .  H o w e v e r ,  c o m p a r e d  t o  n o r m a l  t h r o m b i n ,  u s i n g  i n h i b i t e d  
t h r o m b i n  t h e  i n c r e a s e  i n  X O  a c t i v i t y  d e c r e a s e d  i n  s t a t i s t i c a l  s i g n i f i c a n c e .  T h e r e f o r e  
i n d i c a t i n g  t h a t  i n h i b i t i o n  o f  t h r o m b i n  d o e s  a l t e r  i t s  a c t i v i t y  t o w a r d s  X O ,  h o w e v e r  
t h e s e  r e s u l t s  a r e  n o t  c o n c l u s i v e .
A s  f u r t h e r  w o r k ,  i t  w o u l d  b e  i n t e r e s t i n g  t o  t e s t  t h e  e f f e c t  o f  o t h e r  t h r o m b i n - i n h i b i t o r s  
s u c h  a s  a n t i t h r o m b i n  I I I  a n d  h e p a r i n .  H o w e v e r  c a r e  s h o u l d  b e  t a k e n  a r i d  r e l e v a n t  
c o n t r o l s  p u t  i n  p l a c e  a s  h e p a r i n  b i n d s  t o  X O  ( A d a c h i  et al.t 1 9 9 3 )  a n d  c o u l d  t h e r e f o r e  
i n t e r f e r e  w i t h  a c t i v i t y .  T o  d e m o n s t r a t e  w h e t h e r  o r  n o t  t h e  p r o p o s e d  t h r o m b i n -  
c l e a v a g e  s e q u e n c e  i n  X O  i s  c l e a v e d  b y  t h r o m b i n ,  t h e n  a  m u t a t e d  f o r m  o f  X O  ( a n  
a m i n o - a c i d  s u b s t i t u t i o n  i n  t h e  s e q u e n c e  L - T R G P )  s h o u l d  b e  e x p r e s s e d  a n d  e x p o s e d  
t o  t h r o m b i n .  I f  t h e  i n c r e a s e  i n  a c t i v i t y  i s  n o t  s e e n  w i t h  t h e  m u t a n t  t h e n  i t  i s  p r o b a b l e  
t h a t  t h i s  s e q u e n c e  i s  t h e  t a r g e t  f o r  t h r o m b i n  c l e a v a g e .
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6.5.8 Can Thrombin’s Effect on XO be Reproduced by 
Antioxidants?
X O  c a n  b e  i n a c t i v a t e d  b y  e i t h e r  s e l f - g e n e r a t e d  o r  e x o g e n o u s l y  d e r i v e d  R O S  s p e c i e s  
( T e r a d a  et al.9 1 9 8 8 ;  L i n d e r  et a l . ,  2 0 0 3 ) .  T h e r e f o r e  t h e  p r e s e n c e  o f  a n t i o x i d a n t s ,  s u c h  
a s  c a t a l a s e ,  S O D ,  a n d  a s c o r b i c  a c i d  a r e  l i k e l y  t o  b e  b e n e f i c i a l  t o  e n z y m e  f u n c t i o n .  I  
h y p o t h e s i s e d  t h a t  i f  t h e  p r e s e n c e  o f  a n t i o x i d a n t s  i n c r e a s e d  X O  a c t i v i t y  i n  c o m p a r i s o n  
t o  t h e i r  a b s e n c e  ( s i m i l a r l y  t o  t h e  e f f e c t  o f  a d d i n g  t h r o m b i n ) ,  t h e n  m a y b e  t h r o m b i n  
c o u l d  f u n c t i o n  i n  t h i s  m a n n e r  ( a s  a n  a n t i o x i d a n t )  a n d  t h e r e f o r e  e x p l a i n  t h e  a c t i o n s  o f  
t h r o m b i n  o n  X O  a c t i v i t y .  H o w e v e r ,  a n a l y s i n g  X O  a c t i v i t y  i n  t h e  p r e s e n c e  o f  l o g  
d i l u t i o n s  o f  a n t i o x i d a n t s  d i d  n o t  f i t  m y  h y p o t h e s i s .  T h e  a d d i t i o n  o f  c a t a l a s e  h a d  n o  
e f f e c t  o n  X O  a c t i v i t y  ( F i g u r e  1 1 4 ) ,  b u t  i n  t h e  p r e s e n c e  o f  S O D  X O  a c t i v i t y  w a s  
i n h i b i t e d  ( F i g u r e  1 1 5 ) .  W i t h  t h e  c o m b i n a t i o n  o f  b o t h  S O D  a n d  c a t a l a s e  t h e  i n h i b i t i o n  
o f  X O  a c t i v i t y  o b s e r v e d  w i t h  S O D  a l o n e  w a s  a b o l i s h e d  ( F i g u r e  1 1 6 ) ,  b u t  n o  i n c r e a s e  
i n  X O  a c t i v i t y  w a s  s e e n .  A s  d e s c r i b e d  i n  t h e  i n t r o d u c t o r y  c h a p t e r s  S O D  f u n c t i o n s  t o  
d i s m u t a t e  O 2 ~ g e n e r a t i n g  H 2O 2,  a n d  c a t a l a s e  f u n c t i o n s  i n  t h e  d e g r a d a t i o n  o f  H 2O 2 
f o r m i n g  H 2O  a n d  O 2. T h e r e f o r e  t h e  r e s u l t s  f r o m  t h e  e x p e r i m e n t s  d e s c r i b e d  a b o v e  
s u g g e s t  t h a t  S O D  a n d  X O - g e n e r a t e d  H 2O 2 i n h i b i t s  t h e  e n z y m e .  T h i s  f i n d i n g  a g r e e s  i n  
p a r t  w i t h  r e s u l t s  f r o m  T e r a d a  et al.t 1 9 8 8 ,  w h e r e b y  t h e  c o m b i n a t i o n  o f  S O D  a n d  
c a t a l a s e  p r o t e c t  X O  f r o m  R O S - m e d i a t e d  i n h i b i t i o n .  H o w e v e r ,  t h e i r  p r o t o c o l  d i f f e r e d  
f r o m  t h e  o n e  u s e d  i n  t h i s  t h e s i s .  I n  T e r a d a  et al.9 1 9 8 8  X O  w a s  i n c u b a t e d  w i t h  
h y p o x a n t h i n e  f o r  3 0 m i n s  b e f o r e  a s s e s s m e n t  o f  a c t i v i t y ,  a n d  t h e  p r o t e c t i v e  e f f e c t s  o f  
a n t i o x i d a n t s  w e r e  a s s e s s e d  b y  t h e i r  a d d i t i o n  d u r i n g  t h e  3 0 m i n  i n c u b a t i o n .  T h e y  
d i s c o v e r e d  t h a t  S O D  o r  c a t a l a s e  a l o n e  d o  n o t  f u l l y  p r o t e c t  e n z y m e  a c t i v i t y  b u t  d o  
i m p r o v e  a c t i v i t y  c o m p a r e d  t o  t h e i r  a b s e n c e ,  s u g g e s t i n g  t h a t  O 2 ~ i n h i b i t s  t h e  e n z y m e .  
A s  t h e  a s s e s s m e n t  o f  a c t i v i t y  w a s  o n l y  o v e r  a  o n e  m i n u t e  p e r i o d  ( i n  t h i s  t h e s i s )  t h e  
e f f e c t s  o f  O 2 m a y  n o t  h a v e  b e e n  d e t e c t e d ,  h o w e v e r  i t  i s  p o s s i b l e  t h a t  H 2O 2 i s  
i n h i b i t i n g  t h e  e n z y m e  i n  t h e  s y s t e m  u s e d  i n  t h i s  t h e s i s .  T o  c h e c k  t h i s ,  e x o g e n o u s  
H 2O 2 c o u l d  b e  a d d e d  t o  X O  a n d  c h a n g e s  i n  a c t i v i t y  c o u l d  b e  m e a s u r e d .
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T h e  a n t i o x i d a n t  a s c o r b i c  a c i d  w a s  a l s o  t e s t e d  a g a i n s t  X O  a n d  i n h i b i t e d  t h e  e n z y m e  i n  
a  d o s e - d e p e n d a n t  m a n n e r  ( F i g u r e  1 1 7 ) .  T h e  a d d i t i o n  o f  l O p M  a s c o r b i c  a c i d  d u r i n g  
t h e  X O - a s s a y  h a s  a  v e r y  s i m i l a r  e f f e c t  c o m p a r e d  t o  a l l o p u r i n o l  a t  t h e  s a m e  
c o n c e n t r a t i o n  a n d  s h o w s  g o o d  i n h i b i t i o n  o f  t h e  e n z y m e  ( F i g u r e  1 1 9 ) .  H o w  a s c o r b i c  
a c i d  e f f e c t s  X O  i s  n o t  k n o w n ,  b u t  o t h e r  e n z y m e s  a r e  i n h i b i t e d  b y  a s c o r b i c  a c i d ,  f o r  
e x a m p l e  t y r o s i n e  h y d r o x y l a s e  ( R o s k o s k i  et al., 1 9 9 3 ) .  A  c o m p a r i s o n  b e t w e e n  t h e  
c h e m i c a l  s t r u c t u r e s  o f  a s c o r b i c  a c i d ,  a l l o p u r i n o l ,  a n d  t h e  X O - s u b s t r a t e s  x a n t h i n e  a n d  
p t e r i n  ( F i g u r e  1 2 0 )  r e v e a l e d  t h a t  a s c o r b i c  a c i d  h a s  n o  h o m o l o g o u s  s t r u c t u r e s  a n d  
t h e r e f o r e  i s  u n l i k e l y  t o  i n h i b i t  X O  b y  t h e  s a m e  p r o c e s s  a s  a l l o p u r i n o l ,  o r  b i n d  i n  a  
m a n n e r  s i m i l a r  t o  p t e r i n  a n d  x a n t h i n e .  T o  d i s c o v e r  t h e  m e c h a n i s m  o f  a s c o r b i c  a c i d  
i n h i b i t i o n  o f  X O ,  k i n e t i c  s t u d i e s  s h o u l d  b e  p e r f o r m e d  t o  d e t e r m i n e  w h e t h e r  a s c o r b i c  
a c i d  i s  a  c o m p e t i t i v e  o r  n o n - c o m p e t i t i v e  i n h i b i t o r ,  a l s o  t h e  e f f e c t  o f  a s c o r b i c  a c i d  o n  
t h e  X O - N A D H  o x i d a s e  a s s a y  s h o u l d  b e  a s s e s s e d  a n d  w o u l d  g i v e  a  c l u e  a s  t o  w h i c h  
r e d o x  c e n t r e  o f  X O  i s  b e i n g  i n h i b i t e d .
T h e  d i s c o v e r y  t h a t  a s c o r b i c  a c i d  i n h i b i t s  X O  i s  n o t  n o v e l .  I n  1 9 5 2  F e i g e l s o n  
( F i e g e l s o n ,  1 9 5 2 )  f o u n d  t h a t  a s c o r b i c  a c i d  i n h i b i t s  X O  a c t i v i t y  i n  a n  a s s a y  b a s e d  o n  
t h e  c o n v e r s i o n  o f  x a n t h i n e  t o  u r i c  a c i d .  R e s u l t s  i n  t h e  p u b l i s h e d  p a p e r  a g r e e  w i t h  
t h o s e  i n  t h i s  t h e s i s ,  h o w e v e r  i n  t h e  p u b l i c a t i o n  n o  a t t e m p t  w a s  m a d e  t o  l o o k  a t  t h e  
e f f e c t  o f  t h e  a d d i t i o n  o f  a s c o r b i c  a c i d  t o  a c t i v e  e n z y m e  a s  s h o w n  i n  t h i s  t h e s i s .
T h e  i n h i b i t o r y  a c t i o n  o f  a s c o r b i c  a c i d  o n  X O  i s  a n  i m p o r t a n t  p o i n t  t h a t  i s  n o t  
a c k n o w l e d g e d  i n  t h e  p r e s e n t  l i t e r a t u r e .  A l t h o u g h  t h e r e  a r e  n u m e r o u s  e x a m p l e s  o f  
w h e r e  a u t h o r s  h a v e  n o t  r e c o g n i s e d  X O - i n h i b i t i o n  b y  a s c o r b i c  a c i d  o n l y  t w o  p a p e r s  
w i l l  b e  g i v e n  h e r e  a s  e x a m p l e s .  F i r s t l y ,  t h e  p o t e n t i a l  o f  a s c o r b i c  a c i d  t o  p r e v e n t  t h e  
t o x i c  e f f e c t s  o f  R O S  o n  t h e  r a t  l e n s  w a s  i n v e s t i g a t e d  u s i n g  t h e  x a n t h i n e  
o x i d a s e / x a n t h i n e  s y s t e m  ( V a r m a  et al,  1 9 8 6 ) .  L e n s e s  w e r e  i n c u b a t e d  i n  a  m e d i u m  
c o n t a i n i n g  X O  a n d  x a n t h i n e  w i t h  o r  w i t h o u t  a s c o r b i c  a c i d .  A u t h o r s  d i s c o v e r e d  t h a t  
i n  t h e  a b s e n c e  o f  a s c o r b i c  a c i d  l e n s e s  w e r e  d a m a g e d ,  h o w e v e r  i n  i t s  p r e s e n c e  l e n s e s
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e s c a p e d  d a m a g e .  A u t h o r s  c o n c l u d e d  t h a t  o n e  o f  t h e  f u n c t i o n s  o f  h i g h  l e v e l s  o f  
a s c o r b i c  a c i d  i n  t h e  a q u e o u s  h u m o u r  i s  t o  p r o t e c t  t h e  l e n s  a n d  s u r r o u n d i n g  t i s s u e  
f r o m  R O S  . d a m a g e .  H o w e v e r ,  t h e i r  e x p e r i m e n t  i s  s e r i o u s l y  f l a w e d  a s  t h e  
X O / x a n t h i n e  s y s t e m  m a y  n o t  h a v e  b e e n  g e n e r a t i n g  R O S  i n  t h e  p r e s e n c e  o f  a s c o r b i c  
a c i d  a s  X O  a c t i v i t y  w a s  p r o b a b l y  i n h i b i t e d .  I n  a  s t u d y  o f  t h e  f a i l i n g  h e a r t  i n  a n  a n i m a l  
m o d e l ,  S a a v e d r a  et al  ^ 2 0 0 2  w e r e  a s s e s s i n g  t h e  e f f e c t s  o f  r e d u c i n g  R O S  g e n e r a t i o n .  
T h e  a u t h o r s  d i s c o v e r e d  t h a t  “ a s c o r b a t e  ( l O O O m g )  m i m i c k e d  t h e  b e n e f i c i a l  e n e r g e t i c  
e f f e c t s  o f  a l l o p u r i n o l ,  i n c r e a s i n g  b o t h  c o n t r a c t i l i t y  a n d  e f f i c i e n c y ,  s u g g e s t i n g  a n  
a n t i o x i d a n t  m e c h a n i s m .  A l l o p u r i n o l  h a d  n o  a d d i t i v e  e f f e c t  b e y o n d  t h a t  o f  a s c o r b a t e ”  
( S a a v e d r a  et al. ,  2 0 0 2 ) .  T o  c l a i m  t h a t  a s c o r b i c  a c i d  w a s  w o r k i n g  b y  a n  a n t i o x i d a n t  
m e c h a n i s m  m a y  b e  f a l s e ,  a s  t h e  i n h i b i t i o n  o f  R O S  g e n e r a t i o n  b y  X O  m a y  h a v e  
o c c u r r e d .  T h i s  p o s s i b i l i t y  i s  r e i n f o r c e d  b y  t h e i r  s t a t e m e n t  t h a t  a l l o p u r i n o l  w a s  n o  
m o r e  e f f e c t i v e  t h a n  a s c o r b i c  a c i d ,  p r o b a b l y  a s  b o t h  s u b s t a n c e s  h a v e  t h e  s a m e  
f u n c t i o n ,  i . e .  i n h i b i t i n g  X O .
I n  c o n c l u s i o n  t h e  p r o c e s s  b y  w h i c h  t h r o m b i n  i n c r e a s e s  X O  a c t i v i t y  i s  u n l i k e l y  t o  b e  
b y  a n  a n t i o x i d a n t - b a s e d  m e c h a n i s m ,  a s  t h e  a d d i t i o n  o f  k n o w n  a n t i o x i d a n t s  d o  n o t  
r e p r o d u c e  t h e  e f f e c t s  o f  t h r o m b i n  ( a l s o  t h e r e  i s  n o  m e n t i o n  i n  t h e  l i t e r a t u r e  o f  
t h r o m b i n  a c t i n g  a s  a n  a n t i o x i d a n t ) .  I t  i s  p o s s i b l e  t h a t  t h r o m b i n  e f f e c t s  X O  b y  a  
p r o t e o l y t i c  p r o c e s s ,  h o w e v e r  t h e  f a i l u r e  t o  i n h i b i t  t h r o m b i n  a c t i v i t y  w i t h  h i r u d i n  m a y  
r u l e  t h i s  o u t .  T h e  b i n d i n g  o f  t h r o m b i n  t o  X O  m a y  o c c u r  a n d  c a u s e  a n  a l l o s t r i c  e f f e c t  
o n  e n z y m e  a c t i v i t y  r a t h e r  t h a n  a  d i r e c t  c l e a v a g e  o f  t h e  p r o t e i n .
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7 General Discussion - The Endothelial XOR- 
Release Model and its Implications in Vascular 
Physiology and Pathology.
7.1 Results Chapter Summary
I n  o r d e r  t o  i n v e s t i g a t e  t h e  h y p o t h e s i s  t h a t  t h e  v a s c u l a r  e n d o t h e l i u m  c a n  r e l e a s e  X O R ,  
H U V E C s  w e r e  c h o s e n  a s  a n  e n d o t h e l i a l  m o d e l .  I n  C h a p t e r  3  t h e  c e l l s  i s o l a t e d  f r o m  
t h e  h u m a n  u m b i l i c a l  c o r d  v e i n  b y  c o l l a g e n a s e  d i g e s t i o n  w e r e  c h a r a c t e r i s e d .  U s i n g  
m o r p h o l o g i c a l  a n d  i m m u n o f l u o r e s c e n t  t e c h n i q u e s  t h e  c e l l  t y p e  i s o l a t e d  w a s  s h o w n  t o  
b e  o f  e n d o t h e l i a l  o r i g i n  a n d  t h e r e f o r e  w a s  i n d e e d  t h e  H U V E C .  A l s o  i n  t h i s  c h a p t e r  
t h e  e x p r e s s i o n  o f  t h e  xor  g e n e  a n d  p r o t e i n  i n  t h e  e n d o t h e l i a l  m o d e l  w e r e  s h o w n  u s i n g  
R T - P C R ,  W e s t e r n  b l o t ,  a n d  i m m u n o f l u o r e s c e n t  t e c h n i q u e s .  I n  H U V E C s  X O R  i s  
f o u n d  d i f f u s e l y  w i t h i n  t h e  c y t o p l a s m  a n d  a l s o  i n  p u n c t a t e  s t r u c t u r e s  t h a t  i n d i c a t e  a  
p a c k a g e d  f o r m  o f  t h e  e n z y m e .  T h e  X O R  e n z y m e  i s  n o t  f o u n d  i n  W e i b e l - P a l a d e  
b o d i e s  a s  c o - l o c a l i s a t i o n  w i t h  v W f  w a s  n o t  o b s e r v e d .  I n  o r d e r  t o  m e a s u r e  t h e  
h y p o t h e s i s e d  r e l e a s e  o f  X O R  f r o m  t h e  v a s c u l a r  e n d o t h e l i a l  m o d e l  a  s e n s i t i v e  a s s a y  
w a s  r e q u i r e d .  I n  C h a p t e r  4  a  r a n g e  o f  X O R - a s s a y  t e c h n i q u e s  w e r e  o p t i m i s e d  f o r  
s e n s i t i v i t y  a n d  c o m p a r e d .  C o m p a r e d  t o  t h e  t w o  a s s a y s  b a s e d  o n  O 2 ”  g e n e r a t i o n  ( t h e  
i n - g e l  a s s a y  a n d  l u c i g e n i n - l u m i n e s c e n c e  a s s a y )  a n d  t h e  u r i c  a c i d  a s s a y ,  t h e  
f l u o r e s c e n c e - b a s e d  a s s a y  d e t e c t i n g  t h e  f o r m a t i o n  o f  I X P  p r o v e d  t h e  m o s t  s e n s i t i v e .  
I n  t h e  e x t e n d e d  t i m e  c o u r s e ,  t h e  g e n e r a t i o n  o f  I X P  w a s  l i n e a r  a n d  t h e r e f o r e  r e a c t i o n -  
p r o d u c t  c o u l d  a c c u m u l a t e  b e f o r e  f l u o r e s c e n c e  m e a s u r e m e n t s  w e r e  t a k e n ,  t h u s  m a k i n g  
t h e  a s s a y  m o r e  s e n s i t i v e .
I n  C h a p t e r  5 ,  k n o w n  e n d o t h e l i a l  c e l l  p r o t e i n  s e c r e t i o n  a g o n i s t s  w e r e  a p p l i e d  t o  
H U V E C s  a n d  t h e  r e l e a s e  o f  v W f  w a s  u s e d  a s  a  p o s i t i v e  c o n t r o l  f o r  e n d o t h e l i a l  
a c t i v a t i o n .  I n  t h e  p r e s e n c e  o f  b o t h  h i s t a m i n e  a n d  t h r o m b i n  v W f  w a s  r e l e a s e d  i n  a  
d o s e - d e p e n d e n t  m a n n e r ,  i n d e p e n d e n t  o f  c e l l  d e a t h .  I t  w a s  s h o w n  t h a t  H U V E C s  
c o u l d  r e l e a s e  X O R .  R e l e a s e  o f  X O R  w a s  c o n s t i t u t i v e  b u t  c o u l d  a l s o  b e  s t i m u l a t e d ,
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a n d  i n  d o s e - r e s p o n s e  e x p e r i m e n t s  “ b e l l - s h a p e d ”  r e l e a s e  c u r v e s  w e r e  o b s e r v e d .  T h e  
r e l e a s e  r a t e  o f  X O R  a n d  v W f  i n  h i s t a m i n e  s t i m u l a t e d  H U V E C s  d i f f e r e d ,  p r o v i d i n g  
m o r e  e v i d e n c e  t o  s u g g e s t  t h a t  t h e s e  t w o  p r o t e i n s  a r e  n o t  a s s o c i a t e d  w i t h i n  t h e  
e n d o t h e l i u m .  X O R  r e l e a s e  f r o m  H U V E C s  c a n  b e  s t i m u l a t e d  b y  a  r i s e  i n  i n t r a c e l l u l a r  
c a l c i u m  a n d  i s  r e l i a n t  o n  m i c r o t u b u l e  f u n c t i o n ,  a s  d e m o n s t r a t e d  i n  A 2 3 1 8 7  d o s e -  
r e s p o n s e  a n d  c o l c h i c i n e - t r e a t m e n t  e x p e r i m e n t s ,  r e s p e c t i v e l y .  A s  a  c o n t r o l  t h e  d i r e c t  
e f f e c t  o f  h i s t a m i n e  a n d  t h r o m b i n  o n  p u r i f i e d  X O  w a s  a s s e s s e d .  H i s t a m i n e ,  i n  t h e  
c o n c e n t r a t i o n s  u s e d  i n  t h e  H U V E C  d o s e - r e s p o n s e  e x p e r i m e n t s ,  d i d  n o t  a f f e c t  X O  
a c t i v i t y ,  h o w e v e r  t h r o m b i n  c a u s e d  a  d o s e - d e p e n d e n t  i n c r e a s e  i n  e n z y m e  a c t i v i t y .
I n  c h a p t e r  6  t h e  u n e x p e c t e d  d i s c o v e r y  t h a t  t h r o m b i n  a l t e r s  X O  a c t i v i t y  w a s  e x p l o r e d  
i n  m o r e  d e t a i l .  F i r s d y ,  d o s e - r e s p o n s e  e x p e r i m e n t s  w e r e  r e p e a t e d  o n  p u r i f i e d  X O  a n d  
c o n f i r m e d  f i n d i n g s  f r o m  t h e  p r e c e d i n g  c h a p t e r .  T h e  d o s e - d e p e n d e n t  e f f e c t  o f  
t h r o m b i n  w a s  a l s o  s e e n  w i t h  m i l k  a n d  r a t  s e r u m  X O ,  b u t  n o t  w i t h  r a t  l i v e r ,  a n d  w a s  
c o n f i r m e d  u s i n g  t w o  d i f f e r e n t  X O  a s s a y s .  T h e  c h a n g e  i n  X O  a c t i v i t y  w a s  n o t  
i m m e d i a t e ,  i n s t e a d  a  s h o r t  i n c u b a t i o n  t i m e  ( m i n u t e s )  w a s  r e q u i r e d  f o r  t h r o m b i n ’ s  
e f f e c t  o n  X O  t o  b e  m e a s u r e d .  A l t h o u g h  t h r o m b i n  i n c r e a s e d  X O  e l e c t r o n - d o n a t i n g  
s u b s t r a t e  t u r n o v e r  a  s t a t i s t i c a l l y  s i g n i f i c a n t  i n c r e a s e  i n  t h e  g e n e r a t i o n  o f  O 2 ” b y  X O  
w a s  n o t  o b s e r v e d ,  h o w e v e r  t h e  p r e s e n c e  o f  t h r o m b i n  e n h a n c e d  X O ’s  a n t i b a c t e r i a l  
p r o p e r t i e s  w h i c h  c o u l d  b e  d u e  t o  i n c r e a s e  H 2O 2 g e n e r a t i o n .  T h e  e f f e c t  o f  t h r o m b i n  
o n  X O  c o u l d  b e  s l i g h t l y  r e d u c e d  u s i n g  k n o w n  t h r o m b i n  i n h i b i t o r s ,  h o w e v e r  r e s u l t s  
w e r e  n o t  c o n c l u s i v e .  A n a l y s i s  o f  t h e  X O  a m i n o - a c i d  s e q u e n c e  a n d  c r y s t a l  s t r u c t u r e  
r e v e a l e d  a n  a c c e s s i b l e  t h r o m b i n  c l e a v a g e  s e q u e n c e  h o m o l o g o u s  t o  t h a t  f o u n d  i n  t h e  
f i b r i n o g e n  A a  c h a i n .  T h u s  s u g g e s t i n g  t h a t  t h r o m b i n  c o u l d  c l e a v e  X O ,  a  p r o c e s s  t h a t  
c o u l d  p o t e n t i a l l y  a l t e r  e n z y m e  c o n f i r m a t i o n  a n d  t h e r e f o r e  a c t i v i t y .
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7.2 The Consequences of XOR Release from the 
Vascular Endothelium -  The Results in Context
7.2.1 A Pathological Role
D a t a  p r e s e n t e d  i n  t h i s  t h e s i s  d e m o n s t r a t e  t h a t  X O R  i s  r e l e a s e d  b y  t h e  v a s c u l a r  
e n d o t h e l i u m ;  w i t h i n  t h i s  s e c t i o n  t h e  p o t e n t i a l  r o l e s  f o r  t h e  c i r c u l a t i n g  e n z y m e  w i l l  b e  
d i s c u s s e d .  A s  m e n t i o n e d  i n  t h e  i n t r o d u c t o r y  c h a p t e r s ,  X O R  h a s  s e v e r a l  p a t h o g e n i c  
r o l e s  w i t h i n  t h e  v a s c u l a t u r e .  I n  t h e s e  d i s e a s e  s t a t e s  a  r i s e  i n  c i r c u l a t i n g  e n z y m e  h a s  
o f t e n  b e e n  a t t r i b u t e d  t o  t h e  p a t h o g e n i c  e f f e c t s  o f  X O R ,  f o r  e x a m p l e  i n  p a n c r e a t i t i s -  
d e p e n d e n t  a c u t e  r e s p i r a t o r y  d i s t r e s s  s y n d r o m e .  A s  p r e v i o u s l y  d e s c r i b e d  ( s e e  
I n t r o d u c t i o n  c h a p t e r s )  a  r i s e  i n  c i r c u l a t i n g  X O  i n  p a t i e n t s  w i t h  p a n c r e a t i t i s  h a s  b e e n  
s h o w n  t o  i n s t i g a t e  a  s e c o n d a r y  i n f l a m m a t o r y  e v e n t  a t  t h e  l u n g  t h a t  c a n  l e a d  t o  A R D S .  
U n t i l  n o w  t h e  s o u r c e  o f  c i r c u l a t i n g  X O  r e s p o n s i b l e  f o r  t h i s  l i f e  t h r e a t e n i n g  d i s e a s e  
c o u l d  n o t  b e  e x p l a i n e d .  H o w e v e r  d a t a  f r o m  t h i s  t h e s i s  s u g g e s t s  t h a t  i n f l a m m a t o r y  
m e d i a t o r s  i n  t h e  p a n c r e a s  c o u l d  s t i m u l a t e  t h e  r e l e a s e  o f  X O  f r o m  t h e  l o c a l  v a s c u l a r  
e n d o t h e l i u m ,  t h u s  a c c o u n t i n g  f o r  t h e  i n c r e a s e  i n  p l a s m a  e n z y m e  l e v e l s .
S i m i l a r l y  p a t i e n t s  w i t h  b u r n s  o f t e n  s u f f e r  s e c o n d a r y  c o m p l i c a t i o n s  s u c h  a s  A R D S  
( B h a t i a  a n d  M o o c h h a l a ,  2 0 0 4 ) .  I n  a n i m a l  m o d e l s ,  p l a s m a  X O  l e v e l s  a r e  s h o w n  t o  
i n c r e a s e  f o l l o w i n g  t h e r m a l  i n j u r y  ( F r i e d l  et al., 1 9 8 9 ) ,  a n d  a s  i n  p a n c r e a t i t i s - d e p e n d e n t  
A R D S  c i r c u l a t i n g  X O  c o u l d  l i n k  b u m s  w i t h  s e c o n d a r y  i n f l a m m a t o r y  c o m p l i c a t i o n s .  
I n t e r e s t i n g l y ,  i n  a n i m a l  s t u d i e s ,  t h e  l e v e l s  o f  c i r c u l a t i n g  X O  c o r r e l a t e  w i t h  l e v e l s  o f  
h i s t a m i n e .  A p p r o x i m a t e l y  1 5 m i n s  f o l l o w i n g  t h e r m a l  i n j u r y ,  p l a s m a  h i s t a m i n e  l e v e l s  
p e a k  a t  a b o u t  1 . 4 | i M  w h i c h  c o r r e s p o n d s  t o  a  p e a k  i n  p l a s m a  X O  ( F r i e d l  et al., 1 9 8 9 ) .  
D a t a  f r o m  t h i s  t h e s i s  f i t  t h i s  o b s e r v a t i o n  p e r f e c t l y ,  f i r s t l y  d o s e - r e s p o n s e  e x p e r i m e n t s  
h a v e  d e m o n s t r a t e d  t h a t  h i s t a m i n e  s t i m u l a t e s  t h e  r e l e a s e  o f  X O R  f r o m  e n d o t h e l i a l  
c e l l s ,  a n d  a  c o n c e n t r a t i o n  o f  l p M  h i s t a m i n e  w a s  s h o w n  t o  c a u s e  m a x i m a l  r e l e a s e .  
T h e r e f o r e  r a i s i n g  t h e  p o s s i b i l i t y  t h a t  f o l l o w i n g  t h e r m a l  i n j u r y  a n  i n c r e a s e  i n  p l a s m a  
h i s t a m i n e  l e v e l s  c o u l d  s t i m u l a t e  t h e  r e l e a s e  o f  X O R  f r o m  t h e  e n d o t h e l i u m ,  t h u s  
a c c o u n t i n g  f o r  t h e  i n c r e a s e  i n  c i r c u l a t i n g  e n z y m e  i n  t h i s  p a t h o l o g y .
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I n  t h e  p a t h o l o g i e s  t h a t  l e a d  t o  s e c o n d a r y  i n f l a m m a t i o n  i n  t h e  l u n g  ( f o r  e x a m p l e  
p a n c r e a t i t i s  a n d  t h e r m a l  i n j u r y )  t h a t  m a y  b e  l i n k e d  b y  c i r c u l a t i n g  X O ,  i t  i s  i m p o r t a n t  
t o  r a i s e  t h e  q u e s t i o n ,  w h y  a r e  t h e  l u n g s  a f f e c t e d  a n d  n o t  o t h e r  o r g a n s ?  A s  d e s c r i b e d  
i n  t h e  i n t r o d u c t i o n ,  t h e  p r e s e n c e  o f  O 2 i s  i m p o r t a n t  f o r  i n f l a m m a t i o n  i n  t h e  l u n g  t o  
o c c u r  ( G r a n e l l  et al. ,  2 0 0 4 ) ,  a n d  i t  w a s  h y p o t h e s i s e d  t h a t  c o m p a r e d  w i t h  o t h e r  o r g a n s ,  
o n l y  f r e e - o x y g e n  c o n c e n t r a t i o n s  i n  t h e  l u n g  a r e  a b l e  t o  s u p p o r t  s u f f i c i e n t  R O S -  
g e n e r a t i o n  b y  X O  t o  i n i t i a t e  a n  i n f l a m m a t o r y  e v e n t  ( G r a n e l l  et al,  2 0 0 4 ) .  H o w e v e r ,  
t h e o r e t i c a l l y  t h i s  i s  n o t  t h e  c a s e .  I n  t h e  p r e s e n c e  o f  x a n t h i n e ,  X O  h a s  h a l f  m a x i m a l  
O 2 " - g e n e r a t i n g  a c t i v i t y  a t  ~ 2 6 [ i M  O 2 ( M i l l a r ,  2 0 0 4 ) .  P h y s i o l o g i c a l  d i s s o l v e d  p l a s m a  
o x y g e n  c o n c e n t r a t i o n s  r a n g e  f r o m  1 2 0 - 1 3 5 p M  o n  t h e  a r t e r i a l  s i d e  t o  55-70{jlM o n  t h e  
v e n o u s  s i d e .  A t  t h e s e  c o n c e n t r a t i o n s  o f  o x y g e n ,  O 2 ' " - g e n e r a t i n g  a c t i v i t y  w i l l  b e  c l o s e  
t o  m a x i m a l  i n  t h e  v e n o u s  s i d e  a n d  m a x i m a l  a c t i v i t y  w o u l d  b e  a c h i e v e d  o n  t h e  a r t e r i a l  
s i d e  ( M i l l a r ,  2 0 0 4 ) .  T h e r e f o r e  a n y  p o t e n t i a l  i n c r e a s e  i n  [ O 2]  a t  t h e  l u n g  w o u l d  n o t  
i n c r e a s e  X O  0 2 ’ " - g e n e r a t i n g  a c t i v i t y  c o m p a r e d  t o  o t h e r  o r g a n s .  A l t e r n a t i v e l y ,  o n e  
c o u l d  s p e c u l a t e  t h a t  a s  t h e  l u n g s  c o n s t i t u t e  t h e  f i r s t  v a s c u l a r  b e d  e n c o u n t e r e d  b y  X O  
f o l l o w i n g  i t s  r e l e a s e ,  f r o m  t h e  p a n c r e a s  i n  p a n c r e a t i t i s  f o r  e x a m p l e ,  X O  i s  m o r e  l i k e l y  
t o  c o n c e n t r a t e  a t  t h e  l u n g s  b e f o r e  r e a c h i n g  a n y  o t h e r  o r g a n  a n d  t h u s  c a u s e s  
i n f l a m m a t i o n  a t  t h i s  s i t e .  T h e  r e t e n t i o n  o f  X O  a t  t h e  v a s c u l a r  e n d o t h e l i u m  i s  p o s s i b l y  
m e d i a t e d  b y  t h e  e n d o t h e l i a l  c e l l - s u r f a c e  X O - r e c e p t o r ,  t h e  G A G  ( A d a c h i  et al., 1 9 9 3 ) ,  
t h e r e f o r e  t h r o u g h  e n d o t h e l i a l  a s s o c i a t i o n  t h e  c i r c u l a t i n g  X O  f o r m  m a y  c o n c e n t r a t e  a t  
t h e  l u n g s  ( a s  d i s c u s s e d  i n  t h e  e x a m p l e  a b o v e )  a n d  t h e r e f o r e  c a u s e  o x i d a t i v e  d a m a g e  a t  
s i t e s  d i s t a n t  f r o m  r e l e a s e .
I t  s h o u l d  b e  n o t e d  t h a t  t h e  c o n t r i b u t i o n  o f  X O  t o  o t h e r  v a s c u l a r  p a t h o l o g i e s  ( f o r  
e x a m p l e  c h r o n i c  h e a r t  f a i l u r e  a n d  c o r o n a r y  h e a r t  d i s e a s e )  w e r e  d i s c u s s e d  i n  t h e  
i n t r o d u c t o r y  c h a p t e r s .  I t  i s  c o n c e i v a b l e  t h a t  a n  i n c r e a s e  i n  c i r c u l a t i n g  X O  c o u l d  
c o n t r i b u t e  t o  t h e  a e t i o l o g y  o f  t h e s e  d i s e a s e  s t a t e s .
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7.2.2 Beneficial Roles of Circulating XO?
A s  w i t h  m a n y  i n f l a m m a t o r y  m e d i a t o r s  t h e i r  p r i m a r y  f u n c t i o n  d o e s  n o t  l i e  i n  
p a t h o l o g i c a l  p r o c e s s e s .  T h e i r  r o l e  w i t h i n  t h e  b o d y  i s  t o  e x e r t  a  p r o t e c t i v e  f u n c t i o n ,  
h e n c e  t h e i r  r e t e n t i o n  t h r o u g h  e v o l u t i o n .  T h i s  a l s o  a p p e a r s  t o  b e  t r u e  f o r  X O R .  T h e  
e x p r e s s i o n  o f  X O R  i s  u p - r e g u l a t e d  b y  i n f l a m m a t o r y  m e d i a t o r s ,  s u g g e s t i n g  a  r o l e  
w i t h i n  i n f l a m m a t i o n ,  a n d  X O R  g e n e r a t e d  R O N S  c o n t r i b u t e  t o  t h e  i n f l a m m a t o r y  
p r o c e s s  ( r e v i e w e d  i n  t h e  i n t r o d u c t o r y  c h a p t e r s ) .  A l t h o u g h  t h e  i n f l a m m a t o r y  r o l e s  o f  
X O R  a r e  h i g h l i g h t e d  i n  p a t h o l o g i c a l  p r o c e s s e s  a  p r o t e c t i v e  a n t i m i c r o b i a l  f u n c t i o n  
( d u e  t o  X O R - R O N S  g e n e r a t i n g  p r o p e r t i e s )  f o r  t h e  e n z y m e  i s  b e c o m i n g  c l e a r .  I t  h a s  
l o n g  b e e n  k n o w n  t h a t  X O R  h a s  b a c t e r i c i d a l  p r o p e r t i e s  i n  t h e  p r e s e n c e  o f  t h e  
s u b s t r a t e  h y p o x a n t h i n e  ( G r e e n  a n d  P a u l i ,  1 9 4 3 ) .  M o r e  r e c e n t l y  t h e  d e f e n s i v e  
p r o p e r t i e s  o f  X O R  w e r e  d e m o n s t r a t e d  i n  m i c e  i n f e c t e d  w i t h  Salmonella typhimurium 
( U m e z a w a  et al., 1 9 9 7 )  w h e r e  t h e  g e n e r a t i o n  o f  n o t  j u s t  O i '  b u t  a l s o  O N O O -  w e r e  
p r o p o s e d  t o  b e  a n t i b a c t e r i a l .  A l s o ,  X O - d e r i v e d  R O S  a r e  i m p o r t a n t  f o r  p h a g o c y t i c  
k i l l i n g  i n  m a c r o p h a g e s  ( T a k a o  et al., 1 9 9 6 ;  P o t o k a  et al., 1 9 9 8 ) .
I n  t h e  p r e s e n c e  o f  n i t r i t e ,  t h e  a b i l i t y  o f  X O R  t o  g e n e r a t e  O N O O -  ( r e v i e w e d  i n  t h e  
i n t r o d u c t o r y  c h a p t e r s ) ,  a  p o w e r f u l  b a c t e r i c i d a l  a g e n t  ( B r u n e l l i  et al., 1 9 9 5 ) ,  h a v e  l e a d  
r e s e a r c h e r s  t o  s p e c u l a t e  t h a t  t h e  h i g h  q u a n t i t i e s  o f  X O R  i n  m i l k  m a y  a c t  t o  s t e r i l i s e  
t h e  g u t .  I n d e e d  t h e  g e n e r a t i o n  o f  N O *  b y  h u m a n  m i l k  X O R  i s  g r e a t e s t  i n  t h e  f i r s t  5  
w e e k s  p o s t p a r t u m ,  w h e r e  p r o t e c t i o n  o f  t h e  n e o n a t a l  g u t  w o u l d  b e  m o s t  b e n e f i c i a l  
( S t e v e n s  et al., 2 0 0 0 ) .  A l t h o u g h  n i t r i t e  c o n c e n t r a t i o n s  i n  t h e  g u t  a r e  n o t  p a r t i c u l a r l y  
h i g h ,  t h e  s o u r c e  o f  s u b s t r a t e  f o r  O N O O -  g e n e r a t i o n  b y  X O R  m a y  a c t u a l l y  b e  d e r i v e d  
f r o m  b a c t e r i a l  p a t h o g e n s  t h e m s e l v e s  ( D e M o s s  a n d  H s u ,  1 9 9 1 ) .  X O R  m a y  a t t a c h  t o  
b a c t e r i a l  p a t h o g e n s  v i a  G A G - l i k e  s t r u c t u r e s  o n  t h e  b a c t e r i a l  s u r f a c e  ( R o b e r t s ,  1 9 9 6 )  
a n d  t h e r e f o r e  c a t a l y s e  t h e  g e n e r a t i o n  o f  R O N S  i n  t h e  b a c t e r i a l  m i c r o e n v i r o n m e n t  
w h e r e  n i t r i t e  i s  s e c r e t e d  a n d  c o n c e n t r a t i o n s  a r e  a d e q u a t e .  T h e r e f o r e  t h e  b a c t e r i a  m a y  
i n i t i a t e  t h e i r  o w n  d e s t r u c t i o n .
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T h e r e  i s  a  g r e a t  d e a l  o f  e v i d e n c e  t o  s u g g e s t  a n  a n t i m i c r o b i a l  r o l e  f o r  X O R  a n d  t h e  
e n z y m e  p o t e n t i a l l y  f o r m s  a n  i m p o r t a n t  p a r t  o f  t h e  i n n a t e  i m m u n e  s y s t e m .  U s i n g  d a t a  
f r o m  t h i s  t h e s i s  a  m o d e l  f o r  a  p r o t e c t i v e  f u n c t i o n  o f  X O R  i n  t h e  w o u n d  e n v i r o n m e n t  
h a s  b e e n  p r o p o s e d  ( s e e  F i g u r e  1 2 1 ) .
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Figure 121. The Proposed Model of XO-Release from the Vascular Endothelium in a Wound
Rupture of blood vessels in a wound disrupts the endothelium and allows entry of pathogens. The exposure 
of sub-endothelial structures initiates the coagulation cascade resulting in the formation of active thrombin. 
In the vascular endothelial cell XO may be stored in granules (see Chapter 3). Thrombin stimulates the 
release of XO from the endothelium in a process that is likely to involve a rise in intracellular calcium and 
granule migration by functional microtubules (see Chapter 5). XO-generated ROS can contribute to platelet 
adhesion and therefore the formation of the primary haemostatic plug, which is reinforced by fibrin 
generated from fibrinogen in a process catalysed by thrombin. Interaction of thrombin with XO increases 
XO activity that may enhance the platelet adhesion process and augments XO’s antibacterial properties (see 
Chapter 6), therefore providing protection to the wound. The generation of ROS by XO may up-regulate the 
expression of inflammatory cell-adhesion molecules on the endothelial surface and therefore initiate the 
inflammatory process (not shown in diagram).
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7.2.3 Substrates and Inhibition of Circulating XO
F o r  c i r c u l a t i n g  X O  t o  h a v e  a  p a t h o l o g i c a l  o r  p r o t e c t i v e  f u n c t i o n  e l e c t r o n  d o n a t i n g  
s u b s t r a t e s  ( s u c h  a s  h y p o x a n t h i n e  o r  x a n t h i n e )  w o u l d  h a v e  t o  b e  a v a i l a b l e  t o  t h e  
e n z y m e  f o r  R O S - g e n e r a t i o n  t o  o c c u r .  T o  r e i n f o r c e  t h e  r o l e  o f  X O  i n  A R D S ,  i t  h a s  
b e e n  d e m o n s t r a t e d  t h a t  p l a s m a  l e v e l s  o f  h y p o x a n t h i n e  i n  A R D S  p a t i e n t s  i n c r e a s e  t o  
~37.5[iM i n  n o n - s u r v i v o r s  a n d  ~15.2(jlM i n  s u r v i v o r s ,  c o m p a r e d  t o  c o n t r o l  l e v e l s  o f  
1.4pM ( Q u i n l a n  et al’, 1997), t h e r e f o r e  s u b s t r a t e  i s  a v a i l a b l e .  A s  a l r e a d y  m e n t i o n e d ,  
X O  c a n  b i n d  t o  t h e  v a s c u l a r  c e l l  s u r f a c e  v i a  G A G s .  F o l l o w i n g  b i n d i n g  i t  h a s  b e e n  
d e m o n s t r a t e d  t h a t  X O  m a y  b e  e n d o c y t o s e d  a n d  r e m a i n  a c t i v e  ( H o u s t o n  et al,  1999). 
T h e r e f o r e  X O  c o u l d  a l s o  h a v e  a c c e s s  t o  a n  i n t r a c e l l u l a r  p o o l  o f  s u b s t r a t e ,  h o w e v e r  i t  
h a s  n o t  b e e n  d e m o n s t r a t e d  w h e t h e r  e n d o c y t o s e d  X O  r e m a i n s  a c t i v e  i n  t h e  e n d o s o m e  
o r  i s  r e l e a s e d  i n t o  t h e  c y t o p l a s m .
I n h i b i t i o n  o f  X O  m a y  b e c o m e  a  s t a n d a r d  t r e a t m e n t  f o r  c e r t a i n  d i s e a s e  s t a t e s ,  X O -  
i n h i b i t i o n  i n  p a n c r e a t i t i s - d e p e n d e n t  A R D S ,  f o r  e x a m p l e ,  i s  l i k e l y  t o  b e  b e n e f i c i a l .  A s  
s h o w n  i n  a n i m a l  m o d e l s  o f  p a n c r e a t i t i s ,  t h e  a d m i n i s t r a t i o n  o f  t h e  s p e c i f i c  X O -  
i n h i b i t o r  o x y p u r i n o l  i s  e f f e c t i v e  a t  r e d u c i n g  A R D S  ( F o l c h  et al’, 1998; F o l c h  et al., 
1999). A l s o ,  t h e  u s e  o f  a l l o p u r i n o l  i s  l i k e l y  t o  b e  b e n e f i c i a l  i n  t h e  t r e a t m e n t  o f  o t h e r  
v a s c u l a r  p a t h o l o g i e s ,  s u c h  a s  c h r o n i c  h e a r t  f a i l u r e  a n d  c o r o n a r y  h e a r t  d i s e a s e  ( a s  
d e s c r i b e d  i n  t h e  I n t r o d u c t o r y  C h a p t e r s ) .  A l l o p u r i n o l  i s  c u r r e n t l y  u s e d  a s  a  t r e a t m e n t  
f o r  g o u t  ( R o t t  a n d  A g u d e l o ,  2 0 0 3 )  a n d  t h e r e f o r e  i t s  a d m i n i s t r a t i o n  f o r  o t h e r  
p a t h o l o g i e s  i s  f e a s i b l e .  I t  w a s  i n t e r e s t i n g  t o  r e - d i s c o v e r  t h e  i n h i b i t o r y  f u n c t i o n  o f  
a s c o r b i c  a c i d  o v e r  X O - a c t i v i t y  i n  t h i s  t h e s i s ,  a n d  p o t e n t i a l l y  a s c o r b i c  a c i d  c o u l d  b e  
u s e d  a s  a  X O - i n h i b i t o r  i n  t h e  p a t h o l o g i e s  m e n t i o n e d .  E v i d e n c e  i n  s u p p o r t  o f  t h i s  
s t a t e m e n t  c o m e s  f r o m  a  p u b l i c a t i o n  d e m o n s t r a t i n g  t h a t  a s c o r b i c  a c i d  
s u p p l e m e n t a t i o n  r e d u c e s  s e r u m  u r i c  a c i d  ( t h e  r e a c t i o n  p r o d u c t  o f  X O R )  
c o n c e n t r a t i o n s  ( H u a n g  et al., 2 0 0 5 ) .
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7.2.4 Indications from Xanthinuria
T h e  p o t e n t i a l  r o l e s  o f  X O R  w i t h i n  t h e  b o d y  s h o u l d  b e  h i g h l i g h t e d  i n  x a n t h i n u r i a ,  a  
h e r e d i t a r y  d i s e a s e  t h a t  p r e s e n t s  w i t h  i n a c t i v e  X O R  e n z y m e .  T w o  f o r m s  e x i s t ;  T y p e  I  
x a n t h i n u r i a  i s  c a u s e d  b y  a  m u t a t i o n  i n  t h e  xor g e n e  t h a t  c a n  r e s u l t  i n  a  t r u n c a t e d  
d y s f u n c t i o n a l  e n z y m e  ( I c h i d a  et al., 1 9 9 7 ) ,  w h i l e  i n  T y p e  I I  a  m u t a t i o n  i n  t h e  
m o l y b d e n u m  c o f a c t o r  s u l p h u r a s e  g e n e  r e s u l t s  i n  M o C o - d e f i c i e n c y  a n d  i n a c t i v e  X O R  
e n z y m e  ( I c h i d a  et al., 2 0 0 1 ) .  O n e  c o u l d  h y p o t h e s i s  t h a t  i f  X O R - a n t i b a c t e r i a l  f u n c t i o n ,  
f o r  e x a m p l e ,  w a s  v i t a l  i n  h o s t  d e f e n c e  t h e n  p a t i e n t s  s u f f e r i n g  x a n t h i n u r i a  w o u l d  h a v e  
r e c u r r e n t  i n f e c t i o n .  H o w e v e r ,  t h e r e  a r e  n o  r e p o r t s  o f  p a t i e n t s  w i t h  x a n t h i n u r i a  
s u f f e r i n g  f r o m  a b n o r m a l  b a c t e r i a l  o r  f u n g a l  i n f e c t i o n s .  E i t h e r  a  s u i t a b l e  s t u d y  h a s  n o t  
b e e n  p e r f o r m e d  o r  t h e r e  a r e  o t h e r  p r o c e s s e s  i n  t h e  b o d y  t h a t  c a n  c o m p e n s a t e  f o r  l a c k  
o f  X O R  a c t i v i t y .  F o r  e x a m p l e ,  t h e  g e n e r a t i o n  o f  O i~  b y  N A D P H  o x i d a s e  m a y  s u i t  
t h i s  r o l e .  T o  r e i n f o r c e  t h i s  p o s s i b i l i t y ,  i n  t h e  a b s e n c e  o f  f u n c t i o n a l  N A D P H  o x i d a s e ,  
i n  c h r o n i c  g r a n u l o m a t o u s  d i s e a s e  ( r e v i e w e d  i n  F a n g ,  2 0 0 4 ) ,  r e c u r r e n t  b a c t e r i a l  a n d  
f u n g a l  i n f e c t i o n s  o c c u r .  T h e r e f o r e  s u g g e s t i n g  t h a t  N A D P H  o x i d a s e  i s  a n  i m p o r t a n t  
s o u r c e  o f  O i~  i n  h o s t  d e f e n c e ,  w h i c h  m a y  c o m p e n s a t e  f o r  t h e  l o s s  o f  X O R  a c t i v i t y  i n  
x a n t h i n u r i a .  H o w e v e r  t h e  s t u d i e s  m e n t i o n e d  i n  t h e  B e n e f i c i a l  R o l e s  o f  C i r c u l a t i n g  
X O  s e c t i o n  s u g g e s t  X O  d o e s  f u n c t i o n  a s  a n  a n t i m i c r o b i a l  a g e n t  a n d  d o e s  f u n c t i o n  i n  
v a r i o u s  p a t h o l o g i e s .  T h e r e f o r e ,  d e t a i l e d  s t u d i e s  i n  x a n t h i n u r i a  p a t i e n t s  o r  a n i m a l  
m o d e l s  w o u l d  b e  o f  g r e a t  i n t e r e s t  t o  i n v e s t i g a t e  t h e  a n t i m i c r o b i a l  a n d  i n f l a m m a t o r y  
r o l e s  o f  t h e  X O R  e n z y m e .
7.3 In Summary
I n  t h i s  t h e s i s  i t  w a s  d e m o n s t r a t e d  t h a t  t h e  v a s c u l a r  e n d o t h e l i u m  i s  a  p o t e n t i a l  s o u r c e  
o f  c i r c u l a t i n g  X O R  a n d  t h e r e f o r e  t h e  h y p o t h e s i s  w a s  a c h i e v e d .  X O R  m a y b e  b e  
r e l e a s e d  f r o m  t h e  v a s c u l a r  e n d o t h e l i u m  b y  s t i m u l a t i o n  w i t h  p r o - i n f l a m m a t o r y  a n d  
p r o - t h r o m b o t i c  m e d i a t o r s  b y  a  p r o c e s s  i n d e p e n d e n t  o f  c e l l  d e a t h .  T h e  m e c h a n i s m  
c a n  b e  s t i m u l a t e d  b y  a  r i s e  i n  i n t r a c e l l u l a r  c a l c i u m  a n d  m a y  r e q u i r e  f u n c t i o n a l  
m i c r o t u b u l e s .  X O  a c t i v i t y  i n c r e a s e s  i n  t h e  p r e s e n c e  o f  t h r o m b i n ,  p o s s i b l y  d u e  t o
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p r o t e o l y t i c  c l e a v a g e  o f  X O .  A  p r o t e c t i v e  r o l e  f o r  X O  w a s  d e s c r i b e d  u s i n g  t h e  w o u n d  
e n v i r o n m e n t  a s  a n  e x a m p l e .  T h e  r e l e a s e  p r o c e s s  s h o u l d  b e  i n v e s t i g a t e d  i n  m o r e  d e t a i l ,  
t h e  e f f e c t s  o f  t h r o m b i n  o n  X O  s t u d i e d  i n  m u t a t i o n  e x p e r i m e n t s ,  a n d  t h e  r o l e  o f  X O R  
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8 Appendix I - Methology
8.1 Haematoxylin and Eosin Stain Protocol
T i s s u e s  s e c t i o n s  m o u n t e d  o n  s l i d e s  w e r e  t r e a t e d  b y  s u b m e r s i o n  i n  t h e  f o l l o w i n g  
s o l v e n t s  f o r  t h e  t i m e s  i n d i c a t e d :
•  I c e  c o l d  a c e t o n e  : l - 5 m i n s  ( T i s s u e  F i x a t i o n )
•  T a p  w a t e r  : 5 m i n s  ( R e h y d r a t e  t i s s u e )
•  H a r r i s  H a e m a t o x y l i n  ( p r e p a r e d  1  p a r t  H a e m a t o x y l i n  : 3  p a r t s  w a t e r )  : 5 m i n s
•  T a p  w a t e r  : 5 m i n s
•  A c i d  a l c o h o l  (1% H C 1  i n  I M S ) : l m i n  w i t h  g e n t l e  a g i t a t i o n
•  T a p  w a t e r  : 5 m i n s
•  E o s i n : 0 . 5 m i n
•  T a p  w a t e r  : 5 m i n s
•  I M S  : l m i n
•  I M S  : l m i n
•  X y l e n e  : l m i n
•  X y l e n e  : l m i n
•  A  c o v e r s l i p  w a s  m o u n t e d  o n t o  t h e  t r e a t e d  t i s s u e  s a m p l e  w i t h  e x c e s s  D e P e X  
m o u n t i n g  m e d i u m .
8.2 SDS-PAGE, Western and Dot Blot Recipes
SDS-PAGE Resolving Gel (8%)
10.66mls dlEO
4.0mls 40% Acrylamide (Anachem. Bedfordshire, UK)
5.02mls 1.5M Tris/Base pH8.8 (Promega U K  Ltd. Southampton, UK)
lOOpl 20% SDS (Sigma Aldrich Company Ltd. Dorset, UK)
200pi 10% Ammonium Persulphate (Sigma Aldrich Company Ltd. D orset, UK)
15pi N , N , N ', N  '-Tetra-methyl-ethylenediamine (TEMED) (Sigma Aldrich
Company Ltd. Dorest, UK)
SDS-PAGE Stacking Gel (4%)
• 4.98m ls dH20
• 660pl 40% Acrylamide
• 840pl 1.0M Tris/Base pH6.8
• 33.4pl 20% SDS
• 66pl 10% Ammonium Persulphate
• 8pl TEM ED
SDS-PAGE Running Buffer
•  14 .4g Glycine (VWR International Ltd. Dorset, UK)
•  3.06g Tris/Base
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•  l.Og SDS
•  lOOOmls dH20
pH8.3
SDS-PAGE Sample Buffer
•  6.75mls dH20
® 0.75mls 1M Tris/Base pH6.8
•  2.0g Sucrose (VWR International Ltd. Dorset, UK)
•  ling Bromophenol Blue (Promega UK Ltd. Southampton, UK)
•  0.5mls 2-mercaptoethanol (Sigma Aldrich Company Ltd. Dorset, UK)
Western and Dot Blot Transfer Buffer
•  see SDS-PAGE Running Buffer but made with 20% Methanol (VWR International Ltd. Dorset, UK)
Western and Dot Blot Washing Buffer
•  0.5% Tween 20 (Sigma Aldrich Company Ltd. Dorset, UK) in PBS
Western and Dot Blot Blocking Buffer
•  5% Marvel non-fat dried milk powder in Washing Buffer
8.3 Antibodies
8.3.1 Primary Antibodies
•  M o u s e  M o n o c l o n a l  A n t i - H u a m n  ( 3 - t u b u l i n  C y 3 - C o n j u g a t e d  ( l m g / m l  s t o c k )  
( S i g m a  A l d r i c h  C o m p a n y  L t d .  D o r e s t ,  U K ) .
•  M o u s e  M o n o c l o n a l  A n t i - H u m a n  v W F  ( 2 4 0 | i g / m l )  ( D A K O .  C h a m b r i d g e s h i r e ,  
U K ) .
•  M o u s e  M o n o c l o n a l  A n t i - H u m a n  X a n t h i n e  O x i d a s e / A l d e h y d e  O x i d a s e  
( 2 0 0 { i g / l m l )  ( N e o M a r k e r s .  C A ,  U S A ) .
•  R a b b i t  P o l y c l o n a l  A n t i - H u m a n  v W F  ( 5 . 7 m g / m l  s t o c k )  ( D A K O .
C h a m b r i d g e s h i r e ,  U K ) .
•  R a b b i t  P o l y c l o n a l  A n t i - B o v i n e  X O  ( l O m g / m l  s t o c k )  ( C h e m i c o n  E u r o p e  L t d .  
H a m p s i r e ,  U K ) .
•  R a b b i t  P o l y c l o n a l  A n t i - B o v i n e  X O  P e r o x i d a s e - C o n j u g a t e d  ( l O m g / m l  s t o c k )  
( B i o d e s i g n .  M E ,  U S A ) .
•  R a b b i t  P o l y c l o n a l  A n t i - B o v i n e  X O  ( l O m g / m l  s t o c k )  ( P o l y s c i e n c e s  I n c .  P A ,  
U S A ) .
8.3.2 Secondary Antibodies
•  D o n k e y  A n t i - R a b b i t  I g G - f l u o r e s c e i n  i s o t h i o c y a n a t e  ( F I T C )  c o n j u g a t e d  
( 4 0 0 f i g / m l  s t o c k )  ( S a n t a  C r u z  B i o t e c h n o l o g y .  C A ,  U S A )
•  D o n k e y  A n t i - R a b b i t  I g G - R h o d a m o n e  c o n j u g a t e d  ( 4 0 0 f i g / m l  s t o c k )  ( S a n t a  C r u z  
B i o t e c h n o l o g y .  C A ,  U S A ) .
•  G o a t  A n t i - R a b b i t  W h o l e  A n t i b o d y - U l t r a  S m a l l  G o l d  C o n j u g a t e  ( A u r i o n .  
W a g e n i n g e n ,  T h e  N e t h e r l a n d s ) .
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•  G o a t  A n t i - R a b b i t  F ( a b ) 2- U l t r a  S m a l l  G o l d  C o n j u g a t e  ( A u r i o n .  W a g e n i n g e n ,  T h e  
N e t h e r l a n d s ) .
•  H o r s e  A n t i - M o u s e  I g G - F I T C  c o n j u g a t e d  ( l m g / m l )  ( V e c t o r  L a b o r a t o r i e s .  C A .  
U S A )
•  S w i n e  A n t i - R a b b i t  I g G - H o r s e  R a d i s h  P e r o x i d a s e  ( H R P )  c o n j u g a t e d  ( 1 . 3 m g / m l  
s t o c k )  ( D A K O .  C h a m b r i d g e s h i r e ,  U K ) .
8.4 Preparation of HUVECs for Electron Microscopy
Cell Seeding
•  D i s s o c i a t e  P I  H U V E C s  u s i n g  C e l l  D i s s o c i a t i o n  S o l u t i o n .
•  S e e d  ~ 1 0 0 0  v i a b l e  c e l l s / c a p s u l e  ( 1 5 p l  o f  6 6 0 0 0 c e l l / m l  E C G M ) .
•  F i l l  r e s e r v o i r s  o f  m u l t i - w e l l  p l a t e  w i t h  2 0 0 p i  d H 2 0 .
•  I n c u b a t e  o / n  a t  3 7 ° C  /  5 %  C O 2.
N o t e :  I n  t h e  f o l l o w i n g  p r o t o c o l  t h e  a p p l i c a t i o n  o f  s o l u t i o n s  a r e  i n  1 5 p l  
v o l u m e s / c a p s u l e .
Fixation
•  W a s h  4  t i m e s  i n  P B S .
•  F i x  w i t h  4 %  P a r a f o r m a l d e h y d e  s o l u t i o n  i n  P B S  f o r  1 5 m i n s  a t  R T .
•  W a s h  4  x  l O m i n s  i n  1 %  B S A / P B S  p H 8 . 2 .
Quench Aldehyde Groups
•  R e s i d u a l  a l d e h y d e  g r o u p s  p r e s e n t  a f t e r  a l d e h y d e  f i x a t i o n  m u s t  b e  q u e n c h e d  
u s i n g  5 0 m M  G l y c i n e  i n  P B S ,  i n c u b a t e  w i t h  c e l l s  f o r  5 m i n s  a t  R T .
•  W a s h  3  x  l O m i n s  i n  1 %  B S A / P B S .
Permeablisation
•  I n c u b a t e  c e l l s  w i t h  0 . 2 %  T r i t o n  X - 1 0 0  i n  P B S  f o r  l O m i n s  a t  R T .
•  o r  w i t h  S a p o n i n  i n  P B S  0 . 1 %  f o r  l O m i n s  a t  R T .
•  W a s h  3  x  l O m i n s  i n  1 %  B S A / P B S .
N o t e :  F o r  s a p o n i n  t r e a t e d  c e l l s  a d d  s a p o n i n  t o  a l l  s o l u t i o n s  f o l l o w i n g  t h e  
p e r m e a b l i s a t i o n  s t e p )
Blocking
•  I n c u b a t e  c e l l s  f o r  3 0 m i n s  a t  R T  i n  5 %  g o a t  s e r u m  i n  1 %  B S A / P B S  + / -  0 . 1 %  
S a p o n i n  ( s e r u m  o f  s p e c i e s  s e c o n d a r y  a n t i b o d y  w a s  r a i s e d ) .
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Primary Antibody Application
•  D A K O  R a b b i t  A n t i - H u m a n  v W f  1 5 0 x  d i l u t i o n  i n  b l o c k i n g  b u f f e r ,  i n c u b a t e  
f o r  l h r  a t  R T .
•  o r  P o l y s c i e n c e s  R a b b i t  A n t i - B o v i n e  X O  1 5 0 x  d i l u t i o n  i n  b l o c k i n g  b u f f e r ,  
i n c u b a t e  f o r  l h r  a t  R T .
Wash Step
•  W a s h  4  x  l O m i n s  a t  R / T  i n  1 % B S A / P B S  + / -  0 . 1 %  S a p o n i n .
Secondary Antibody Application
•  A u r i o n  G o a t  A n t i - R a b b i t  U l t r a  S m a l l  G o l d  C o n j u g a t e  ( w h o l e  a n t i b o d y  u s e d  i n  
T r i t o n  X - 1 0 0  p e r m a b i l i s e d  c e l l s  a n d  F ( a b ) 2 f o r  s a p o n i n  p e r m e a b i l i s e d  c e l l s ) .  
l O O x  d i l u t i o n  i n  b l o c k i n g  b u f f e r ,  i n c u b a t e  f o r  1 . 5 - 2 h r  R / T .
Wash Step
•  W a s h  4  x  l O m i n s  a t  R / T  i n  1 % B S A / P B S  + / -  0 . 1 %  S a p o n i n .
Silver Enhancement
•  W a s h  c e l l s  1 0  x  5  m i n s  i n  C IH 2O  ( C e l l s  m u s t  b e  r i n s e d  t h o r o u g h l y  w i t h  d H 2 0
b e f o r e  t h e  a d d i t i o n  o f  s i l v e r  e n h a n c e m e n t  r e a g e n t s ,  s e e  m a n u f a c t u r e r s
i n s t r u c t i o n s ) .
•  M i x  e q u a l  v o l u m e s  o f  e n h a n c e r  a n d  i n i t i a t o r  a n d  a p p l y  t o  c e l l s  f o r  3 0 m i n s  a t  
R T .
N o t e :  A f t e r  a  c e r t a i n  t i m e  s i l v e r  m a y  p r e c i p i t a t e  s p o n t a n e o u s l y  p r o d u c i n g  a  
b a c k g r o u n d  s i g n a l .  T h i s  t i m e  i s  t e m p e r a t u r e  d e p e n d e n t ,  a t  2 4 ° C  t h e  s o l u t i o n  w i l l  b e  
s t a b l e  f o r  a t  ~ 3 5 m i n s .  I f  e n h a n c e m e n t  i s  n e e d e d  b e y o n d  t h i s  t i m e  p e r i o d  r e m o v e  o l d  
s o l u t i o n  a n d  a p p l y  a  f r e s h  s o l u t i o n  t o  c e l l s .
•  W a s h  5  x  5 m i n s  i n  d H 2 0 .
Uranyl Acetate Stain
•  A p p l y  a  0 . 1 %  s o l u t i o n  o f  U A  i n  d i s t i l l e d  w a t e r  t o  t h e  c e l l s  f o r  5 m i n s .
•  W a s h  2  x  5 m i n s  i n  d H 2 0 .
N o t e :  s t a i n i n g  f o r  t h i s  p e r i o d  w i l l  r e s u l t  i n  a  l i g h t  s t a i n  o f  c e l l u l a r  c o m p o n e n t s  t h a t
s h o u l d n ’t  i n t e r f e r e  w i t h  t h e  i m m u n o - g o l d  s t a i n i n g .
Imaging Buffer
•  A s p i r a t e  a n d  f i l l  w i t h  Q X - 1 0 2  i m a g i n g  b u f f e r .
•  C l o s e  t h e  c a p s u l e  f o r  i m a g i n g  u s i n g  b a c k  s c a t t e r e d  e l e c t r o n  d e t e c t i o n  i n  a
s c a n n i n g  e l e c t r o n  m i c r o s c o p e .
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G A P D H - F o r w a r d  5 ’ A A A  G G G  T C A  T C A  T C T  C T G  G C  3 ’
G A P D H - R e v e r s e  5 ’ T G A  C A A  A G T  G G T  C G T  T G A  G G  3 ’
S t o c k  c o n c e n t r a t i o n  =  7 . 5 p m o l e s / p i  
E x p e c t e d  P r o d u c t  S i z e  =  5 7 6  b a s e  p a i r s
R a t  X O R :
X O R - F o r w a r d  5 ’ C T G  T C C  A T C  G A G  A T C  C C C  T A  3 ’
X O R - R e v e r s e  5 ’ T C T  C A G  C C C  T C A  A G A  C C A  C T  3 *
S t o c k  c o n c e n t r a t i o n  =  l O O p m o l e s / m l  
E x p e c t e d  P r o d u c t  S i z e  =  2 8 8  b a s e  p a i r s
8.5.2 PCR Programmes
G A P D H :
I n i t i a l  D e n a t u r a t i o n :  5 m i n s ,  9 4 ° C
D e n a t u r a t i o n :  4 5 s e c s ,  9 4 ° C  "1
A n n e a l i n g :  4 5 s e c s ,  5 5 ° C  r  3 0  c y c l e s
E x t e n s i o n :  4 5 s e c s ,  7 2 ° C  J
F i n a l  E x t e n s i o n :  l O m i n s ,  7 2 ° C
F i n a l  H o l d :  4 ° C
R a t  X O R :
I n i t i a l  D e n a t u r a t i o n :  5 m i n s ,  9 4 ° C
D e n a t u r a t i o n :  4 5 s e c s ,  9 4  ° C  "I
A n n e a l i n g :  4 5 s e c s ,  5 8 ° C  r  3 0  c y c l e s
E x t e n s i o n :  6 0 s e c s ,  7 2 ° C  J
F i n a l  E x t e n s i o n :  l O m i n s ,  7 2 ° C
F i n a l  H o l d :  4 ° C
8.5.3 Agarose Gel Recipe
T r i s - B o r a t e  ( T B E )  B u f f e r  ( 5 x ) :  
5 4 g  T r i s - B a s e  
2 7 . 5 g  B o r i c  A c i d  
2 . 9 2 g  E D T A
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p H 8
•  A d d  0 . 3 g  A g a r o s e  p e r  2 5 m l s  l x  T B E  b u f f e r  ( h e a t e d  u n t i l  a g a r o s e  d i s s o l v e d ) .
•  C o o l  u n d e r  r u n n i n g  c o l d  w a t e r .
•  A d d  2 p l  l m g / m l  e t h i d i u m  b r o m i d e  p e r  2 5 m l s  T B E  b u f f e r  u s e d .
•  P o u r  g e l  i n t o  c a s t i n g  t a n k  i n  f u m e  h o o d  a n d  l e a v e  a t  r o o m  t e m p e r a t u r e  u n t i l  
s e t .
8.6 In-Gel Assay XOR-Activity Detection Solution
C o n c e n t r a t i o n s  u s e d  i n  O z e r  et aL, 1 9 9 8  a r e  l i s t e d  b e l o w .  T h e  c o n c e n t r a t i o n s  o f  t h e s e  
s o l u t i o n s  w e r e  o p t i m i s e d  i n  e x p e r i m e n t s  d e c r i b e d  i n  S e c t i o n  4 . 4 . 2 .
•  5 0 m M  T r i s - H C l ,  p H 7 . 6
•  5 0 0 [ i M  X x a n t h i n e
•  2 5 0 [ i M  N i t r o b l u e  T e t r a z o l i u m
8.7 Preparation of Rat Liver and Plasma Samples
F e m a l e  L e w i s  r a t s  ( H a r l a n - O l a c .  L i n c o l n s h i r e ,  U K ) ,  w e i g h i n g  a p p r o x i m a t e l y  2 0 0 g  
e a c h ,  w e r e  f e d  w i t h  e i t h e r :
i )  5 0 m g / k g / d  a l l o p u r i n o l  s u s p e n d e d  i n  1 %  c a r o x y m e t h y l c e l l u l o s e  ( S i g m a  A l d r i c h  
C o m p a n y  L t d .  D o r e s t ,  U K . )  o r ,
i i )  r a t  c h o w  ( I C N  B i o c h e m i c a l s .  O h i o ,  U S A )  s u p p l e m e n t e d  w i t h  0 . 7 g  s o d i u m  
t u n g s  t a t e / k g .
A f t e r  a  p e r i o d  o f  t h r e e  w e e k s  a n i m a l s  w e r e  h u m a n e l y  k i l l e d  b y  C O 2 e x p o s u r e .  F r o m  
e a c h  a n i m a l  1 m l  o f  b l o o d  w a s  c o l l e c t e d  i n  a n  e p p e n d o r f  c o n t a i n i n g  l O O g l  o f  
8 0 m g / m l  t r i s o d i u m  c i t r a t e ,  i n v e r t e d  t w i c e ,  a n d  c e n t r i f u g e d  a t  7 1 5 2 r p m  f o r  3 m i n s .  
P l a s m a  w a s  p i p e t t e d  i n t o  a  f r e s h  e p p e n d o r f  a n d  w a s  s t o r e d  a t  - 7 0 ° C  b e f o r e  a n a l y s i s .  
L i v e r s  w e r e  a l s o  i s o l a t e d  a n d  w e r e  s n a p - f r o z e n  i n  l i q u i d - N 2 . S a m p l e s  o f  r a t  l i v e r  w e r e  
g r o u n d  i n  l i q u i d - N 2 a n d  t h e  r e s u l t i n g  p o w d e r  w a s  s u s p e n d e d  i n  5 0 m M  p o t a s s i u m  
p h o s p h a t e  b u f f e r  ( p H 7 . 4 ) ,  c o n t a i n i n g  O . l m M  E D T A ,  O . l m M  P M S F ,  a n d  l f i g / m l
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p e p s t a t i n ,  l e u p e p t i n ,  a n t i p a i n ,  a n d  a p r o t i n i n  ( S i g m a  A l d r i c h  C o m p a n y  L t d .  D o r e s t ,  
U K ) .  S u s p e n s i o n s  w e r e  c e n t r i f u g e d  a t  1 3 ’O O O r p m  f o r  l O m i n s .  T h e  s u p e r n a t a n t  w a s  
c o l l e c t e d  i n  a  f r e s h  e p p e n d o r f  a n d  s t o r e d  a t  - 7 0 ° C  b e f o r e  a n a l y s i s .
8.8 Lysis Buffer
0 . 2 %  T r i t o n  X - 1 0 0  i n  H B S S
+  1 j r g / m l  A n t i p a i n  ( S i g m a  A l d r i c h  C o m p a n y  L t d .  D o r e s t ,  U K )
+  1  f i g / m l  A p r o t i n i n  ( S i g m a  A l d r i c h  C o m p a n y  L t d .  D o r e s t ,  U K )
+  1  f i g / m l  L e u p e p t i n  ( S i g m a  A l d r i c h  C o m p a n y  L t d .  D o r e s t ,  U K )
+  l f i g / m l  P h e n y l m e t h y l s u l p h o n y l  F l o r i d e  ( P M S F ;  S i g m a  A l d r i c h  C o m p a n y  L t d .  
D o r e s t ,  U K )
C h i l l e d  t o  4 ° C  b e f o r e  u s e .
8-233
.kuncN FL’u i i iMtn  } I
References
8-234
J a i i i - j  ■, I k ‘ \ \  i i w  m I ’ l l l  1 I i l UM S
9 References
A d a c h i ,  T . ,  F u k u s h i m a ,  T . ,  U s a m i ,  Y . ,  &  H i r a n o ,  K .  ( 1 9 9 3 ) .  B i n d i n g  o f  h u m a n  
x a n t h i n e  o x i d a s e  t o  s u l p h a t e d  g l y c o s a m i n o g l y c a n s  o n  t h e  e n d o t h e l i a l - c e l l  s u r f a c e .  The 
Biochemical Journal 2 8 9 ,  5 2 3 - 5 2 7 .
A l b e r t s ,  B . ,  B r a y ,  D . ,  L e w i s ,  J . ,  R a f f ,  M . ,  R o b e r t s ,  K . ,  &  W a t s o n ,  J . D .  ( 1 9 9 4 ) .  T h e  
c y t o s k e l e t o n .  I n  Molecular Biology of the Cell ( E d s . R o b e r t s o n ,  M . ,  A d a m s ,  R . ,  C o b e r t ,  
S . M . ,  &  G o e r t z e n ,  D ) .  p p  7 8 7 - 8 6 1 .  G a r l a n d  P u b l i s h i n g  I n c .  L o n d o n ,  U K .
A l - K h a l i d i ,  U . A . S . ,  &  C h a g l a s s i a n ,  T . H .  ( 1 9 6 5 ) .  T h e  s p e c i e s  d i s t r i b u t i o n  o f  x a n t h i n e  
o x i d a s e .  Biochemical Journal 9 7 ,  3 1 8 - 3 2 0 .
A m a y a ,  Y . ,  Y a m a z a k i ,  K - I . ,  S a t o ,  M . ,  N o d a ,  K . ,  N i s h i n o ,  T . ,  &  N i s h i n o ,  T .  ( 1 9 9 0 ) .  
P r o t e o l y t i c  c o n v e r s i o n  o f  x a n t h i n e  d e h y d r o g e n a s e  f r o m  t h e  N A D - d e p e n d e n t  t y p e  t o  
t h e  C>2- d e p e n d e n t  t y p e .  2 6 5 ,  1 4 1 7 0 - 1 4 1 7 5 .
A n g e r m u l l e r ,  S . ,  B r u d e r ,  G . ,  V o l k l ,  A . ,  W e s c h ,  H . ,  &  F a h i m i ,  H . D .  ( 1 9 8 7 ) .  
L o c a l i s a t i o n  o f  x a n t h i n e  o x i d a s e  i n  c r y s t a l l i n e  c o r e s  o f  p e r o x i s o m e s .  A  c y t o c h e m i c a l  
a n d  b i o c h e m i c a l  s t u d y .  European Journal of Cell Biology. 4 5 ,  1 3 7 - 1 4 4 .
A n r a t h e r ,  J . ,  C s i z m a d i a ,  V . ,  S o a r e s ,  M . P . ,  &  W i n k l e r ,  H .  R e g u l a t i o n  o f  N F - x B  R e l A  
p h o s p h o r y l a t i o n  a n d  t r a n s c r i p t i o n a l  a c t i v i t y  b y  p 2 1 ras a n d  p r o t e i n  k i n a s e  C £  i n  p r i m a r y  
e n d o t h e l i a l  c e l l s .  The Journal of Biological Chemistry. 2 7 4 ,  1 3 5 9 4 - 1 3 6 0 3 .
A r c h e r ,  S . L . ,  H u a n g ,  J . M . C . ,  H a m p l ,  V . ,  N e l s o n ,  D . P . ,  S h u l t z ,  P . J . ,  &  W e i r ,  E . K .
( 1 9 9 4 ) .  N i t r i c  o x i d e  a n d  c G M P  c a u s e  v a s o r e l e a x a t i o n  b y  a c t i v a t i o n  o f  a  c h a r y b d o x i n -  
s e n s i t i v e  K  c h a n n e l  b y  c G M P - d e p e n d e n t  p r o t e i n  k i n a s e .  PNAS. 9 1 ,  7 5 8 3 - 7 5 8 7 .
Avis, P.G., Bergel, F. and Bray, R.C. (1956) Cellular constituents. The chemistry oF 
xanthine oxidase. Part III. Estimates of co-factors and the catalytic activities of 
enzyme fractions from cow’s milk, journal of Chemical Society. 1219—1226.
B a c a l l a o ,  R . ,  K i a i ,  K . ,  &  J e s a i t i s ,  L .  ( 1 9 9 5 ) .  G u i d i n g  p r i n c i p l e s  o f  s p e c i m e n  
p r e s e r v a t i o n .  I n  Handbook of Biological Confocal Microscopy. ( E d .  P a w l e y ,  J . B . )  p p .  3 1 1 -  
3 2 5 .  P l e n u m  P r e s s ,  N e w  Y o r k ,  U S A .
B a j z a r ,  L . ,  M a n u e l ,  R . ,  &  N e s h e i m ,  M . E .  ( 1 9 9 5 ) .  P u r i f i c a t i o n  a n d  c h a r a c t e r i s a t i o n  o f  
T A F I ,  a  t h r o m b i n - a c t i v a t a b l e  f i b r i n o l y s i s  i n h i b i t o r .  The Journal of Biological Chemistry. 
2 7 0 , 1 4 4 7 7 - 1 4 4 8 4 .
B a t t e l l i ,  M . G . ,  A b b o n d a n z a ,  A . ,  M u s i a n i ,  S . ,  B u o n a m i c i ,  L . ,  S t r o c c h i ,  P . ,  T a z z a r i ,  P . L . ,  
G r a m a n t i e r i ,  L . ,  &  S t i r p e ,  F .  ( 1 9 9 9 ) .  D e t e r m i n a t i o n  o f  x a n t h i n e  o x i d a s e  i n  h u m a n
9-235
s e r u m  b y  a  c o m p e t i t i v e  e n z y m e - l i n k e d  i m m u n o s o r b e n t  a s s a y  ( E L I S A ) .  Clinica Chimica 
Acta. 2 8 1 , 1 4 7 - 1 5 8 .
B a t t e l l i ,  M . G . ,  M u s i a n i ,  S . ,  V a l g i m i g l i ,  M . ,  G r a m a n t i e r i ,  L . ,  T o m a s s o n i ,  F . ,  B o l o n d i ,  L . ,  
&  S t r i p e ,  F .  ( 2 0 0 1 ) .  S e r u m  x a n t h i n e  o x i d a s e  i n  h u m a n  l i v e r  d i s e a s e .  The American 
Journal of Gastroenterology. 9 6 ,  1 1 9 4 - 1 1 9 9 .
B a y e l e ,  H . K . ,  M u r d o c k ,  P . J . ,  P e r r y ,  D . J . ,  &  P a s i ,  K . J .  ( 2 0 0 2 ) .  S i m p l e  s h i f t s  i n  
r e d o x / t h i o l  b a l a n c e  t h a t  p e r t u r b  b l o o d  c o a g u l a t i o n .  FEBS Letters. 5 1 0 ,  6 7 - 7 0 .
B a y r a k t u t a n ,  U . ,  B l a y n e y ,  L . ,  &  S h a h ,  A . M .  ( 2 0 0 0 )  M o l e c u l a r  c h a r a c t e r i s a t i o n  a n d  
l o c a l i s a t i o n  o f  t h e  N A D ( P ) H  o x i d a s e  c o m p o n e n t s  gp91-phox a n d  p 2 2 -phox i n  
e n d o t h e l i a l  c e l l s .  Arteriosclerosis, Thrombosis, and Vascular Biology. 2 0 , 1 9 0 3 - 1 9 1 1 .
B e c k m a n ,  J .  S . ,  P a r k s ,  D . A . ,  P e a r s o n ,  J . D . ,  M a r s h a l l ,  P . A . ,  &  F r e e m a n ,  B . A .  ( 1 9 8 9 ) .  A  
s e n s i t i v e  f l u o r o m e t r i c  a s s a y  f o r  m e a s u r i n g  x a n t h i n e  d e h y d r o g e n a s e  a n d  o x i d a s e  i n  
t i s s u e s .  Free Radical Biology and Medicine. 6 ,  6 0 7 - 6 1 5 .
B e l l o r i n i ,  M . ,  L e e ,  D . K . ,  D o n t o n e l ,  J . C . ,  Z e m z o u r u m i ,  K . ,  R o e d e r ,  R . G . ,  T o r a ,  L . ,  &  
M a n t o v a n i ,  R .  ( 1 9 9 7 ) .  C C A A T  b i n d i n g  N F - Y  -  T B P  i n t e r a c t i o n s :  N F - Y B  a n d  N F -  
Y C  r e q u i r e  s h o r t  d o m a i n s  a d j a c e n t  t o  t h e i r  h i s t o n e  f o l d  m o t i f s  f o r  a s s o c i a t i o n  w i t h  
T B P  b a s i c  r e s i d u e s .  Nucleic Acids Research. 2 5 ,  2 1 7 4 - 2 1 8 1 .
B e r g ,  J . M . ,  T y m o c z k o ,  J . L . ,  &  S t r y e r ,  L .  ( 2 0 0 1 ) .  N u c l e o t i d e  B i o s y n t h e s i s .  I n :  
Biochemistry. ( E d s .  M o r a n ,  S . ,  S a n t e e ,  M . ,  D i V i t t o r i o ,  S . ,  H a d l e r ,  G . L . ,  Z i m m e r m a n ,  P . ,  
&  W o n g ,  V ) .  p p .  6 9 3 - 7 1 4 .  W .  H .  F r e e m a n  a n d  C o m p a n y ,  N e w  Y o r k ,  U S A .
B e r g l u n d ,  L . ,  R a s m u s s e n ,  J . T . ,  A n d e r s e n ,  M . D . ,  R a s m u s s e n ,  M . S . ,  &  P e t e r s e n ,  T . E .
( 1 9 9 5 ) .  P u r i f i c a t i o n  o f  t h e  b o v i n e  x a n t h i n e  o x i d o r e d u c t a s e  f r o m  m i l k  f a t  g l o b u l e  
m e m b r a n e s  a n d  c l o n i n g  o f  c o m p l e m e n t a r y  d e o x y r i b o n u c l e i c  a c i d .  Journal of Dairy 
Science. 7 9 ,  1 9 6 - 2 0 4 .
B e v i l a c q u a ,  M . P . ,  P o b e r ,  J . S . ,  M e n d r i c k ,  D . L . ,  C o t r a n ,  R . S . ,  &  G i m b r o n e ,  M . A .  
( 1 9 8 7 ) .  I d e n t i f i c a t i o n  o f  a n  i n d u c i b l e  e n d o t h e l i a l - l e u k o c y t e  a d h e s i o n  m o l e c u l e .  PNAS. 
8 4 ,  9 2 3 8 - 9 2 4 2 .
B h a t i a ,  M . ,  &  M o o c h h a l a ,  S .  ( 2 0 0 4 ) .  R o l e  o f  i n f l a m m a t o r y  m e d i a t o r s  i n  t h e  
p a t h o p h y s i o l o g y  o f  a c u t e  r e s p i r a t o r y  d i s t r e s s  s y n d r o m e .  The Journal of Pathology. 2 0 2 ,  
1 4 5 - 1 5 6 .
B i r c h ,  K . A . ,  E w e n s t e i n ,  B . M . ,  G o l a n ,  D . E . ,  &  P o b e r ,  J . S .  ( 1 9 9 4 ) .  P r o l o n g e d  p e a k  
e l e v a t i o n s  i n  c y t o p l a s m i c  f r e e  c a l c i u m  i o n s ,  d e r i v e d  f r o m  i n t r a c e l l u l a r  s t o r e s ,  c o r r e l a t e  
w i t h  t h e  e x t e n t  o f  t h r o m b i n - s t i m u l a t e d  e x o c y t o s i s  i n  s i n g l e  h u m a n  u m b i l i c a l  v e i n  
e n d o t h e l i a l  c e l l s .  Journal of Cellular Physiology. 1 6 0 ,  5 4 5 - 5 5 4 .
.1;111il“ i  I l e w  i n s t  i n f ' h i  > r i i c - i -
B o d e ,  W . ,  T u r k ,  D . ,  &  K a r s h i k o v ,  A .  ( 1 9 9 2 ) .  T h e  r e f i n e d  1 . 9 - A  X - r a y  c r y s t a l  s t r u c t u r e  
o f  D - P h e - P r o - A r g  c h l o r o m e t h y l k e t o n e - i n h i b i t e d  h u m a n  a - t h r o m b i n :  s t r u c t u r e  
a n a l y s i s ,  o v e r a l l  s t r u c t u r e ,  e l e c t r o s t a t i c  p r o p e r t i e s ,  d e t a i l e d  a c t i v e - s i t e  g e o m e t r y ,  a n d  
s t r u c t u r e - f u n c t i o n  r e l a t i o n s h i p s .  Protein Science. 1 ,  4 2 6 - 4 7 1 .
B o n i n i ,  M . G . ,  M i y a m o t o ,  S . ,  D i  M a s c i o ,  P . ,  &  A u g u s t o .  ( 2 0 0 4 ) .  P r o d u c t i o n  o f  t h e  
c a r b o n a t e  r a d i c a l  a n i o n  d u r i n g  x a n t h i n e  o x i d a s e  t u r n o v e r  i n  t h e  p r e s e n c e  o f  
b i o c a r b o n a t e .  The Journal of Biological Chemistry. 2 7 9 ,  5 1 8 3 6 - 5 1 8 4 3 .
B o u n a s s i s i ,  V . ,  &  V e n t e r ,  J . C .  ( 1 9 7 6 ) .  H o r m o n e  a n d  n e u r o t r a n s m i t t e r  r e c e p t o r s  i n  a n  
e s t a b l i s h e d  v a s c u l a r  e n d o t h e l i a l  c e l l  l i n e .  PNAS. 7 3 ,  1 6 1 2 - 1 6 1 6 .
B r a d f o r d ,  M . M .  ( 1 9 7 6 ) .  A  r a p i d  a n d  s e n s i t i v e  m e t h o d  f o r  t h e  q u a n t i t a t i o n  o f  
m i c r o g r a m  q u a n t i t i e s  o f  p r o t e i n  u t i l i z i n g  t h e  p r i n c i p l e  o f  p r o t e i n - d y e  b i n d i n g .  
Analytical Biochemistry. 7 2 ,  2 4 8 - 2 5 4 .
B r a d l e y ,  J . R . ,  J o h n s o n ,  D . R . ,  &  P o b e r ,  J . S .  ( 1 9 9 3 ) .  E n d o t h e l i a l  a c t i v a t i o n  b y  h y d r o g e n  
p e r o x i d e .  S e l e c t i v e  i n c r e a s e s  o f  i n t r a c e l l u l a r  a d h e s i o n  m o l e c u l e - 1  a n d  m a j o r  
h i s t o c o m p a t i b i l i t y  c o m p l e x  c l a s s  I .  The American Journal of Pathology. 1 4 2 , 1 5 9 8 - 1 6 0 9 .
B r i z i o ,  C . ,  B a r i l e ,  M . ,  &  B r a n d s c h ,  R .  ( 2 0 0 2 ) .  F l a v i n y l a t i o n  o f  t h e  p r e c u r s o r  o f  
m i t o c h o n d r i a l  d i m e t h y l g l y c i n e  d e h y d r o g e n a s e  b y  i n t a c t  a n d  s o l u b i l i s e d  m i t o c h o n d r i a .  
FEBS Fetters. 5 2 2 , 1 4 1 - 1 4 6 .
B r u n e l l i ,  L . ,  C r o w ,  J . P . ,  B e c k m a n ,  J . S .  ( 1 9 9 5 ) .  T h e  c o m p a r a t i v e  t o x i c i t y  o f  n i t r i c  o x i d e  
a n d  p e r o x y n i t r i t e  t o  Escherichia coli. Archives in Biochemistry and Biophysics. 3 1 6 ,  3 2 7 - 3 3 4 .
B u t k o w s k i ,  R . J . ,  E l i o n ,  J . ,  D o w n i n g ,  M . R . ,  &  M a n n ,  K . G .  ( 1 9 7 7 ) .  P r i m a r y  s t r u c t u r e  o f  
h u m a n  p r o t h r o m b i n  2  a n d  a - t h r o m b i n .  The Journal of Biological Chemistry. 2 5 2 ,  4 9 4 2 -  
4 9 5 7 .
C a z z a n i g a ,  G . ,  T e r a o ,  M . ,  S c h i a v o ,  P . L . ,  G a l b i t i ,  F . ,  S e g a l l a ,  F . ,  S e l d i n ,  M . F . ,  &  
G a r a t t i n i ,  E .  ( 1 9 9 4 ) .  C h r o m o s o m a l  m a p p i n g ,  i s o l a t i o n ,  a n d  c h a r a c t e r i s a t i o n  o f  t h e  
m o u s e  x a n t h i n e  d e h y d r o g e n a s e  g e n e .  Genomics. 2 3 ,  3 9 0 - 4 0 2 .
C h a n c e ,  B . ,  S i e s ,  H . ,  &  B o v e r i s ,  A .  ( 1 9 7 9 ) .  H y d r o p e r o x i d e  m e t a b o l i s m  i n  m a m m a l i a n  
o r g a n s .  Physiological Reviews. 5 9 ,  5 2 7 - 6 0 5 .
C h e n ,  X - L . ,  Z h a n g ,  Q . ,  Z h a o ,  R . ,  D i n g ,  X . ,  T u m m a l a ,  P . E . ,  &  M e d f o r d ,  R . M .  ( 2 0 0 3 ) .  
R a c l  a n d  s u p e r o x i d e  a r e  r e q u i r e d  f o r  t h e  e x p r e s s i o n  o f  c e l l  a d h e s i o n  m o l e c u l e s  
i n d u c e d  b y  t u m o r  n e c r o s i s  f a c t o r - a  i n  e n d o t h e l i a l  c e l l s .  The Journal of Pharmacology and 
Experimental Therapeutics. 3 0 5 ,  5 7 3 - 5 8 0 .
9-237
.Link' - .  I l e w  ii iM' i i I ’ l i l  > T h ,w is
C h e n ,  J . ,  A n d e r s o n ,  J . B . ,  D e W e e s e - S c o t t ,  C . ,  F e d o r o v a ,  N . D . ,  G e e r ,  L . Y . ,  H e ,  S . ,  
H u r w i t z ,  D . I . ,  J a c k s o n ,  J . D . ,  J a c o b s ,  A . R . ,  L a n c z y c k i ,  C . J . ,  L i e b e r t ,  C . A . ,  L i u ,  C . ,  
M a d e j ,  T . ,  M a r c h l e r - B a u e r ,  A . ,  M a r c h l e r ,  G . H . ,  M a z u m d e r ,  R . ,  N i k o l s k a y a ,  A . N . ,  R a o ,  
B . S . ,  P a n c h e n k o ,  A . R . ,  S h o e m a k e r ,  B . A . ,  S i m o n y a n ,  V . ,  S o n g ,  J . S . ,  T h i e s s e n ,  P . A . ,  
V a s u d e v a n ,  S . ,  W a n g ,  Y . ,  Y a m a s h i t a ,  R . A . ,  Y i n ,  J  . J . ,  &  B r y a n t ,  S . H .  ( 2 0 0 3 a ) .  M M D B :  
E n t r e z ' s  3 D - s t r u c t u r e  d a t a b a s e .  Nucleic Acids Research. 3 1 ,  4 7 4 - 4 7 7 .
C h e n n a ,  R . ,  S u g a w a r a ,  H . ,  K o i k e ,  T . ,  L o p e z ,  R . ,  G i b s o n ,  T . J . ,  H i g g i n s ,  D . G . ,  &  
T h o m p s o n ,  J . D .  ( 2 0 0 3 ) .  M u l t i p l e  s e q u e n c e  a l i g n m e n t  w i t h  t h e  C l u s t a l  s e r i e s  o f  
p r o g r a m s .  Nucleic Acids Research. 3 1 ,  3 4 9 7 - 3 5 0 0 .
C h o i ,  K - S . ,  G h u m a n ,  J . ,  K a s s a m ,  G . ,  K a n g ,  H - M . ,  F i t z p a t r i c k ,  S . L . ,  &  W a i s m a n ,  D . M .
( 1 9 9 8 ) .  A n n e x i n  I I  t e t r a m e r  i n h i b i t s  p l a s m i n - d e p e n d e n t  f i b r i n o l y s i s .  Biochemistry. 3 7 ,  
6 4 8 - 6 5 5 .
C h u ,  A . J . ,  B e y d o u n ,  S . ,  M a t h e w s ,  S . T . ,  &  H o a n g ,  J .  ( 2 0 0 3 ) .  N o v a l  a n t i c o a g u l a n t  
p o l y e t h y l e n i m i n e :  i n h i b i t o r s  o f  t h r o m b i n - c a t a l y z e d  f i b r i n  f o r m a t i o n .  Archives of 
Biochemistry and Biophysics. 4 1 5 ,  1 0 1 - 1 0 8 .
C l u t t o n ,  P . ,  M i e r m o u n t ,  A . ,  &  F r e e d m a n ,  J . E .  ( 2 0 0 4 ) .  R e g u l a t i o n  o f  e n d o g e n o u s  
r e a c t i v e  o x y g e n  s p e c i e s  i n  p l a t e l e t s  c a n  r e v e r s e  a g g r e g a t i o n .  Arteriosclerosis, Thrombosis, 
and Vascular Biology. 2 4 ,  1 8 7 - 1 9 2 .
C o o p e r ,  D . ,  S t o k e s ,  K . Y . ,  T a i l o r ,  A . ,  &  G r a n g e r ,  D . N .  ( 2 0 0 2 ) .  O x i d a t i v e  s t r e s s  
p r o m o t e s  b l o o d  c e l l - e n d o t h e l i a l  c e l l  i n t e r a c t i o n s  i n  t h e  m i c r o c i r c u l a t i o n .  Cardiovascular 
Toxicology. 0 2 ,  1 6 5 - 1 8 0 .
C o r b i s i e r ,  P . ,  H o u b i o n ,  A . ,  &  R e m a d e ,  J .  ( 1 9 8 7 ) .  A  n e w  t e c h n i q u e  f o r  h i g h l y  s e n s i t i v e  
d e t e c t i o n  o f  s u p e r o x i d e  d i s m u t a s e  a c t i v i t y  b y  c h e m i l u m i n e s c e n c e .  Analytical 
Biochemistry. 1 6 4 ,  2 4 0 - 2 4 7 .
C z e r n i e c k i ,  B . ,  G a d ,  S . C . ,  R e i l l y ,  C . ,  S m i t h ,  A . C . ,  &  W i t z ,  G .  P h o r b o l  d i a c e t a t e  
i n h i b i t s  s u p e r o x i d e  a n i o n  r a d i c a l  p r o d u c t i o n  a n d  t u m o r  p r o m o t i o n  b y  m e z e r e i n .  
Carcinogenesis. 7 , 1 6 3 7 - 1 6 4 1 .
D a v i e ,  E . W . ,  &  R a t n o f f ,  O . D .  ( 1 9 6 4 ) .  W a t e r f a l l  s e q u e n c e  f o r  i n t r i n s i c  b l o o d  c l o t t i n g .  
Science. 1 4 5 , 1 3 1 0 - 1 3 1 2 .
D e e n e y ,  J . T . ,  V a l i v u l l a h ,  H . M . ,  D a p p e r ,  C . H . ,  D y l e w s k i ,  D . P . ,  &  K e e n a n ,  T . W .  
( 1 9 8 5 ) .  M i c r o l i p i d  d r o p l e t s  i n  m i l k  s e c r e t i n g  m a m m a r y  e p i t h e l i a l  c e l l s :  e v i d e n c e  t h a t  
t h e y  o r i g i n a t e  f r o m  e n d o p l a s m i c  r e t i c u l u m  a n d  a r e  p r e c u r s o r s  o f  m i l k  l i p i d  g l o b u l e s .  
European Journal of Cell Biology. 3 8 ,  1 6 - 2 6 .
9-238
. f . ' i i k ' - i  ( k  v\ i i i Mi n M i l ) i
D e  C r i s t o f a r o ,  R . ,  A k h a v a n ,  S . ,  A l t o m a r e ,  C . ,  C a r o t t i ,  A . ,  P e y v a n d i ,  F . ,  &  M a n n u c c i ,  
P . M .  ( 2 0 0 4 ) .  A  n a t u r a l  p r o t h r o m b i n  m u t a n t  r e v e a l s  a n  u n e x p e c t e d  i n f l u e n c e  o f  A -  
c h a i n  s t r u c t u r e  o n  t h e  a c t i v i t y  o f  h u m a n  a - t h r o m b i n .  The Journal of Biological Chemistry. 
2 7 9 , 1 3 0 3 5 - 1 3 0 4 3 .
D e l l a  C o r t e ,  E . ,  &  S t i r p e ,  E .  ( 1 9 6 8 ) .  R e g u l a t i o n  o f  x a n t h i n e  o x i d a s e  i n  r a t  l i v e r :  
m o d i f i c a t i o n s  o f  e n z y m e  a c t i v i t y  o f  r a t  l i v e r  s u p e r n a t a n t  o n  s t o r a g e  a t  2 0  d e g r e e s .  The 
Biochemical journal 1 0 8 ,  3 4 9 - 3 5 1 .
D e l l a  C o r t e ,  E . ,  &  S t i r p e ,  E .  ( 1 9 7 2 ) .  T h e  r e g u l a t i o n  o f  r a t  l i v e r  x a n t h i n e  o x i d a s e .  The 
Biochemical journal. 1 2 6 ,  7 3 9 - 7 4 5 .
D e M o s s ,  J . A . ,  &  H s u ,  P . Y .  ( 1 9 9 1 ) .  N a r K  e n h a n c e s  n i t r a t e  u p t a k e  a n d  n i t r i t e  e x c r e t i o n  
i n  Escherichia coli. Journal of Bacteriology. 1 7 3 ,  3 3 0 3 - 3 3 1 0 .
D i  C e r a ,  E .  ( 2 0 0 3 ) .  T h r o m b i n  i n t e r a c t i o n s .  CHEST. 1 2 4 , 1 1 S - 1 7 S .
D i c k i n s o n ,  D . A . ,  &  F o r m a n ,  H . J .  ( 2 0 0 2 ) .  C e l l u l a r  g l u t a t h i o n e  a n d  t h i o l s  m e t a b o l i s m .  
Biochemical Pharmacology. 6 4 ,  1 0 1 9 - 1 0 2 6 .
D i G r e g o r i o ,  K . A . ,  C i l e n t o ,  E . V . ,  &  L a n t z ,  R . C .  ( 1 9 8 7 ) .  M e a s u r e m e n t  o f  s u p e r o x i d e  
r e l e a s e  f r o m  s i n g l e  p u l m o n a r y  a l v e o l a r  m a c r o p h a g e s .  American Journal of Physiology. 252, 
C 6 7 7 - C 6 8 3 .
D i k o v ,  A . ,  A l e x a n d r o v ,  I . ,  R u s s i n o v a ,  A . ,  &  B o y a d j i e v a - M i c h a i l o v a ,  A .  ( 1 9 8 8 ) .  
U l t r a c y t o c h e m i c a l  d e m o n s t r a t i o n  o f  e n z y m e s  b y  r e d u c t i o n  o f  p o t a s s i u m  
h e x a c y a n o f e r r a t e  ( I I I ) .  A  m e t h o d  f o r  d e m o n s t r a t i o n  o f  x a n t h i n e  o x i d a s e .  Acta 
Histochemica. 8 3 , 1 0 7 - 1 1 5 .
D o e h n e r ,  W . ,  S c h o e n e ,  N . ,  R a u c h h a u s ,  M . ,  L e y v a - L e o n ,  F . ,  P a v i t t ,  D . V . ,  R e a v e l e y ,
D . A . ,  S c h u l e r ,  G . ,  C o a t s ,  A . J . S . ,  A n k e r ,  S . D . ,  &  H a m b r e c h t ,  R .  ( 2 0 0 2 ) .  E f f e c t s  o f  
x a n t h i n e  o x i d a s e  i n h i b i t i o n  w i t h  a l l o p u r i n o l  o n  e n d o t h e l i a l  f u n c t i o n  a n d  p e r i p h e r a l  
b l o o d  f l o w  i n  h y p e r u r i c e m i c  p a t i e n t s  w i t h  c h r o n i c  h e a r t  f a i l u r e .  Circulation. 1 0 5 ,  2 6 1 9 -  
2 6 2 4 ) .
D o e l ,  J . J . ,  G o d b e r ,  B . L . ,  E i s e n t h a l ,  R . ,  &  H a r r i s o n ,  R .  ( 2 0 0 1 )  R e d u c t i o n  o f  o r g a n i c  
n i t r a t e s  c a t a l y s e d  b y  x a n t h i n e  o x i d o r e d u c t a s e  u n d e r  a n a e r o b i c  c o n d i t i o n s .  Biochimica et 
Biophysica Acta. 1 5 2 7 ,  8 1 - 8 7 .
E d m o n d s o n ,  D . E . ,  &  N e w t o n - V i n s o n ,  P .  ( 2 0 0 1 ) .  T h e  c o v a l e n t  F A D  o f  m o n o a m i n e  
o x i d a s e :  s t r u c t u r a l  a n d  f u n c t i o n a l  r o l e  a n d  m e c h a n i s m  o f  t h e  f l a v i n y l a t i o n  r e a c t i o n .  
Antioxidants and Redox Signalling 3 ,  7 8 9 - 8 0 6 .
9-239
i a i i k ' s  1 U ' \ \  i n s o i i i ' l l  I )  T l i e s  i s
E h r h a r d t ,  C . ,  K n e u e r ,  C . ,  &  B a k o w s k y ,  U .  ( 2 0 0 4 ) .  S e l e c t i n s - a n  e m e r g i n g  t a r g e t  f o r  
d r u g  d e l i v e r y .  Advanced Drug Delivery Reviews. 5 6 ,  5 2 7 - 5 4 9 .
E m e i s ,  J . J . ,  v a n  d e n  E i j n d e n - S c h r a u w e n ,  Y ,  v a n  d e n  H o o g e n ,  C . M . ,  d e  P r i e s t e r ,  W . ,  
W e s t m u c k e t t ,  A . ,  &  L u p u ,  F .  ( 1 9 9 7 ) .  A n  e n d o t h e l i a l  s t o r a g e  g r a n u l e  f o r  t i s s u e - t y p e  
p l a s m i n o g e n  a c t i v a t o r .  The Journal of Cell Bio logy. 1 3 9 ,  2 4 5 - 2 5 6 .
E n r o t h ,  C . ,  E g e r ,  B . T . ,  O k a m o t o ,  K . ,  N i s h i n o ,  T . ,  N i s h i n o ,  T . ,  &  P a i ,  E . F .  ( 2 0 0 0 ) .  
C r y s t a l  s t r u c t u r e s  o f  b o v i n e  m i l k  x a n t h i n e  d e h y d r o g e n a s e  a n d  x a n t h i n e  o x i d a s e :  
s t r u c t u r e - b a s e d  m e c h a n i s m  o f  c o n v e r s i o n .  PN AS. 9 7 , 1 0 7 2 3 - 1 0 7 2 8 .
E s m o n ,  C . T . ,  &  O w e n ,  W . G .  ( 1 9 8 1 ) .  I d e n t i f i c a t i o n  o f  a n  e n d o t h e l i a l  c e l l  c o f a c t o r  f o r  
t h r o m b i n - c a t a l y z e d  a c t i v a t i o n  o f  p r o t e i n  C .  PN AS. 7 8 ,  2 2 4 9 - 2 2 5 2 .
E s m o n ,  C . T . ,  E s m o n ,  N . L . ,  &  H a r r i s ,  K . W .  ( 1 9 8 2 ) .  C o m p l e x  f o r m a t i o n  b e t w e e n  
t h r o m b i n  a n d  t h r o m b o m o d u l i n  i n h i b i t s  b o t h  t h r o m b i n - c a t a y l z e d  f i b r i n  f o r m a t i o n  
a n d  f a c t o r  V  a c t i v a t i o n .  The Journal of Biological Chemistry. 2 5 7 ,  7 9 4 4 - 7 9 4 7 .
E s m o n ,  N . L . ,  O w e n ,  W . G . ,  &  E s m o n ,  C . T .  ( 1 9 8 2 ) .  I s o l a t i o n  o f  a  m e m b r a n e - b o u n d  
c o f a c t o r  f o r  t h r o m b i n - c a t a l y z e d  a c t i v a t i o n  o f  p r o t e i n  C .  The Journal of Biological 
Chemistry. 2 5 7 ,  8 5 9 - 8 6 4 .
E s m o n ,  C . T .  ( 1 9 8 9 ) .  T h e  r o l e s  o f  p r o t e i n  C  a n d  t h r o m b o m o d u l i n  i n  t h e  r e g u l a t i o n  o f  
b l o o d  c o a g u l a t i o n .  The Journal of Biological Chemistry. 2 6 4 ,  4 7 4 3 - 4 7 4 6 .
E s m o n ,  C . T .  ( 2 0 0 0 ) .  R e g u l a t i o n  o f  b l o o d  c o a g u l a t i o n .  Biochimica et Biophysica Acta. 
1 4 7 7 ,  3 4 9 - 3 6 0 .
F a l c i a n i ,  F . ,  T e r a o ,  M . ,  G o l d w u r m ,  S . ,  R o n c h i ,  A . ,  G a t t i ,  A . ,  M i n o i a ,  C . ,  C a l z i ,  M . L . ,  
S a l m o n a ,  M . ,  C a z z a n i g a ,  G . ,  &  G a r a t t i n i ,  E .  ( 1 9 9 4 ) .  M o l y b d e n u m  ( V I )  s a l t s  c o n v e r t  
t h e  x a n t h i n e  o x i d o r e d u c t a s e  a p o p r o t e i n  i n t o  t h e  a c t i v e  e n z y m e  i n  m o u s e  L 9 2 9  
f i b r o b l a s t i c  c e l l s .  Biochemical Journal. 2 9 8 ,  6 9 - 7 7 .
F a r q u h a r s o n ,  C . A . J . ,  B u t l e r ,  R . ,  H i l l ,  A . ,  B e l c h ,  J . J . F . ,  &  S t r u t h e r s ,  A . D .  ( 2 0 0 2 ) .  
A l l o p u r i n o l  i m p r o v e s  e n d o t h e l i a l  d y s f u n c t i o n  i n  c h r o n i c  h e a r t  f a i l u r e .  Circulation. 1 0 6 ,  
2 2 1 - 2 2 6 .
F a u l k n e r ,  K . ,  &  F r i d o v i c h ,  I .  ( 1 9 9 3 ) .  L u m i n o l  a n d  l u c i g e n i n  a s  d e t e c t o r s  f o r  0 2 . - .  Tree 
Radical Biology and Medicine. 1 5 ,  4 4 7 - 4 5 1 .
F e i g e l s o n ,  P .  ( 1 9 5 2 ) .  T h e  i n h i b i t i o n  o f  x a n t h i n e  o x i d a s e  i n  v i t r o  b y  t r a c e  a m o u n t s  o f  / -  
a s c o r b i c  a c i d .  The Journal of Biological Chemistry. 1 9 7 ,  8 4 3 - 8 5 0 .
9-240
f l e u  i i i s n i i I ' i l l )  ’ i l iCMs
F l e m i n g ,  I .  ( 2 0 0 1 ) .  C y t o c h r o m e  P 4 5 0  e n z y m e s  i n  v a s c u l a r  h o m e o s t a s i s .  Circulation 
Research. 8 9 ,  7 5 3 - 7 6 2 .
F o l c h ,  E . ,  G e l p i ,  E . ,  R o s e l l o - C a t a f a u ,  J . ,  &  C l o s a ,  D .  ( 1 9 9 8 ) .  F r e e  r a d i c a l s  g e n e r a t e d  
b y  x a n t h i n e  o x i d a s e  m e d i a t e  p a n c r e a t i t i s - a s s o c i a t e d  o r g a n  f a i l u r e .  Digestive Diseases and 
Science. 4 3 ,  2 4 0 5 - 2 4 1 0 .
F o l c h ,  E . ,  S a l a s ,  A . ,  P a n e s ,  J . ,  G e l p i ,  E . ,  R o s e l l o - C a t a f a u ,  J . ,  A n d e r s o n ,  D . C . ,  N a v a r r o ,  
S . ,  P i q u e ,  J . M . ,  F e r n a n d e z - C r u z ,  L . ,  &  C l o s a ,  D .  ( 1 9 9 9 ) .  R o l e  o f  P - s e l e c t i n  a n d  I C A M -  
1  i n  p a n c r e a t i t i s - i n d u c e d  l u n g  i n f l a m m a t i o n  i n  r a t s :  s i g n i f i c a n c e  o f  o x i d a t i v e  s t r e s s .  
Annals of Surgery. 2 3 0 ,  7 9 2 - 7 9 8 .
F o l c h ,  E . ,  S a l a s ,  A . ,  P r a t s ,  N . ,  P a n e s ,  J . ,  P i q u e ,  J . M . ,  G e l p i ,  E ,  R o s e l l o - C a t a f a u ,  J . ,  &  
C l o s a ,  D .  ( 2 0 0 0 ) .  H 2O 2 a n d  P A R S  m e d i a t e  l u n g  P - s e l e c t i n  u p r e g u l a t i o n  i n  a c u t e  
p a n c r e a t i t i s .  Free Radical Biology and Medicine. 2 8 , 1 2 8 7 - 1 2 9 4 .
F o r m a n ,  H . J . ,  &  A z z i ,  A .  ( 1 9 9 7 ) .  O n  t h e  v i r t u a l  e x i s t e n c e  o f  s u p e r o x i d e  a n i o n s  i n  
m i t o c h o n d r i a :  t h o u g h t s  r e g a r d i n g  i t s  r o l e  i n  p h y s i o l o g y .  FASEB Journal. 1 1 ,  3 7 4 - 3 7 5 .
F u r c h g o t t ,  R . F . ,  &  Z a w a d z k i ,  J . V .  ( 1 9 8 0 ) .  T h e  o b l i g a t o r y  r o l e  o f  e n d o t h e l i a l  c e l l s  i n  
t h e  r e l a x a t i o n  o f  a r t e r i a l  s m o o t h  m u s c l e  b y  a c e t y l c h o l i n e .  Nature. 2 8 8 ,  3 7 3 - 3 7 6 .
F r a a i j e ,  M . W . ,  v a n  D e n  H e u v e l ,  R . H . ,  v a n  B e r k e l ,  W . J . ,  &  M a t t e v i  A .  ( 2 0 0 0 ) .  
S t r u c t u r a l  a n a l y s i s  o f  f l a v i n y l a t i o n  i n  v a n i l l y l - a l c o h o l  o x i d a s e .  Journal of Biological 
Chemistry. 2 7 5 ,  3 8 6 5 4 - 3 8 6 5 8 .
F r a n k e ,  W . W . ,  H e i d ,  H . W . ,  G r u n d ,  C . ,  W i n t e r ,  S . ,  F r e u d e n s t e i n ,  C . ,  S c h m i d ,  E . ,  
J a r a s c h ,  E - D . ,  &  K e e n a n ,  T . W .  ( 1 9 8 1 ) .  A n t i b o d i e s  t o  t h e  m a j o r  i n s o l u b l e  m i l k  f a t  
g l o b u l e  m e m b r a n e - a s s o c i a t e d  p r o t e i n :  s p e c i f i c  l o c a t i o n  i n  a p i c a l  r e g i o n s  o f  l a c t a t i n g  
e p i t h e l i a l  c e l l s .  The Journal of Cell Biology. 8 9 ,  4 8 5 - 4 9 4 .
F r a z z o n ,  J . ,  F i c k , J . R . ,  &  D e a n ,  D . R .  ( 2 0 0 2 ) .  B i o s y n t h e s i s  o f  i r o n - s u l p h u r  c l u s t e r s  i s  a  
c o m p l e x  a n d  h i g h l y  c o n s e r v e d  p r o c e s s .  Biochemical Society Transactions. 3 0 ,  6 8 0 - 6 8 5 .
F r e d e r i k s ,  W . M . ,  &  V r e e l i n g - S i n d e l a r o v a ,  H .  ( 2 0 0 2 ) .  U l t r a s t r u c t u r a l  l o c a l i s a t i o n  o f  
x a n t h i n e  o x i d o r e d u c t a s e  a c t i v i t y  i n  i s o l a t e d  r a t  l i v e r  c e l l s .  Acta Histochemica. 1 0 4 ,  2 9 - 3 7 .
F r e e d m a n ,  J . E . ,  L o s c a l z o ,  J . ,  B a r n a r d ,  M . R . ,  A l p e r t ,  C . ,  K e a n e y ,  J . F . ,  &  M i c h e l s o n ,
A . D .  ( 1 9 9 7 ) .  N i t r i c  o x i d e  i s  r e l e a s e  f r o m  a c t i v a t e d  p l a t e l e t s  i n h i b i t s  p l a t e l e t  
r e c r u i t m e n t .  Journal of Clinical Investigation. 1 0 0 ,  3 5 0 - 3 5 6 .
F r e n e t t e ,  P . S . ,  D e n i s ,  C . V . ,  W e i s s ,  L . ,  J u r k ,  K . ,  S u b b a r a o ,  S . ,  K e h r e l ,  B . ,  H a r t w i g ,  J . H . ,  
V e s t w e b e r ,  D . ,  &  W a g n e r ,  D . D .  ( 2 0 0 0 ) .  P - s e l e c t i n  g l y c o p r o t e i n  l i g a n d  1  ( P S G L - 1 )  i s
9-241
.Ki i ik' s 1 l ew  i n s u n P h i )  I ' i i eM^
e x p r e s s e d  o n  p l a t e l e t s  a n d  c a n  m e d i a t e  p l a t e l e t - e n d o t h e l i a l  i n t e r a c t i o n s  i n  v i v o .  The 
journal of'Experimental Medicine. 1 9 1 ,  1 4 1 3 - 1 4 2 2 .
F r i d o v i c h ,  I .  ( 1 9 7 8 ) .  T h e  b i o l o g y  o f  o x y g e n  r a d i c a l s .  Science. 2 0 1 ,  8 7 5 - 8 8 0 .
F r i d o v i c h ,  I .  ( 1 9 9 7 ) .  S u p e r o x i d e  a n i o n  r a d i c a l ,  s u p e r o x i d e  d i m u t a s e s ,  a n d  r e l a t e d  
m a t t e r s .  The Journal of Biological Chemistry. 2 7 2 , 1 8 5 1 5 - 1 8 5 1 7 .
F r i e d l ,  H . P . ,  T i l l ,  G . O . ,  R y a n ,  U . S . ,  &  W a r d ,  P . A .  ( 1 9 8 9 ) .  M e d i a t o r - i n d u c e d  a c t i v a t i o n  
o f  x a n t h i n e  o x i d a s e  i n  e n d o t h e l i a l  c e l l s .  FASEB Journal. 3 ,  2 5 1 2 - 2 5 1 8 .
F r i e d l ,  H . P . ,  T i l l ,  G . O . ,  T r e n t z ,  O . ,  &  W a r d ,  P . A .  ( 1 9 8 9 ) .  R o l e s  o f  h i s t a m i n e ,  
c o m p l e m e n t  a n d  x a n t h i n e  o x i d a s e  i n  t h e r m a l  i n j u r y  o f  s k i n .  American Journal of 
Pathology. 1 3 5 ,  2 0 3 - 2 1 7
F u r i e ,  B . ,  &  F u r i e ,  B . C .  ( 1 9 9 2 ) .  M o l e c u l a r  a n d  c e l l u l a r  b i o l o g y  o f  b l o o d  c o a g u l a t i o n .  
The New England Journal of Medicine. 3 2 6 ,  8 0 0 - 8 0 6 .
G a b o u r y ,  J . ,  W o o d m a n ,  R . C . ,  G r a n g e r ,  D . N . ,  R e i n h a r d t ,  P . ,  &  K u b e s ,  P .  ( 1 9 9 3 ) .  
N i t r i c  o x i d e  p r e v e n t s  l e u k o c y t e  a d h e r e n c e :  r o l e  o f  s u p e r o x i d e .  American Journal of 
Physiology. 2 6 5 ,  H 8 6 2 - 8 6 7 .
G a b o u r y ,  J . P . ,  A n d e r s o n ,  D . C . ,  K u b e s ,  P .  ( 1 9 9 4 ) .  M o l e c u l a r  m e c h a n i s m s  i n v o l v e d  i n  
s u p e r o x i d e - i n d u c e d  l e u k o c y t e - e n d o t h e l i a l  c e l l  i n t e r a c t i o n s  i n  v i v o .  American Journal of 
Physiology. Heart and Circulatory Physiology. 2 6 6 ,  F I 6 3 7 - H 6 4 2 .
G a r a t t i n i ,  E . ,  M e n d e l ,  R . ,  R o m a o ,  M . J . ,  W r i g h t ,  R . ,  &  T e r a o ,  M .  ( 2 0 0 3 ) .  M a m m a l i a n  
m o l b d o - f l a v o e n z y m e s ,  a n  e x p a n d i n g  f a m i l y  o f  p r o t e i n s :  s t r u c t u r e ,  g e n e t i c s ,  
r e g u l a t i o n ,  f u n c t i o n  a n d  p a t h o p h y s i o l o g y .  Biochemical Journal. 3 7 2 , 1 5 - 3 2 .
G e n g ,  J . G . ,  B e v i l a c q u a ,  M . P . ,  M o o r e ,  K . L . ,  M c I n t y r e ,  T . M . ,  P r e s c o t t ,  S . M . ,  K i m ,  J . M . ,  
B l i s s ,  G . A . ,  Z i m m e r m a n ,  G . A . ,  &  M c E v e r ,  R . P .  ( 1 9 9 0 ) .  R a p i d  n e u t r o p h i l  a d h e s i o n  t o  
a c t i v a t e d  e n d o t h e l i u m  m e d i a t e d  b y  G M P - 1 4 0 .  Nature. 3 4 3 ,  7 5 7 - 5 6 0 .
G h i o ,  A . J . ,  K e n n e d y ,  T . P . ,  S t o n e h u e r n e r ,  J . ,  C a r t e r ,  J . D . ,  S k i n n e r ,  K . A . ,  P a r k s ,  D . A . ,  
&  H o i d a l ,  J . R .  ( 2 0 0 2 ) .  I r o n  r e g u l a t e s  x a n t h i n e  o x i d a s e  a c t i v i t y  i n  t h e  l u n g .  American 
Journal of Physiology. Lung Cellular and Molecular Physiology. 2 8 3 ,  L 5 6 3 - L 5 7 2 .
G o d b e r ,  B . ,  S a n d e r s ,  S . ,  H a r r i s o n ,  R . ,  E i s e n t h a l ,  R . ,  a n d  B r a y ,  R . C .  ( 1 9 9 7 ) .  >  o r  =  
9 5 %  o f  x a n t h i n e  o x i d a s e  i n  h u m a n  m i l k  i s  p r e s e n t  a s  t h e  d e m o l y b d o  f o r m ,  l a c k i n g  
m o l y b d o p t e r i n .  Biochemical Society Transactions. 2 5 ,  5 1 9 S .
G o d b e r  B L ,  D o e l  J J ,  D u r g a n  J ,  E i s e n t h a l  R ,  H a r r i s o n  R  ( 2 0 0 0 ) .  A  n e w  r o u t e  t o  
p e r o x y n i t r i t e :  a  r o l e  f o r  x a n t h i n e  o x i d o r e d u c t a s e .  FEBS Letters. 4 7 5 ,  9 3 - 9 6 .
9-242
. l i m i t 1 ' - I l e w  i i i  m  m i I ' l i D ' l i i e s i .
G o d b e r ,  B . L . J . ,  D o e l ,  J . J . ,  G o u l t ,  T . A . ,  E i s e n t h a l ,  R . ,  &  H a r r i s o n ,  R .  ( 2 0 0 1 ) .  S u i c i d e  
i n a c t i v a t i o n  o f  x a n t h i n e  o x i d o r e d u c t a s e  d u r i n g  r e d u c t i o n  o f  i n o r g a n i c  n i t r i t e  t o  n i t r i c  
o x i d e .  The Biochemical Journal. 3 5 8 ,  3 2 5 - 3 3 3 .
G o r l a c h ,  A . ,  B r a n d e s ,  R . P . ,  N g u y e n ,  K . ,  A m i d i ,  M . ,  D e h g h a n i ,  F . ,  &  B u s s e ,  R .  ( 2 0 0 0 ) .  
A  g p 9 1 p h o x  c o n t a i n i n g  N A D P H  o x i d a s e  s e l e c t i v e l y  e x p r e s s e d  i n  e n d o t h e l i a l  c e l l s  i s  a  
m a j o r  s o u r c e  o f  o x y g e n  r a d i c a l  g e n e r a t i o n  i n  t h e  a r t e r i a l  w a l l .  Circulation Research. 8 7 ,  
2 6 - 3 2 .
G r a b o v s k y ,  V . ,  F e i g e l s o n ,  S . ,  C h e n ,  C . ,  B l e i j s ,  D . A . ,  P e l e d ,  A . ,  C i n a m o n ,  G . ,  B a l e u x ,  
F . ,  A r e n z a n a - S e i s d e d o s ,  F . ,  L a p i d o t ,  T . ,  v a n  K o o y k ,  Y . ,  L o b b ,  R . R . ,  &  A l o n ,  R .  
S u b s e c o n d  i n d u c t i o n  o f  a 4  i n t e g r i n  c l u s t e r i n g  b y  i m m o b i l i z e d  c h e m o k i n e s  s t i m u l a t e s  
l e u k o c y t e  t e t h e r i n g  a n d  r o l l i n g  o n  e n d o t h e l i a l  v a s c u l a r  c e l l  a d h e s i o n  m o l e c u l e  1  u n d e r  
f l o w  c o n d i t i o n s .  The Journal of Experimental Medicine. 1 9 2 ,  4 9 5 - 5 0 5 .
G r a f ,  L . ,  B a r a t ,  E . ,  B o r v e n b e g ,  J . ,  H e r m a n n ,  I . ,  &  P a t t h y ,  A .  ( 1 9 7 6 ) .  A c t i o n  o f  
t h r o m b i n  o n  o v i n e ,  b o v i n e  a n d  h u m a n  p i t u i t a r y  g r o w t h  h o r m o n e s .  European Journal of 
Biochemistry. 6 4 ,  3 3 3 - 3 4 0 .
G r a n e l l ,  S . ,  S e r r a n o - M o l l a r ,  A . ,  F o l c h - P u y ,  E . ,  N a v a j a s ,  D . ,  F a r r e ,  R . ,  B u l b e n a ,  O . ,  &  
C l o s a ,  D .  ( 2 0 0 4 ) .  O x y g e n  i n  t h e  a l v e o l a r  s p a c e  m e d i a t e s  l u n g  i n f l a m m a t i o n  i n  a c u t e  
p a n c r e a t i t i s .  Free Radical Biology &  Medicine. 3 7 ,  1 6 4 0 - 1 6 4 7 .
G r a v e n ,  K . K . ,  T r o x l e r ,  R . F . ,  K o r n f e l d ,  H . ,  P a n c h e n k o ,  M . V . ,  &  F a r b e r ,  H . W .  ( 1 9 9 4 ) .  
R e g u l a t i o n  o f  e n d o t h e l i a l  c e l l  g l y e r a l d e h y d e - 3 - p h o s p h a t e  d e h y d r o g e n a s e  e x p r e s s i o n  
b y  h y p o x i a .  The Journal of Biological Chemistry. 2 6 9 ,  2 4 4 4 6 - 2 4 4 5 3 .
G r e e n ,  D . E . ,  &  P a u l i ,  R .  ( 1 9 4 3 ) .  T h e  a n t i b a c t e r i a l  a c t i o n  o f  t h e  x a n t h i n e  o x i d a s e  
s y s t e m .  Proceedings of the Society for Experimental Biology and Medicine. 5 4 ,  1 4 8 - 1 5 0 .
G r i f f i n ,  J . H .  ( 1 9 9 5 ) .  T h e  t h r o m b i n  p a r a d o x .  Nature. 3 7 8 ,  3 3 7 - 3 3 8 .
G r u e n h a g e n ,  J . A . ,  &  Y e u n g ,  E . S .  ( 2 0 0 4 ) .  I n v e s t i g a t i o n  o f  G  p r o t e i n - i n i t i a t e d ,  C a 2 + -  
d e p e d e n t  r e l e a s e  o f  A T P  f r o m  e n d o t h e l i a l  c e l l s .  Biochimica et Biophysica Acta. 1 6 9 3 ,  1 3 5 -  
1 4 6 .
G r y g l e w s k i ,  R . J . ,  P a l m e r ,  R . M . J . ,  &  M o n c a d a ,  S .  ( 1 9 8 6 ) .  S u p e r o x i d e  a n i o n  i s  i n v o l v e d  
i n  t h e  b r e a k d o w n  o f  e n d o t h e l i u m - d e r i v e d  v a s c u l a r  r e l a x a t i o n  f a c t o r .  Nature. 3 2 0 ,  4 5 4 -  
4 5 6 .
G u i c e ,  K . S . ,  O l d h a m ,  K . T . ,  C a t y ,  M . G . ,  J o h n s o n ,  K . J . ,  &  W a r d ,  P . A .  ( 1 9 8 9 ) .  
N e u t r o p h i l - d e p e n d e n t ,  o x y g e n - r a d i c a l  m e d i a t e d  l u n g  i n j u r y  a s s o c i a t e d  w i t h  a c u t e  
p a n c r e a t i t i s .  Annals of Surgery. 2 1 0 ,  7 4 0 - 7 4 7 .
9-243
.h i incs  I k - \ \  h i m m P i l l ) T h e s i s
G u t h i k o n d a ,  S . ,  S i n k e y ,  C . ,  B a r e n z ,  T . ,  &  H a y n e s ,  W . G .  ( 2 0 0 3 ) .  X a n t h i n e  o x i d a s e  
i n h i b i t i o n  r e v e r s e s  e n d o t h e l i a l  d y s f u n c t i o n  i n  h e a v y  s m o k e r s .  Circulation. 1 0 7 ,  4 1 6 - 4 2 1 .
G y l l e n h a m m e r ,  H .  ( 1 9 8 7 ) .  L u c i g e n i n  c h e m i l u m i n e s c e n c e  i n  t h e  a s s e s s m e n t  o f  
n e u t r o p h i l  s u p e r o x i d e  p r o d u c t i o n ,  journal of Immunological Methods. 9 7 ,  2 0 9 - 2 1 3 .
H a i n i n g ,  J . L . ,  &  L e g a n ,  J . S .  ( 1 9 6 7 ) .  F l u o r o m e t r i c  a s s a y  f o r  x a n t h i n e  o x i d a s e .  Analytical 
biochemistry. 2 1 ,  3 3 7 - 3 4 3 .
H a n c o c k ,  J . T .  ( 1 9 9 9 ) .  N i t r i c  o x i d e ,  h y d r o g e n  p e r o x i d e ,  a n d  c a r b o n  m o n o x i d e .  I n  Cell 
Signalling, p p  1 6 7 - 1 8 4 .  A d d i s o n  W e s l e y  L o n g m a n  L i m i t e d ,  E n g l a n d ,  U K .
H a n c o c k ,  J . T . ,  S a l i s b u r y ,  V . ,  O v e j e r o - B o g l i o n e ,  M . C . ,  C h e r r y ,  R . ,  H o a r e ,  C . ,  
E i s t e n t h a l ,  R . ,  &  H a r r i s o n ,  R .  ( 2 0 0 2 ) .  A n t i m i c r o b i a l  p r o p e r t i e s  o f  m i l k :  d e p e n d e n c e  
o n  p r e s e n c e  o f  x a n t h i n e  o x i d a s e  a n d  n i t r i t e .  Antimicrobial Agents and Chemotherapy. 4 6 ,  
3 3 0 8 - 3 3 1 0 .
H a r r i s ,  C . M . ,  &  M a s s e y ,  V .  ( 1 9 9 7 ) .  T h e  r e a c t i o n  o f  r e d u c e d  x a n t h i n e  d e h y d r o g e n a s e  
w i t h  m o l e c u l a r  o x y g e n .  The Journal of biological Chemistry. 2 7 2 ,  8 3 7 0 - 8 3 7 9 .
H a r r i s o n ,  R .  ( 2 0 0 2 ) .  S t r u c t u r e  a n d  f u n c t i o n  o f  x a n t h i n e  o x i d o r e d u c t a s e :  w h e r e  a r e  w e  
n o w ?  Tree Radical Bio log)) and Medicine. 3 3 ,  7 7 4 - 7 9 7 .
H a t t o r i ,  R . ,  H a m i l t o n ,  K . K . ,  F u g a t e ,  R . D . ,  M c E v e r ,  R . P . ,  &  S i m s ,  P . J .  ( 1 9 8 8 ) .  
S t i m u l a t e d  s e c r e t i o n  o f  e n d o t h e l i a l  v o n  W i l l e b r a n d  F a c t o r  i s  a c c o m p a n i e d  b y  r a p i d  
r e d i s t r i b u t i o n  t o  t h e  c e l l  s u r f a c e  o f  t h e  i n t r a c e l l u l a r  g r a n u l e  m e m b r a n e  p r o t e i n  G M P -  
1 4 0 .  The Journal of Biological Chemistry. 2 6 4 ,  7 7 6 8 - 7 7 7 1 .
H a u g l a n d  2 0 0 2 a .  A c c e s s o r i e s  a n d  r e s o u r c e s .  I n  Handbook of Fluorescent Probes and 
Research Products. ( E d s .  G r e g o r y ,  J . ,  a n d  S p e n c e ,  M . T . Z . ) .  p p  8 7 7 - 9 0 8 .  M o l e c u l a r  
P r o b e s .  U S A .
H a y a s h i ,  Y . ,  S a w a ,  Y . ,  N i s h i m u r a ,  M . ,  F u k u y a m a ,  N . ,  I c h i k a w a ,  H . ,  O h t a k e ,  S . ,  
N a k a z a w a ,  H . ,  &  M a t s u d a ,  H .  ( 2 0 0 4 ) .  P e r o x y n i t r i t e ,  a  p r o d u c t  b e t w e e n  n i t r i c  o x i d e  
a n d  s u p e r o x i d e  a n i o n ,  p l a y s  a  c y t o t o x i c  r o l e  i n  t h e  d e v e l o p m e n t  o f  p o s t - b y p a s s  
s y s t e m i c  i n f l a m m a t o r y  r e s p o n s e .  European Journal of Cardio-thoracic Surgery. 2 6 ,  2 7 6 - 2 8 0 .
H e i d ,  H . W . ,  S c h n o l z e r ,  M . ,  &  K e e n a n ,  T . W  ( 1 9 9 6 ) .  A d i p o c y t e  d i f f e r e n t i a t i o n - r e l a t e d  
p r o t e i n  i s  s e c r e t e d  a s  a  c o n s t i t u e n t  o f  m i l k  l i p i d  g l o b u l e  m e m b r a n e .  Biochemical Journal. 
3 2 0 , 1 0 2 5 - 1 0 3 0 .
H i r a n o ,  K ,  &  K a n a i d e ,  H .  ( 2 0 0 3 ) .  R o l e  o f  p r o t e a s e - a c t i v a t e d  r e c e p t o r s  i n  t h e  v a s c u l a r  
s y s t e m .  Journal of Atherosclerosis and Thrombosis. 1 0 ,  2 1 1 - 2 2 5 .
9-244
i l e u  i n s u n I ‘ I I I )  T l ie s U
H o m e r ,  K . A . ,  a n d  B e i g h t o n ,  D .  ( 1 9 9 0 ) .  F l u o r m o t e r i c  d e t e r m i n a t i o n  o f  b a c t e r i a l  
p r o t e a s e  a c t i v i t y  u s i n g  f l u o r e s c e i n  i s o t h i o c y a n a t e  l a b e l e d  p r o t e i n s  a s  s u b s t r a t e s .  
Analytical Biochemistry. 1 9 1 ,  1 3 3 - 1 3 7 .
H o r n i g ,  B . ,  A r a k a w a ,  N . ,  K o h l e r ,  C . ,  &  D r e x l e r ,  H .  ( 1 9 9 8 ) .  V i t a m i n  C  i m p r o v e s  
e n d o t h e l i a l  f u n c t i o n  o f  c o n d u i t  a r t e r i e s  i n  p a t i e n t s  w i t h  c h r o n i c  h e a r t  f a i l u r e .  
Circulation. 9 7 ,  3 6 3 - 3 6 8 .
H o u g h ,  L . B .  ( 2 0 0 1 ) .  G e n o m i c s  m e e t s  h i s t a m i n e  r e c e p t o r s :  n e w  s u b t y p e s ,  n e w  
r e c e p t o r s .  Molecular Pharmacology. 5 9 ,  4 1 5 - 4 1 9 .
H o u s t o n ,  M . ,  E s t e v e z ,  A . ,  C h u m l e y ,  P . ,  A s l a n ,  M . ,  M a r k l u n d ,  S . ,  P a r k s ,  D . A . ,  &  
F r e e m a n ,  B . A .  ( 1 9 9 9 ) .  B i n d i n g  o f  x a n t h i n e  o x i d a s e  t o  t h e  v a s c u l a r  e n d o t h e l i u m .  The 
Journal of Biological Chemistry. 2 7 4 ,  4 9 8 5 - 4 9 9 4 .
H o y e r ,  L . W . ,  d e  l o s  S a n t o s ,  R . P . ,  &  H o y e r ,  J . R .  ( 1 9 7 3 ) .  L o c a l i z a t i o n  i n  e n d o t h e l i a l  
c e l l s  b y  i m m u n o f l u o r e s c e n t  m i c r o s c o p y .  The Journal of Clinical Investigation. 5 2 ,  2 7 3 7 -  
2 7 4 4 .
H s u - L i n ,  S - C . ,  B e r m a n ,  C . L . ,  F u r i e ,  B . C . ,  A u g u s t ,  D . ,  &  F u r i e ,  B .  ( 1 9 8 4 ) .  A  p l a t e l e t  
m e m b r a n e  p r o t e i n  e x p r e s s e d  d u r i n g  p l a t e l e t  a c t i v a t i o n  a n d  s e c r e t i o n  s t u d i e s  u s i n g  a  
m o n o c l o n a l  a n t i b o d y  s p e c i f i c  f o r  t h r o m b i n - a c t i v a t e d  p l a t e l e t s .  The Journal of Biological 
Chemistry. 2 5 9 ,  9 1 2 1 - 9 1 2 6 .
H u a n g ,  Y - C ,  T . ,  G h i o ,  A . J . ,  N o z i k - G r a y c k ,  E . ,  &  P i a n t a d o s i ,  C . A .  ( 2 0 0 1 ) .  V a s c u l a r  
r e l e a s e  o f  n o n h e m e  i r o n  i n  p e r f u s e d  r a b b i t  l u n g s .  American Journal of Physiology. Lung 
Cellular and Molecular Plysiology 2 8 0 ,  L 4 7 4 - L 4 8 1 .
H u a n g ,  H . Y . ,  A p p e l ,  L . J . ,  C h o i ,  M . J . ,  G e l b e r ,  A . C . ,  C h a r l e s t o n ,  J . ,  N o r k u s ,  E . P . ,  &  
M i l l e r ,  E . R .  ( 2 0 0 5 ) .  T h e  e f f e c t s  o f  v i t a m i n  C  s u p p l e m e n t a t i o n  o n  s e r u m  
c o n c e n t r a t i o n s  o f  u r i c  a c i d :  r e s u l t s  f r o m  a  r a n d o m i s e d  c o n t r o l l e d  t r i a l .  Arthritis and 
Rheumatism. 5 2 , 1 8 4 3 - 1 8 4 7 .
H u i e ,  R . E . ,  &  P a d m a j a ,  S .  ( 1 9 9 3 ) .  T h e  r e a c t i o n  o f  N O  w i t h  s u p e r o x i d e .  Free Radical 
Research Communications. 1 8 ,  1 9 5 - 1 9 9 .
H u n t ,  J . ,  &  M a s s e y ,  V .  ( 1 9 9 4 ) .  S t u d i e s  o f  t h e  r e d u c t i v e  h a l f - r e a c t i o n  o f  m i l k  x a n t h i n e  
d e h y d r o g e n a s e .  The Journal of Biological Chemistry. 2 6 9 , 1 8 9 0 4 - 1 8 9 1 4 .
H u o ,  Y . ,  &  L e y ,  K .  ( 2 0 0 1 ) .  A d h e s i o n  m o l e c u l e s  a n d  a t h e r o g e n e s i s .  Acta Physiologica 
Scandinavica. 1 7 3 ,  3 5 - 4 3 .
9-245
J i 1111l ' ■' I low  inson l ’ h l ) T i i - j ‘<i'
H y n e s ,  R . O .  ( 1 9 9 2 ) .  I n t e g r i n s ;  v e r s a t i l i t y ,  m o d u l a t i o n ,  a n d  s i g a n l i n g  i n  c e l l  a d h e s i o n .  
Cell. 6 9 , 1 1 - 2 5 .
I c h i d a ,  K . ,  A m a y a ,  Y . ,  N o d a ,  K . ,  M i n o s h i m a ,  S . ,  H o s o y a ,  T . ,  S a k a i ,  O . ,  S h i m ,  N . ,  &  
N i s h i n o ,  T .  ( 1 9 9 3 ) .  C l o n i n g  o f  t h e  c D N A  e n c o d i n g  h u m a n  x a n t h i n e  d e h y d r o g e n a s e  
( o x i d a s e ) :  s t r u c t u r a l  a n a l y s i s  o f  t h e  p r o t e i n  a n d  c h r o m o s o m a l  l o c a t i o n  o f  t h e  g e n e .  
Gene. 1 3 3 ,  2 7 9 - 2 8 4 .
I c h i d a ,  K . ,  A m a y a ,  Y . ,  K a m a y a n i ,  N . ,  N i s h i n o ,  T . ,  H o s o y a ,  T . ,  &  S a k a i ,  O .  ( 1 9 9 7 ) .  
I n d e n t i f i c a t i o n  o f  t w o  m u t a t i o n s  i n  h u m a n  x a n t h i n e  d e h y d r o g e n a s e  g e n e  r e s p o n s i b l e  
f o r  c l a s s i c a l  t y p e  I  x a n t h i n u r i a .  The journal of Clinical Investigation. 9 9 ,  2 3 9 1 - 2 3 9 7 .
I c h i d a ,  K . ,  M a t s u m u r a ,  T . ,  S a k u m a ,  R . ,  H o s o y a ,  T . ,  &  N i s h i n o ,  T .  ( 2 0 0 1 ) .  M u t a t i o n  o f  
h u m a n  m o l y b d e n u m  c o f a c t o r  s u l f u r a s e  g e n e  i s  r e s p o n s i b l e  f o r  c l a s s i c a l  x a n t h i n u r i a  
t y p e  I I .  Biochemical and Biophysical Research Communications. 2 8 2 ,  1 1 9 4 - 1 2 0 0 .
I c h i k a w a ,  M . ,  N i s h i n o ,  T . ,  N i s h i n o ,  T . ,  &  I c h i k a w a ,  A .  ( 1 9 9 2 ) .  S u b c e l l u l a r  l o c a l i s a t i o n  
o f  x a n t h i n e  o x i d a s e  i n  r a t  h e p a t o c y t e s :  h i g h - r e s o l u t i o n  i m m u n o e l e c t r o n  m i c r o s c o p i c  
s t u d y  c o m b i n e d  w i t h  b i o c h e m i c a l  a n a l y s i s .  The journal of Histochemistry and Cytochemistry. 
4 0 ,  1 0 9 7 - 1 1 0 3 .
I c h i k a w a ,  H . ,  W o l f ,  R . E . ,  A w ,  T . Y . ,  O h n o ,  N . ,  C o e ,  L . ,  G r a n g e r ,  D . N . ,  Y o s h i k a w a ,  
T . ,  &  A l e x a n d e r ,  J . S .  ( 1 9 9 7 ) .  E x o g e n o u s  x a n t h i n e  p r o m o t e s  n e u t r o p h i l  a d h e r e n c e  t o  
c u l t u r e d  e n d o t h e l i a l  c e l l s .  American journal ofPhysio log)/. 2 7 3 ,  G 3 4 2 - G 3 4 7 .
I g n a r r o ,  L . J . ,  &  K a d o w i t z ,  P . J .  ( 1 9 8 5 ) .  T h e  p h a r m a c o l o g i c a l  a n d  p h y s i o l o g i c a l  r o l e  o f  
c y c l i c  G M P  i n  v a s c u l a r  s m o o t h  m u s c l e  r e l a x a t i o n .  Annual Reviews: Pharmacology and 
Toxicology. 2 5 , 1 7 1 - 1 9 1 .
I g n a r r o ,  L . J . ,  B u g a ,  G . M . ,  W o o d ,  K . S . ,  B y r n s ,  R . E . ,  &  C h a u d h u r i ,  G .  ( 1 9 8 7 ) .  
E n d o t h e l i u m - d e r i v e d  r e l a x i n g  f a c t o r  p r o d u c e d  a n d  r e l e a s e d  f r o m  a r t e r y  a n d  v e i n  i s  
n i t r i c  o x i d e .  PNAS. 8 4 ,  9 2 6 5 - 6 2 6 9 .
I n g e n i t o ,  E . F . ,  C r a i g ,  J . M . ,  L a b e s s e ,  J . ,  G a u t i e r ,  M . ,  &  R u t s t e i n ,  D . D .  ( 1 9 5 8 ) .  C e l l s  o f  
h u m a n  h e a r t  a n d  a o r t a  g r o w n  i n  t i s s u e  c u l t u r e .  A .M .A . Archives of Pathology. 6 5 ,  3 5 5 -  
3 5 9 .
I n o u e ,  S . ,  N a k a o ,  A . ,  K i s h i m o t o ,  W . ,  M u r a k a m i ,  H . ,  I t o h ,  K . ,  I t o h ,  T . ,  H a r a d a ,  A . ,  
N o n a m i ,  T . ,  &  T a k a g i ,  H .  ( 1 9 9 5 ) .  A n t i - n e u t r o p h i l  a n t i b o d y  a t t e n u a t e s  t h e  s e v e r i t y  o f  
a c u t e  l u n g  i n j u r y  i n  r a t s  w i t h  e x p e r i m e n t a l  a c u t e  p a n c r e a t i t i s .  Archives of Surgery. 1 3 0 ,  
9 3 - 9 8 .
I s h h i ,  T . ,  A o k i ,  N . ,  N o d a ,  A . ,  A d a c h i ,  T . ,  N a k a m u r a ,  R . ,  &  M a t s u d a ,  T .  ( 1 9 9 5 ) .  
C a r b o x y - t e r m i n a l  c y t o p l a s m i c  d o m a i n  o f  m o u s e  b u t y r o p h i l i n  s p e c i f i c a l l y  a s s o c i a t e s
9-246
J l ine -  I L 'V \  n i v . i n
w i t h  a  1 5 0 - k D a  p r o t e i n  o f  m a m m a r y  e p i t h e l i a l  c e l l s  a n d  m i l k  f a t  g l o b u l e  m e m b r a n e .  
biochimica et Biophysica Acta. 1 2 4 5 ,  2 8 5 - 2 9 2 .
J a c k ,  L . J . W . ,  &  M a t h e r ,  I . H .  ( 1 9 9 0 ) .  C l o n i n g  a n d  a n a l y s i s  o f  c D N A  e n c o d i n g  b o v i n e  
b u t y r o p h i l i n ,  a n  a p i c a l  g l y c o p r o t e i n  e x p r e s s e d  i n  m a m m a r y  t i s s u e  a n d  s e c r e t e d  i n  
a s s o c i a t i o n  w i t h  t h e  m i l k - f a t  g l o b u l e  m e m b r a n e  d u r i n g  l a c t a t i o n .  The Journal of 
biological Chemistry. 2 6 5 ,  1 4 4 8 1 - 1 4 4 8 6 .
J a f f e ,  E . A . ,  N a c h m a n ,  R . L . ,  B e c k e r ,  C . G . ,  &  M i n i c k ,  C . R .  ( 1 9 7 3 ) .  C u l t u r e  o f  h u m a n  
e n d o t h e l i a l  c e l l s  d e r i v e d  f r o m  u m b i l i c a l  v e i n s .  The Journal of Clinical Investigation. 5 2 ,  
2 7 4 5 - 2 7 5 6 .
J a f f e ,  E . A . ,  H o y e r ,  L . W . ,  &  N a c h m a n ,  R . L .  ( 1 9 7 3 a ) .  S y n t h e s i s  o f  a n t i h e m o p h i l i c  
f a c t o r  a n t i g e n  b y  c u l t u r e d  h u m a n  e n d o t h e l i a l  c e l l s .  The Journal of Clinical Investigation. 
5 2 ,  2 7 5 7 - 2 6 7 4 .
J a h n ,  B . ,  &  H a n s c h ,  G . M .  ( 1 9 9 0 ) .  O x y g e n  r a d i c a l  g e n e r a t i o n  i n  h u m a n  p l a t e l e t s :  
d e p e n d e n c e  o n  1 2 - l i p o x y g e n a s e  a c t i v i t y  a n d  o n  g l u t a t h i o n e  c y c l e .  International Archives 
of Allergy and Applied Immunology. 9 3 ,  7 3 - 7 9 .
J a r a s c h ,  E - D . ,  G r u n d ,  C . ,  B r u d e r ,  G . ,  H e i d ,  H . W . ,  K e e n a n ,  T . W . ,  &  F r a n k e ,  W . W .  
( 1 9 8 1 ) .  L o c a l i s a t i o n  o f  x a n t h i n e  o x i d a s e  i n  m a m m a r y - g l a n d  e p i t h e l i u m  a n d  c a p i l l a r y  
e n d o t h e l i u m .  Cell. 2 5 ,  6 7 - 8 2 .
J a r a s c h ,  E - D . ,  B r u d e r ,  G . ,  &  H e i d ,  H . W .  ( 1 9 8 6 ) .  S i g n i f i c a n c e  o f  x a n t h i n e  o x i d a s e  i n  
c a p i l l a r y  e n d o t h e l i a l  c e l l s .  Acta Physiologica Scandinavica: Supplementum. 5 4 8 ,  3 9 - 4 6 .
J o h n s o n ,  K . J . ,  F a n t o n e ,  J . C . ,  K a p l a n ,  J . ,  &  W a r d ,  P . A .  ( 1 9 8 1 ) .  I n  v i v o  d a m a g e  o f  r a t  
l u n g s  b y  o x y g e n  m e t a b o l i t e s .  The Journal of Clinical Investigation. 6 7 ,  9 8 3 - 9 9 3 .
J o n e s ,  D . A . ,  A b b a s i ,  O . ,  M c l n t i r e ,  L . V . ,  M c E v e r ,  R . P . ,  &  S m i t h ,  C . W .  ( 1 9 9 3 ) .  P -  
s e l e c t i n  m e d i a t e s  n e u t r o p h i l  r o l l i n g  o n  h i s t a m i n e  s t i m u l a t e d  e n d o t h e l i a l  c e l l s .  
biophysical Journal. 6 5 ,  1 5 6 0 - 1 5 6 9 .
J o n e s o n ,  T . ,  &  B a r - S a g i ,  D .  A  r a c l  e f f e c t o r  s i t e  c o n t r o l l i n g  m i t o g e n s i s  t h r o u g h  
s u p e r o x i d e  p r o d u c t i o n .  The Journal of biological Chemistry. 2 7 3 , 1 7 9 9 1 - 1 7 9 9 4 .
K a g a w a ,  H . ,  &  F u j i m o t ,  S .  ( 1 9 8 7 ) .  E l e c t r o n - m i c r o s c o p i c  a n d  i m m u n o h i s t o c h e m i c a l  
a n a l y s e s  o f  W e i b e l - P a l a d e  b o d i e s  i n  t h e  h u m a n  u m b i l i c a l  v e i n  d u r i n g  p r e g n a n c y .  Cell 
and Tissue Research. 2 4 9 ,  5 5 7 . 5 6 3 .
K a h n ,  M . L . ,  N a k a n i s h i - M a t s u i ,  M . ,  S h a p i r o ,  M . J . ,  I s h i h a r a ,  H . ,  &  C o u g h l i n ,  S . R .
( 1 9 9 9 ) .  P r w o t e a s e - a c t i v a t e d  r e c e p t o r s  1 a n d  4  m e d i a t e  a c t i v a t i o n  o f  h u m a n  p l a t e l e t s  
b y  t h r o m b i n .  The Journal of Clinical Investigation. 1 0 3 ,  8 7 9 - 8 8 7 .
9-247
J : i I I ' I L ' S  I L ’ W  i l l M H 1
K e i t h ,  T . P . ,  R i l e y ,  M . A . ,  K r e i t m a n ,  M . ,  L e w o n t i n ,  R . C . ,  C u r t i s ,  D . ,  &  C h a m b e r s ,  G .  
( 1 9 8 7 ) .  S e q u e n c e  f o r  t h e  s t r u c t u r e  g e n e  x a n t h i n e  d e h y d r o g e n a s e  ( r o s y  l o c u s )  i n  
D r o s o p h i l a  m e l a n g a s t e r .  Genetics. 1 1 6 ,  6 7 - 7 3 .
K e l m ,  M .  ( 1 9 9 9 ) .  N i t r i c  o x i d e  m e t a b o l i s m  a n d  b r e a k d o w n .  Biochimica et Biophysica Acta. 
1 4 1 1 ,  2 7 3 - 2 8 9 .
K i k k a w a ,  R . ,  Y a m a m o t o ,  T . ,  F u k u s h i m a ,  T . ,  Y a m a d a ,  H . ,  &  H o r i i ,  I .  ( 2 0 0 5 ) .  
I n v e s t i g a t i o n  o f  a  h e p a t o t o x i c i t y  s c r e e n i n g  s y s t e m  i n  p r i m a r y  c e l l  c u l t u r e s .  The Journal 
of Toxicological Sciences. 3 0 ,  6 1 - 7 2 .
K i s k e r ,  C . ,  S c h i n d e l i n ,  H . ,  &  R e e s ,  D . C .  ( 1 9 9 7 ) .  M o l y b d e n u m - c o f a c t o r - c o n t a i n i n g  
e n z y m e s :  s t r u c t u r e  a n d  m e c h a n i s m .  Annual Review of Biochemistry. 6 6 ,  2 3 3 - 2 6 7 .
K i t c h e n ,  B . J .  ( 1 9 7 4 ) .  A  c o m p a r i s o n  o f  t h e  p r o p e r t i e s  o f  m e m b r a n e s  i s o l a t e d  f r o m  
b o v i n e  s k i m  m i l k  a n d  c r e a m .  Biochimica et Biophysica Acta. 3 5 6 ,  2 5 7 - 2 6 9 .
K n o p ,  M . ,  &  G e r k e ,  V .  ( 2 0 0 2 ) .  C a 2 + - r e g u l a t e d  s e c r e t i o n  o f  t i s s u e - t y p e  p l a s m i n o g e n  
a c t i v a t o r  a n d  v o n  w i l l e b r a n d  f a c t o r  i n  h u m a n  e n d o t h e l i a l  c e l l s .  Biochimica et Biophysica 
Acta. 1 6 0 0 ,  1 6 2 - 1 6 7 .
K o i k e ,  K . ,  M o o r e ,  F . A . ,  M o o r e ,  E . E . ,  R e a d ,  R . A . ,  C a r l ,  V . S . ,  &  B a n e r j e e ,  A .  ( 1 9 9 3 ) .  
G u t  i s c h e m i a  m e d i a t e s  l u n g  i n j u r y  b y  a  x a n t h i n e  o x i d a s e - d e p e n d e n t  n e u t r o p h i l  
m e c h a n i s m .  Journal of Surgical Research. 5 4 ,  4 6 9 - 4 7 3 .
K o o i j ,  A . ,  S c h i l l e r ,  H . J . ,  S c h i j n s ,  M . ,  V a n  N o o r d e n ,  C . J . F . ,  &  F r e d e r i k s ,  W . M .  ( 1 9 9 4 ) .  
C o n v e r s i o n  o f  x a n t h i n e  d e h y d r o g e n a s e  i n t o  x a n t h i n e  o x i d a s e  i n  r a t  l i v e r  a n d  p l a s m a  
a t  t h e  o n s e t  o f  r e p e r f u s i o n  a f t e r  i s c h e m i a .  Hepatology. 1 9 , 1 4 8 8 - 1 4 9 5 .
K r i s t e n s e n ,  S . R .  ( 1 9 9 4 ) .  M e c h a n i s m s  o f  c e l l  d a m a g e  a n d  e n z y m e  r e l e a s e .  Danish 
Medical Bulletin. 4 1 ,  4 2 3 - 4 3 3 .
K u b e s ,  P . ,  S u z u k i ,  M . ,  &  G r a n g e r ,  D . N .  ( 1 9 9 1 ) .  N i t r i c  o x i d e :  a n  e n d o g e n o u s  
m o d u l a t o r  o f  l e u k o c y t e  a d h e s i o n .  PNAS. 8 8 ,  4 6 5 1 - 4 6 5 5 .
K u h l m a n n ,  C . R . W . ,  M o s t ,  A . K . ,  L i ,  F . ,  M u n z ,  B . M . ,  S c h a e f e r ,  C . A . ,  W a l t h e r ,  S . ,  
R a e d l e - H u r s t ,  T . ,  W a l d d e c k e r ,  B . ,  P i p e r ,  H . M . ,  T i l l m a n n s ,  H . ,  &  W i e c h a ,  J .  ( 2 0 0 5 ) .  
E n d o t h e l i n - I - i n d u c e d  p r o l i f e r a t i o n  o f  h u m a n  e n d o t h e l i a l  c e l l s  d e p e n d s  o n  a c t i v a t i o n  
o f  K +  c h a n n e l s  a n d  C a 2 +  i n f l u x .  Acta Physiologica Scandinavica. 1 8 3 ,  1 6 1 - 1 6 9 .
K u n s t .  F . ,  O g a s a w a r a ,  N . ,  M o s z e r ,  I . ,  e t  a l .  ( 1 9 9 7 ) .  T h e  c o m p l e t e  g e n o m e  s e q u e n c e  o f  
t h e  g r a m - p o s i t i v e  b a c t e r i u m  B a c i l l u s  s u b t i l i s .  Nature. 3 9 0 ,  2 4 9 - 2 5 6 .
. 9-248
I ; i i i k - n  I l e v ,  i n M i n I ’h h  11iv
K u p p u s a m y ,  P . ,  &  Z w e i e r ,  J . L .  ( 1 9 8 9 ) .  C h a r a c t e r i z a t i o n  o f  f r e e  r a d i c a l  g e n e r a t i o n  b y  
x a n t h i n e  o x i d a s e .  E v i d e n c e  f o r  h y d r o x y l  r a d i c a l  g e n e r a t i o n .  Journal of Biological 
Chemistry. 2 6 4 ,  9 8 8 0 - 9 8 8 4 .
K u w a b a r a ,  Y . ,  N i s h i n o ,  T . ,  O k a m o t o ,  K . ,  M a t s u m u r a ,  T . ,  E g e r ,  B . T . ,  P a i ,  E . F . ,  &  
N i s h i n o ,  T .  ( 2 0 0 3 ) .  U n i q u e  a m i n o  a c i d s  c l u s t e r  f o r  s w i t c h i n g  f r o m  t h e  d e h y d r o g e n a s e  
t o  o x i d a s e  f o r m  o f  x a n t h i n e o x i d o r e d u c t a s e .  PNAS. 1 0 0 ,  8 1 7 0 - 8 1 7 5 .
L a n d m e s s e r ,  U . ,  &  D r e x l e r ,  H .  ( 2 0 0 2 ) .  A l l o p u r i n o l  a n d  e n d o t h e l i a l  f u n c t i o n  i n  h e a r t  
f a i l u r e .  F u t u r e  o r  f a n t a s y ?  Circulation. 1 0 6 ,  1 7 3 - 1 7 5 .
L a n d m e s s e r ,  U . ,  S p e i k e r m a n n ,  S . ,  D i k a l o v ,  S . ,  T a t g e ,  H . ,  W i l k e ,  R . ,  K o h l e r ,  C . ,  
H a r r i s o n ,  D . G . ,  H o r n i g ,  B . ,  &  D r e x l e r ,  H .  ( 2 0 0 2 ) .  V a s c u l a r  o x i d a t i v e  s t r e s s  a n d  
e n d o t h e l i a l  d y s f u n c t i o n  i n  p a t i e n t s  w i t h  c h r o n i c  h e a r t  f a i l u r e :  R o l e  f o r  x a n t h i n e -  
o x i d a s e  a n d  e x t r a c e l l u l a r  s u p e r o x i d e  d i s m u t a s e .  Circulation. 1 0 6 ,  3 0 7 3 - 3 0 7 8 .
L a n d m e s s e r ,  U . ,  D i k a l o v ,  S . ,  P r i c e ,  S . R . ,  M c C a n n ,  L . ,  F u k a i ,  T . ,  H o l l a n d ,  S . M . ,  M i t c h ,  
W . E . ,  &  H a r r i s o n ,  D . G .  ( 2 0 0 3 ) .  O x i d a t i o n  o f  t h e  t e t r a h y d r o b i o p t e r i n  l e a d s  t o  
u n c o u p l i n g  o f  e n d o t h e l i a l  c e l l  n i t r i c  o x i d e  s y n t h a s e  i n  h y p e r t e n s i o n .  The Journal of 
Clinical Investigation. I l l ,  1 2 0 1 - 1 2 0 9 .
L a p o s a t a ,  M . ,  D o v n a r s k y ,  D . K . ,  &  S h i n ,  H . S .  ( 1 9 8 3 ) .  T h r o m b i n - i n d u c e d  g a p  
f o r m a t i o n  i n  c o n f l u e n t  e n d o t h e l i a l  c e l l  m o n o l a y e r s  i n  v i t r o .  Blood. 6 2 ,  5 4 9 - 5 5 6 .
L a r s e n ,  E . ,  C e l i ,  A . ,  G i l b e r t ,  G . E . ,  F u r i e ,  B . C . ,  E r b a n ,  J . K . ,  B o n f a n t i ,  R . ,  W a g n e r ,
D . D . ,  F u r i e ,  B .  P A D G E M  p r o t e i n :  a  r e c e p t o r  t h a t  m e d i a t e s  t h e  i n t e r a c t i o n  o f  
a c t i v a t e d  p l a t e l e t s  w i t h  n e u t r o p h i l s  a n d  m o n o c y t e s .  Cell. 5 9 ,  3 0 5 - 3 1 2 .
L e a v i s ,  P . C . ,  R o s e n f e l d ,  S . ,  &  L u ,  R . C .  ( 1 9 7 8 ) .  C l e a v a g e  o f  a  s p e c i f i c  b i n d  i n  t r o p o n i n  
C  b y  t h r o m b i n .  Biochimica et Biophysica Acta. 5 3 5 ,  2 8 1 - 2 8 6 .
L e e ,  C - L ,  L i u ,  X . ,  &  Z w e i e r ,  J . L .  ( 2 0 0 0 ) .  R e g u l a t i o n  o f  x a n t h i n e  o x i d a s e  b y  n i t r i c  
o x i d e  a n d  p e r o x y n i t r i t e .  The Journal of Biological Chemistry. 2 7 5 ,  9 3 6 9 - 9 3 7 6 .
L e u n g ,  L . L . K . ,  &  H a l l ,  S . W .  ( 2 0 0 0 ) .  D i s s o c i a t i o n  o f  t h r o m b i n ’ s  s u b s t r a t e  i n t e r a c t i o n s  
u s i n g  s i t e - d i r e c t e d  m u t a g e n e s i s .  Trends in Cardiovascular Medicine. 1 0 ,  8 9 - 9 2 .
L i ,  J - M . ,  &  S h a h ,  A . M .  ( 2 0 0 2 ) .  I n t r a c e l l u l a r  l o c a l i s a t i o n  a n d  p r e a s s e m b l y  o f  t h e  
N A D P H  o x i d a s e  c o m p l e x  i n  c u l t u r e d  e n d o t h e l i a l  c e l l s .  The Journal of Biological 
Chemistry. 2 7 7 , 1 9 9 5 2 - 1 9 9 6 0 .
L i ,  J - M . ,  &  S h a h ,  A . M .  ( 2 0 0 4 ) .  E n d o t h e l i a l  c e l l  s u p e r o x i d e  g e n e r a t i o n :  r e g u l a t i o n  a n d  
r e l e v a n c e  f o r  c a r d i o v a s c u l a r  p a t h o p h y s i o l o g y .  American Journal of Physiology. P^ egulatory, 
Integrative, and Comparative Physiology. 2 8 7 ,  R 1 0 1 4 - R 1 0 3 0 .
9-249
I i c u  i i i s o r , P I i D T I k -m
L i n d e r ,  N . ,  R a p o l a ,  J . ,  &  R a i v i o ,  K . O .  ( 1 9 9 9 ) .  C e l l u l a r  e x p r e s s i o n  o f  x a n t h i n e  
o x i d o r e d u c t a s e  p r o t e i n  i n  n o r m a l  h u m a n  t i s s u e .  Laboratory Investigation. 7 9 ,  9 6 7 - 9 7 3 .
L i n d e r ,  N . ,  M a r t e l i n ,  E . ,  L a p a t t o ,  R . ,  &  R a i v i o ,  K . O .  ( 2 0 0 3 ) .  P o s t t r a n s l a t i o n a l  
i n a c t i v i a t i o n  o f  h u m a n  x a n t h i n e  o x i d o r e d u c t a s e  b y  o x y g e n  u n d e r  s t a n d a r d  c e l l  c u l t u r e  
c o n d i t i o n s .  The American Journal of Physiology: Cell Physiology. 2 8 5 ,  C 4 8 - C 5 5 .
L i n k e ,  A . ,  R e c c h i a ,  F . ,  Z h a n g ,  X . ,  &  H i n t z e ,  T . H .  ( 2 0 0 3 ) .  A c u t e  a n d  c h r o n i c  
e n d o t h e l i a l  d y s f u n c t i o n :  i m p l i c a t i o n s  i n  d e v e l o p m e n t  o f  h e a r t  f a i l u r e .  Heart Failure 
Reviews. 8 ,  SI-97.
L i o v i c h ,  S . I . ,  &  F r i d o v i c h ,  I .  ( 1 9 9 7 ) .  L u c i g e n i n  ( B i s - N - m e t h y l a c r i d i n i u m )  a s  a  
m e d i a t o r  o f  s u p e r o x i d e  a n i o n  p r o d u c t i o n .  Archives of Biochemistry and Biophysics. 3 3 7 ,  
1 1 5 - 1 2 0 .
L i o v i c h ,  S . I . ,  &  F r i d o v i c h ,  I .  ( 1 9 9 8 ) .  L u c i g e n i n  a s  m e d i a t o r  o f  s u p e r o x i d e  p r o d u c t i o n :  
r e v i s i t e d .  Free Radical Biology and Medicine. 2 5 ,  9 2 6 - 9 2 8 .
L i u ,  Y . ,  F i s k u m ,  G . ,  &  S c h u b e r t ,  D .  ( 2 0 0 2 ) .  G e n e r a t i o n  o f  r e a c t i v e  o x y g e n  s p e c i e s  b y  
t h e  m i t o c h o n d r i a l  e l e c t r o n  t r a n s p o r t  c h a i n .  Journal of Neuro chemistry. 8 0 ,  7 8 0 - 7 8 7 .
L o ,  W . W . ,  &  F a n ,  T . P .  ( 1 9 8 7 ) .  H i s t a m i n e  s t i m u l a t e s  i n o s i t o l  p h o s p h a t e  a c c u m u l a t i o n  
v i a  t h e  H I - r e c e p t o r  i n  c u l t u r e d  h u m a n  e n d o t h e l i a l  c e l l s .  Biochemical and Biophysical 
Research Communications. 1 4 8 ,  4 7 - 5 3 .
L o ,  S . K . ,  J a n a k i d e v i ,  K . ,  L a i ,  L . ,  &  M a l i k ,  A . B .  ( 1 9 9 3 ) .  H y d r o g e n  p e r o x i d e - i n d u c e d  
i n c r e a s e  i n  e n d o t h e l i a l  a d h e s i v e n e s s  i s  d e p e n d e n t  o n  I C A M - 1  e x p r e s s i o n .  American 
Journal of Physiology. Hung Cellular and Molecular Physiology. 2 6 4 ,  L 4 0 6 - 4 1 2 .
L o s c a l z o ,  J .  ( 2 0 0 1 ) .  N i t r i c  o x i d e  i n s u f f i c i e n c y ,  p l a t e l e t  a c t i v a t i o n ,  a n d  a r t e r i a l  
t h r o m b o s i s .  Circulation Research. 8 8 ,  7 5 6 - 7 6 2 .
L o s c h e n ,  G . ,  F l o h e ,  L . ,  &  C h a n c e ,  B .  ( 1 9 7 1 ) .  R e s p i r a t o r y  c h a i n  l i n k e d  H 2O 2 
p r o d u c t i o n  i n  p i g e o n  h e a r t  m i t o c h o n d r i a .  FEBS Letters. 1 8 ,  2 6 1 - 2 6 4 .
L o s c h e n ,  G . ,  A z z i ,  A . ,  R i c h t e r ,  C . ,  &  F o l h e ,  L .  ( 1 9 7 4 ) .  S u p e r o i x d e  r a d i c a l s  a s  
p r e c u r s o r s  o f  m i t o c h o n d r i a l  h y d r o g e n  p e r o x i d e .  FEBS Letters. 4 2 ,  6 8 - 7 2 .
L o w r y ,  O . H . ,  B e s s e y ,  O . A . ,  &  C r a w f o r d ,  E . J .  ( 1 9 4 9 ) .  P t e r i n e  O x i d a s e .  Journal of 
Biological Chemistry. 1 8 0 ,  3 9 9 - 4 1 0 .
L u m ,  H . ,  &  R o e b u c k ,  K . A .  ( 2 0 0 1 ) .  O x i d a n t  s t r e s s  a n d  e n d o t h e l i a l  c e l l  d y s f u n c t i o n .  
American Journal of Physiology: Cell Physiology. 2 8 0 ,  C 7 1 9 - C 7 4 1 .
9-250
I L 1". i n ' . ,  i n P h i )  T h e s i s
L y e r ,  L . ,  &  F a r e e d ,  J .  ( 1 9 9 5 ) .  D e t e r m i n a t i o n  o f  t h e  s p e c i f i c  a c t i v i t y  o f  r e c o m b i n a n t  
h i r u d i n  u s i n g  a  t h r o m b i n  t i t r a t i o n  m e t h o d .  Thrombosis Research. 7 8 ,  2 5 9 - 2 6 3 .
L y n c h ,  R . E . ,  &  F r i d o v i c h ,  I .  ( 1 9 7 9 ) .  A u t o i n a c t i v a t i o n  o f  x a n t h i n e  o x i d a s e :  t h e  r o l e  o f  
s u p e r o x i d e  r a d i c a l  a n d  h y d r o g e n  p e r o x i d e .  Biochimica et Biophysica Acta. 5 7 1 , 1 9 5 - 2 0 0 .
M a c F a r l a n e ,  R . G .  ( 1 9 6 4 ) .  A n  e n z y m e  c a s c a d e  i n  t h e  b l o o d  c l o t t i n g  m e c h a n i s m ,  a n d  
i t s  f u n c t i o n  a s  a  b i o c h e m i c a l  a m p l i f i e r .  Nature. 2 0 2 ,  4 9 8 - 4 9 9 .
M a c i a g ,  T . ,  K a d i s h ,  J . ,  W i l k i n s ,  L . ,  S t e m e r m a n ,  M . B . ,  &  W e i n s t e i n ,  R .  ( 1 9 8 2 ) .  
O r g a n i z a t i o n a l  b e h a v i o u r  o f  h u m a n  u m b i l i c a l  v e i n  e n d o t h e l i a l  c e l l s .  The Journal of Cell 
Biology. 9 4 ,  5 1 1 - 5 2 0 .
M a c K e n z i e ,  A . ,  W i l s o n ,  H . L . ,  K i s s - T o t h ,  E . ,  D o w e r ,  S . K . ,  M o r t h ,  R . A . ,  &  
S u r p r e n a n t ,  A .  ( 2 0 0 1 ) .  R a p i d  s e c r e t i o n  o f  i n t e r l e u k i n - 1  (3 b y  m i c r o v e s i c l e  s h e d d i n g .  
Immunity. 8 ,  8 2 5 - 8 3 5 .
M a d e j ,  T . ,  M a r c h l e r - B a u e r ,  A . ,  M a r c h l e r ,  G . H . ,  M a z u m d e r ,  R . ,  N i k o l s k a y a ,  A . N . ,  R a o ,
B . S . ,  P a n c h e n k o ,  A . R . ,  S h o e m a k e r ,  B . A . ,  S i m o n y a n ,  V . ,  S o n g ,  J . S . ,  T h i e s s e n ,  P . A . ,  
V a s u d e v a n ,  S . ,  W a n g ,  Y . ,  Y a m a s h i t a ,  R . A . ,  Y i n ,  J . J . ,  &  B r y a n t ,  S . H .  ( 2 0 0 3 ) .  M M D B :  
E n t r e z ' s  3 D - s t r u c t u r e  d a t a b a s e .  Nucleic Acids Research. 3 1 ,  4 7 4 - 4 7 7 .
M a n n ,  K . G . ,  B u t e n a s ,  S . ,  &  B r u m m e l ,  K .  ( 2 0 0 3 ) .  T h e  d y n a m i c s  o f  t h r o m b i n  
f o r m a t i o n .  Arteriosclerosis, Thrombosis, and Vascular Biology. 2 3 , 1 7 - 2 5 .
M a n t o v a n i ,  R .  ( 1 9 9 8 ) .  A  s u r v e y  o f  1 7 8  N F - Y  b i n d i n g  C C A A T  b o x e s .  Nucleic A cid  
Research. 2 6 , 1 1 3 5 - 1 1 4 3 .
M a n t o v a n i ,  R .  ( 1 9 9 9 ) .  T h e  m o l e c u l a r  b i o l o g y  o f  t h e  C C A A T - b i n d i n g  f a c t o r  N F - Y .  
Gene. 2 3 9 , 1 5 - 2 7 .
M a r k l e y ,  H . G . ,  F a i l l a c e ,  L . A . ,  &  M e z e y ,  E .  ( 1 9 7 3 ) .  X a n t h i n e  o x i d a s e  a c t i v i t y  i n  r a t  
b r a i n .  Biochimica et Biophysica Acta. 3 0 9 ,  2 3 - 3 1 .
M a r t e l i n ,  E . ,  P a l v i m o ,  J . J . ,  L a p a t t o ,  R . ,  &  R a i v i o ,  K . O .  ( 2 0 0 0 ) .  N u c l e a r  f a c t o r  Y  
a c t i v a t e s  t h e  h u m a n  x a n t h i n e  o x i d o r e d u c t a s e  g e n e  p r o m o t e r .  FEBS Tetters. 4 8 0 ,  8 4 -  
88 .
M a r t e l i n ,  E . ,  L a p a t t o ,  R . ,  &  R a i v i o ,  K . O .  ( 2 0 0 2 ) .  R e g u l a t i o n  o f  x a n t h i n e  
o x i d o r e d u c t a s e  b y  i n t r a c e l l u l a r  i r o n .  America Journal of Physiology. Cell Physiology. 2 8 3 ,  
C 1 7 2 2 - C 1 7 2 8 .
9-251
11'jw i i i> im P h D  'I I k " ' i '■
M a r u y a m a ,  Y .  ( 1 9 6 3 ) .  T h e  h u m a n  e n d o t h e l i a l  c e l l  i n  t i s s u e  c u l t u r e .  Zeitschriff fur 
Zellforschung und Mikroscopische Anatomie. 6 0 ,  6 0 - 6 9 .
M a s s e y ,  V . ,  B r u m b y ,  P . E . ,  &  K o m a i ,  H .  ( 1 9 6 9 ) .  S t u d i e s  o n  m i l k  x a n t h i n e  o x i d a s e .  
S o m e  s p e c t r a l  a n d  k i n e t i c  p r o p e r t i e s .  Journal of Biological Chemistry. 2 4 4 ,  1 6 8 2 - 1 6 9 1 .
M a s s e y ,  V . ,  K o m a i ,  H . ,  P a l m e r ,  G . ,  &  E l i o n ,  G . B .  ( 1 9 7 0 ) .  O n  t h e  m e c h a n i s m  o f  
i n a c t i v a t i o n  o f  x a n t h i n e  o x i d a s e  b y  a l l o p u r i n o l  a n d  o t h e r  p y r a z o l o  [ 3 , 4 - d ]  p y r i m i d i n e s .  
The Journal of Biological Chemistry. 2 4 5 ,  2 8 3 7 - 2 8 4 4 .
M a t h e r ,  I . H . ,  &  K e e n a n ,  T . W .  ( 1 9 9 8 ) .  O r i g i n  a n d  s e c r e t i o n  o f  m i l k  l i p i d s .  Journal of 
Mammary Gland Biology and Neoplasia. 3 ,  2 5 9 - 2 7 3 .
M c C o r d ,  J . M . ,  &  F r i d o v i c h ,  I .  ( 1 9 6 8 ) .  T h e  r e d u c t i o n  o f  c y t o c h r o m e  c  b y  m i l k  
x a n t h i n e  o x i d a s e .  The Journal of Biological Chemistry. 2 4 3 ,  5 7 5 3 - 5 7 6 0 .
M c C o r d ,  J . M . ,  &  F r i d o v i c h ,  I .  ( 1 9 6 9 ) .  S u p e r o x i d e  d i s m u t a s e  a n  e n z y m i c  f u n c t i o n  f o r  
e r y t h r o c u p r e i n  ( h e m o c u p r e i n ) .  The Journal of Biological Chemistry. 2 4 4 ,  6 0 4 9 - 6 0 5 5 .
M c C o r d ,  J . M .  ( 1 9 8 5 )  O x y g e n - d e r i v e d  r a d i c a l s  i n  p o s t i s c h e m i c  t i s s u e  i n j u r y .  The New 
England Journal of Medicine. 3 1 2 , 1 5 9 - 1 6 3 .
M c E v e r ,  R . P . ,  B e c k s t e a d ,  J . H . ,  M o o r e ,  K . L . ,  M a r s h a l l - C a r l s o n ,  L . ,  &  B a i n t o n ,  D . F .  
( 1 9 8 9 ) .  G M P - 1 4 0 ,  a  p l a t e l e t  a - g r a n u l e  m e m b r a n e  p r o t e i n ,  i s  a l s o  s y n t h e s i z e d  b y  
v a s c u l a r  e n d o t h e l i a l  c e l l s  a n d  i s  l o c a l i z e d  i n  W e i b e l - P a l a d e  b o d i e s .  The Journal of 
Clinical Investigation. 8 4 ,  9 2 - 9 9 .
M c M a n a m a n ,  J . L . ,  H a n s o n ,  L . ,  N e v i l l e ,  M . C . ,  &  W r i g h t ,  R . M .  ( 2 0 0 0 ) .  L a c t o g e n i c  
h o r m o n e s  r e g u l a t e  x a n t h i n e  o x i d o r e d u c t a s e  a n d  b e t a - c a s e i n  l e v e l s  i n  m a m m a r y  
e p i t h e l i a l  c e l l s  b y  d i s t i n c t  m e c h a n i s m s .  Archives of Biochemistry and Biophysics. 3 7 3 ,  3 1 8 -  
3 2 7 .
M c M a n a m a n ,  J . L . ,  &  B a i n ,  D . L .  ( 2 0 0 2 ) .  S t r u c t u r a l  a n d  c o n f o r m a t i o n a l  a n a l y s i s  o f  t h e  
o x i d a s e  t o  d e h y d r o g e n a s e  c o n v e r s i o n  o f  x a n t h i n e  o x i d o r e d u c t a s e .  Journal of Biological 
Chemistry. 2 7 7 ,  2 1 2 6 1 - 2 1 2 6 8 .
M c P e r s o n ,  D . B . ,  K i l k e r ,  R . P . ,  &  F o l e y ,  T . D .  ( 2 0 0 2 ) .  S u p e r o x i d e  a c t i v a t e s  c o n s t i t u t i v e  
n i t r i c  o x i d e  s y n t h a s e  i n  a  b r a i n  p a r t i c u l a t e  f r a c t i o n .  Biochemical and Biophysical Research 
Communications. 2 9 6 ,  4 1 3 - 4 1 8 .
M i c h a u x ,  G . ,  &  C u t l e r ,  D . F .  ( 2 0 0 4 ) .  H o w  t o  r o l l  a n  e n d o t h e l i a l  c i g a r :  t h e  b i o g e n e s i s  
o f  W e i b e l - P a l a d e  b o d i e s .  Traffic. 5 ,  6 9 - 7 8 .
9-252
j j i i i o '. I l ow i i iMin P h i  > I Ik-sis
M i l l a r  T M ,  S t e v e n s  C R ,  B e n j a m i n  N ,  E i s e n t h a l  R ,  H a r r i s o n  R ,  &  B l a k e  D R  ( 1 9 9 8 ) .  
X a n t h i n e  o x i d o r e d u c t a s e  c a t a l y s e s  t h e  r e d u c t i o n  o f  n i t r a t e s  a n d  n i t r i t e  t o  n i t r i c  o x i d e  
u n d e r  h y p o x i c  c o n d i t i o n s .  FEBS Letters. 4 2 7 ,  2 2 5 - 2 2 8 .
M i l l a r ,  T . M .  ( 1 9 9 9 ) .  N o v e l  a s p e c t s  o f  t h e  f u n c t i o n  a n d  a c t i v i t y  o f  x a n t h i n e  o x i d a s e .  
Doctoral Dissertation. U n i v e r s i t y  o f  B a t h ,  U K .
M i l l a r ,  T . M . ,  K a n c z l e r ,  J . M . ,  B o d a m y a l i ,  T . ,  B l a k e ,  D . R . ,  &  S t e v e n s ,  C . R .  ( 2 0 0 2 ) .  
X a n t h i n e  o x i d a s e  i s  a  p e r o x y n i t r i t e  s y n t h a s e :  n e w l y  i d e n t i f i e d  r o l e s  f o r  a  v e r y  o l d  
e n z y m e .  Redox Report. 7 ,  6 5 - 7 0 .
M i l l a r ,  T . M .  ( 2 0 0 4 ) .  P e r o x y n i t r i t e  f o r m a t i o n  f r o m  t h e  s i m u l t a n e o u s  r e d u c t i o n  o f  
n i t r i t e  a n d  o x y g e n  b y  x a n t h i n e  o x i d a s e .  FEBS Letters. 5 6 2 , 1 2 9 - 1 3 3 .
M i u r a ,  H . ,  B o s n j a k ,  J . J . ,  N i n g ,  G . ,  S a i t o ,  T . ,  M i u r a ,  M . ,  &  G u t t e r m a n ,  D . D .  ( 2 0 0 3 ) .  
R o l e  f o r  h y d r o g e n  p e r o x i d e  i n  f l o w - i n d u c e d  d i l a t i o n  o f  h u m a n  c o r o n a r y  a r t e r i o l e s .  
Circulation Research. 9 2 ,  e 3 1 - e 4 0 .
M i i n z e l ,  T . ,  &  H a r r i s o n ,  D . G .  ( 1 9 9 9 ) .  I n c r e a s e d  s u p e r o x i d e  i n  h e a r t  f a i l u r e :  a  
b i o c h e m i c a l  b a r o r e f l e x  g o n e  a w r y .  Circulation. 1 0 0 ,  2 1 6 - 2 1 8 .
M i i n z e l ,  T . ,  F e i l ,  R . ,  M i i l s c h ,  A . ,  L o h m a n n ,  S . M . ,  H o f m a n n ,  F . ,  &  W a l t e r ,  U .  ( 2 0 0 3 ) .  
P h y s i o l o g y  a n d  p a t h o p h y s i o l o g y  o f  v a s c u l a r  s i g n a l l i n g  c o n t r o l l e d  b y  c y c l i c  g u a n o s i n e  
3 ’,  5 ’- c y c l i c  m o n o p h o s p h a t e - d e p e n d e n t  p r o t e i n  k i n a s e .  Circulation. 1 0 8 ,  2 1 7 2 - 2 1 8 3 .
M u r r e l l ,  G . A . C . ,  F r a n c i s ,  M . J . O . ,  &  B r o m l e y ,  L .  ( 1 9 9 0 ) .  M o d u l a t i o n  o f  f i b r o b l a s t  
p r o l i f e r a t i o n  b y  o x y g e n  f r e e  r a d i c a l s .  The Biochemical Journal. 2 6 5 ,  6 5 9 - 6 6 5 .
N a c h m a n ,  R . L . ,  &  J a f f e ,  E . A .  ( 2 0 0 4 ) .  E n d o t h e l i a l  c e l l  c u l t u r e :  b e g i n n i n g s  o f  m o d e m  
v a s c a u l r  b i o l o g y .  The Journal of Clinical Investigation. 1 1 4 , 1 0 3 7 - 1 0 4 0 .
N i s h i n o ,  T . ,  &  O k a m o t o ,  K .  ( 2 0 0 0 ) .  T h e  r o l e  o f  t h e  [ 2 F e - 2 S ]  c l u s t e r  c e n t e r s  i n  
x a n t h i n e  o x i d o r e d u c t a s e .  Journal of Inorganic Biochemistry. 8 2 ,  4 3 - 4 9 .
O ’B y r n e ,  S . ,  S h i r o d a r i a ,  C . ,  M i l l a r ,  T . ,  S t e v e n s ,  C . ,  B l a k e ,  D . ,  &  B e n j a m i n ,  N .  ( 2 0 0 0 ) .  
I n h i b i t i o n  o f  p l a t e l e t  a g g r e g a t i o n  w i t h  g l y c e r y l  t r i n i t r a t e  a n d  x a n t h i n e  o x i d o r e d u c t a s e .  
The Journal of Tharamcology and Experimental Therapeutics. 2 9 2 ,  3 2 6 - 3 3 0 .
O s s o v k a y a ,  V . S . ,  &  B u n n e t t ,  N . W .  ( 2 0 0 3 ) .  P r o t e a s e - a c t i v a t e d  r e c e p t o r s :  c o n t r i b u t i o n  
t o  p h y s i o l o g y  a n d  d i s e a s e .  Physiological Reviews. 8 4 ,  5 7 9 - 6 2 1 .
O u r y ,  T . D . ,  &  D a y ,  B . J . ,  &  C r a p o ,  J . D .  ( 1 9 9 6 ) .  E x t r a c e l l u l a r  s u p e r o x i d e  d i s m u t a s e  i n  
v e s s e l s  a n d  a i r w a y s  o f  h u m a n s  a n d  b a b o o n s .  Free Radical Biolog)! and Medicine. 2 0 ,  9 5 7 -  
9 6 5 .
9-253
1 D u  il' iMin P h D  T I i c m .
O w e n ,  W . G . ,  &  E s m o n ,  C . T .  ( 1 9 8 1 ) .  F u n c t i o n a l  p r o p e r t i e s  o f  a n  e n d o t h e l i a l  c e l l  
c o f a c t o r  f o r  t h r o m b i n - c a t a l y z e d  a c t i v a t i o n  o f  p r o t e i n  C .  The Journal of biological 
Chemistry. 2 5 6 ,  5 5 3 2 - 5 5 3 5 .
O z e r ,  N . ,  M u f t u o g l u ,  M . ,  &  H a m d i ,  O . I .  ( 1 9 9 8 ) .  A  s i m p l e  a n d  s e n s i t i v e  m e t h o d  f o r  
t h e  a c t i v i t y  s t a i n i n g  o f  x a n t h i n e  o x i d a s e .  Journal of Biochemical and Biophysical Methods. 3 6 ,  
9 5 - 1 0 0 .
P a g a n o ,  P . J . ,  T o r n h e i m ,  K . ,  Sc C o h e n ,  R . A .  ( 1 9 9 3 ) .  S u p e r o x i d e  a n i o n  p r o d u c t i o n  b y  
r a b b i t  t h o r a c i c  a o r t a :  e f f e c t  o f  e n d o t h e l i u m - d e r i v e d  n i t r i c  o x i d e .  American Journal of 
Physiology. 2 6 5 ,  H 7 0 7 - H 7 1 2 .
P a g e ,  S . ,  P o w e l l ,  D . ,  B e n b o u b e t r a ,  M . ,  S t e v e n s ,  C . R . ,  B l a k e ,  D . R . ,  S e l a s e ,  F . ,  
W o l s t e n h o l m e ,  A . J . ,  &  H a r r i s o n ,  R .  ( 1 9 9 8 ) .  X a n t h i n e  o x i d o r e d u c t a s e  i n  h u m a n  
m a m m a r y  e p i t h e l i a l  c e l l s :  a c t i v a t i o n  i n  r e s p o n s e  t o  i n f l a m m a t o r y  c y t o k i n e s .  Biochimica 
et Biophysica Acta. 1 3 8 1 , 1 9 1 - 2 0 2 .
P a l l i s t e r ,  C .  ( 1 9 9 4 ) .  H a e m o s t a s i s :  a n  o v e r v i e w .  I n  Blood Physiology and Pathophysiology. 
p p .  4 4 7 - 4 8 0 .  ( E d s .  N o t  P u b l i s h e d ) .  B u t t e r w o r t h - H e i n e m a n n ,  O x f o r d ,  U K .
P a l m e r ,  R . M . ,  F e r r i g e ,  A . G . ,  &  M o n c a d a ,  S .  ( 1 9 8 7 ) .  N i t r i c  o x i d e  r e l e a s e  a c c o u n t s  f o r  
t h e  b i o l o g i c a l  a c t i v i t y  o f  e n d o t h e l i a l - d e r i v e d  r e l a x i n g  f a c t o r .  Nature. 3 2 7 ,  5 2 4 - 5 2 6 .
P a r k ,  I - W ,  U l l r i c h ,  C . K . ,  S c h o e n b e r g e r ,  E . ,  G a n j u ,  R . K . ,  &  G r o o p m a n ,  J . E .  ( 2 0 0 1 ) .  
H I V - 1  t a t  i n d u c e s  m i c r o v a s c u l a r  e n d o t h e l i a l  a p o p t o s i s  t h r o u g h  c a s p a s e  a c t i v a t i o n .  The 
Journal of Immunology. 1 6 7 ,  2 7 6 6 - 2 7 7 1 .
P a r t r i d g e ,  C . A . ,  B l u m e n s t o c k ,  F . A . ,  &  M a l i k ,  A . B .  ( 1 9 9 2 ) .  P u l m o n a r y  m i c r o v a s c u l a r  
e n d o t h e l i a l  c e l l s  c o n s t i t u t i v e l y  r e l e a s e  x a n t h i n e  o x i d a s e .  Archives of Biochemistry and 
Biophysics. 2 9 4 , 1 8 4 - 1 8 7 .
P a t e l ,  K . D . ,  Z i m m e r m a n ,  G . A . ,  P r e c o t t ,  S . M . ,  M c E v e r ,  R . P . ,  &  M c I n t y r e ,  T . M .
( 1 9 9 1 ) .  O x y g e n  r a d i c a l s  i n d u c e  h u m a n  e n d o t h e l i a l  c e l l s  t o  e x p r e s s  G M P - 1 4 0  a n d  
n e u t r o p h i l s .  The Journal of Cell Biology. 1 1 2 ,  7 4 9 - 7 5 9 .
P e r r e l l a ,  M . A . ,  &  Y e t ,  S . F .  ( 2 0 0 3 ) .  R o l e  o f  h e m e  o x y g e n a s e - 1  i n  c a r d i o v a s c u l a r  
f u n c t i o n .  Current Pharmaceutical Design. 9 ,  2 4 7 9 - 2 4 8 7 .
P f e f f e r ,  K . D . ,  H u e c k s t e a d t ,  T . P . ,  &  H o i d a l ,  J . R .  ( 1 9 9 4 ) .  X a n t h i n e  d e h y d r o g e n a s e  a n d  
x a n t h i n e  o x i d a s e  a n d  g e n e  e x p r e s s i o n  i n  r e n a l  e p i t h e l i a l  c e l l s .  C y t o k i n e  a n d  s t e r o i d  
r e g u l a t i o n .  The Journal of Immunology. 1 5 3 ,  1 7 8 9 - 1 7 9 7 .
9 - 2 5 4 .
J a m c ' .  1 l e u  i i w ' i i l ’h l ) I I k u i >
P o c o c k ,  G . ,  &  R i c h a r d s ,  C . D .  ( 1 9 9 9 ) .  T h e  h e a r t  a n d  c i r c u l a t i o n .  I n  Human Physiology 
the Basis of Medicine. O x f o r d  U n i v e r s i t y  P r e s s .  O x f o r d ,  U K .
P o r a s u p h a t a n a ,  S . ,  T s a i ,  P . ,  &  R o s e n ,  G . M .  ( 2 0 0 3 ) .  T h e  g e n e r a t i o n  o f  f r e e  r a d i c a l s  b y  
n i t r i c  o x i d e  s y n t h a s e .  Comparative Biochemistry and Physiology. 1 3 4 ,  2 8 1 - 2 8 9 .
P o r r a s  A G ,  O l s o n  J S ,  P a l m e r  G .  ( 1 9 8 1 ) .  T h e  r e a c t i o n  o f  r e d u c e d  x a n t h i n e  o x i d a s e  
w i t h  o x y g e n .  K i n e t i c s  o f  p e r o x i d e  a n d  s u p e r o x i d e  f o r m a t i o n .  Journal of Biological 
Chemistry. 2 5 6 ,  9 0 9 6 - 9 1 0 3 .
P o t o k a ,  D . A . ,  T a k a o ,  S . ,  O w a k i ,  T . ,  B u l k l e y ,  G . B . ,  &  K l e i n ,  A . S .  ( 1 9 9 8 ) .  E n d o t h e l i a l  
c e l l s  p o t e n t a t e  o x y g e n - m e d i a t e d  K u p p f e r  c e l l  p h a g o c y t i c  k i l l i n g .  Free Radical Biology 
and Medicine. 2 4 ,  1 2 1 7 - 1 2 2 7 .
P r e s c o t t ,  L . M . ,  H a r l e y ,  J . P . ,  &  K l e i n ,  D . A .  ( 1 9 9 6 ) .  M i c r o b i a l  g r o w t h .  I n  Microbiology. 
( E d s .  S i e v e r s ,  E . M . ,  S t a n t o n ,  T . ,  W i l d e ,  J . L . ,  B a n o w e t z ,  J . K . ,  &  H a n c o c k ,  L ) .  p p l l 4 -  
1 5 1 .  W m .  C .  B r o w n  P u b l i s h e r s ,  L o n d o n ,  U K .
Q u i n l a n ,  G . J . ,  L a m b ,  N . J . ,  T i l l e y ,  R . ,  E v a n s ,  T . W . ,  &  G u t t e r i d g e ,  J . M .  ( 1 9 9 7 ) .  P l a s m a  
h y p o x a n t h i n e  l e v e l s  i n  A R D S :  i m p l i c a t i o n s  f o r  o x i d a t i v e  s t r e s s ,  m o r b i d i t y ,  a n d  
m o r t a l i t y .  American Journal of Respiratory and Critical Care Medicine. 1 5 5 ,  4 7 9 - 4 8 4 .
R a n g ,  H . P . ,  D a l e ,  M . M . ,  R i t t e r ,  J . M . ,  &  M o o r e ,  P . K .  ( 2 0 0 3 ) .  T h e  v a s c u l a r  s y s t e m .  I n  
Pharamcology. p p  2 8 5 - 3 1 3 .  ( E d s .  H u n t e r ,  L ) .  C h u r c h i l l  L i v i n g s t o n e ,  L o n d o n ,  U K .
R a d o m s k i ,  M . W . ,  P a l m e r ,  R . M . ,  &  M o n c a d a ,  S .  ( 1 9 8 7 )  T h e  a n t i - a g g r e g a t i n g  p r o e r t i e s  
o f  v a s c u l a r  e n d o t h e l i u m :  i n t e r a c t i o n s  b e t w e e n  p r o s t a c y c l i n  a n d  n i t r i c  o x i d e .  British 
Journal of Pharmacology. 9 2 ,  6 3 9 - 6 4 6 .
R a j a g o p a l a n ,  K . V .  ( 1 9 9 7 ) .  B i o s y n t h e s i s  a n d  p r o c e s s i n g  o f  t h e  m o l y b d e n u m  c o f a c t o r s .  
Biochemical Society Transactions. 2 5 ,  7 5 7 - 7 6 1 .
R e i s s ,  J . ,  &  J o h n s o n ,  J . L .  ( 2 0 0 3 ) .  M u t a t i o n s  i n  t h e  m o l y b d e n u m  c o f a c t o r  b i o s y n t h e t i c  
g e n e s  M O C S 1 ,  M O C S 2 ,  a n d  G E P H .  Human Mutation. 2 1 ,  5 6 9 - 5 7 6 .
R o b e r t s ,  I . S .  T h e  b i o c h e m i s t r y  a n d  g e n e t i c s  o f  c a p s u l a r  p o l y s a c c h a r i d e  p r o d u c t i o n  i n  
b a c t e r i a .  Annual Reviews in Microbiology. 5 0 ,  2 8 5 - 3 1 5 .
R o s e ,  T . ,  &  D i  C e r a ,  E .  ( 2 0 0 2 ) .  T h r e e - d i m e n s i o n a l  m o d e l l i n g  o f  t h r o m b i n - f i b r i n o g e n  
i n t e r a c t i o n .  The Journal ofBiochemicstry. 2 7 7 , 1 8 8 7 5 - 1 8 8 8 0 .
R o s k o s k i ,  R . ,  G a h n ,  L . G . ,  &  R o s k o s k i ,  L . M .  ( 1 9 9 3 ) .  I n a c t i v a t i o n  o f  p h o s p h o r y l a t e d  
r a t  t y r o s i n e  h y d r o x y l a s e  b y  a s c o r b a t e  i n  v i t r o .  Euorpean Journal of Biochemistry. 2 1 8 ,  3 6 3 -  
3 7 0 .
9-255
.hi11io^ I l ow iiiM m
R o s n o b l e t ,  C . ,  V i s c h e r ,  U . M . ,  G e r a r d ,  R . D . ,  I r m i n g e r ,  J - C . ,  H a l b a n ,  P . A . ,  &  K r u i t h o f ,  
E . K . O .  ( 1 9 9 9 ) .  S t o r a g e  o f  t i s s u e - t y p e  p l a s m i n o g e n  a c t i v a t o r  i n  W e i b e l - P a l a d e  b o d i e s  
o f  h u m a n  e n d o t h e l i a l  c e l l s .  Arteriosclerosis, Thrombosis, and Vascular Biology. 1 9 ,  1 7 9 6 -  
1 8 0 3 .
R o t r o s e n ,  D . ,  &  G a l l i n ,  J . I .  ( 1 9 8 6 ) .  H i s t a m i n e  t y p e  I  r e c e p t o r  o c c u p a n c y  i n c r w a s e s  
e n d o t h e l i a l  c y t o s o l i c  c a l c i u m ,  r e d u c e s  F - a c t i n ,  a n d  p r o m o t e s  a l b u m i n  d i f f u s i o n  a c r o s s  
c u l t u r e d  e n d o t h e l i a l  m o n o l a y e r s .  The Journal of Biological Chemistry. 1 0 3 , 2 3 7 9 - 2 3 8 7 .
R o t t ,  K . T . ,  &  A g u d e l o ,  C . A .  ( 2 0 0 3 ) .  G out. JA M A . 2 1 ,  2 8 5 7 - 2 8 6 0 .
R o u q u e t t e ,  M . ,  P a g e ,  S . ,  B r y a n t ,  R . ,  B e n o u b e t r a ,  M . ,  S t e v e n s ,  C . R . ,  B l a k e ,  D . R . ,  
W h i s h ,  W . D . ,  H a r r i s o n ,  R . ,  &  T o s h ,  D .  ( 1 9 9 8 ) .  X a n t h i n e  o x i d o r e d u c t a s e  i s  
a s y m m e t r i c a l l y  l o c a l i s e d  o n  t h e  o u t e r  s u r f a c e  o f  h u m a n  e n d o t h e l i a l  a n d  e p i t h e l i a l  c e l l s  
i n  c u l t u r e .  FEBS Tetters. 4 2 6 ,  3 9 7 - 4 0 1 .
R y d e l ,  T . J . ,  R a v i c h a n d r a n ,  K . G . ,  T u l i n s k y ,  A . ,  B o d e ,  W . ,  H u b e r ,  R . ,  R o i t s c h ,  C . ,  &  
F e n t o n ,  J . W .  ( 1 9 9 0 ) .  T h e  s t r u c t u r e  o f  a  c o m p l e x  o f  r e c o m b i n a n t  h i r u d i n  a n d  h u m a n  
a l p h a - t h r o m b i n .  Science. 2 4 9 ,  2 7 7 - 2 8 0 .
S a a v e d r a ,  W . F . ,  P a o l o c c i ,  N . ,  S t  J o h n ,  M . E . ,  S k a f ,  M . W . ,  S t e w a r t ,  G . C . ,  X i e ,  J - S . ,  
H a r r i s o n ,  R . W . ,  Z e i c h n e r ,  J . ,  M u d r i c k ,  D . ,  M a r b a n ,  E . ,  K a s s ,  D . A . ,  &  H a r e ,  J . M .  
( 2 0 0 2 ) .  I m b a l a n c e  b e t w e e n  x a n t h i n e  o x i d a s e  a n d  n i t r i c  o x i d e  s y n t h a s e  s i g n a l l i n g  
p a t h w a y s  u n d e r l i e s  m e c h a n o e n e r g e t i c  u n c o u p l i n g  i n  t h e  f a i l i n g  h e a r t .  Circulation 
Research. 9 0 ,  2 9 7 - 3 0 4 .
S a d l e r ,  J . E .  ( 1 9 9 8 ) .  B i o c h e m i s t r y  a n d  g e n e t i c s  o f  v o n  W i l l e b r a n d  f a c t o r .  Annual Review 
in Biochemistry. 6 7 ,  3 9 5 - 4 2 4 .
S a k s e l a ,  M . ,  L a p a t t o ,  R . ,  &  R a i v i o ,  K . O .  ( 1 9 9 9 ) .  I r r e v e r s i b l e  c o n v e r s i o n  o f  x a n t h i n e  
d e h y d r o g e n a s e  i n t o  x a n t h i n e  o x i d a s e  b y  a  m i t o c h o n d r i a l  p r o t e a s e .  FEBS Tetters. 4 4 3 ,  
1 1 7 - 1 2 0 .
S a l v e m i n i ,  D . ,  d e  N u c c i ,  G . ,  S n e d d o n ,  J . M . ,  &  V a n e ,  J . R .  ( 1 9 8 9 ) .  S u p e r o x i d e  a n i o n s  
e n h a n c e  p l a t e l e t  a d h e s i o n  a n d  a g g r e g a t i o n .  British Journal of Pharmacology. 9 7 ,  1 1 4 5 -  
1 1 5 0 .
S a n d e r s ,  S . A . ,  E i s e n t h a l ,  R . ,  &  H a r r i s o n ,  R .  ( 1 9 9 7 ) .  N A D H  o x i d a s e  a c t i v i t y  o f  h u m a n  
x a n t h i n e  o x i d o r e d u c t a s e .  European Journal of Biochemistry. 2 4 5 ,  5 4 1 - 5 4 8 .
S a s a k i ,  S . ,  O s a n a i ,  T . ,  T o m i t a ,  H . ,  M a t s u n a g a ,  T . ,  M a g o t a ,  K . ,  &  O k u m u r a ,  K .  ( 2 0 0 4 ) .  
T u m o r  n e c r o s i s  f a c t o r  a l p h a  a s  a n  e n d o g e n o u s  s t i m u l a t o r  f o r  c i r c u l a t i n g  c o u p l i n g  
f a c t o r  6 .  Cardiovascular Research. 6 2 ,  5 7 8 - 5 8 6 . ,
9-256
. 1; i u k : s  I L " . \  i n s o n I’h l ) ' T11c  -i
S a s e ,  K . ,  &  M i c h e l ,  T .  ( 1 9 9 5 ) .  E x p r e s s i o n  o f  c o n s t i t u t i v e  e n d o t h e l i a l  n i t r i c  o x i d e  
s y n t h a s e  i n  h u m a n  b l o o d  p l a t e l e t s .  Ufe Sciences. 5 7 ,  2 0 4 9 - 2 0 5 5 .
S c h a r d i n g e r ,  F .  ( 1 9 0 2 ) .  U b e r  d a s  V e r h a l t e n  d e r  K u h m i l c h  g e g e n  M e t h y l e n b l a u  u n d  
s e i n e  V e r w e n d u n g  z u r  U n t e r s c h e i d u n g  v o n  u n g e k o c h t e r  u n d  g e k o c h t e r  M i l c h .  
Untersuch Nahrungs Genussmittel. 5 ,  1 1 1 3 - 1 1 2 1 .
S c h u l t z ,  A . C . ,  N y g a a r d ,  P . ,  &  S a x i l d ,  H . H .  ( 2 0 0 1 ) .  F u n c t i o n a l  a n a l y s i s  o f  1 4  g e n e s  t h a t  
c o n s t i t u t e  t h e  p u r i n e  c a t a b o l i c  p a t h w a y  i n  B a c i l l u s  s u b t i l i s  a n d  e v i d e n c e  f o r  a  n o v e l  
r e g u l o n  c o n t r o l l e d  b y  t h e  P u c R  t r a n s c r i p t i o n  a c t i v a t o r .  Journal of Bacteriology. 1 8 3 ,  3 2 9 3 -  
3 3 0 2 .
S c h u l t z ,  E . ,  A n t e r ,  E . ,  &  K e a n e y ,  J . F .  ( 2 0 0 4 ) .  O x i d a t i v e  s t r e s s ,  a n t i o x i d a n t s ,  a n d  
e n d o t h e l i a l  f u n c t i o n .  Current Medicinal Chemistry. 1 1 ,  1 0 9 3 - 1 1 0 4 .
S h e e h a n ,  J . P . ,  &  S a d l e r ,  J . E .  ( 1 9 9 4 ) .  M o l e c u l a r  m a p p i n g  o f  t h e  h e p a r i n - b i n d i n g  
e x o s i t e  o f  t h r o m b i n .  PN^4S. 9 1 ,  5 5 1 8 - 5 5 2 2 .
S i m a k ,  J . ,  H o l a d a ,  K . ,  &  V o s t a l ,  J . G .  ( 2 0 0 2 ) .  R e l e a s e  o f  a n n e x i n  V - b i n d i n g  m e m b r a n e  
m i c r o p a r t i c l e s  f r o m  c u l t u r e d  h u m a n  u m b i l i c a l  v e i n  e n d o t h e l i a l  c e l l s  a f t e r  t r e a t m e n t  
w i t h  c a m p t o t h e c i n .  BMC Cell Biology. 3 : 1 1 .
S i n h a ,  S . ,  &  W a g n e r ,  D . D .  ( 1 9 8 7 ) .  I n t a c t  m i c r o t u b u l e s  a r e  n e c e s s a r y  f o r  c o m p l e t e  
p r o c e s s i n g ,  s t o r a g e  a n d  r e g u l a t e d  s e c r e t i o n  o f  v o n  W i l l e b r a n d  f a c t o r  b y  e n d o t h e l i a l  
c e l l s .  'European Journal of Cell Biology. 4 3 ,  3 7 7 - 3 8 3 .
S k r y p i n a ,  N . A . ,  T i m o f e e v a ,  A . V . ,  K h a s p e k o v m  G . L . ,  S a v o c h k i n a ,  L . P . ,  
& B e a b e a l a s h v i l l i ,  R . S .  ( 2 0 0 3 ) .  T o t a l  R N A  s u i t a b l e  f o r  m o l e c u l a r  b i o l o g y  a n a l y s i s .  
Journal of Biotechnology. 1 0 5 ,  1 - 9 .
S m i t h ,  C . J . ,  S u n ,  D . ,  H o e g l e r ,  C . ,  R o t h ,  B . S . ,  Z h a n g ,  X . ,  Z h a o ,  G . ,  X u ,  X . B . ,  K o b a r i ,  
Y . ,  P r i t c h a r d ,  K . ,  S e s s a ,  W . C . ,  &  H u n t z e ,  T . H .  ( 1 9 9 6 ) .  R e d u c e d  g e n e  e x p r e s s i o n  o f  
v a s c u l a r  r n e o t h e l i a l  N O  s y n t h a s e  a n d  c y c l o o x y g e n a s e - 1  i n  h e a r t  f a i l u r e .  Circulation 
Research. 7 8 ,  5 8 - 6 4 .
S p e d e n ,  D . J .  ( 2 0 0 3 ) .  X a n t h i n e  o x i d a s e  i n  i n f l a m m a t o r y  a r t h r i t i s .  D o c t o r a l  d i s s e r t a t i o n .  
U n i v e r s i t y  o f  B a t h ,  B a t h ,  U K .
S p i e k e r m a n n ,  S . ,  L a n d m e s s e r ,  U . ,  D i k a l o v ,  S . ,  B r e d t ,  M . ,  G a m e z ,  G . ,  T a t g e ,  H . ,  
R e e p d c h l a g e r ,  N . ,  H o r n i g ,  B . ,  D r e x l e r ,  H . ,  &  H a r r i s o n ,  D . G .  ( 2 0 0 3 ) .  E l e c t r o n  s p i n  
r e s o n a n c e  c h a r a c t e r i s a t i o n  o f  v a s c a u l r  x a n t h i n e  a n d  N A D ( P ) H  o x i d a s e  a c t i v i t y  i n  
p a t i e n t s  w i t h  c o r o n a r y  a r t e r y  d i s e a s e .  Circulation. 1 0 7 , 1 3 8 3 - 1 3 8 9 .
9-257
J i i i i i l ' - .  I lew in-.i ' i i I ’Ii D T I i-.'m -,
S p r i n g e r ,  T . A .  ( 1 9 9 4 ) .  T r a f f i c  s i g n a l s  f o r  l y m p h o c y t e  r e c i r c u l a t i o n  a n d  l e u k o c y t e  
e m i g r a t i o n ;  t h e  m u l t i s t e p  p a r a d i g m .  Cell. 7 6 ,  3 0 1 - 3 1 4 .
S t a n i e k ,  K . ,  &  N o h l ,  H .  ( 2 0 0 0 ) .  A r e  m i t o c h o n d r i a  a  p e r m a n e n t  s o u r c e  o f  r e a c t i v e  
o x y g e n  s p e c i e s ?  Biochimica et Biophysica Acta. 1 4 6 0 ,  2 6 8 - 2 7 5 .
S t a m l e r ,  J . S . ,  S i n g e l ,  D . J . ,  L o s c a l z o ,  J .  ( 1 9 9 2 ) .  B i o c h e m i s t r y  o f  n i t r i c  o x i d e  a n d  i t s  
r e d o x - a c t i v e  f o r m s .  Science. 2 5 8 , 1 8 9 8 - 1 9 0 2 .
S t e v e n s ,  C . R . ,  M i l l a r ,  T . M . ,  C l i n c h ,  J . G . ,  K a n c z l e r ,  J . M . ,  B o d a m y a l i ,  T . ,  &  B l a k e ,  D . R .
( 2 0 0 0 ) .  A n t i b a c t e r i a l  p r o p e r t i e s  o f  x a n t h i n e  o x i d a s e  i n  h u m a n  m i l k .  The Lancet. 3 5 6 ,  
8 2 9 - 8 3 0 .
S t i r p e ,  F . ,  &  D e l l a  C o r t e ,  E .  ( 1 9 6 9 ) .  T h e  r e g u l a t i o n  o f  r a t  l i v e r  x a n t h i n e  o x i d a s e .  
Journal of Biological Chemistry. 2 4 4 ,  3 8 5 5 - 3 8 6 3 .
S t o r c h ,  J . ,  &  F e r b e r ,  E .  ( 1 9 8 8 ) .  D e t e r g e n t - a m p l i f i e d  c h e m i l u m i n e s c e n c e  o f  l u c i g e n i n  
f o r  d e t e r m i n a t i o n  o f  s u p e r o x i d e  a n i o n  p r o d u c t i o n  b y  N A D P H - o x i d a s e  a n d  x a n t h i n e  
o x i d a s e .  Analytical Biochemistry. 1 6 9 ,  2 6 2 - 2 6 7 .
S t - P i e r r e ,  J . ,  B u c k i n g h a m ,  J . A . ,  R o e b u c k ,  S . J . ,  &  B r a n d ,  M . D .  ( 2 0 0 2 ) .  T o p o l o g y  o f  
s u p e r o x i d e  p r o d u c t i o n  f r o m  d i f f e r e n t  s i t e s  i n  t h e  m i t o c h o n d r i a l  e l e c t r o n  t r a n s p o r t  
c h a i n .  The Journal of Biological Chemistry. 211 ,  4 4 7 8 4 - 4 4 7 9 0 .
S t r a l i n ,  P . ,  K a r l s s o n ,  K . ,  J o h a n s s o n ,  B . O . ,  &  M a r k l u n d ,  S . L .  ( 1 9 9 5 ) .  T h e  i n t e r s t i t i u m  
o f  t h e  h u m a n  a r t e r i a l  w a l l  c o n t a i n s  v e r y  l a r g e  a m o u n t s  o f  e x t r a c e l l u l a r  s u p e r o x i d e  
d i s m u t a s e .  Arteriosclerosis, Thrombosis, and Vascular Biolog)!. 1 5 ,  2 0 3 2 - 2 0 3 6 .
S u g a m a ,  Y . ,  T i r u p p a t h i ,  C . ,  J a n a k i d e v i ,  K . ,  A n d e r s o n ,  T . T . ,  F e n t o n ,  J . W . ,  &  M a l i k ,  
A . B .  ( 1 9 9 2 ) .  T h r o m b i n - i n d u c e d  e x p r e s s i o n  o f  e n d o t h e l i a l  P - s e l e c t i n  a n d  i n t r a c e l l u l a r  
a d h e s i o n  m o l e c u l e - 1 :  a  m e c h a n i s m  o f  s t a b i l i s i n g  n e u t r o p h i l  a d h e s i o n .  The Journal of 
Cell Biolog. 1 1 9 ,  9 3 5 - 9 4 4 .
S u z u k i ,  M . ,  I n a u e n ,  W . ,  K v i e t y s ,  P . R . ,  G r i s h a m ,  M . B . ,  M e i n i n g e r ,  C . ,  S c h e l l i n g ,  M . E . ,  
G r a n g e r ,  H . J . ,  &  G r a n g e r ,  D . N .  ( 1 9 8 9 ) .  S u p e r o x i d e  m e d i a t e s  r e p e r f u s i o n - i n d u c e d  
l e u k o c y t e - e n d o t h e l i a l  c e l l  i n t e r a c t i o n s .  American Journal of Physiology. 2 5 7 ,  H I  7 4 0 -  
H 1 7 4 5 .
T a b e n g w a ,  E . M . ,  B e n z a ,  R . L . ,  G r e n e t t ,  H . E . ,  &  B o o y s e ,  F . M .  ( 2 0 0 0 ) .
H y p e r t r i g l y c e r i d e m i c  V L D L  d o w n r e g u l a t e s  t i s s u e  p l a s m i n o g e n  a c t i v a t o r  g e n e  
t r a n s c r i p t i o n  t h r o u g h  c i s - r e p r e s s i v e  r e g i o n ( s )  i n  t h e  t i s s u e  p l a s m i n o g e n  a c t i v a t o r  
p r o m o t e r  i n  c u l t u r e d  h u m a n  e n d o t h e l i a l  c e l l s .  Arteriosclerosis, Thrombosis, and Vascular 
Biolog. 2 0 , 1 6 7 5 - 1 6 8 1 .
9-258
.Ui i i i js i l owinsun P i l l  )  i i i ; ' - ! - ,
T a k a n o ,  M . ,  M e n e s h i a n ,  A . ,  S h e i k h ,  E . ,  Y a m a k a w a ,  Y . ,  W i l k i n s ,  K . B . ,  H o p k i n s ,  E . A . ,  
&  B u l k l e y ,  G . B .  ( 2 0 0 2 ) .  R a p i d  u p r e g u l a t i o n  o f  e n d o t h e l i a l  P - s e l e c t i n  e x p r e s s i o n  v i a  
r e a c t i v e  o x y g e n  s p e c i e s  g e n e r a t i o n .  American Journal of Physiology. 2 8 3 ,  H 2 0 5 4 - H 2 0 6 1 .
T a k a o ,  S . ,  S m i t h ,  E . H . ,  W a n g ,  D . ,  C h a n ,  C . K . ,  B u l k l e y ,  G . B . ,  &  K l e i n ,  A . S .  ( 1 9 9 6 ) .  
R o l e  o f  r e a c t i v e  o x y g e n  i n t e r m e d i a t e s  i n  m u r i n e  p e r i t o n e a l  m a c r o p h a g e  p h a g o c y t o s i s  
a n d  p h a g o c y t i c  k i l l i n g .  American Journal of Physiology. Cell Physiology. 2 7 1 ,  C 1 2 7 8 - C 1 2 8 4 .
T a n ,  S . ,  Y o k o y a m a ,  Y . ,  D i c k e n s ,  E . ,  C a s h ,  T . G . ,  F r e e m a n ,  B . A . ,  &  P a r k s ,  D . A .  
X a n t h i n e  o x i d a s e  a c t i v i t y  i n  t h e  c i r c u l a t i o n  o f  r a t s  f o l l o w i n g  h e m o r r h a g i c  s h o c k .  Free 
Radical Biology &  Medicine. 1 5 ,  4 0 7 - 4 1 5 .
T a y l o r ,  F . B . ,  P e e r ,  G . T . ,  L o c k h a r t ,  M . S . ,  F e r r e l l ,  G . ,  &  E s m o n ,  C . T .  ( 2 0 0 1 ) .  
E n d o t h e l i a l  c e l l  p r o t e i n  C  r e c e p t o r  p l a y s  a n  i m p o r t a n t  r o l e  i n  p r o t e i n  C  a c t i v a t i o n  i n  
v i v o .  Blood. 9 7 , 1 6 8 5 - 1 6 8 8 .
T e r a d a ,  L . S . ,  B e e h l e r ,  C . J . ,  B a n e r j e e ,  A . ,  B r o w n ,  J . M . ,  G r o s s o ,  M . A . ,  H a r k e n ,  A . H . ,  
M c C o r d ,  J . M . ,  &  R e p i n e ,  J . E .  ( 1 9 8 8 ) .  H y p e r o x i a  a n d  s e l f -  o r  n e u t r o p h i l - g e n e r a t e d  O 2 
m e t a b o l i t e s  i n a c t i v a t e  x a n t h i n e  o x i d a s e .  Journal of Applied Physiology. 6 5 ,  2 3 4 9 - 2 3 5 3 .
T e r a d a ,  L . S . ,  D o r m i s h ,  J . J . ,  S h a n l e y ,  P . F . ,  L e f f ,  J . A . ,  A n d e r s o n ,  B . O . ,  &  R e p i n e ,  J . E .
( 1 9 9 2 ) .  C i r c u a l t i n g  x a n t h i n e  o x i d a s e  m e d i a t e s  l u n g  n e u t r o p h i l  s e q u e s t r a t i o n  a f t e r  
i n t e s t i n a l  i s c h e m i a - r e p e r f u s i o n .  American Journal of Physiology. 2 6 3 ,  L 3 9 4 - L 4 0 1 .
T e r a d a ,  L . S . ,  H y b e r t s o n ,  B . M . ,  C o n n e l l y ,  K . G . ,  W e i l l ,  D . ,  P i e r m a t t e i ,  D . ,  &  R e p i n e ,  
J . E .  ( 1 9 9 7 ) .  X O  i n c r e a s e s  n e u t r o p h i l  a d h e r e n c e  t o  e n d o t h e l i a l  c e l l s  b y  a  d u a l  I C A M - 1  
a n d  P - s e l e c t i n - m e d i a t e d  m e c h a n i s m .  Journal of Applied Physiology. 8 2 ,  8 6 6 - 8 7 3 .
T e r a o ,  M . ,  C a z z a n i g a ,  C . ,  G h e z z i ,  P . ,  B i a n c h i ,  M . ,  F a l c i a n i ,  F . ,  P e r a n i ,  P . ,  &  G a r a t t i n i ,
E .  ( 1 9 9 2 ) .  M o l e c u l a r  c l o n i n g  o f  c D N A  c o d i n g  f o r  m o u s e  l i v e r  x a n t h i n e  
d e h y d r o g e n a s e .  R e g u l a t i o n  o f  i t s  t r a n s c r i p t  b y  i n t e r f e r o n s  i n  v i v o .  The Biochemical 
Journal. 2 8 3 ,  8 6 3 - 8 7 0 .
T i l l y ,  B . C . ,  T e r t o o l e n ,  L . G . ,  L a m b r e a c h t s ,  A . C . ,  R e m o r i e ,  R . ,  d e  L a a t ,  S . W . ,  &  
M o o l e n a a r ,  W . H .  ( 1 9 9 0 ) .  H i s t a m i n e - H l - r e c e p t o r - m e d i a t e d  p h o s p h o i n o s i t i d e  
h y d r o l y s i s ,  C a 2 +  s i g n a l l i n g  a n d  m e m b r a n e - p o t e n t i a l  o s c i l l a t i o n s  i n  h u m a n  H e L a  
c a r c i n o m a  c e l l s .  The Biochemical Journal. 2 6 6 ,  2 3 5 - 2 4 3 .
T u r r e n s ,  J . F . ,  &  B o v e r i s ,  A .  ( 1 9 8 0 ) .  G e n e r a t i o n  o f  s u p e r o x i d e  a n i o n  b y  t h e  N A D H  
d e h y d r o g e n a s e  o f  b o v i n e  h e a r t  m i t o c h o n d r i a .  The Biochemical Journal. 1 9 1 ,  4 2 1 - 4 2 7 .
T u r r e n s ,  J . F . ,  A l e x a n d r e ,  A . ,  &  L e h n i n g e r ,  A . L .  ( 1 9 8 5 ) .  U b i s e m i q u i n o n e  i s  t h e  
e l e c t r o n  d o n o r  f o r  s u p e r o x i d e  f o r m a t i o n  b y  c o m p l e x  I I I  o f  h e a r t  m i t o c h o n d r i a .  
Archives ofBiochemistiy and Biophysics. 2 3 7 ,  4 0 8 - 4 1 4 .
9-259
. lames I-lev. i i w m I ’ l i l )  T l ie -m
U m e z a w a ,  K . ,  A k a i k e ,  T . ,  F u j i i ,  T . ,  S u g a ,  M . ,  S e t o g u c h i ,  K . ,  O z a w a ,  A . ,  &  M a e d a ,  H .  
( 1 9 9 7 ) .  I n d u c t i o n  o f  n i t r i c  o x i d e  s y n t h e s i s  a n d  x a n t h i n e  o x i d a s e  a n d  t h e i r  r o l e s  i n  t h e  
a n t i m i c r o b i a l  m e c h a n i s m  a g a i n s t  S a l m o n e l l a  t y p h i m u r i u m  i n f e c t i o n  i n  m i c e .  Infection 
and Immunity. 6 5 ,  2 9 3 2 - 2 9 4 0 .
v a n  M o u r i k ,  J . A . ,  d e  W i r ,  T . R . ,  &  V o o r b e r g ,  J .  ( 2 0 0 2 ) .  B i o g e n e s i s  a n d  e x o c y t o s i s  o f  
W e i b e l - P a l a d e  b o d i e s .  Histochemistry and Cell Biology. 1 1 7 , 1 1 3 - 1 2 2 .
V a n W i j k ,  M . J . ,  V a n B a v e l ,  E . ,  S t u r k ,  A . ,  &  N i e u w l a n d ,  R .  ( 2 0 0 3 ) .  M i c r o p a r t i c l e s  i n  
c a r d i o v a s c u l a r  d i s e a s e s .  Cardiovascualr Research. 5 9 ,  2 7 7 - 2 7 8 .
V a r m a ,  S . D . ,  M o r r i s ,  S . M . ,  B a u e r ,  S . A . ,  &  K o p p e n o l ,  W . H .  ( 1 9 8 6 ) .  I n  v i t r o  d a m a g e  t o  
r a t  l e n s  b y  x a n t h i n e - x a n t h i n e  o x i d a s e :  p r o t e c t i o n  b y  a s c o r b a t e .  Experimental Eye 
Research. 4 3 , 1 0 6 7 - 1 0 7 6 .
V a s q u e z - V i v a r ,  J . ,  H o g g ,  N . ,  P r i t c h a r d ,  K . A . ,  M a r t a s e k ,  P . ,  &  K a l y a n a r a m a n ,  B .  
( 1 9 9 7 ) .  S u p e r o x i d e  a n i o n  f o r m a t i o n  f r o m  l u c i g e n i n :  a n  e l e c t r o n  s p i n  r e s o n a n c e  s p i n -  
t r a p p i n g  s t u d y .  FEBS Letters. 4 0 3 , 1 2 7 - 1 3 0 .
V a s q u e z - V i v a r ,  J . ,  K a l y a n a r a m a n ,  B . ,  M a r t a s e k ,  P . ,  H o g g ,  N . ,  M a s t e r s ,  B . S . S . ,  K a r o u i ,  
H . ,  T o r d o ,  P . ,  &  P r i t c h a r d ,  K . A .  ( 1 9 9 8 ) .  S u p e r o x i d e  g e n e r a t i o n  b y  e n d o t h e l i a l  n i t r i c  
o x i d e  s y n t h a s e :  t h e  i n f l u e n c e  o f  c o f a c t o r s .  PN A S. 9 5 ,  9 2 2 0 - 9 2 2 5 .
V a s q u e z - V i v a r ,  J . ,  K a l y a n a r a m a n ,  B . ,  &  M a r t a s e k ,  P .  ( 2 0 0 3 ) .  T h e  r o l e  o f  
t e t r a h y d r b i o p t e r i n  i n  s u p e r o x i d e  g e n e r a t i o n  f r o m  e N O S :  e n z y m o l o g y  a n d
p h y s i o l o g i c a l  i m p l i c a t i o n s .  Free Radical Research. 3 7 ,  1 2 1 - 1 2 7 .
V e r n e t ,  C . ,  B o r e t t o ,  J . ,  M a t t e i ,  M - G . ,  T a k a h a s h i ,  M . ,  J a c k ,  L . J . W . ,  M a t h e r ,  I . H . ,  
R o u q u i e r ,  S . ,  &  P o n t a r o t t i ,  P .  ( 1 9 9 3 ) .  E v o l u t i o n a r y  s t u d y  o f  m u l t i g e n e i c  f a m i l i e s  
m a p p i n g  c l o s e  t o  t h e  h u m a n  M H C  c l a s s  I  r e g i o n .  Journal of Molecular Evolution. 3 7 ,  6 0 0 -  
6 1 2 .
V i s c h e r ,  U . M . ,  &  W o l l h e i m ,  C . B .  ( 1 9 9 7 ) .  E p i n e p h e r i n e  i n d u c e s  v o n  W i l l e b r a n d  f a c t o r  
r e l e a s e  f r o m  c u l t u r e d  e n d o t h e l i a l  c e l l s :  i n v o l v e m e n t  o f  c y c l i c  A M P - d e p e n d e n t  
s i g n a l l i n g  i n  e x o c y t o s i s .  Thrombosis and Haemostasis. 7 7 ,  1 1 8 2 - 1 1 8 8 .
V i s c h e r ,  U . M . ,  L a n g ,  U . ,  &  W o l l h e i m ,  C . B .  ( 1 9 9 8 ) .  A u t o c r i n e  r e g u l a t i o n  o f  e n d o t h e l i a l  
e x o c y t o s i s :  v o n  w i l l e b r a n d  f a c t o r  r e l e a s e  i s  i n d u c e d  b y  p r o s t a c y c l i n  i n  c u l t u r e d  
e n d o t h e l i a l  c e l l s .  FEBS Letters. 4 2 4 ,  2 1 1 - 2 1 5 .
V i s h e r ,  U . M . ,  B a r t h ,  H . ,  &  W o l l h e i n ,  C . B .  ( 2 0 0 0 ) .  R e g u l a t e d  v o n  W i l l e b r a n d  f a c t o r  
s e c r e t i o n  i s  a s s o c i a t e d  w i t h  a g o n i s t - s p e c i f i c  p a t t e r n s  o f  c y t o s k e l e t a l  r e m o d e l l i n g  i n  
c u l t u r e d  e n d o t h e l i a l  c e l l s .  Arteriosclerosis,  Thrombosis, and Vascular Biology. 2 0 ,  8 8 3 - 8 9 1 .
9-260
l a m e s  I l e w  i i w m P h D  Tl i c s i
V e r g n o l l e ,  N . ,  H o l l e n b u r g ,  M . D . ,  &  W a l l a c e ,  J . L .  ( 1 9 9 9 ) .  P r o -  a n d  a n t i - i n f l a m m a t o r y  
a c t i o n s  o f  t h r o m b i n :  a  d i s t i n c t  r o l e  p r o t e i n a s e - a c t i v a t e d  r e c e p t o r - 1  ( P A R - 1 ) .  British 
Journal of Pharmacology. 1 2 6 ,  1 2 6 2 - 1 2 6 8 .
V e r g n o l l e ,  N . ,  D e r i a n ,  C . K . ,  A n d r e a ,  M . R . D . ,  S t e i n h o f f ,  M . ,  &  A n d r a d e - G o r d o n ,  P .  
( 2 0 0 2 ) .  C h a r a c t e r i z a t i o n  o f  t h r o m b i n - i n d u c e d  l e u k o c y t e  r o l l i n g  a n d  a d h e r e n c e :  a  
p o t e n t i a l  p r o i n f l a m m a t o r y  r o l e  f o r  p r o t e i n a s e - a c t i v a t e d  r e c e p t o r - 4 .  The Journal of 
Immunology. 1 6 9 , 1 4 6 7 - 1 4 7 3 .
V o n  A n d r i a n ,  U . H . ,  H a n s e l l ,  P . ,  C h a m b e r s ,  D . ,  B e r g e r ,  E . M . ,  F i l h o ,  I . T . ,  B u t c h e r ,
E . C . ,  &  A r f o r s ,  K . E .  ( 1 9 9 2 ) .  L - s e l e c t i n  f u n c t i o n  i s  r e q u i r e s  f o r  p 2- i n t e g r i n - m e d i a t e d  
n e u t r o p h i l  a d h e s i o n  a t  p h y s i o l o g i c a l  s h e a r  s t r e s s  r a t e s  i n  v i v o .  The American Journal of 
Physiology. 2 6 3 ,  H 1 0 3 4 - H 1 0 4 4 .
W a n g ,  J . ,  V a n  P r a a g h ,  A . ,  H a m i l t o n ,  E . ,  W a n g ,  Q . ,  Z o u ,  B . ,  M u r a n j a n ,  M . ,  M u r p h y ,  
N . B . ,  &  B l a c k ,  S . J .  ( 2 0 0 2 ) .  S e r u m  x a n t h i n e  o x i d a s e :  o r i g i n ,  r e g u l a t i o n ,  a n d  
c o n t r i b u t i o n  t o  c o n t r o l  o f  t r y p a n o s o m e  p a r a s i t e m i a .  Antioxidants and Redox Signaling. 4 ,  
1 6 1 - 1 7 8 .
W a t s o n ,  P . ,  J o n e s ,  A . T . ,  &  S t e p h e n s ,  D . J .  ( 2 0 0 5 ) .  I n t r a c e l l u l a r  t r a f i i c k i n g  p a t h w a y s  
a n d  d r u g  d e l i v e r y :  f l u o r e s c e n c e  i m a g i n g  o f  l i v i n g  a n d  f i x e d  c e l l s .  Advanced Drug Delivery 
Reviews. 5 7 ,  4 3 - 6 1 .
W a u d ,  W . R . ,  &  R a j a g o p a l a n ,  K . V .  ( 1 9 7 6 ) .  T h e  m e c h a n i s m  o f  c o n v e r s i o n  o f  r a t  l i v e r  
x a n t h i n e  d e h y d r o g e n a s e  f r o m  a n  N A D + - d e p e n d e n t  f o r m  ( t y p e  D )  t o  a n  0 2 -  
d e p e n d e n t  f o r m  ( t y p e  O ) .  Archives of Biochemistry and Biophysics. 1 7 2 ,  3 6 5 - 3 7 9 .
W e b e r ,  K . S . ,  v o n  H u n d e l s h a u s e n ,  P . ,  C l a r k - L e w i s ,  I . ,  w e b e r ,  P . C . ,  &  W e b e r ,  C .
( 1 9 9 9 ) . D i f f e r e n t i a l  i m m o b i l i z a t i o n  a n d  h i e r a r c h i c a l  i n v o l v e m e n t  o f  c h e m o k i n e s  i n  
m o n o c y t e  a r r e s t  a n d  t r a n s m i g r a t i o n  o n  i n f l a m e d  e n d o t h e l i u m  i n  s h e a r  f l o w .  European 
Journal of Immunology. 2 9 ,  7 0 0 - 7 1 2 .
W e i b e l ,  E . R . ,  &  P a l a d e ,  G . E .  ( 1 9 6 4 ) .  N e w  c y t o p l a s m i c  c o m p o n e n t s  i n  a r t e r i a l  
e n d o t h e l i a .  The Journal of Cell Biology. 2 3 ,  1 0 1 - 1 1 2 .
W e n t z e l ,  P . ,  E j d e s j o ,  A . ,  &  E r i k s s o n ,  U . J .  ( 2 0 0 3 ) .  M a t e r n a l  d i a b e t e s  i n  v i v o  a n d  h i g h  
g l u c o s e  i n  v i t r o  d i m i n i s h  G A P D H  a c t i v i t y  i n  r a t  e m b r y o s .  Diabetes. 5 2 ,  1 2 2 2 - 1 2 2 8 .
W h i t e ,  C . R . ,  D a r l e y - U s m e r ,  V . ,  B e r r i n g t o n ,  W . R . ,  M c A d a m s ,  M . ,  G o r e ,  J . Z . ,  
T h o m p s o n ,  J . A . ,  P a r k s ,  D . A . ,  T a r p e y ,  M . M . ,  & F r e e m a n ,  B . A .  ( 1 9 9 6 ) .  C i r c u l a t i n g  
p l a s m a  x a n t h i n e  o x i d a s e  c o n t r i b u t e s  t o  v a s c u l a r  d y s f u n c t i o n  i n  h y p e r c h o l e s t e r o l e m i c  
r a b b i t s .  PN AS. 9 3 ,  8 7 4 5 - 8 7 4 9 .
9-261
J ; i t i i L " >  I k ' V .  i l i - n i I ’ h l )  T h c s i - .
W i n g r e n ,  A . G . ,  B j o r k d a h l ,  O . ,  L a b u d a ,  T . ,  B j o r k ,  L . ,  A n d e r s s o n ,  U . ,  G u l l b e r g ,  U . ,  
H e d l u n d ,  G . ,  S j o g r e n ,  H . O . ,  K a l l a n d ,  T . ,  W i d e g r e n ,  B . ,  &  D o h l s t e n ,  M .  ( 1 9 9 6 ) .  
F u s i o n  o f  a  s i g n a l  s e q u e n c e  t o  t h e  i n t e r l e u k i n - 1  b e t a  g e n e  d i r e c t s  t h e  p r o t e i n  f r o m  
c y t o p l a s m i c  a c c u m u l a t i o n  t o  e x t r a c e l l u l a r  r e l e a s e .  Cellular Immunology. 1 6 9 ,  2 2 6 - 2 3 7 .
W o l t m a n n ,  G . ,  M c N u l t y ,  C . A . ,  D e w s o n ,  G . ,  S y m o n ,  F . A . ,  &  W a r d l a w ,  A n d r e w .
( 2 0 0 0 ) .  I n t e r l e u k i n e - 1 3  i n d u c e s  P S G L - l / P - s e l e c t i n - d e p e n d e n t  a d h e s i o n  o f  
e o s i n o p h i l s ,  b u t  n o t  n e u t r o p h i l s ,  t o  h u m a n  u m b i l i c a l  v e i n  e n d o t h e l i a l  c e l l s  u n d e r  f l o w .  
Blood. 9 5 ,  3 1 4 6 - 3 1 5 2 .
W r i g h t ,  R . M . ,  V a i t a i t i s ,  G . M . ,  W i l s o n ,  C . M . ,  R e p i n e ,  T . B . ,  T e r a d a ,  L . S . ,  &  R e p i n e ,  J . E .
( 1 9 9 3 ) .  c D N A  c l o n i n g ,  c h a r a t e r i z a t i o n ,  a n d  t i s s u e - s p e c i f i c  e x p r e s s i o n  o f  h u m a n  
x a n t h i n e  d e h y d r o g e n a s e / x a n t h i n e  o x i d a s e .  PN AS. 9 0 ,  1 0 6 9 0 - 1 0 6 9 4 .
X u ,  P . ,  H u e c k s t e a d t ,  T . P . ,  &  H o i d a l ,  J . R .  ( 1 9 9 6 ) .  M o l c u l a r  c l o n i n g  a n d  c h a r a t e r i z a t i o n  
o f  t h e  h u m a n  x a n t h i n e  d e h y d r o g e n a s e  g e n e  ( X D H ) .  Genomics. 3 4 , 1 7 3 - 1 8 0 .
X u ,  P . ,  Z h u ,  X . L . ,  H u e c k s t e a d t ,  T . P . ,  B r o t h m a n ,  A . R . ,  &  H o i d a l ,  J . R .  ( 1 9 9 4 ) .  
A s s i g n m e n t  o f  h u m a n  x a n t h i n e  d e h y d r o g e n a s e  g e n e  t o  c h r o m o s o m e  2 p 2 2 .  Genomics. 
2 3 ,  2 8 9 - 2 9 1 .
X u ,  P . ,  L a V a l l e e ,  P . ,  &  H o i d a l ,  J . R .  ( 2 0 0 0 ) .  R e p r e s s e d  e x p r e s s i o n  o f  t h e  h u m a n  
x a n t h i n e  o x i d o r e d u c t a s e  g e n e .  E - b o x  a n d  T A T A - l i k e  e l e m e n t s  r e s t r i c t  g r o u n d  s t a t e  
t r a n s c r i p t i o n a l  activity. Journal of Biological Chemistry. 21S,  5 9 1 8 - 5 9 2 6 .
Y a m a w a k i ,  H . ,  H a e n d e l e r ,  J . ,  & B e r k ,  B . C .  ( 2 0 0 3 ) .  T h i o e d o x i n  a  k e y  r e g u l a t o r  o f  
c a r d i o v a s c u l a r  f u n c t i o n .  Circulation Research. 9 3 , 1 0 2 9 - 1 0 3 3 .
Y a o ,  L . ,  P a n ,  J . ,  S e t i a d i ,  H . ,  P a t e l ,  K . D . ,  &  M c E v e r ,  R . P .  ( 1 9 9 6 ) .  I n t e r l e u k i n  4  o r  
o n c o s t a t i n  M  i n d u c e s  a  p r o l o n g e d  i n c r e a s e  i n  P - s e l e c t i n  m R N A  a n d  p r o t e i n  i n  h u m a n  
e n d o t h e l i a l  c e l l s .  The Journal of Experimental Medicine. 1 8 4 ,  8 1 - 9 2 .
Z h a n g ,  Z . ,  B l a k e ,  D . r . ,  S t e v e n s ,  C . R . ,  K a n c z l e r ,  J . M . ,  W i n y a r d ,  P . G . ,  S y m o n s ,  M . C . ,  
B e n b o u b e t r a ,  M . ,  &  H a r r i s o n ,  R .  ( 1 9 9 8 ) .  A  r e a p p r a i s a l  o f  x a n t h i n e  d e h y d r o g e n a s e  a n d  
o x i d a s e  i n  h y p o x i a - r e p e r f u s i o n  i n j u r y :  t h e  r o l e  o f  N A D H  a s  a n  e l e c t r o n  d o n o r .  Free 
Radical Research. 2 8 , 1 5 1 - 1 6 4 .
Z h o u ,  Q . ,  H e l l e r m a n n ,  G . R , .  &  S o l o m o n s o n ,  L . P .  ( 1 9 9 5 ) .  N i t r i c  o x i d e  r e l e a s e  f r o m  
r e s t i n g  h u m a n  p l a t e l e t s .  Thrombosis Research. 7 7 ,  8 7 - 9 6 .
Z i m m e r m a n ,  G . A . ,  M c I n t y r e ,  T . M . ,  M e h r a ,  M . ,  &  P r e s c o t t ,  S . M .  ( 1 9 9 0 ) .  E n d o t h e i a l  
c e l l - a s s o c i a t e d  p l a t e l e t - a c t i v a t i n g  f a c t o r :  a  n o v e l  m e c h a n i s m  f o r  s i g n a l l i n g  i n t e r c e l l u l a r  
a d h e s i o n .  The Journal of Cell Biology. 1 1 0 ,  5 2 9 - 5 4 0 .
9-262
J u l i u s  1  L - w  i h m i i i I ’ l l D ' l l l f S l N
Z o u k i ,  C . ,  Z h a n g ,  S - L ,  C h a n ,  J . S . D . ,  &  F i l e p ,  J . G .  ( 2 0 0 1 ) .  P e r o x y n i t r i t e  i n d u c e s  
i n t e g r i n - d e p e n d e n t  a d h e s i o n  o f  h u m a n  n e u t r o p h i l s  t o  e n d o t h e l i a l  c e l l s  v i a  a c t i v a t i o n  
o f  t h e  R a f - l / M E K / E r k  p a t h w a y .  FASEB Journal 1 5 ,  2 5 - 2 7 .
Z u p a n c i c ,  G . ,  O g d e n ,  D . ,  M a g n u s ,  G . J . ,  W h e e l e r - J o n e s ,  C . ,  &  C a r t e r ,  T . D .  ( 2 0 0 2 ) .  
D i f f e r e n t i a l  e x o c y t o s i s  f r o m  h u m a n  e n d o t h e l i a l  c e l l s  e v o k e d  b y  h i g h  i n t r a c e l l u l a r  C a 2+  
c o n c e n t r a t i o n .  Journal of Physiology. 5 4 4 . 3 ,  7 4 1 - 7 5 5 .
9-263
